AUTHOR INDEX

Pages 1-2424 and Supplement 89–90

A

Aamar S, 1628
Abbey S, 1720 (ab)
Abdool-Carrim AT, 1798
Abe A, 1517
Abeles AM, 659
Abou Zahr Z, 2363
Abrahamowicz M, 968
Abrahams JL, 463
Abramson L, 1088, 1687, 2012
Abril A, 795, 1095
Abu-Shakra M, 458, 1711 (ab)
Abud-Mendoza C, 1814
Accordi B, S89–61
Ackerman IN, 1047
Adachi J, 1732 (ab)
Adami S, 1648
Adams K, S90–56, S90–59
Adler S, 4
Agard C, 2157
Agarwal S, 997
Agematsu K, 875
Agewall S, 1341
Aghdassi E, 254, 1378
Agik S, 73
Agrawal S, 871
Aguilar-Chavez E, 247
Ahmad Y, 735
Ahmed K, 795
Ahn CW, 1231
Aikawa NE, 167
Airo' P, 112
Aizer J, 1280
Ajeganova S, 1146
Akamata K, 539
Akar S, 1996
Akhavan P, 1555, 1559, 1583, 1729 (ab), 1730 (ab), 1733 (ab)
Akil M, 1265
Akiyama K, 1019
Akkoc N, 594, 1996
Alacacioglu A, 594
Alarcón GS, 1603
Albert L, 1712 (ab)
Albertini G, S89–77
Albuquerque EN, 141
Alcaraz-Lopez MF, 247
Alcorn N, 883
Aletaha D, S90–47, S90–74
Alexanderson H, 2134
Alfredsson L, 1509
Aliabadi P, 359
Aliprantis AO, 112
Alivernini S, 2276
Allanore Y, 112, 532, 997, 1097
Allard JP, 1004
Allen KD, 337
Allenbach Y, 1835
Allez M, 2179
Almeida I, 197
Almodovar R, 1008
Alraqi S, 662
Alsina M, 1035
Alten R, 1728 (ab)
Alunno A, 1758
Amin YE, 180
Amoura Z, 997, 1835
An J-M, 728, 1399
Anand P, 1710 (ab)
Anbar A, 1979
Anckaert D, 1728 (ab)
Anderson JD, 1139
Andrade LE, 2104
Anis AH, 910, 1706 (ab)
Antohe JL, 946
Antonelli A, 979
Antoniou J, 1215
Aouba A, 125
Apps A, 1716 (ab)
Aquino MM, S89–49, S89–82
Arai E, 345
Arai S, 1659
Aranda R, 1546
Arat S, 2127
Araújo NC, 1948
Archambault WT, 610
Archibald D, 1746 (ab), 1747 (ab)
ARChiVe Investigators Network, 1088, 1687, 2012
Arden NK, 1056
Ariani A, 1641
Arias M, 1035
Arimura Y, 545
Aringer M, 2153
Arkachaisri T, 286
Ärlestig L, 939
Armstrong AW, 2198, 2204
Arnett FC, 997
Arumugam R, S89–32
Asami T, 1363
Asano Y, 539
Ash Z, 2184
Ashcroft DM, 240
Askanase A, 1711 (ab)
Askling J, 1583
Aslanov R, 1722 (ab), 1751 (ab), 1752 (ab)
Association des Sclérodermiques de France, 532
Ates H, 594
Atisha-Fregoso Y, 504
Atkinson A, 1483
Atsumi T, 1293, 1363
Atteno M, S89–36, S89–49, S89–82
Atzeni F, 849, 1179, 2222, S89–97
Auffray-Calvier E, 1026
Avila-Armengol HE, 1632
Avina-Zubieta JA, 1701 (ab), 1702 (ab), 1741 (ab), 1742 (ab)
Avouac J, 532, 997
Aydin SZ, 795, S89–11
Ayearst R, 1722 (ab)
Azab A, 1979
Azevedo VF, 141

B

Bachmeyer C, 2041
Bachta A, 795
Bacié-Boutry M-A, 1418
Backman C, 1738 (ab)
Backteman K, 1840
Badley E, 1748 (ab), 1749 (ab)
Badot V, 2127
Bae S-C, 226
Baek H-J, 1902
Baer AN, 2363
Baggiani A, 552
Bagovich M, 1726 (ab)
Bailen R, 1901
Bailly F, 2179
Bain L, 1747 (ab)
Bainbridge L, 1724 (ab)
Bakan B, 2045
Baker M, 1715 (ab), 1719 (ab)
Bakewell CJ, 404
Bakker MF, 22
Bal A, 1758
Balbir-Gurman A, 2361
Baldini C, 804
Balint PV, 795
Ballinari P, 656
Balsa A, 1166
Bancroft T, 784, 2303
Bang S-Y, 2321
Banwell B, 2227
Bao J, 1903
Baptist E, 2118
Baranda-Cándido L, 1814
Barausse G, 1648
Barber CEH, 454, 1711 (ab), 1772, 2231
Barbieri F, S89–44
Barcelos A, 131, 2315
Baria N, 1748 (ab)
Barisoni L, 510
Barnabe C, 1221, 1493, 1704 (ab), 1705 (ab), 1729 (ab), 1734 (ab), 1735 (ab), 1738 (ab), 1772
Barnetche T, 712, 1192
Baron M, 524, 787, 1707 (ab), 1709 (ab), 1724 (ab), 1829
Barr S, 1704 (ab), 1705 (ab), 1734 (ab), 1735 (ab), 1738 (ab)
Barra L, 1704 (ab), 1725 (ab)
Barrett A, 600
Barrier JH, 2157
Barry SC, 2021
Barten D-JJA, 1064
Bartoloni E, 1758
Barton A, 929, 1485, 1781
Bass AR, 1280
Bastuji-Garin S, 893
Baszis K, 1088, 1687
Batthish M, 2227
Batticciotto A, S89–97
Battié MC, 822
Baur N, 1744 (ab)
Bawa S, 1764
Bayraktar R, 106
Bayry J, 450
Beattie K, 1719 (ab)
Becciolini A, 1248
Begovich AB, 1603
Behin A, 1835
Beigelman C, 1835
Bele-Philippe P, 1418
Belisle P, 1734 (ab)
Bell A, 1748 (ab)
Bell DA, 1704 (ab), 1725 (ab)
Bell E, 1717 (ab)
Bell MJ, 1717 (ab), 2088
Ben-Chetrit E, 1628
Bencivenga A, 1875
Benditt R, 1741 (ab)
Benegas M, 2315
Benelli G, 1678
Bengtsson AA, 1619
Benjoar M, 2041
Benseler SM, 1088, 1687, 1698, 1723 (ab), 1875, 2012, 2227
Bensen W, 949, 1715 (ab), 1719 (ab), 1726 (ab), 1728 (ab)
Benveniste O, 1835
Berenbaum F, 2327
Beretta L, 112
Berger MF, 1859
Bergeron L, 1749 (ab)
Bergin D, 200, 1893
Bergman G, 1198
Bergman R, 198
Bergner R, 2153
Berman DS, 448
Berman JR, 1280
Bernatsky S, 1717 (ab), 1724 (ab), 1731 (ab), 1734 (ab)
Bernstein CN, 1726 (ab), 1792, 2253
Bernstein JE, 610
Berthelot J-M, 310
Bertin P, 2327
Bertolazzi C, 1248, 1641
Bertolini N, S89–36
Bértolo MB, 141
Bessette L, 949, 1221, 1728 (ab)

AUTHOR INDEX

Pages 1-2424 and Supplement 89–90

A

Aamar S, 1628
Abbey S, 1720 (ab)
Abdool-Carrim AT, 1798
Abe A, 1517
Abeles AM, 659
Abou Zahr Z, 2363
Abrahamowicz M, 968
Abrahams JL, 463
Abramson L, 1088, 1687, 2012
Abril A, 795, 1095
Abu-Shakra M, 458, 1711 (ab)
Abud-Mendoza C, 1814
Accordi B, S89–61
Ackerman IN, 1047
Adachi J, 1732 (ab)
Adami S, 1648
Adams K, S90–56, S90–59
Adler S, 4
Agard C, 2157
Agarwal S, 997
Agematsu K, 875
Agewall S, 1341
Aghdassi E, 254, 1378
Agik S, 73
Agrawal S, 871
Aguilar-Chavez E, 247
Ahmad Y, 735
Ahmed K, 795
Ahn CW, 1231
Aikawa NE, 167
Airo' P, 112
Aizer J, 1280
Ajeganova S, 1146
Akamata K, 539
Akar S, 1996
Akhavan P, 1555, 1559, 1583, 1729 (ab), 1730 (ab), 1733 (ab)
Akil M, 1265
Akiyama K, 1019
Akkoc N, 594, 1996
Alacacioglu A, 594
Alarcón GS, 1603
Albert L, 1712 (ab)
Albertini G, S89–77
Albuquerque EN, 141
Alcaraz-Lopez MF, 247
Alcorn N, 883
Aletaha D, S90–47, S90–74
Alexanderson H, 2134
Alfredsson L, 1509
Aliabadi P, 359
Aliprantis AO, 112
Alivernini S, 2276
Allanore Y, 112, 532, 997, 1097
Allard JP, 1004
Allen KD, 337
Allenbach Y, 1835
Allez M, 2179
Almeida I, 197
Almodovar R, 1008
Alraqi S, 662
Alsina M, 1035
Alten R, 1728 (ab)
Alunno A, 1758
Amin YE, 180
Amoura Z, 997, 1835
An J-M, 728, 1399
Anand P, 1710 (ab)
Anbar A, 1979
Anckaert D, 1728 (ab)
Anderson JD, 1139
Andrade LE, 2104
Anis AH, 910, 1706 (ab)
Antohe JL, 946
Antonelli A, 979
Antoniou J, 1215
Aouba A, 125
Apps A, 1716 (ab)
Aquino MM, S89–49, S89–82
Arai E, 345
Arai S, 1659
Aranda R, 1546
Arat S, 2127
Araújo NC, 1948
Archambault WT, 610
Archibald D, 1746 (ab), 1747 (ab)
ARChiVe Investigators Network, 1088, 1687, 2012
Arden NK, 1056
Ariani A, 1641
Arias M, 1035
Arimura Y, 545
Aringer M, 2153
Arkachaisri T, 286
Ärlestig L, 939
Armstrong AW, 2198, 2204
Arnett FC, 997
Arumugam R, S89–32
Asami T, 1363
Asano Y, 539
Ash Z, 2184
Ashcroft DM, 240
Askanase A, 1711 (ab)
Askling J, 1583
Aslanov R, 1722 (ab), 1751 (ab), 1752 (ab)
Association des Sclérodermiques de France, 532
Ates H, 594
Atisha-Fregoso Y, 504
Atkinson A, 1483
Atsumi T, 1293, 1363
Atteno M, S89–36, S89–49, S89–82
Atzeni F, 849, 1179, 2222, S89–97
Auffray-Calvier E, 1026
Avila-Armengol HE, 1632
Avina-Zubieta JA, 1701 (ab), 1702 (ab), 1741 (ab), 1742 (ab)
Avouac J, 532, 997
Aydin SZ, 795, S89–11
Ayearst R, 1722 (ab)
Azab A, 1979
Azevedo VF, 141

B

Bachmeyer C, 2041
Bachta A, 795
Bacié-Boutry M-A, 1418
Backman C, 1738 (ab)
Backteman K, 1840
Badley E, 1748 (ab), 1749 (ab)
Badot V, 2127
Bae S-C, 226
Baek H-J, 1902
Baer AN, 2363
Baggiani A, 552
Bagovich M, 1726 (ab)
Bailen R, 1901
Bailly F, 2179
Bain L, 1747 (ab)
Bainbridge L, 1724 (ab)
Bakan B, 2045
Baker M, 1715 (ab), 1719 (ab)
Bakewell CJ, 404
Bakker MF, 22
Bal A, 1758
Balbir-Gurman A, 2361
Baldini C, 804
Balint PV, 795
Ballinari P, 656
Balsa A, 1166
Bancroft T, 784, 2303
Bang S-Y, 2321
Banwell B, 2227
Bao J, 1903
Baptist E, 2118
Baranda-Cándido L, 1814
Barausse G, 1648
Barber CEH, 454, 1711 (ab), 1772, 2231
Barbieri F, S89–44
Barcelos A, 131, 2315
Baria N, 1748 (ab)
Barisoni L, 510
Barnabe C, 1221, 1493, 1704 (ab), 1705 (ab), 1729 (ab), 1734 (ab), 1735 (ab), 1738 (ab), 1772
Barnetche T, 712, 1192
Baron M, 524, 787, 1707 (ab), 1709 (ab), 1724 (ab), 1829
Barr S, 1704 (ab), 1705 (ab), 1734 (ab), 1735 (ab), 1738 (ab)
Barra L, 1704 (ab), 1725 (ab)
Barrett A, 600
Barrier JH, 2157
Barry SC, 2021
Barten D-JJA, 1064
Bartoloni E, 1758
Barton A, 929, 1485, 1781
Bass AR, 1280
Bastuji-Garin S, 893
Baszis K, 1088, 1687
Batthish M, 2227
Batticciotto A, S89–97
Battié MC, 822
Baur N, 1744 (ab)
Bawa S, 1764
Bayraktar R, 106
Bayry J, 450
Beattie K, 1719 (ab)
Becciolini A, 1248
Begovich AB, 1603
Behin A, 1835
Beigelman C, 1835
Bele-Philippe P, 1418
Belisle P, 1734 (ab)
Bell A, 1748 (ab)
Bell DA, 1704 (ab), 1725 (ab)
Bell E, 1717 (ab)
Bell MJ, 1717 (ab), 2088
Ben-Chetrit E, 1628
Bencivenga A, 1875
Benditt R, 1741 (ab)
Benegas M, 2315
Benelli G, 1678
Bengtsson AA, 1619
Benjoar M, 2041
Benseler SM, 1088, 1687, 1698, 1723 (ab), 1875, 2012, 2227
Bensen W, 949, 1715 (ab), 1719 (ab), 1726 (ab), 1728 (ab)
Benveniste O, 1835
Berenbaum F, 2327
Beretta L, 112
Berger MF, 1859
Bergeron L, 1749 (ab)
Bergin D, 200, 1893
Bergman G, 1198
Bergman R, 198
Bergner R, 2153
Berman DS, 448
Berman JR, 1280
Bernatsky S, 1717 (ab), 1724 (ab), 1731 (ab), 1734 (ab)
Bernstein CN, 1726 (ab), 1792, 2253
Bernstein JE, 610
Berthelot J-M, 310
Bertin P, 2327
Bertolazzi C, 1248, 1641
Bertolini N, S89–36
Bértolo MB, 141
Bessette L, 949, 1221, 1728 (ab)

Betteridge J, 1433
Beukelman T, 1867, 1880, 2341
Beutler A, 1735 (ab), 1736 (ab)
Bhayana R, 1725 (ab)
Bianchi WA, 141
Biasi D, 1179, 1648
Bienfang D, 295
Bienvenu B, 125
Bijlsma JWJ, 22
Bili A, 946
Binard A, 310
Binder M, 1407
Bingham CO III, 1706 (ab), 1707 (ab)
Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, 929
Birtwhistle R, 1749 (ab)
Bizzaro N, 2104
Blackmore H, 218
Blanco FJ, 2294
Blanco P, 1192
Blanco R, 1166, 1275
BLISS-76 Study Group, 1632
Blocka KLN, 1711 (ab), 1713 (ab), 1727 (ab), 2088
Blockmans D, 2127
Bloom BJ, 720
Boavida P, 645
Boccassini L, S89–97
Bocchino M, S89–82
Boehncke W-H, 441
Boesen M, S89–44
Bogo MR, 6
Boiardi L, S89–77
Boileau C, 997
Boire G, 1155, 1707 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 2071, 2081, 2088
Bollen ELEM, 2118
Bombardier C, 1555, 1559, 1583, 1729 (ab), 1730 (ab), 1737 (ab), 2088, S90–3, S90–11, S90–56, S90–59
Bombardieri S, 552, 804
Bonfa E, 167
Bonfiglioli R, 141
Bongartz T, 2148
Bonner A, 524, 1707 (ab), 1708 (ab), 1709 (ab), 1738 (ab)
Bookman AAM, 1895, 2088
Boon H, 1750 (ab), 1751 (ab)
Boros CA, 2021
Bortoluzzo AB, 141, 1971
Bos W, 1914
Bossini-Castillo L, 997
Botsios C, 1179
Bouaziz M, 997
Bourgou Z, 2041
Bowyer SL, 1088, 1687
Boyd S, 1735 (ab)
Boyd T, 1737 (ab)
Boyle J, 1717 (ab), 1728 (ab)
Bozkaya G, 594
Bracaglia C, 1287
Braga da Silva JA, 141
Brahmbhatt B, 2225
Branco JC, 131, 1757
Braun A, 510
Braun J, 836
Breilh D, 2223
Brenol CV, 6
Brenol JCT, 6
Brinks R, 2111
British Society for Rheumatology Biologics Register, 240
Britten N, 1717 (ab)
Brocq O, 2327
Broen JCA, 112
Brooks S, 1716 (ab), 1717 (ab), 1728 (ab), 1739 (ab), 1747 (ab)
Brown EE, 1603
Brown H, 1724 (ab)
Brown J, 1732 (ab)
Brown LS, 1666
Brown MA, 131
Brózik H, 1078
Bruce B, 669
Bruce IN, 735
Brun JG, 2008
Bruner V, 2332, S89–49, S89–82
Brunese L, S89–54
Brunner HI, 174
Brzosko M, 1898
Buchanan J, 1185
Buchbinder R, 1047, S90–21, S90–28, S90–34, S90–40, S90–47, S90–74, S90–81
Budhani S, 174
Buie H, 1735 (ab)
Bulatovic M, 2032
Buonuomo PS, 1287
Burgos-Vargas R, 830, 1859, 2315
Burki V, 816
Burmester G-R, 1728 (ab), 2153
Burnett H, 1735 (ab)
Burrell S, 1909
Burt RK, 206
Busch RE, 1139
Butendieck RR, 1095
Buyon JP, 510, 1296
Bykerk VP, 1155, 1221, 1555, 1559, 1583, 1707 (ab), 1728 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 2071, 2081, 2088
Byrne A, 1751 (ab)

C

Cabral DA, 1088, 1687, 1875, 2012
Cabrera-Villalba S, 1929
Cacoub P, 1819
Cagnoli PC, 959
Cai Y-W, 135
Caimmi C, 1648
Cairns E, 1704 (ab), 1725 (ab)
Cakci A, 1758
Calabrese F, S89–61
Caldito G, 986
Callahan LF, 337
Callejas JL, 1275
Callejas-Rubio JL, 2294
Callis Duffin K, 421, 2198, 2204
Campana A, 1287
Campana C, 1844
Campanholo C, 141
Campillo S, 1088, 1687, 1875
Campos LMA, 167
Camps S, 125
Can G, 594
Canadian Early Arthritis Cohort Study, 1155
Canadian Scleroderma Research Group, 524, 787, 1724 (ab), 1829
Canestri S, 2276
Cañete JD, 1035, 1929
Canizares M, 1748 (ab)
Canoso JJ, 1296
Canoui-Poitrine F, 893
Cantagrel A, 1714 (ab)
Cantini F, 795, S89–71
Cao J, 868
Capener D, 1265
Caperon A, S89–19
Caplan L, 1139
Caramaschi P, 1648
Carbone Y, 2104
Carette S, 303, 1711 (ab), 1726 (ab)
Carey JJ, 200, 1893
Carlsten H, 1987
Carmona FD, 112, 1275
Carneiro S, 141
Caron M, 1829
Carotti M, 1641
Carpenter T, 1705 (ab), 1706 (ab), 1748 (ab)
Carpentier P, 997
CARRA Registry Investigators, 1867, 2341
CaRRDS Study Group, 1042
Carreira P, 112, 1275, 2294
Carroll LJ, 822
Carter C, 1740 (ab)
Carty A, 1722 (ab)
Carulli C, 1678
Caruso A, S89–77
Carvalho HMS, 141
Carvalho JF, 167
Casasola-Vargas J, 830
Caso F, S89–49
Cassara E, S89–71
Cassell S, 653
Castañeda S, 1166, 1275
Castiglione F, 2332
Castro-Lizano N, 247
Catalan T, 653
Catalano O, S89–49
Catanese J, 1603
Catanoso M, 849, S89–77
CATCH Investigators, 2081
CATCH Scientific Advisory Committee, 1728 (ab), 1729 (ab), 1730 (ab), 1733 (ab)
Catrina AI, 679
Cats-Baril WL, 1280
Cauli A, 654, 849, 2201, S89–15
Cavaco S, 770
Cavallo R, 871
Cavill C, 154
Ceccarelli C, 1678
Ceccarelli F, 41
Cederholm T, 327
Cellucci T, 1723 (ab)
Cengiz B, 106
Cénit MC, 2294
Cetin GY, 106
Chahade WH, 1948
Cham WT, 2021
Chan D, 1744 (ab)
Chandran V, 185, 427, 1722 (ab), 1723 (ab), 1735 (ab), 1736 (ab), 1745 (ab), 1746 (ab), 1850, 2216, S89–65
Chang C-M, 1765
Chang C-T, 1611
Chang M, 1603
Chang R, 1716 (ab)
Chang W-C, 1765
Chang Y-C, 1611
Chapman PT, 2098
Charles P, 929
Charles-Schoeman C, 94
Chartier M, 1728 (ab)
Charuel J-L, 1835
Chatham WW, 1632
Chaussé G, 1722 (ab)
Chaves J, 2315
Checa A, 2362
Chédeville G, 1875
Chehab G, 2111
Chehab MR, 195
Cheifetz AS, 1500
Chelli Bouaziz M, 322
Chen C-H, 1013
Chen H, 2088
Chen H-A, 1013
Chen J-C, 337
Chen N, 63, 558
Chen P-C, 1013, 1611
Chen W-S, 1013
Chen X-N, 558
Chen Y-X, 558
Cheng CK, 1555
Cheng J, 1159
Chetaille A-L, 1875
Cheung AM, 1378
Cheung JM, 716
Cheung PP, 816
Chevalier X, 893
Chiarolanza I, S89–77
Chien C-C, 1013
Chies JAB, 6

Chin L, 1745 (ab)
Chiocchia G, 997
Chiou S-Y, 135
Chira P, 1088, 1687, 2012
Chiu B, 583
Chiu P, 1744 (ab)
Chlubek D, 10
Choe J-Y, 874
Chogle AR, 873
Choi C-B, 226
Choi H-J, 1902
Choi KS, 2321
Choi M, 707, 1729 (ab)
Choi ST, 933, 1902
Choi S-J, 1902
Choi V, 1714 (ab)
Choinère M, 1720 (ab)
Choquette D, 1715 (ab), 1752 (ab)
Chou C-T, 1013
Chow A, 1715 (ab), 1721 (ab)
Chow K-M, 1942
Chow S, 1744 (ab)
Chowdhary V, 1964
Choy EH, 28, 470, 1775
Choy G, 1748 (ab)
Christensen R, 1198
Chrousos GP, 60
Chuang F-R, 1611
Chui RK, 2267
Chung C, 2235
Cibere J, 1706 (ab), 1745 (ab)
Cid MC, 795
Cifaldi MA, 63, 1712 (ab)
Cimmino MA, 389, 795, S89–44
Cipriani P, 1179
Cividino A, 1719 (ab), 1745 (ab), 1746 (ab), 2247
Civinini R, 1678
Clancy M, 359
Clancy RM, 510
Clark JD, 1509
Claudepierre P, 893
Clauw DJ, 959
Cleuziou C, 310
Clifford A, 1909
Coenen MJ, 112
Cogan E, 119, 2127
Cohen J-D, 1098
Cohen MJ, 1628
Cohen P, 125
Cohen SB, 2235
Colaci M, 979
Colbert RA, 2341
Colebatch AN, S90–62, S90–81
Collantes-Estevez E, 1008, 2315
Colley L, 910, 1741 (ab)
Collins S, 1728 (ab)
Combe B, 712, 1533, 2327
Condliffe R, 1265
Connault J, 2157
Conner-Spady B, 822
Consolaro A, 856
Contin-Bordes C, 1192
Conway R, 200, 887, 1893, 2310
Cook R, 1723 (ab)
Cooney T, 1716 (ab)
Cooper TM, 1934
Corkill MM, 877
Cornelis F, 1490
CORPOREA Study Group, 131
CORRONA Investigators, 904
Cortina S, 174
Cortis E, 1287
Cosnes A, 997
Costa IP, 141
Costa L, 154, 849, S89–36, S89–49, S89–82
Costedoat-Chalumeau N, 1819, 1835
Coteur G, 1706 (ab), 1707 (ab)
Cotofana S, 161
Cott C, 1749 (ab)
Coughlan RJ, 200, 1893
Coustet B, 997
Coutinho E, 770
Cox-Dublanski M, 1717 (ab)
Cozzi L, S89–61
Cracowski J-L, 997
Crawford R, 621
Creaser C, 1729 (ab)
Criswell LA, 1603
Crittenden DB, 1458
Cron RQ, 1880
Cronstein BN, 1458
Crowson CS, 481, 795, 954, 1355
Crowther M, 878
Cruz M, 131
Cuccagna C, 2359
Cuchacovich R, 185, 187
Cullen G, 1500
Cunnane G, 2310
Curtis JR, 1326
Cushen B, 651
Custodio MK, 1807
Cuthbertson D, 303
Cutolo M, 1113
Cymet A, 1378
Czihal M, 314, 1899

D

D'Agostino MA, 2211
D'Angelo S, 184, 849, 1110, 1483, S89–22, S89–54, S89–103
da Rocha LF Jr., 2221
DaCosta D, 1378
Daïen CI, 1533
Daïen V, 1533
Dalbeth N, 841, 874
Dale N, 735
Damjanov NS, 18
Dancea S, 946
Dancey P, 1875
Danchenko N, 262
Daniel S, 2163
Dantas AT, 1320, 2221
Darweesh H, 1979
Dasgupta B, 795
Dastmalchi M, 1299
Daumas A, 665
Davidge-Pitts C, 1095
Davies C, 1265
Davies OR, 1326, 1715 (ab)
Davis A, 1748 (ab), 1749 (ab)
Davis P, 1735 (ab)
Davis TE, 1867
Davison S, 1727 (ab), 1731 (ab), 1732 (ab)
Dayer J-M, S89–61
De Angelis R, 1248
De Bandt M, 310
De Benedetti F, 1287
de Faire U, 1146
de Jonge R, 2032
De Keyser F, 2127
de Kruif M, 1914
De Langhe E, 2127
De Leon F, 1732 (ab)
De Lucia O, 849, 2045, S89–29
De Marco G, 849, S89–29
de Menthon M, 125
De Miguel E, 1901
de Rotta MCFJ, 2032
de Sousa EV, 131
De Vera MA, 1539
De Vincenzo A, 1716 (ab)
Dedeke AB, 1934
Dehghan N, 1742 (ab)
Dejaco C, 795
Dekker JM, 2261
del Amo M, 795
Del Pino-Montes J, 1008
Del Puente A, S89–36, S89–49, S89–82
Del Rio APT, 1971
Delgado M, 1166
DeMicco DA, 1433
Demiryurek AT, 106
Denholm JT, 1297
Dent P, 1875
Denton CP, 2294
Denton J, 2043
Depresseux G, 2127
Descalzo MA, 1424
Deshpande GA, 148, 1296
Desjardins O, 1737 (ab)
Dessein PH, 1798
Dessouki O, 2046
Detillieux S, 1713 (ab)
Dewar C, 1711 (ab)
Dhindsa N, 1701 (ab)
Di Carlo M, 1248
Di Domenicantonio A, 979
Di Franco M, 41
Di Geso L, 1488
Di Lernia V, S89–77
Di Maggio A, S89–61
Di Minno G, 334, 568, 1042
Di Minno MND, 334, 568, 1042, 2332
Di Munno O, 552
Dias D, 197
Dieudé P, 112, 532, 997
Diez-Perez A, 461
Dijkmans BAC, 100
Dimic A, 836
Ding B, 1509
Ding J, 574
Diot E, 997
Direskeneli H, 795
Distler JHW, 2294
Dixon-Bourque M, 1728 (ab)
Djabarouti S, 2223
Docken WP, 295
Donadi EA, 1524
Donmez S, 106
Dontas I, 1215
Dooley A, 1559, 1583
Dörner T, 1130, 2153
dos Santos MF, 1739 (ab)
Dostrovsky N, 1724 (ab)
Dottori M, 1248
Dougados M, 816, 1546, 1706 (ab), 1707 (ab), 1714 (ab), 2064, 2235, 2327
Douglas KMJ, 218
Doyle A, 841
Drakos SG, 1385
Dranitzki Z, 1628
Dreher D, 161
Drost P, 1198
Drotar D, 174
Duarte A, 167
Duarte ÂLBP, 141, 1320
Duarte AL, 2221
Duarte-Garcia A, 1392
Dubourg O, 1835
Duffau P, 1192
Duffy CM, 1750 (ab), 1751 (ab), 1875
Duftner C, 795
Duncan B, 1706 (ab)
Dunussi-Joannopoulos K, 1509
Duong A, 1751 (ab)
Dupas B, 2157
Dupuy A-M, 1533
Durcan L, 2310
Durnez A, 816
Dye-Torrington D, 1721 (ab)
Dziedziejko V, 10

E

Ea H-K, 233
Eberhard BA, 374, 1088, 1687, 2012
Eckstein F, 161
Economu-Dubosc A, 893
Edberg JC, 1603
Ede K, 1088, 1687, 2012
Eder L, 185, 564, 1703 (ab), 1711 (ab), 1722 (ab)
Edmundowicz D, 262
Edwards CJ, S90–62, S90–81
Edwards NL, 1450
Edworthy S, 1734 (ab)
Efthimiou P, 664
Egurbide MV, 2294
Eijgelshoven I, 1198
El-Gabalawy HS, 1701 (ab), 1726 (ab), 1792, 2253

El-Shaarawy N, 180, 1305, 1979
El-Taha M, 904
Elahi M, 997
Elder JT, 431
Elegbe A, 1714 (ab)
Elgbe A, 1546
Elhai M, 816
Elhan AH, 2170
Elliot CA, 1265
Ellis C, 1413
Ellison WT, 610
Emad Y, 1305, 1979
Embuldeniya G, 1717 (ab)
Emery P, 701, 1715 (ab), 1741 (ab), 2235
Engelbrecht M, 1334, S90–3, S90–17
Englund M, 161
Erdogan BD, 2170
Erhan C, 1996
Eriksson P, 1840
Ernerudh J, 1840
Ertugrul BM, 199
Ervin JE, 610
Esdaile JM, 910, 968, 1745 (ab)
Esmon C, 510
Espígol-Frigolé G, 795
Espinosa G, 2294
Espinosa V, 1705 (ab)
Espinoza LR, 185, 187, 445, 1314, 2216
Espitia O, 2157
Espitia-Thibault A, 2157
Esposito A, S89–36
Esposito C, S89–36
Ewals JAPM, 1906
Ezzat A, 1743 (ab)

F

Fabreguet I, 816
Fahmi H, 635
Fahrleitner-Pammer A, 600
Falcón MJ, 1424
Fallahi P, 979
Fan CM, 574
Fang H, 759, 777, 1231, 1392
Faraawi R, 1719 (ab)
Farewell VT, 1371
Farrell M, 662
Farrenq V, 893
Fayyad R, 1433
Fedele AL, 2276
Feehan L, 1493
Feinn R, 986
Feld J, 198
Feldman BM, 276, 1483
Felicetti M, S89–61
Felson DT, 359, 1481
Fend F, 269
Feng Y, 574
Ferguson DJ, 2104
Ferland D, 1707 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab)
Fernandes AW, 784, 2303
Fernandes G, 1004
Fernández-Fernández FJ, 186
Fernández-Gutiérrez B, 1166
Fernández-Sueiro JL, 677, 1008, 1035
Ferraccioli G, 2276, S89–94
Ferrara N, S89–54, S89–74
Ferrari R, 655, 707
Ferrari SM, 979
Ferreiro-Iglesias A, 1509
Ferrero G, 389
Ferri C, 979, 1179
Ferro F, 804
Feydy A, 1097
Fezatte HB, 610
Fidler WK, 2088
Filippi RZ, 2049
Filippucci E, 1488, 1641
Filocamo G, 856
Finlayson H, 1727 (ab)
Fiocco U, S89–61
Fischer K, 1898
Fischer-Betz R, 2111, 2153
Fisher BA, 929
Fisher MC, 904
Fisk JD, 1371
Fitzcharles M-A, 1720 (ab), 1749 (ab), 1750 (ab)
Fitzgerald AA, 2088
FitzGerald O, 398, 427, 434, 2189, 2196, S89–7
Flanagan C, 1221
Fleck M, 2153
Fleischmann R, 1706 (ab), 1707 (ab)
Fleming BC, 1473
Flicinski J, 1898
Flipo R-M, 1418, 1714 (ab)
Foglia F, S89–36
Fonollosa V, 112, 2294
Fonseca C, 1725 (ab), 2294
Fonseca JE, 131
Font P, 1008, 2315
Fontana V, 1524
Fontenoy A-M, 1026
Forestier A, 2175
Førre Ø, 1341
Forsblad-d'Elia H, 1987
Forsythe A, 1450
Fortin PR, 254, 968, 1378
Foschi V, 1179
Fossel AH, 295
Fox DA, 2059
Fox RI, 1117
Fragiadaki K, 60
Fragoso-Loyo H, 504
Frallonardo P, 1844
Frampton C, 877, 2098
França ILA, 167
France J, 1764
Frances C, 997
Franek BS, 73, 1238
Frank C, 1749 (ab)
Franks A, 510
Fraser C, 1727 (ab)
Frech TM, 1385
Freemont TJ, 2043
Freimuth WW, 1632
French Society of Rheumatology and the Club Rhumatismes et Inflammation, 2327
French Vasculitis Study Group, 125
Frerix M, 2177
Freundlich B, 836
Fries JF, 669
Fritzler MJ, 787, 1716 (ab), 1724 (ab), 1734 (ab), 2104
Frostegård J, 1146, 2233
Fukuda T, 1659
Furst DE, 784, 1326, 2303

G

Gabriel SE, 481, 954
Gaddy JR, 1934
Gagnon D, 1748 (ab)
Gaillez C, 1714 (ab)
Galdino SL, 1320, 2221
Galeazzi M, 1179
Galindo G, 1539
Gallego M, 2294
Gamez-Nava JI, 247
Gammaitoni A, 1056
Gamsa A, 1720 (ab), 1749 (ab)
Gandhi R, 2046
Ganser G, 1294
Gantes M-Á, 1424
García de la Peña P, 2294
García-Hernández FJ, 2294
Garcia-Manero G, 1308
García-Portales R, 2294
Garcia-Valladares I, 185, 187, 1314
Gardam MA, 1583, 1730 (ab)
Garg A, 413, 2204, 2214
Garlaschi G, 389
Garred P, 463
Garrido M, 1819
Gasparovic C, 752
Gathany T, 1185, 1736 (ab)
Gaujoux T, 233
Gaujoux-Viala C, 233
Gavi MBO, 141
Gay J, 2175
Gaynor P, 352
Gazi S, 1215
Gazzola K, S89–61
Gebarski S, 959
Geetha D, 1413
Geijer M, 1987
Gelber AC, 672
Gelfand JM, 2204, S89–24
Genovese MC, 1185, 1546
Georgoulas T, 1215
Gerdan V, 1996
Geri G, 1819
Gerli R, 1179, 1758
Germans MR, 2051
Gervitz LM, 1326
Ghannouchi MM, 322
Gheita T, 1979
Gheorghiade M, 206
Giampietro C, 233
Giardina A, 1179
Gibbs S, 1303
Gibson N, 359, 1481
Ginzler E, 510
Giuggioli D, 979
Gjevre J, 1709 (ab)
Gladman DD, 185, 254, 391, 413, 418, 434, 564, 654, 1074, 1702 (ab), 1703 (ab), 1711 (ab), 1719 (ab), 1721 (ab), 1722 (ab), 1723 (ab), 1735 (ab), 1736 (ab), 1737 (ab), 1742 (ab), 1744 (ab), 1745 (ab), 1746 (ab), 1850, 2181, 2193, 2196, 2214, S89–103
Godinho F, 131
Gogebakan B, 106
Goldminz AM, S89–86
Goldsmith CH, 1706 (ab)
Goldstein N, 1735 (ab)
Golightly YM, 337
Gómez-García I, 2294
Gómez-Puerta JA, 1929
Gomez-Reino JJ, 1509
Gonçalves A, 770
Gonçalves CR, 141
Gono T, 79
Gonter NJ, 795
Gonzalez A, 1509
González B, 1424
Gonzalez-Gay MA, 112, 1166, 1275, 2294
Gonzalez-Lopez L, 247
Gonzalez-Montoya N, 247
González-Vaquero C, 1166
Good J, 1880
Goodall JC, 1918
Gordon DL, 157
Gordon RD, 610
Gorodischer R, 2163
Gorodkin R, 735
Gossec L, 816
Got M, 1721 (ab)
Göthlin J, 1987
Gottenberg J-E, 893, 2327
Gottlieb AB, 2204, S89–86
Goubella A, 119
Gourh P, 997
Goyal J, 195
Goycochea-Robbles M, 1713 (ab)
Goykhman P, 448
Graft CC, 959
Grainger AJ, 1786
Granel B, 665
Grant A, 1733 (ab)
Granton JT, 276
GRAPPA 3PPsA Study Group, 654
Grasland A, 125
Grassi W, 1248, 1488, 1641, 2211, S89–39

Gratacós J, 1008
Grayson PC, 303, 359
Greco CM, 262
Greenberg JD, 904, 1458
Greene ER, 752
Gremese E, 1179, 2276, S89–94
Grenier P, 1835
Greth W, 784, 2303
Griffiths CEM, 1654
Grika EP, 516
Grim GA, 1934
Grosbein HA, 276
Grose RH, 2021
Gross WL, 658
Grossi S, 804
Grubisic M, 1741 (ab)
Grunke M, 1334
Gruppo Italiano di Studio sulle Early Arthritides, 1179
Gu M, 1752 (ab)
Gudbjornsson B, 1441
Gudjonsson JE, 1441
Gudsookar V, 1769
Guedes-Pinto H, 131
Guedj M, 997
Guérette B, 1711 (ab)
Guermazi A, 359, 1745 (ab)
Guiducci S, 1678
Guiguet M, 1835
Guillevin L, 125, 2041
Guillon B, 1026
Guillot X, 657, 1482
Gullstrand B, 1619
Gunnarsson C, 1740 (ab)
Guo B, 868
Guo Y-C, 1765
Gupta P, 720
Gutierrez M, 1248, 1488, 1641, S89–39
Gutiérrez M, 2315
Guttman A, 916
Guyot P, 1198
Guzman J, 1088, 1705 (ab), 2012
Gyenes G, 1741 (ab)

H

Ha A, 1725 (ab)
Ha YJ, 933
Hachulla E, 997, 2175
Haddad A, 1711 (ab), 1745 (ab), 1746 (ab)
Haddad E, 1875
Hafström I, 1146
Hakendorf P, 157
Hall A, 1739 (ab)
Halliday W, 2227
Hamdi W, 322
Hamidou MA, 1026, 2157
Hammoudeh M, 1675
Han C, 1185, 1736 (ab)
Hanaoka M, 79
Hands R, 2049
Hanley D, 1732 (ab)
Hanly JG, 1371, 1711 (ab), 1909, 2104
Hanna S, 352
Hanouna A, 2041
Haouel M, 322
Haque S, 735
Hara A, 545
Hara M, 79
Hara R, 864
Hara T, 864
Haraoui B, 949, 1155, 1221, 1559, 1583, 1707 (ab), 1711 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 1741 (ab), 2071, 2081, 2088
Hardcastle SA, 1303
Harding S, 524, 1709 (ab)
Hargunani R, 645
Harigai M, 486, 1487
Harley D, 1739 (ab)
Harley JB, 1238
Harmsen WS, 2148
Haroon M, 651, 662, S89–7
Harris J, 1738 (ab)
Harrison A, 877
Harrison MJ, 735
Harrison T, 1729 (ab)
Hart D, 2253
Harvard SS, 910
Hasegawa H, 2053
Haselwood DM, 610
Hashiba Y, 1291
Hashkes PJ, 2012
Hasija R, 1888
Hassanzadeh R, 1764
Hassell A, 470
Hatcher L, 1748 (ab)
Hatron P-Y, 2175
Hauber AB, 1056
Haubitz M, 2153
Haugen IK, 161, 203
Hawker GA, 276
Hawkins C, 1483
Hazleman B, 795
Hazlewood GS, 1555, 1559, 1583, 1729 (ab), 1730 (ab), 1733 (ab), 1738 (ab), S90–11
Hedberg M, 1987
Heegaard NH, 463
Heijstek MW, 2032
Heil SG, 2032
Heiligenhaus A, 1294
Heinz C, 1294
Heitmann S, 2153
Helliwell PS, 398, 1786, 2196, S89–19, S89–54
Helmick CG, 337
Hemmati I, 1713 (ab)
Hemmelgarn B, 1734 (ab)
Henderson JM, 2088
Henes JC, 269, 2153
Henrotin YE, 1107
Hensor EMA, 1786
Heo HM, 1854
Herlin T, 2352
Hernández MV, 1929
Hernández V, 1424
Hernández-Beriain JA, 1424
Herrera-van Oostdam D, 1814
Herrick AL, 112, 1654, 2043, 2294
Hersh AO, 1088, 1687, 2012
Herson S, 1835
Hervier B, 1835
Hesselstrand R, 2294
Hetland ML, 46
Hewitt S, 1378
Hewlett S, 1775
Hiepe F, 2153
Higgins GC, 1088, 1687, 2012
Hill C, 1265
Hill Gaston JS, 1918
Hilme E, 1987
Hiltz M, 1727 (ab)
Hirschfield GM, 254
Hitchon CA, 1155, 1701 (ab), 1707 (ab), 1726 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 1792, 2071, 2081, 2088, 2253
Hjeltnes G, 1341
Ho K-W, 844
Ho P, 735, 1485
Hochberg MC, 352, 904
Hochman J, 1221
Hodgson RJ, 1786
Hoffman GS, 303
Hoffmann U, 314
Hofstee HMA, 100
Hollan I, 1341
Holle J, 2153
Holme I, 1433
Homik J, 1704 (ab), 1705 (ab), 1734 (ab), 1737 (ab), 1739 (ab)
Honkanen VEA, 365
Horiuchi T, 1363
Hoshi D, 476
Hou H, 1716 (ab)
Hou Y-F, 1506
Hough DR, 1632
Houng M, 2225
Houssiau FA, 2127
Hsia EC, 1185
Hsieh C-P, 1306
Hsu Y-W, 1765
Hu A, 1709 (ab)
Huang C-C, 1611
Huang C-H, 135
Huang D, 254
Huang K, 686
Huang S, 1717 (ab)
Huber AM, 1687, 1875
Hubert MM, 1712 (ab)
Hudoba de Badyn M, 1721 (ab)
Hudson M, 787, 1707 (ab), 1717 (ab), 1724 (ab), 1829
Huggins J, 174
Hughes M, 2043
Huisman MV, 2118
Huizinga TWJ, 2118
Humphrey-Murto S, 1737 (ab)
Hung P-H, 135
Hung VW, 1955
Hunt M, 1716 (ab)
Hunzelmann N, 112, 2294
Hurdman J, 1265
Hurst M, 2098
Husson J, 2175
Hwang D-Y, 1765
Hyrich KL, 240

I

Iacobaeus E, 1299
Iagnocco A, 795
Iannone F, 1179, S89–100
Iannuccelli C, 41
Ibanez D, 1702 (ab), 1719 (ab), 1721 (ab), 1742 (ab)
Ibba-Manneschi L, 1678
Ibrahim A, 1485
Ibrahim F, 28, 470
Ibrahim I, 1485
Ichimura Y, 539
Ida H, 875
Ide S, 1363
Iervolino S, 334, 568, 1042, 2332
Ilowite NT, 374, 382
Imagawa T, 864
Imundo LF, 1088, 1687, 2012
Inci M, 2045
Inman RD, 583
Innocenti M, 1678
Inoue E, 476
Insalaco A, 1287
Ioannidis G, 1732 (ab)
Ionescu L, 1326
Iorga SR, 784, 2303
Iorio R, 2359
Ipenburg J, 2098
Irwin MR, 1807
Ishaq S, 720
Ishida T, 1104
Ishiguro N, 345
Ishikawa H, 1517
Ishimori ML, 448
Ismail A, 1979
Ito H, 1766
Ito S, 1517
Iwanicki R, 1738 (ab)
Izmirly PM, 510

J

JA21963 Study Group, 486
Jacobs JWG, 22
Jacobsen S, 463, 1619
Jacquier A, 665
Jadon D, 154
Jakob F, 600
Jamal S, 2071
James JA, 1934
Jansen G, 2032
Jawa H, 1004
Jawaheer D, 46
Jay GD, 1473

Jayakar J, 1703 (ab)
Jayasundara KS, 2066
Jean S, 1717 (ab)
Jearn L-H, 1493
Jelinek JS, 1445
Jeon J-Y, 728, 1399
Jilkine K, 1701 (ab)
Jimenez SA, 1241
Jogestrand T, 1146
Johansson Å, 1619
Johansson G, 327
Johnson FR, 1056
Johnson N, 1731 (ab), 1875
Johnson SR, 276, 1726 (ab)
Jolly M, 73
Jones A, 1749 (ab)
Jones N, 1714 (ab)
Jones PB, 841
Jönsen A, 1619
Joo B, 2321
Jordan JM, 337
Jorgensen P, 1743 (ab)
Joseph L, 1734 (ab)
Ju JH, 86
Juanola X, 1008
Jung K-H, 2000
Jung L, 1088, 1687, 2012
Junkins-Hopkins JM, 660
Junta CM, 1524
Jurencak R, 1718 (ab)

K

Kaczorowski J, 1705 (ab)
Kadono T, 539
Kaeley GS, 404, 2211
Kageyama M, 1207
Kahan A, 532, 997, 1097
Kahlil H, 1715 (ab), 1726 (ab), 1752 (ab)
Kairys A, 959
Kaiser R, 1603
Kajalainen A, 2008
Kalache F, 1221
Kalman-Lamb G, 1703 (ab)
Kaloudi O, S89–71
Kamal A, 180
Kamal H, 1979
Kandolf R, 1099
Kang E-J, 933
Kanz L, 269
Kao AH, 262
Kapoor M, 635
Kaposi NP, 795
Karaahmet OZ, 1758
Karimeddini M, 986
Kariya-Kaneko Y, 1291
Karp I, 968
Karras D, 600
Karsh J, 1497
Karunanayake C, 1723 (ab)
Kato M, 1293
Katsumata Y, 79
Katz SJ, 1705 (ab), 1706 (ab), 1718 (ab), 1744 (ab), 1748 (ab), 1912
Kaufman KM, 1238
Kautiainen H, 377, 2008
Kavanaugh A, 653, 1334, 1711 (ab), 1715 (ab), 1735 (ab), 1736 (ab), 1741 (ab), S89–90
Kaveri SV, 450
Kawaguchi Y, 79
Kawano S, 1904
Kawasaki Y, 694
Kayser G, 1407
Kchir MM, 322
Keeling SO, 822, 1718 (ab), 1741 (ab)
Keenan RT, 1458
Keiserman M, 141
Kelsall J, 1539, 1713 (ab)
Kempe K, 1207
Kennedy C, 1716 (ab), 1739 (ab), 1747 (ab)
Kerttula LI, 365
Keystone EC, 1155, 1185, 1326, 1707 (ab), 1711 (ab), 1715 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 2066, 2071, 2081
Khalidi NA, 303, 878, 1724 (ab)
Khalil H, 1740 (ab)
Khan MA, 1675
Khan S, 1934, 2363
Khanna D, 1326, 1450
Khattri S, 1125
Khemani C, 1888
Kherani R, 1727 (ab)
Khimdas S, 524, 1709 (ab)
Khoryati L, 1192
Khraishi M, 1559, 1583, 1714 (ab), 1722 (ab), 1728 (ab), 1751 (ab), 1752 (ab), 2088
Khraishi S, 1722 (ab)
Khubchandani RP, 1888
Kiani AN, 1231, 2286
Kidling R, 1265
Kiely DG, 1265
Kiely PDW, 470
Kiener H, 112
Kikuchi M, 864
Kim H-A, 728, 1399, 1902
Kim H-S, 2000
Kim H-Y, 86
Kim J-M, 86
Kim JH, 186, 870
Kim J-H, 1465
Kim JJ, 2000
Kim S-K, 874
Kim S, 1088, 1687, 2012
Kim T-H, 2321
Kim T-J, 809
Kim T-Y, 1493
Kim Y-B, 2321
Kim Y-G, 1854
Kim YJ, 226
Kimberly RP, 1603
Kimura M, 148
Kimura Y, 1867, 2341
Kingsbury DJ, 1088, 1687, 2012
Kirbiyik H, 594
Kirchner HL, 946
Kirwan J, 1775
Kisacik B, 106, 1996
Kishimoto M, 148, 1296, 1700
Kitas GD, 218
Kiyohara C, 1363
Klareskog L, 1509
Klatzmann D, 1819
Klein WS, 1934
Klein-Gitelman M, 1088, 1687, 2012
Kleinert S, 1130
Klingberg E, 1987
Klinkhoff AV, 716
Knee Enthesitis Working Group, 1979
Knickle K, 1717 (ab)
Knight A, 2008
Ko G, 1720 (ab)
Ko K, 1238
Kobashi G, 1363
Kobayashi D, 1348
Kobayashi T, 148
Koca SS, 106
Koeleman BP, 2294
Koenig AS, 836
Koetter I, 269
Koh B-R, 728, 1902
Kohem CL, 141
Kohsaka H, 2053
Kokkonen H, 327
Kollert F, 1407
Kon T, 1207
Konatalapalli RM, 1445
Konno T, 2221
Konsta M, 60
Koo BS, 1854
Kopansky-Giles D, 1746 (ab)
Kopec J, 1706 (ab), 1745 (ab)
Koppen H, 1906
Koren G, 2163
Korendowych E, 154
Korkmaz C, 1756
Korppi M, 377
Koseki Y, 79
Koski JM, 452
Kostine M, 1192
Kotani T, 1104
Kötter I, 2153
Kotyla PJ, 701
Koumakis E, 532, 816, 997, 1097
Kovacevic LV, 18
Kovacs D, 2059
Kraut R, 1718 (ab)
Kremer JM, 904, 1714 (ab), 2235
Kreuter A, 2294
Kristensen KD, 2352
Krueger GG, 1735 (ab), 1736 (ab), 2204
Krumbiegel D, 2021
Kuan W-P, 2267
Kubassova O, S89–44
Kucharz EJ, 701
Kudalkar D, 174
Kuet K-P, 1781
Kuhlencordt P, 314
Kuller LH, 262
Kumabe M, 73
Kumar AA, 73
Kun EW, 844, 1955, 2267
Kung T, 1221
Kuperman M, 1413
Kupper H, 1741 (ab)
Kurasawa K, 1659
Kuriya B, 1155
Kuroda T, 1348, 1517
Kurzawski M, 10
Kusaoi M, 1207
Kuseler A, 2352
Kushner I, 880
Kvien TK, 161, 1326, 1433
Kwan BC-H, 1942
Kwok S-K, 86
Kydd A, 1710 (ab), 1735 (ab)
Kyushu Sapporo SLE Study Group, 1363

L

La Verde V, 1648
Labrecque J, 1734 (ab)
Lacaille D, 910, 1701 (ab), 1702 (ab), 1713 (ab), 1717 (ab), 1724 (ab), 1743 (ab), 2088
Ladeb MF, 322
Lafforgue P, 2327
Lafontaine D, 1712 (ab)
Lai FM-M, 1942
Laki J, 1299
Lamas JR, 1166
Lambert RG, 1666
Lamprecht P, 658
Lan G, 1171
Landewé RB, 1326, S90–47, S90–74
Landolt-Marticorena C, 1711 (ab)
Landry M, 1749 (ab)
Lane NE, 161
Lang B, 1875
Langdahl BL, 600
Lange U, 2177
Langefeld CD, 1238
Langford CA, 303
Langman B, 2041
Lapadula G, 1179, S89–100
LaRosa J, 1433
Las Heras F, 583
Latinis KM, 1632
Laubender RP, 1334
Laughlin S, 1698, 2227
Launay D, 2175
Laupacis A, 2088
Lawrence S, 1718 (ab)
Lawson EF, 1088, 1687, 2012
Laxer RM, 1698, 1875
Lazaro E, 2223
Lazovskis J, 2088

Le Bars M, 1546, 1714 (ab), 1728 (ab)
Le Blay P, 712
Le Clercq S, 949
Le EN, 660
Le Guen J, 125
Le Guern V, 125
Le Loet X, 1714 (ab)
Le Louët H, 893
Le Riche N, 1710 (ab)
Le T, 276
Learch TJ, 1900
Leask A, 1703 (ab)
LeBlanc CMA, 1875
Lebmeier M, 1198
Leccese P, 1110
LeClercq SA, 1221, 1559, 1583
Lee C-K, 1854
Lee D-C, 1465
Lee H-S, 135
Lee J-S, 2321
Lee JB, 1241
Lee JJY, 1378
Lee JS, 809
Lee JS, 2000
Lee J, 1902
Lee J, 1708 (ab)
Lee K-A, 1723 (ab)
Lee K-L, 2267
Lee P, 276, 992
Lee S, 2321
Lee S-J, 809
Lee S-S, 809
Lee T, 2012
Lee YC, 295
Lefebvre G, 2175
Lefort MH, 1619
Légaré J, 1559, 1583
Legault K, 878, 1745 (ab)
Lehane PB, 2235
Lehman A, 1743 (ab)
Lehmann RA, 1458
Leite NH, 141
Leleu X, 2175
Lems WF, 600
LePage J, 1747 (ab)
LeParc J-M, 2327
Leroy X, 2175
Lester S, 2142
Letho-Gyselinck H, 657
Leung M-H, 2267
Leung Y-Y, 844, 2267
Leux C, 2157
Levin JH, 1934
Levine SM, 1413
Levy A, 2163
Levy D, 1746 (ab), 1875
Lewalter T, 1099
Lewicki M, 701
Li C, 1859
Li DY, 1385
Li EK-M, 844, 1942, 1955, 2267
Li J, 2220
Li L, 1724 (ab), 1743 (ab), 1748 (ab), 1749 (ab)
Li M, 974, 2267
Li PK-T, 1942
Li R-J, 2267
Li SC, 1088, 1687, 2012
Li T, 1903
Li T, 262
Li TK, 2267
Li X, 743
Li X, 2088
Li Y, 1603
Li-Yu J, 1859
Liakou C, 1215
Liang C-C, 1611
Liang D, 868
Liang MH, 295
Liao H-T, 1013
Ligeiro D, 131
Lim H, 1709 (ab)
Lim MJ, 1902
Lima J, 2286
Lima SAL, 141
Limón-Camacho L, 830
Limper M, 1914
Lin L, 1752 (ab)
Lin N, 686
Lin S-H, 135
Lin S-Y, 1611
Lin Y-J, 1013
Linari S, 1678
Lioté F, 233
Lipinska J, 1078
Lisse JR, 610
Liu J, 1171
Liu R, 1159
Liu S, 1703 (ab)
Liu S, 1711 (ab)
Liu W-B, 1506
Liu X, 974
Liu Y-G, 686
Livingston B, 1708 (ab)
Lix L, 1717 (ab), 1724 (ab)
Ljung L, 2008
Ljunggren Ö, 600
Llorente L, 504, 830
Lo Nigro A, 1844, S89–61
Lobo M, 841
Loduca SMA, 1948
Lofrano M, 568
Loftus EV Jr., 2148
Longo N, 1722 (ab), 1726 (ab), 1751 (ab)
Loock J, 658
Lood C, 1619
López-Longo FJ, 2294
López-Mejías R, 1035
Lorentzon M, 1987
Lorenz H, 1728 (ab)
Lorenzin M, 1844
Loussouarn D, 1026
Louzada-Junior P, 1524
Love TJ, 1441
Loveless JE, 2235
Lovell DJ, 1088, 1687, 2012
Lovric S, 2153
Lozano F, 1035
Lu H, 1308
Lu J, 1942
Lu J-Q, 1744 (ab)
Lu W, 1171
Lubrano E, 849, 2201, S89–22, S89–54, S89–74, S89–103
Luca NJC, 1483
Lucas K, 2247
Luciano N, 804
Ludvigsson JF, 1964
Luggen M, 1546
Luijtens K, 1326, 1715 (ab)
Lumezanu E, 1445
Lunardi F, S89–61
Lundberg IE, 1299
Lundberg K, 929
Lundon K, 1716 (ab), 1739 (ab), 1747 (ab)
Lunt M, 240
Lupoli R, 1042
Lupton T, 1716 (ab)
Luqmani RA, 455, 795
Luukkainen R, 2008
Luyendijk J, 2118
Lyberg T, 1341
Lyddell C, 707
Lynd LD, 910
Lyritis GP, 1215

M

Ma MHY, 470
Macchioni P, 795, S89–77
MacDonald TM, 32
Macedo C, 1524
Machín S, 1424
MacIntyre N, 1719 (ab)
Mack M, 1736 (ab)
MacKenzie M, 1716 (ab)
Mackinnon A, 1711 (ab)
MacMullan P, 210
Madhok R, 883, 2294
Maezawa R, 1659
Magaña-Aquino M, 1814
Magder LS, 759, 1231, 1392, 2286
Mahler M, 787, 2104
Mahmourides G, 1748 (ab)
Mahomed NN, 2046
Maisawa S, 486
Maisonobe T, 1835
Majumdar SR, 822
Makino H, 545
Makino S, 1104
Mäkitie OM, 365
Makrygiannakis D, 679
Maksymowych WP, 822, 1666, 1704 (ab), 1705 (ab), 1734 (ab)
Maldonado Cocco J, 2315
Manara M, 849, S89–29
Mandl P, 795
Manetti M, 1678
Mangan C, 1764
Manger B, S90–3
Manguso F, 2332
Manning JB, 1654
Mannion AF, 656
Mantovani LG, S89–103
Manzi S, 262, 1632
Maradit-Kremers H, 795
Marangoni RG, 1971
Marcelli C, 2327
March L, 1710 (ab)
Marchesoni A, 849, 1179, 2045, 2222, S89–29, S89–54
Marcus R, 795
Marengo MF, 1308
Marin F, 600
Marinho A, 770
Marinou I, 1781
Marion M, 1238
Mariz HA, 1320, 2221
Markewitz BA, 1385
Marks JL, S90–62, S90–81
Markula-Patjas KP, 365
Marques MMC, 1524
Marques-Neto JF, 1971
Marra C, 1741 (ab)
Marra CA, 910
Marshall D, 1729 (ab)
Martel M-J, 1712 (ab)
Martel M-O, 1749 (ab), 1750 (ab)
Martel-Pelletier J, 635
Martell K, 1741 (ab)
Martín J, 112, 997, 1166, 1275, 2294
Martin L, 1704 (ab), 1705 (ab), 1729 (ab), 1734 (ab), 1735 (ab), 1738 (ab)
Martínez-Martínez MU, 1814
Martínez-Taboada VM, 795
Martini A, 856
Martins da Silva A, 770
Martiny FL, 6
Masaki Y, 1256
Mason T, 1088, 1687, 2012
Masri KR, 1139
Massarotti E, 1706 (ab)
Masui Y, 539
Matarese A, S89–82
Mathieu A, 654, 1761, S89–15
Matok I, 2163
Matos M, 131
Matsuda M, 1291
Matsudaira R, 1207
Matsui K, 148
Matsushita M, 1207
Matteson EL, 481, 795, 954, 1355, 2148
Matucci-Cerinic M, 1678
Mavrangelos C, 2021
Mavros P, 1056
Maxwell JR, 1781
Mayes M, 997
Maynard JW, 777
Maz M, 795
Mazieres B, 2327
Mazzantini M, 552, 1761
McAlear CA, 303

McAlister F, 1741 (ab)
McBain D, 1732 (ab)
McBryde ES, 1297
McCormick N, 1701 (ab), 1741 (ab)
McCoy SS, 954
McCune WJ, 959, 1632
McCurdy D, 1088, 1687, 2012, 2231
McDonald-Blumer H, 1744 (ab), 1746 (ab)
McDonough E, 1722 (ab)
McGill N, 1726 (ab)
McGill V, 1726 (ab)
McGonagle D, 1481, S89–11
McGwin G Jr., 1603
McHugh J, 154
McHugh NJ, 154, S89–32
McIlroy J, 1746 (ab)
McInnes I, 1735 (ab), 1736 (ab)
McKay JD, 1632
McMurtry M, 1741 (ab)
McQueen FM, 841, 874, 2229
McVagh J, 1701 (ab)
Mease PJ, 391, 398, 413, 415, 421, 445, 654, 1735 (ab), 1736 (ab), 2181, 2189, 2196, 2198, 2214, S89–90
Méaux-Ruault N, 125
Mebus CA, 720
Medkour F, 893
Meehan S, 510
Mehta B, 664
Mehta PK, 448
Meirelles ES, 141
Melchiorre D, 849, 1678
Mellström D, 1987
Ménard H, 1750 (ab)
Mendel A, 1712 (ab)
Mendoza FA, 1241
Menin R, 141
Mereuta MO, 871
Merkel PA, 303
Merrill JT, 510
Merz CNB, 448
Mesko B, 916
Mevorach D, 1628
Meyer M, 816
Meyer O, 672, 997
Miccoli M, 552
Michaud K, 54, 1139
Middelkoop HAM, 2118
Mierdel S, 1747 (ab)
Miettunen P, 1731 (ab), 1875
Mifflin S, 1732 (ab)
Migita K, 875
Migliorini P, 1490
Migone T-S, 1632
Mihu CN, 1308
Mikkelsen K, 1341
Mikolaitis RA, 73
Mikuls TR, 1139
Milchert M, 1898
Milia AF, 1678
Millard DJ, 2021
Mineau F, 635
Minissian M, 448
Miraglia JL, 167
Mittoo S, 1895
Miyamae T, 864
Miyasaka N, 1487, 2053
Moctezuma JF, 830
Modesti V, 1844
Mohamed AF, 1056
Mohan C, 1231
Moher D, 1750 (ab), 1751 (ab)
Molena B, S89–61
Moll C, 1035
Moll JMH, S89–1
Molloy E, 662
Momohara S, 476
Monach PA, 303
Montalbano S, S89–36
Monteiro C, 197
Montepaone M, 849
Montilla C, 1008, 1035
Moore DJ, 1781
Moore TL, 1654
Morales-Romero J, 247
Moran J, 1717 (ab)
Moreira I, 770
Morel J, 712, 1533
Morfini M, 1678
Morgan DeWitt E, 1867
Mori M, 864
Mori S, 1292
Morinobu A, 1904
Morishita K, 1088, 2012
Moriuchi H, 875
Morris SJ, 946
Morrison S, 1378
Mosher DP, 1221, 1559, 1583, 1738 (ab), 2088
Mosko J, 254
Mota FH, 1934
Moulin D, 1720 (ab)
Mourão AF, 131
Mouterde G, 712
Mouthon L, 125, 450, 997
Moutsopoulos HM, 516
Mozaffarian N, 1711 (ab)
Muangchan C, 1120, 1708 (ab), 1709 (ab)
Mubashir A, 986
Mudivarthy S, 1736 (ab)
Muhammad K, 1130
Mulero J, 1008, 2315
Müller-Ladner U, 2153, 2177, S90–3, S90–17
Muñoz-Gomariz E, 2315
Muo C-H, 1611
Murakami S, 1348
Murasawa A, 1517
Murayama G, 1207
Murphey MD, 1445
Murphy FT, 1185
Murphy MJ, 32
Murray AK, 1654
Murray JA, 1964
Murtaugh MA, 1385
Muscal E, 1088, 1687, 2012
Musset L, 1819, 1835
Musshoff K, 1099
Mustafa KN, 1675
Myasoedova E, 1355

N

Nagle SJ, 1241
Nagy L, 916
Naimark D, 1730 (ab)
Nair B, 1709 (ab)
Nakajima A, 476
Nakano M, 1348, 1517
Nakashima H, 345
Nakazono K, 1517
Nam J-Y, 1399
Nanda K, 1088
Nanji JA, 707
Nanki T, 1487
Nannini C, 795, S89–71
Naparstek Y, 1628
Naranjo A, 1424
Nardacchione R, S89–61
Narita I, 1348, 1517
Narvaez J, 2294
Narvestad E, 463
Nassi L, 1088, 1687
Néel A, 1026, 2157
Nelson S, 174
Nemoto T, 1207
Nessim S, 1829
Neville C, 968, 1378
Neville J, 174
Nevitt M, 161
Nguyen M, 1701 (ab)
Ni L-Y, 558
Nicassio PM, 1807
Niccoli L, S89–71
Nicholson IC, 2021
Nicolai R, 1287
Nicolaou S, 1745 (ab)
Niewold TB, 73, 1238
Nijpels G, 2261
Nikpour M, 1711 (ab)
Nimmo M, 1721 (ab)
Nishida Y, 345
Nishimura K, 1904
Niu J, 359
Nived O, 1711 (ab)
Noda S, 539
Nordberg E, 795
Nordin A, 2294
Nordström D, 2008
Norton GR, 1798
Noss EH, 295
Nossent JC, 2142
Novack V, 458
Nozawa T, 864
Núñez-Alvarez CA, 504
Nurmohamed MT, 885, 1317, 2261
Nüßlein H, 1728 (ab)
Nyhof-Young J, 1717 (ab)

O

O'Connor D, 1721 (ab)
O'Connor P, 1786
O'Donnell JL, 2098
O'Neil KM, 1088, 1687, 2012
O'Rielly D, 1703 (ab)
O'Shea FD, 887, 2310
Ocmant A, 119
Oen K, 1723 (ab), 1875
Ogasawara M, 1207
Ogawa N, 1256
Ogunyemi B, 1752 (ab)
Ohinmaa A, 1705 (ab), 1734 (ab)
Okada H, 1659
Okada M, 1296, 1700
Okayama A, 1291
Oliveira RDR, 1524
Olivieri I, 184, 849, 1110, 1483, 2201, 2211, S89–22, S89–54, S89–103
Oliviero F, 1844, S89–61
Olmstead R, 1807
Olsen J, 46
Olszynski W, 1727 (ab), 1731 (ab), 1732 (ab)
Omair MA, 992, 1895
Omisade A, 1371
On PV, 1712 (ab)
Onat AM, 106, 1996
Onen F, 1996
Onuma S, 1207
Orcel P, 233
Ormseth SR, 1807
Orozco G, 1781
Ortego-Centeno N, 112
Ortiz A, 869
Osborne RH, 1047
Oshiawa H, 148
Oshikata C, 1019
Osman M, 1735 (ab)
Ossowski A, 10
Osteoarthritis Initiative Investigators, 161
Oster G, 54
Østergaard M, 408, 2211
Ostermeier E, 2153
Otaki Y, 1517
Otani H, 1517
Otawa S, 1715 (ab), 1719 (ab), 1726 (ab), 1752 (ab)
Owada T, 1659
Owens CM, 645
Oxczarek A, 701
Ozaki S, 1766
Özçakar ZB, 2170
Ozgen M, 106
Ozkan F, 2045
Ozturk B, 199
Ozturk MA, 1996
Oztuzcu S, 106
Ozyurt K, 2045

P

Paccou J, 1418
Padera RF, 295
Padula A, 1110, S89–103

Padyukov L, 1509
Paget SA, 1280
Pagnoux C, 125, 1026, 1739 (ab)
Pai KS, 186, 870
Paira S, 869
Pal J, 1721 (ab)
Palanichamy A, 1130
Palazzi C, 184, 1110, 1483, S89–22, S89–54, S89–103
Palleiro D, 2315
Palm Ø, 2294
Pan H-F, 1755
Pan W-P, 1506
Pan X-X, 558
Pandey J, 2048
Pangan AL, 1666
Panopalis P, 1720 (ab), 1749 (ab), 1750 (ab)
Panoulas VF, 218
Panush RS, 2059, 2225
Papaioannou N, 1215
Papanicolas LE, 157
Paparo F, 389, S89–44
Papneja A, 1702 (ab), 1719 (ab)
Paradiso M, 41
Parafiniuk M, 10
Paras E, 2227
Parasuraman S, 1185
Pardeo M, 1287
Parikh K, 1095
Parisi A, S89–36
Parison D, 1712 (ab)
Park D-J, 809
Park JH, 2000
Park S-H, 86
Park SJ, 186, 870
Park W, 720, 1902
Park Y-W, 809, 2000
Parker JL, 2066
Parker T, 2104
Parodi M, 389, S89–44
Parrish EJ, 1280
Parsons WJ, S89–54
Parussini E, 1533
Pascual-Salcedo D, 1166
Passalent L, 1716 (ab), 1739 (ab), 1747 (ab)
Passos GA, 1524
Paternotte S, 816
Paterson G, 1738 (ab)
Pavelka K, 836
Pawlik A, 10
Payet J, 816
Pazzola G, S89–77
Pease C, 795
Pedersen TK, 2352
Pedersen TR, 1433
Pederzoli S, 856
Peebles CL, 2104
Peeva V, 1378
Pehlivan Y, 106, 1996
Pejnovic NN, 18
Pelajo CF, 1867
Pellegrin J-L, 2223
Pelletier J-P, 610, 635
Pellett F, 1723 (ab)
Peloso PM, 1056
Peluso R, 334, 568, 1042, 2332, S89–49, S89–82
Pencharz J, 1559, 1583
Pendl J, 174
Peng C, 904
Peng D-D, 686
Peng W-J, 1755
Penney C, 1738 (ab)
Pepe P, 804
Pereira D, 564, 1703 (ab)
Pereira IA, 141
Pereira J, 1720 (ab)
Pereira RMR, 167
Perey B, 1727 (ab)
Perez-Ruiz F, 1859
Pericleous L, 1198
Peschken CA, 1701 (ab), 1726 (ab), 1734 (ab), 1792, 2227, 2253
Peter H-H, 1407, 1728 (ab)
Peterfy C, 1741 (ab)
Peters MJL, 2261
Petit-Teixeira E, 1490
Petrek M, 1755
Petri MA, 759, 777, 1231, 1392, 1603, 2286
Petrover D, 2179
Pettersson T, 2008
Phillips SB, 610
Pi D, 1721 (ab)
Pi S, 1721 (ab)
Piatek J, 10
Piga M, 1761
Pillinger MH, 1458
Pilote L, 968
Pimentel-Santos FM, 131, 1757
Pineau CA, 968, 1378
Ping L, 1256
Ping L, 1171
Pinheiro MM, 141
Pinto C, 770
Pinto P, 131
Pipitone N, 795, S89–77
Piskin O, 594
Pisters MF, 1064
Pistorio A, 856
Pitta ID, 2221
Pitta IR, 1320
Pitta MGR, 1320, 2221
Pitzalis C, 2049
Plant D, 929
Plantone D, 2359
Podani J, 916
Poggenborg RP, 408
Pohjankoski H, 377
Poliska S, 916
Polito E, 141
Pollard LC, 28
Polydefkis M, 2363
Poncet C, 1714 (ab), 1728 (ab)
Ponge T, 2157
Ponticiello A, S89–82
Poór G, 795
Pope JE, 524, 787, 1120, 1155, 1221, 1378, 1559, 1583, 1704 (ab), 1706 (ab), 1707 (ab), 1708 (ab), 1709 (ab), 1710 (ab), 1725 (ab), 1728 (ab), 1729 (ab), 1730 (ab), 1732 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 1742 (ab), 2071, 2081, 2088, 2247
Porru G, 654, 849
Postmus PE, 100
Prasadam I, 621
Prasse A, 1407
Pratesi F, 1490
Prati C, 233, 657, 1482, 2327
Prevosto C, 1918
Primiano G, 2359
Pritzker KPH, 583
Probst C, 1407
Proulx J, 1720 (ab)
Proven A, 2008
Provenzano G, 849
Prud'Homme A, 125
Przepiera-Bedzak H, 1898
Psarelis S, 1215
Pui K, 841
Puig JG, 1901
Punaro M, 2012
Punzi L, 1844, S89–61
Purcaru O, 1715 (ab)
Puxeddu I, 1490
Pyne L, 1707 (ab), 2081

Q

Qin L, 1955
Qin Y-H, 686
Qualls C, 752
Quevedo-Abeledo JC, 1424
Quinn MA, 2062
Quismorio A, 2225
Qureshi AA, 2204

R

Rabinovich CE, 1088, 1687
Radanov BP, 656
Rademacher A, 314
Rader T, 1751 (ab)
Radner H, S90–47, S90–74
Radstake TRDJ, 112, 997, 2294
Ragab Y, 180, 1305, 1979
Rahman MU, 1185
Rahman M, 1706 (ab)
Rahman P, 431, 1703 (ab), 1726 (ab)
Raja R, 2098
Rajaram S, 1265
Rajpathak S, 382
Rajzbaum G, 600
Rakoczy J, 701
Ramírez J, 1035, 1929
Ramiro S, S90–47, S90–74
Ramonda R, 1844
Ramos-Remus C, 836
Rampakakis E, 1715 (ab), 1719 (ab), 1722 (ab), 1737 (ab), 1751 (ab), 1752 (ab)
Ramsey SE, 1088, 1875, 2012
Ramsey-Goldman R, 1603
Rand JH, 382
Rantalaiho V, 2008
Rantapää-Dalhqvist S, 939
Rasker JJ, 1979
Rassi DM, 1524
Raterman HG, 885
Ravelli A, 856
Raychaudhuri SP, 437
Redmond AC, 1786
Reed AM, 2134
REGISPONSER Study Group, 1008
Reiff A, 1088, 1687, 2012
Ren H, 558
Renner JB, 337
Rentz AM, 63
Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan, 545
Resende GG, 141
Reveille JD, 1603
Revelli M, 389
Revelo MP, 1385
Revicki D, 63
Rezaei E, 1723 (ab)
Rhee C, 1710 (ab)
Rheumatoid Arthritis Network and Coordinated Project, 1509
Ribeiro A, 131
Ribeiro SL, 141
Richard E, 2051
Richards BL, S90–21, S90–28, S90–34, S90–40
Richards D, 1717 (ab)
Richette P, 1311, 2179
Richez C, 1192
Riddell C, 1711 (ab)
Riemekasten G, 112, 269, 2294
Rigolet A, 1835
Rillo O, 2315
Rimar D, 2055
Ringold S, 1867
Riolo G, 193
Rischmueller M, 2142
Risser R, 352
Ritchlin CT, 394, 423, 434, 2184, 2189, S89–57
Rivera T, 510
Rizek R, 2046
Robbins L, 1280
Roberts K, 1743 (ab)
Roberts VC, 1934
Robertson JM, 1934
Robin M, 2327
Robinson DB, 1701 (ab), 1726 (ab), 1792, 2253
Robledo G, 1166
Roccatello D, 871
Rocha FAC, 141
Rocha LF Jr., 1320
Rocha LF, 1971
Rocha-Muñoz AD, 247
Rodan LH, 1698
Rode M, 1739 (ab)
Rodríguez C, 1008

Rodriguez-Jimenez NA, 247
Rodríguez-Lozano C, 1424
Rodríguez-Rodríguez L, 1275
Roemer F, 359
Rogalsky C, 1716 (ab)
Rogers P, 1539
Rohekar G, 1710 (ab)
Rohekar S, 1710 (ab), 1725 (ab)
Rokutanda R, 1700
Roldan CA, 752
Roll P, 1130, 2153
Román-Acosta S, 1814
Román-Ivorra JA, 2294
Romano E, 1678
Ronneberger M, 1334
Roots R, 1724 (ab)
Rosa RF, 1948
Rose CD, 1888
Rosen CF, 1722 (ab), 2204
Rosenberg A, 1723 (ab), 1875
Rosenblum G, 1710 (ab)
Rosendahl K, 645
Rosenkranz M, 1088, 1687, 2012
Rosenzwajg M, 1819
Rosner I, 2055
Ross S, 1717 (ab)
Rossi D, 871
Rossi P, 665
Roth J, 1718 (ab), 1875
Rothfield N, 986
Rotunno L, 849, S89–29
Roubaud-Baudron C, 125
Roure F, 816
Roux-Lombard P, S89–61
Roverano S, 869
Rowe D, 1728 (ab)
Roy S, 63
Royle L, 463
Rozin AP, 2361
Rozmovits L, 1739 (ab)
Rubaltelli L, S89–61
Rubbert-Roth A, 2153
Rubio-Tapia A, 1964
Rudd PM, 463
Ruderman E, 206
Rudinsky C, 1735 (ab)
Ruffini L, 1761
Ruiz B, 997
Ruiz-Esquide V, 1929
Rumsey D, 1723 (ab)
Ruperto N, 856, 1503
Rush R, 1717 (ab)
Russell AS, 655, 707, 1704 (ab), 1714 (ab), 1912
Russo A, 871
Russolillo A, 568, 1042
Ryan A, 1740 (ab)

S

Saad A, 1979
Saad CGS, 167
Saadoun D, 1819
Saarimaki A, 1738 (ab)
Sabbagh D, 1648
Sada K-E, 545
Saeed F, 986
Saegusa J, 1904
Saeki T, 1348
Sáenz R, 2315
Safranow K, 10
Saito H, 1019
Sakai T, 1517
Sakarya S, 199
Saketkoo LA, 1314
Salaffi F, 1179, 1641
Salamé P, 1748 (ab)
Salazar-Paramo M, 247
Sale J, 1717 (ab)
Salmon JE, 1280
Salvador G, 1929
Salvarani C, 795, 849, 1761, S89–77
Salvatore M, S89–49
Samara AM, 1971
Samdanis V, 1215
Sampaio-Barros PD, 141, 1971, 2315
Sampalis J, 1715 (ab), 1719 (ab), 1722 (ab), 1726 (ab), 1737 (ab), 1751 (ab), 1752 (ab)
Sampson AR, 610
Sánchez-Guerrero J, 504
Sandell C, 1840
Sander O, 2111
Sandhu S, 1717 (ab)
Sanduzzi A, S89–82
Sanmartí R, 1035, 1929
Santiago MB, 141
Santo AH, 496
Santoboni G, 1758
Santos E, 197, 770
Santos H, 131
Santra S, 1741 (ab)
Saqui O, 1004
Saraux A, 310
Sargeant J, 1717 (ab)
Sari I, 594
Sartorius JA, 946
Sarzi-Puttini P, 849, S89–97
Sato EI, 496
Sato H, 1348, 1517
Sato S, 539
Sattar A, 262
Sauchelli D, 2359
Sauma MFLC, 141
Saurenmann R, 1778
Savolainen A, 377
Sawitzke AD, 1385
Sayarlioglu M, 106, 1996
Sayer JA, 1756
Sayre E, 1713 (ab), 1741 (ab), 1745 (ab)
Scagliori E, S89–61
Scarpa R, 334, 568, 849, 1042, 2201, 2332, S89–4, S89–36, S89–44, S89–49, S89–54, S89–74, S89–82
Scarsbrook D, 716
Schaeverbeke T, 1192, 2327
Schanberg LE, 2341
Scheiman Elazary A, 1628
Scheinberg M, 2049
Schenk Y, 22
Schett G, 1709 (ab)
Schiappapietra B, 856
Schiavenato M, 182
Schieir O, 1555, 1559, 1583
Schiff MH, 1326, 1546
Schikler KN, 1088, 1687, 2012
Schirmer M, 795
Schlesinger N, 195
Schmalzing M, 269
Schmeling H, 1731 (ab), 1875
Schmidt WA, 795
Schmidt Z, 795
Schmidt-Wilcke T, 959
Schneck L, 1458
Schneider M, 2111, S90–17
Schneider R, 1716 (ab), 1739 (ab), 1747 (ab), 1875
Schnez A, 1334
Schnitzer TJ, 610
Schoenmaker N, 2051
Schroeder J, 206
Schuerwegh AJ, 2294
Schulze-Koops H, 314, 1334, 2153
Schumacher HR Jr., 1859
Schwartz TA, 337
Schwenger E, 910
Sciascia S, 871
Scinocca M, 1704 (ab), 1725 (ab)
Scorza R, 112
Scott DL, 28, 470
Scrivo R, 41
Scuccimarri R, 1875, 2012
Seary E, 276
Seddighzadeh M, 1509
Sedlis SP, 1458
Sefik-Bukilica MN, 18
Sekiya F, 1207
Semb AG, 1433
Sen SS, 1056
Seo P, 303, 1413
Sequeira D, 1748 (ab)
Serné EH, 100
Serrano A, 1275
Servidei S, 2359
Sesma P, 186
Seto Y, 476
Sette A, 1490
Sfikakis PP, 60
Sfriso P, S89–61
Shah B, 1458
Shah SJ, 206
Shahouri SH, 1139
Shaikh S, 1726 (ab)
Shang Q, 2267
Shanmugarajah S, 1703 (ab), 1722 (ab)
Shao M-B, 686
Sharma S, 1721 (ab)
Sharpe T, 1880
Shaver TS, 1139
Shaw J, 1712 (ab)
Sheikh S, 1723 (ab)
Sheng X, 32
Sherber NS, 660
Shi D, 868
Shibata T, 1766
Shidara K, 476
Shiff N, 1705 (ab), 1723 (ab), 1731 (ab), 1875
Shim J-S, 226
Shin JI, 186, 870
Shin M-G, 809
Shiozawa K, 694
Shiozawa S, 694
Shir Y, 1720 (ab), 1749 (ab), 1750 (ab)
Shivashankar R, 2148
Shojania K, 1721 (ab), 1742 (ab)
Sholter DE, 2088
Shoor S, 669
Shourt CA, 481
Shroff A, 878
Shu J, 1717 (ab)
Shufelt CL, 448
Shupak R, 1716 (ab), 1739 (ab), 1747 (ab)
Shvartsbeyn M, 510
Sibbitt WL Jr., 752
Sibilia J, 997, 1714 (ab), 2327
Siddle HJ, 1786
Sidney J, 1490
Silva CA, 167
Silverman ED, 1698
Simard JF, 1964
Simeón CP, 112, 1275, 2294
Siminovitch KA, 1726 (ab), 1792
Simkin PA, 890
Simpson K, 1712 (ab)
Sinclair L, 1739 (ab)
Singer J, 1745 (ab)
Singer NG, 1687, 2012
Singh AG, 899
Singh JA, 1450
Singh PP, 899
Singh S, 899
Sirignano C, S89–49
Sison C, 374
Skare TL, 141
Slee TM, 2118
Slobodin G, 2055
Slott Jensen H, 795
Smit-Vandezande M, 1728 (ab)
Smith D, 1740 (ab)
Smith JP, 218
Smith V, 1113, 2127
Smolen J, 1714 (ab), 1715 (ab), 1741 (ab)
Smolewska E, 1078
Smolik I, 2253
Smuczek J, 1742 (ab)
Smulders YM, 100
Snowden N, 735
So A, 583
So MW, 1854
Soever L, 1716 (ab), 1739 (ab), 1747 (ab)
Soini IH, 365
Solans R, 1275

Solari N, 856
Solau-Gervais E, 1418
Soldatovic II, 18
Sole E, 461
Soliman MM, 240
Solmaz D, 1996
Solomon A, 1798
Solomon DH, 2059
Song J-S, 933, 1902
Soon GS, 1698, 1723 (ab)
Sop G, 594
Soriano ER, S89–67
Soscia E, 2332, S89–49
Soucy E, 1721 (ab)
Souza DCC, 496
Soyfoo MS, 119
Spadaro A, 849, S89–54, S89–74
Spalding S, 1088, 1687
Spanish Giant Cell Arteritis Group, 1275
Spanish Scleroderma Group, 1275, 2294
Spanish Systemic Sclerosis Group, 112
Spano A, S89–82
Specker C, 2153
Spek A, 1914
Spinelli FR, 41
Spouge D, 1711 (ab)
Spriggs D, 2229
Stamp LK, 877, 2098
Stanciu R, 1835
Stanczyk J, 1078
Starz T, 1
Ste-Marie P, 1720 (ab), 1749 (ab), 1750 (ab)
Steber C, 1716 (ab)
Steckmen I, 2315
Steele R, 787, 1829
Stehouwer CDA, 2261
Steiman A, 1221, 1702 (ab), 1719 (ab)
Steup-Beekman GM, 2118
Stevens AM, 1088, 1687, 2012
Stevens BA, 1798
Stevens R, 1709 (ab)
Stewart M, 1095
Stinson J, 1750 (ab), 1751 (ab)
Stock TC, 720
Stohl W, 1632
Stoll ML, 1880
Stordeur P, 119
Stoustrup P, 2352
Stoykov I, 600
Strach K, 1099
Stramare R, S89–61
Strand CV, 63, 1450, 1715 (ab)
Street AC, 1297
Striegel K, 986
Stringer E, 1875
Stroehmann I, 1099
Sturge M, 1703 (ab)
Su J, 254
Su L, 1371
Suarez-Almazor ME, 247, 1308
Sudol M, 1727 (ab)
Sugai S, 1256
Sugaya M, 539
Sugaya T, 1517
Sugimoto K, 1207
Sugiura H, 345
Suh C-H, 728, 1399, 1902
Sulli A, 1113
Summers K, 1732 (ab)
Sun G-Z, 1506
Sun H-S, 1506
Sun L, 1725 (ab)
Sun Y, 1155, 1726 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1792
Sundgren PC, 959
Sundquist J, 743
Sundquist K, 743
Sundström B, 327
Sung F-C, 1611
Sung I-H, 2321
Sussman G, 564
Sutton E, 1737 (ab)
Sutton-Tyrrell K, 262
Svenson L, 1731 (ab), 1734 (ab)
Swart A, 2104
Swift AJ, 1265
Symmons DPM, 240
Syrotuik J, 1715 (ab)
Szajubok JCM, 1948
Szamosi S, 916
Szekanecz Z, 916
Szeto C-C, 1942

T

Tada K, 1207
Tada Y, 539
Tada Y, 1363
Tagoe CE, 1125
Takada K, 2053
Takahashi H, 1363
Takahashi M, 2046
Takahashi T, 539
Takasaki Y, 1207
Takei K, 1948
Takeuchi T, 1104
Takken T, 1064
Talarico R, 552, 804
Talley NJ, 1355
Tam L-S, 844, 1711 (ab), 1942, 1955, 2267
Tamaki Z, 539
Tamura N, 1207
Tan AL, 1481, S89–11
Tan TC, 759
Tanabe N, 1348, 1517
Tanaka E, 476
Tanaka Y, 486, 694, 809
Tandon N, 1736 (ab), 1740 (ab)
Tang XL, 1955
Taniguchi A, 476
Taniguchi T, 539
Tappeiner C, 1294
Tarantino G, 1042
Tardella M, 1248, 1641
Tarner IH, S90–3, S90–17
Tatibouet S, 787, 1724 (ab)
Tatò F, 314
Tavares R, 2088
Tavoni A, 804
Tayer-Shifman O, 1628
Taylan A, 594
Taylor J, 174
Taylor KE, 1603
Taylor PC, 1198
Taylor SD, 1056
Taylor WJ, 841
Taylor-Gjevre R, 1709 (ab)
Tegzová D, 1632
Teh BW, 1297
Teh L-S, 735
Teixeira VH, 1490
Teixeira-Pinto A, 770
Tektonidou MG, 60
Tennant M, 1735 (ab)
ter Borg EJ, 22
Terrier B, 1819
Tezcan ME, 1996
Thanh N, 1705 (ab), 1734 (ab)
Thavaneswaran A, 564, 1703 (ab), 1722 (ab), 1723 (ab), 1745 (ab), 1746 (ab), 1850
Thiele RG, 182
Thomas J, 1701 (ab), 1702 (ab)
Thomas L, 893
Thompson A, 1710 (ab)
Thomson J, 1559, 1583
Thomson LEJ, 448
Thorne A, 1745 (ab)
Thorne JC, 949, 1155, 1221, 1559, 1583, 1707 (ab), 1728 (ab), 1729 (ab), 1730 (ab), 1733 (ab), 1737 (ab), 1738 (ab), 1747 (ab), 2071, 2081, 2088, 2247
Tian J, 1171
Tiemann K, 1099
Tiev K, 997
Tillett W, 154
Timenetsky MCS, 167
Tinazzi I, 1648
Ting TV, 174
Tingey T, 1742 (ab)
To CH, 1392
Toda K, 1294
Toiviainen-Salo S-M, 365
Tokuda Y, 148
Toledano K, 2361
Tolosa C, 2294
Toloza SMA, 445, 1711 (ab), 2216
Tolusso B, 2276
Tomasson G, 303
Tomlinson GA, 276, 1729 (ab), 2088
Toms TE, 218
Ton E, 22
Tonetta S, 1648
Tönnesmann E, 1099
Tonon R, 1717 (ab), 1728 (ab)
Tonooka K, 1766
Tony H-P, 1130, 2153
Torok KS, 286
Torralba KD, 2059
Torre C, 552
Torres RJ, 1901
Touitou D, 1835
Touitou I, 1888
Touma Z, 1711 (ab)
Toupin April K, 1750 (ab), 1751 (ab)
Toupin K, 1738 (ab)
Tournis S, 1215
Towheed TE, 193
Toyama S, 1207
Toyama T, 539
Tozzi AE, 1287
Tracy RP, 262
Tremaine WJ, 2148
Tremblay J-L, 2088
Treurniet FFE, 1906
Trindade H, 131
Troelsen LN, 463
Troost D, 2051
Trudes G, 167
Truedsson L, 1619
Tsang K, 112
Tse SML, 1875
Tseung L, 2267
Tsuburai T, 1019
Tsui FWL, 583
Tsui HW, 583
Tsukushi S, 345
Tsurikisawa N, 1019
Tucker LB, 1705 (ab), 1875
Tugwell P, 1717 (ab), 1738 (ab), 1750 (ab), 1751 (ab)
Turpin K, 1716 (ab)
Twilt M, 1723 (ab)
Tydén H, 1619
Tyrrell H, 2235
Tyrrell P, 1723 (ab)

U

Uddin M, 1703 (ab)
Uh M, 1711 (ab)
Uhl M, 1407
Umekita K, 1291
Unger L, 2153
Unlu E, 1758
Urakawa H, 345
Uribe AG, 1088, 1687, 1705 (ab), 2012
Urowitz MB, 254, 1074, 1702 (ab), 1711 (ab), 1719 (ab), 1721 (ab), 1742 (ab)
Uto K, 694
Utrecht Rheumatoid Arthritis Cohort Study Group, 22
Utset TO, 73, 1632
Utsunomiya M, 148
Uyar G, 199
Uziel E, 2163

V

Vacca A, 654
Valdimarsson H, 1441
Valesini G, 41
Valle-Onate R, 445, 2216

Valta HL, 365
van Albada-Kuipers IA, 22
van Buchem MA, 2118
van de Stadt L, 1914
van den Hurk K, 2261
van der Heijde DM, 1326, 1735 (ab), S90–1, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62, S90–74, S90–81
van der Mast RC, 2118
van der Veen MJ, 22
van der Wee NJA, 2118
van Gorp E, 1914
van Halm VP, 2261
van Laar JM, 2294
van Mater H, 2012
Van Praet J, 2127
van Schaardenburg D, 1914
van Schaik RHN, 2032
van Sijl AM, 2261
van Vollenhoven R, 1715 (ab), 2008
Vander Cruyssen B, 2315
Vanderhoek L, 1732 (ab)
Vanthuyne M, 2127
Varadi C, 916
Varaprasad IR, 871
Vargas-Rojas MI, 830
Varisco V, 849
Vasconcelos C, 770
Vasculitis Clinical Research Consortium, 303
Vázquez-Mellado J, 830, 2315
Veale D, 651
Veenhof C, 1064
Vega-Hinojosa O, 2216
Vega-Lopez A, 247
Veinot P, 1717 (ab)
Veit TD, 6
Venables PJ, 929
Ventura D, S89–97
Venuturupalli S, 1769
Vera-Llonch M, 54
Verazza S, 856
Verity MA, 94
Verna C, 2352
Verstappen SMM, 22
Viallard J-F, 2223
Viana VST, 167
Vieira WP, 141
Vilá LM, 1603
Villalta D, 2104
Villiger PM, 4
Viñas O, 1929
Vio S, 1844
Vischio J, 986
Vista ES, 1934
Vitiello M, S89–36
Vlachoyiannopoulos PG, 516
Vlahos B, 836
Vogel W, 269
Vogel-Claussen J, 2286
Vohra S, 1751 (ab)
Voiculescu A, 2111
Voll RE, 1407
Vonk MC, 112, 2294
Vonk Noordegraaf A, 100
Vordenbäumen S, 2111
Voskuyl AE, 100, 2261, 2294

W

Wada T, 545
Wada Y, 1348
Wade J, 949, 1713 (ab)
Wadey V, 1746 (ab)
Wahezi DM, 382, 1088, 1687, 2012
Wakasugi D, 79
Wakefield RJ, 795, 1786
Walker D, 470
Walker H, 1727 (ab)
Walker K, 1732 (ab)
Wallace DJ, 448, 1632, 1769
Wållberg-Jonsson S, 327
Waller KA, 1473
Wallis D, 154
Walsh DA, 470
Walsh JB, 600
Wang B-X, 1755
Wang C, 1710 (ab)
Wang H, 1445
Wang I-K, 1611
Wang J, 1755
Wang L, 1171
Wang M, 1742 (ab)
Wang M-F, 135
Wang S, 2267
Wang S-C, 2220
Wang S, 1139
Wang X, 1171
Wang X, 720
Wang Z, 974
Ward MM, 1900
Warmington K, 1716 (ab), 1739 (ab), 1747 (ab)
Warnatz K, 1407
Warrington KJ, 303
Washio M, 1363
Wasko MC, 946
Watanabe Duffy K, 1875
Watson DJ, 1056
Watson KD, 240
Wautrecht J-C, 119
Weber D, 1733 (ab)
Webster F, 1717 (ab)
Wei JC-C, 135, 1306, 1765
Wei L, 32
Wei N, 720
Weiguo X, 1256
Weinblatt ME, 1706 (ab), 1707 (ab), 1711 (ab)
Weinstein A, 1445
Weisman MH, 448, 1807, 1900
Weiss PF, 1867, 2341
Weltfriend S, 198
Wendling D, 233, 657, 1482, 2327
Wessel J, 1746 (ab)
Wessels JA, 1906
West SC, 2229
Westhovens R, 1714 (ab), 2127
White AJ, 2012
White M, 1751 (ab)
Whittle SL, S90–21, S90–28, S90–34, S90–40
Wigley FM, 660
Wiik A, 1341
Wild JM, 1265
Williams R, 470
Williamson L, 1303
Wilson AG, 1781
Wilson F, 2310
Witt MN, 1334
Witte T, 2294
Wiznitzer A, 2163
Wohlreich M, 352
Wolbink G, 1914
Wolburg H, 1099
Wolfe F, 1139, 1750 (ab)
Wolgram M, 1743 (ab)
Wollenhaupt J, 1706 (ab)
Wong B, 1726 (ab)
Wong C-K, 1955
Wong H, 1745 (ab)
Wong K, 1701 (ab)
Wong P, 2235
Wong P, 1721 (ab)
Wong R, 1749 (ab)
Wong R-H, 135
Woodcock JL, 421
Woodiwiss AJ, 1798
Woon P-Y, 1765
Worthington J, 112, 1781, 2294
Wouters CH, 1888
Wu C-C, 1306
Wu T, 1231
Wu Z, 1185
Wulffraat NM, 2032
Wun C-C, 1433

X

Xavier RM, 6
Xiao Y, 621
Xie Q, 2220
Ximenes AC, 141
Xu J, 558
Xu P, 1171
Xu SX, 510
Xu W, 1735 (ab)

Y

Yacyshyn E, 1735 (ab), 1739 (ab), 1744 (ab)
Yalçinkaya F, 2170
Yamada D, 539
Yamada Y, 345, 1207
Yamaji K, 1207
Yamanaka H, 79, 476
Yamane T, 694
Yamazaki H, 1487
Yang L, 868
Yang M, 868
Yang S-F, 135
Yau I, 1723 (ab)
Yazici Y, 1714 (ab)
Yee H, 510
Yen J-H, 1765
Yen T-H, 1611
Yeung H, S89–24
Yeung RSM, 1875
Yildiz Y, 594
Yim C-W, 2267
Ying K-Y, 2267
Yohannes S, 1743 (ab)
Yokogawa N, 1296
Yokota S, 864
Yoo B, 1854
Yoo D-H, 2000
Yoon B-Y, 1902
Yoshida K, 148
Yoshihara R, 694
Yoshinari NH, 1971
You D, 787
Young A, 470
Young D, 1880
Younis S, 2055
Ytterberg SR, 303, 2134
Yu C-M, 2267
Yu C-T, 1306
Yu H-J, 558
Yu S-L, 2267
Yu X, 1171
Yurkovich M, 1702 (ab)

Z

Zadeh A, 2286
Zampogna G, S89–44
Zarco P, 1008
Zeft A, 2012
Zeidler H, 212
Zeng X, 974
Zezon A, 1125
Zhang C-Q, 1506
Zhang C-Y, 1903
Zhang H, 1159
Zhang LX, 1473
Zhang W, 558
Zhang X, 1707 (ab)
Zhang Y, 1256
Zhao J, 1903
Zhong ZJ, 1632
Zhou T-B, 686
Zhou XJ, 1231
Zhu P, 574
Zhu T-Y, 844, 1955, 2267
Zhuang C, 1159
Ziakas PD, 516
Ziglioli T, 1179
Zinsmeister AR, 2148
Zintzaras E, 516
Zirkzee EJM, 2118
Zirlik A, 1407
Zisman D, 198
Zissel G, 1407
Zivojinovic SM, 18
Zola H, 2021
Zöller B, 743
Zouch I, 322
Zoulim A, 125
Zucchetta P, 1844
Zummer M, 1559, 1583, 1722 (ab), 1850
Zwi LJ, 2229

A

Abatacept
asthma, 1903
biological therapy, 1198
drug toxicity, 1546, 1728 (ab), 1903
Great Britain, 1198
methotrexate, 1198
psoriasis, S89–100
psoriatic arthritis, S89–100
questionnaires, 1736 (ab)
review, 1198
rheumatoid arthritis, 1198, 1546, 1714 (ab), 1728 (ab), 1736 (ab), 1903
Second Update on Psoriatic Disease, S89–100
T-lymphocytes, S89–100
tumor necrosis factor inhibitor, 1546
Acetylcysteine
antineutrophil cytoplasmic antibodies, 186
antineutrophil cytoplasmic antibody-associated vasculitis, 186
Acro-osteolysis
diabetes mellitus, 2364
Activities of daily living
dermatomyositis, 2134
myositis, 2134
polymyositis, 2134
questionnaires, 2134
remission induction, 1704 (ab)
rheumatoid arthritis, 1704 (ab)
United States, 2134
Acute kidney injury
diagnosis, 200
Ehlers-Danlos syndrome, 200
renal artery, 200
Acute-phase reaction
arthralgia, 1914
arthritis, 1914
biological markers, 1914
predictive factors, 1914
Adalimumab
C-reactive protein, 1741 (ab)
cost-benefit analysis, 1712 (ab)
etanercept, 1179
infliximab, 1179
Italy, 1179
juvenile idiopathic arthritis, 1712 (ab)
methotrexate, 1179, 1741 (ab)
outcome assessment, 63
patient compliance, 1179
psoriasis, S89–77
psoriatic arthritis, S89–77
quality of life, 63
rheumatoid arthritis, 63, 1179, 1741 (ab)
Second Update on Psoriatic Disease, S89–77
Adipokines
obesity, 2046
osteoarthritis, 2046
shoulder joint, 2046
Adolescent
hydroxychloroquine, 174
patient compliance, 174
systemic lupus erythematosus, 174
telecommunications, 174
young adult, 174
Adult-onset Still's disease
anakinra, 2008
biological markers, 1399
calgranulin A, 1399
calgranulin B, 1399
comorbidity, 1305
diagnosis, 199
disease activity, 1399
endocarditis, 199
fever of unknown origin, 199
follistatin-related proteins, 1399
interleukin-1, 2008
interleukin-18, 1399, 2000
Korea, 2000
lichen planus, 1305
mycophenolate mofetil, 1305
natural killer cells, 2000
Wissler's syndrome, 2008
Adverse effects
comorbidity, 2359
dermatomyositis, 2359
inflammation, 2359
paraneoplastic syndromes, 2359
treatment outcome, 2359
African Americans
disease susceptibility, 73
human UBE2L3 protein, 73
interferon-alpha, 73
systemic lupus erythematosus, 73
Age of onset
ankylosing spondylitis, 887, 1008, 1013
differential diagnosis, 1008
diffuse scleroderma, 1241
fibrosis, 1241
juvenile-onset ankylosing spondylitis, 887, 1013
mycophenolate mofetil, 1241
scleroderma, 1241
signs and symptoms, 1008, 1013, 1110
spondylarthritis, 1110
treatment outcome, 1013, 1241
Aged
comorbidity, 665
giant cell arteritis, 665
myocarditis, 665
Alcohol drinking
epidemiology, 1363
Japan, 1363
risk factors, 1363
smoking, 1363
systemic lupus erythematosus, 1363
Allopurinol
drug toxicity, 659
febuxostat, 659
hypersensitivity, 659
Amputation
hand, 1648
longitudinal studies, 1648
scleroderma, 1648
Amyloidosis
biological therapy, 1348
comorbidity, 878
disease severity, 2170
familial Mediterranean fever, 2170
genetic predisposition to disease, 2170
giant cell arteritis, 878
polymyalgia rheumatica, 878
prognosis, 1348
rheumatoid arthritis, 1348
siblings, 2170
Anakinra
adult-onset Still's disease, 2008
interleukin-1, 2008
Wissler's syndrome, 2008
Anaphylaxis
drug hypersensitivity, 2225
etanercept, 2225
Androgen receptors
genetic polymorphism, 10
rheumatoid arthritis, 10
women's health, 10
Angiotensin-converting enzyme inhibitors
genetic polymorphism, 686
INDEL mutation, 686
lupus nephritis, 686
meta-analysis, 686
systemic lupus erythematosus, 686
Ankle
bone fractures, 868
diagnosis, 868
gouty arthritis, 868
talus, 868
Ankle joint
diagnosis, 180
rheumatoid arthritis, 180
synovial cysts, 180
Ankylosing spondylitis
age of onset, 887, 1008, 1013
ankylosis, 583
Arab world, 1675
asymptomatic diseases, S89–22
atherogenic diet, 327
atlanto-axial joint, 2321
beta catenin, 583
body mass index, 2310
bone, 1987
bone density, 1987
Canada, 1666, 1725 (ab)
cardiovascular diseases, 1433
carotid arteries, 322, 327
cell-derived microparticles, 594
chondrocytes, 583
comorbidity, 322, 2148
Crohn disease, 2148
cytokines, 1918
delayed diagnosis, 1996
dendritic cells, 1918
diagnosis, 1996
differential diagnosis, 1008
disability, 1710 (ab)
disease activity, 327
disease progression, 2321
endothelium, 594
epidemiology, 2148
etanercept, 836
ethnic groups, 1675
Europe, 2315
exercise, 2310
fatty acids, 327
genetic polymorphism, 135
genetic predisposition to disease, 131, 135, 1756, 1765
HLA-B27 antigen, 1675
human ANKH protein, 131, 1756
human CCR6 protein, 1765
human IL12B protein, 135
hypertrophy, 583
incidence, 2148
infliximab, 1725 (ab)
intervertebral disc displacement, 1996
juvenile-onset ankylosing spondylitis, 887, 1013
kidney calculi, 1756
Latin America, 2315
lipoproteins, 1433
low back pain, 1996
lumbar vertebrae, 1996

magnetic resonance imaging, 1666
minimally important difference, 1666
morbidity, 131
outcome measures, 1424
patient satisfaction, 1424
photon absorptiometry, 1987
physician's practice patterns, 1418
population characteristics, 2315
prevalence, 1675, 2321
psoriatic arthritis, 1433, 2327, S89–22
quality of life, 1424
remission induction, 1418
respiratory function tests, 1854
rheumatoid arthritis, 1710 (ab), 1765, 1918
risk factors, 322, 1433, 2321
rituximab, 2327
Second Update on Psoriatic Disease, S89–22
self-assessment, 1424
signs and symptoms, 1008, 1013, 2310
single nucleotide polymorphism, 1765
smoking, 1710 (ab)
spinal fractures, 1987
spine, 1987
spondylarthritis, 1666, 2327
spondylarthropathy, 2148, S89–22
sulfasalazine, 836
Taiwan, 1765
Th1 cells, 830
Th17 cells, 830
treatment outcome, 836, 1013, 2327
tumor necrosis factor inhibitor, 830, 836, 1418, 1854

Ankylosis
ankylosing spondylitis, 583
beta catenin, 583
chondrocytes, 583
HLA-B27 antigen, 2177
hypertrophy, 583
psoriatic arthritis, 2177

Annexin A5
antiphospholipid antibodies, 382
systemic lupus erythematosus, 382

Antibodies
disease-modifying antirheumatic drugs, 1835
interstitial lung diseases, 1835
myositis, 1835
rheumatic diseases, 1716 (ab)
triage, 1716 (ab)

Anticitrullinated protein antibody
anticitrullinated vimentin antibody, 1506
biological markers, 675, 694
comorbidity, 1493
diagnosis, 1506, 1929
disease activity, 694
disease progression, 675, 694, 1078
genetic predisposition to disease, 1490
juvenile idiopathic arthritis, 1078
lung diseases, 1493
prognosis, 675, 694
rheumatoid arthritis, 675, 694, 929, 1490, 1493, 1506, 1509, 1929
Spain, 1509
STAT3 transcription factor, 1509
STAT4 transcription factor, 1509
Sweden, 1509
tumor necrosis factor inhibitor, 929

Anticitrullinated vimentin antibody
anticitrullinated protein antibody, 1506
diagnosis, 1506
rheumatoid arthritis, 1506

Antidepressive agents
arthritis, S90–21
drug toxicity, S90–21
review, S90–21
3e Initiative 2010, S90–21

Antiglomerular basement membrane disease
drug toxicity, 1904
rheumatoid arthritis, 1904
tumor necrosis factor inhibitor, 1904

Antimalarials
biological therapy, 1769
systemic lupus erythematosus, 1769

Antineutrophil cytoplasmic antibodies
acetylcysteine, 186
antineutrophil cytoplasmic antibody-associated vasculitis, 186
B-cell lymphoma, 4
comorbidity, 2053
cyclophosphamide, 2012
diagnosis, 1088
disease severity, 2012
etiology, 4
granulomatosis with polyangiitis (Wegener's), 2053
Japan, 545
meningitis, 2053
microscopic polyangiitis, 455, 545
mortality, 455
predictive factors, 2012
propylthiouracil, 558
recurrence, 455, 545
registries, 1088
remission, 4
renal insufficiency, 558, 2053
risk factors, 455, 545
vasculitis, 558, 1088, 2012

Antineutrophil cytoplasmic antibody-associated vasculitis
acetylcysteine, 186
antineutrophil cytoplasmic antibodies, 186
drug toxicity, 2153
Germany, 2153
meta-analysis, 1742 (ab)
microscopic polyangiitis, 125
mortality, 1742 (ab)
rituximab, 125, 2153
treatment outcome, 2153
Wegener granulomatosis, 125

Antinuclear antibodies
autoantibodies, 787
autoimmune diseases, 2104
intercellular signaling peptides and proteins, 2104
rheumatic diseases, 2104
systemic lupus erythematosus, 2104
systemic sclerosis, 787

Antiphospholipid antibodies
annexin A5, 382
systemic lupus erythematosus, 382

Antiphospholipid syndrome
comorbidity, 1628
lung diseases, 1628
morbidity, 516
mortality, 516
systemic lupus erythematosus, 516

Antirheumatic agents
Canada, 1497, 1555, 1559, 1583
disease management, 1497, 1559, 1583
history of medicine, 1497
needs assessment, 1555
physician's practice patterns, 1555
practice guideline, 1497, 1555, 1559, 1583
rheumatoid arthritis, 1497, 1555, 1559, 1583

Antisynthetase syndrome
comorbidity, 1299
immunosuppression, 1299
polymyositis, 1299
progressive multifocal leukoencephalopathy, 1299
review, 1299

Anxiety
central nervous system lupus vasculitis, 770
comorbidity, 770
depression, 770
neurologic manifestations, 770
systemic lupus erythematosus, 770

Aorta
carotid arteries, 1291
risk factors, 1291
Takayasu arteritis, 1291

Aortic aneurysm
aortitis, 2157
giant cell arteritis, 2157
prognosis, 2157

Aortitis
aortic aneurysm, 2157
giant cell arteritis, 2157
prognosis, 2157

Apolipoproteins E
dyslipidemia, 218
genetic polymorphism, 218
inflammation, 218
rheumatoid arthritis, 218
single nucleotide polymorphism, 218

Apoptosis
articular cartilage, 1473
chondrocytes, 1473
epithelial cells, 1117, 1256
hyaluronic acid, 1473
NF-kappa B, 1256
p38 mitogen-activated protein kinases, 1256
pharmacology, 679
rheumatoid arthritis, 679
salivary glands, 1117, 1256
Sjögren's syndrome, 1117, 1256
synovial fluid, 1473
tumor necrosis factor inhibitor, 679

Apremilast
methotrexate, 1709 (ab)
psoriatic arthritis, 1709 (ab)

Arab world
ankylosing spondylitis, 1675
ethnic groups, 1675
HLA-B27 antigen, 1675
prevalence, 1675

Arteries
color Doppler ultrasonography, 314
diagnosis, 314
giant cell arteritis, 314
ischemia, 314

Arthralgia
acute-phase reaction, 1914
arthritis, 1120, 1914
autoimmune thyroiditis, 1120
biological markers, 1914
predictive factors, 1914

Arthritis
acute-phase reaction, 1914
antidepressive agents, S90–21
arthralgia, 1120, 1914
autoimmune thyroiditis, 1120
biological markers, 1914
Canada, 2071
cardiovascular diseases, S90–81
central muscle relaxants, S90–34
classification, 2071
clinical trials as topic, 1733 (ab)
combination drug therapy, S90–47
comorbidity, S90–74, S90–81
continuing education, 1739 (ab)
corticosteroids, S90–17
delivery of health care, 1716 (ab)
diagnosis, 1726 (ab), 1746 (ab)
disease activity, 1737 (ab), 2071
drug therapy, S90–1, S90–81
drug toxicity, 1735 (ab), S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62
early diagnosis, 1733 (ab), 1746 (ab), 2071
education, 1716 (ab)
ethnic groups, 1743 (ab)
etiology, 1706 (ab)
gastrointestinal tract, S90–74
hand, 1739 (ab)
handheld computers, 1751 (ab)
health services accessibility, 1749 (ab)
hematoma, 2361
hydroxychloroquine, 1735 (ab)
Internet, 1746 (ab)
kidney diseases, S90–81
liver, S90–74
medical education, 1747 (ab)
mentors, 1717 (ab)
neurotransmitter agents, S90–28
nonsteroidal antiinflammatory agents, S90–56, S90–62
opioid analgesics, S90–40
pain management, S90–1, S90–11, S90–17, S90–34, S90–47, S90–59, S90–74
pain measurement, S90–3
pain perception, 1743 (ab)
paracetamol, S90–11, S90–62
patient satisfaction, 1747 (ab)
peer group, 1717 (ab)
physician's practice patterns, 1739 (ab)
predictive factors, 1914
pregnancy, S90–59
process assessment, 1749 (ab)
quality of life, 1727 (ab)
questionnaires, 1751 (ab)
review, S90–1, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
rheumatoid factor, 1737 (ab)
shoulder joint, 2361
social work, 1727 (ab)
synovial fluid, 1726 (ab)
synovitis, 2071
thermography, 1739 (ab)
3e Initiative 2010, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62, S90–74, S90–81
treatment outcome, S90–3
triage, 1706 (ab), 1748 (ab)
vitamin D, 1703 (ab)
vitamin D deficiency, 1703 (ab)
Arthrography
magnetic resonance imaging, 1786
metatarsophalangeal joint, 1786
rheumatoid arthritis, 1786
Arthroplasty
hand, 1727 (ab)
juvenile idiopathic arthritis, 1727 (ab)
Articular cartilage
apoptosis, 1473
chondrocytes, 890, 1473
histological techniques, 890
hyaluronic acid, 1473
synovial fluid, 1473
Ascites
limited scleroderma, 1712 (ab)
splenomegaly, 1712 (ab)
Asthma
abatacept, 1903
drug toxicity, 1903
rheumatoid arthritis, 1903
Asymptomatic diseases
ankylosing spondylitis, S89–22
psoriatic arthritis, S89–22
Second Update on Psoriatic Disease, S89–22
spondylarthropathy, S89–22
Atherogenic diet
ankylosing spondylitis, 327
carotid arteries, 327
disease activity, 327
fatty acids, 327
Atherosclerosis
cardiovascular diseases, 2233, 2261
carotid arteries, 2233, 2261
comorbidity, 2233, 2261
rheumatoid arthritis, 2233, 2261
Atlanto-axial joint
ankylosing spondylitis, 2321
disease progression, 2321
prevalence, 2321
risk factors, 2321
Autoantibodies
antinuclear antibodies, 787
disease severity, 2127
genetic predisposition to disease, 997, 1238
human TNFSF4 protein, 997
interferon-alpha, 1238
meta-analysis, 997
mortality, 2127
scleroderma, 997
systemic lupus erythematosus, 1238, 1708 (ab)
systemic sclerosis, 787, 2127
Autoimmune diseases
antinuclear antibodies, 2104
autoimmunity, 532
DNA copy number variations, 1703 (ab)
ethnic groups, 1934
France, 532
genetic predisposition to disease, 532
giant cell arteritis, 1275
hepatitis B antibodies, 1291
immunosuppression, 1291
intercellular signaling peptides and proteins, 2104
intravenous immunoglobulins, 450
North American Indians, 1934
regulatory T-lymphocytes, 450
rheumatic diseases, 1934, 2104
risk factors, 1275, 1291
scleroderma, 1275
single nucleotide polymorphism, 1275
systemic lupus erythematosus, 2104
systemic sclerosis, 532
TNF receptor-associated factor 6, 1275
Autoimmune thyroiditis
arthralgia, 1120
arthritis, 1120
Autoimmunity
autoimmune diseases, 532
France, 532, 893
genetic predisposition to disease, 532
psoriasis, 893
rheumatoid arthritis, 893
rituximab, 893
systemic sclerosis, 532
Azathioprine
comorbidity, 1104
drug toxicity, 1104
interstitial lung diseases, 1104
rheumatoid arthritis, 1104

B

B-cell lymphoma
antineutrophil cytoplasmic antibodies, 4
etiology, 4
remission, 4
B-lymphocytes
biological markers, 2276
enthesis, S89–94
interleukin-21, 1819
lymphocyte depletion, 2276
rheumatoid arthritis, 2276
Second Update on Psoriatic Disease, S89–94
spondylarthropathy, S89–94
systemic lupus erythematosus, 1819
T-lymphocytes, 1819
Th17 cells, S89–94
treatment outcome, 2276
tumor necrosis factor inhibitor, S89–94
ZAP-70 protein-tyrosine kinase, 2276
Back pain
classification, 822
questionnaires, 822
self-assessment, 822
Bacterial infection
biological markers, 728, 1518
C-reactive protein, 728, 1518
calcitonin, 728, 1518
rheumatoid arthritis, 1518
S100 proteins, 728
systemic lupus erythematosus, 728
Bacterial overgrowth syndrome
See blind loop syndrome, 1004
Belimumab
comorbidity, 1632
systemic lupus erythematosus, 1632
vaccines, 1632
Beta catenin
ankylosing spondylitis, 583
ankylosis, 583
chondrocytes, 583
hypertrophy, 583
Biological agents
cost-benefit analysis, 1712 (ab)
physical fitness, 1725 (ab)
rheumatoid arthritis, 1712 (ab), 1725 (ab)
Biological markers
acute-phase reaction, 1914
adult-onset Still's disease, 1399
anticitrullinated protein antibody, 675, 694

arthralgia, 1914
arthritis, 1914
B-lymphocytes, 2276
bacterial infection, 728, 1518
biomedical research, S89–106
Brazil, 1948
C-reactive protein, 728, 1518
calcitonin, 728, 1518
calgranulin A, 1399
calgranulin B, 1399
central nervous system lupus vasculitis, 504
comorbidity, 2193
diagnosis, 1407, 1948, S89–65, S89–106
disease activity, 427, 694, 1399, 1948
disease progression, 434, 675, 694
follistatin-related proteins, 1399
genetic predisposition to disease, S89–106
genome-wide association study, 2193
glycosylation, 463
GRAPPA 2010, 423, 427, 434
GRAPPA 2011, 2181, 2189, 2193
human CC18 protein, 1407
human LCN2 protein, 1231
imatinib, 1732 (ab)
immunoglobulin G, 463
inflammation, 1407
interferon-alpha, 504
interleukin-18, 1399
joints, 463
lupus nephritis, 1231, 1948
lymphocyte depletion, 2276
magnetic resonance imaging, S89–61
mannose binding lectin, 463
monocyte chemoattractant protein, 1948
outcome assessment, 795
outcome measures, 2181
polymyalgia rheumatica, 795
predictive factors, 1914, S89–57
prognosis, 675, 694
psoriasis, 423, 427, 434, 2181, 2193, S89–65
psoriatic arthritis, 423, 427, 434, 2181, 2189, 2193, S89–57, S89–61, S89–65, S89–106
questionnaires, 434
radiography, 2189
retroperitoneal fibrosis, 1407
rheumatoid arthritis, 463, 675, 694, 1518, 2276
S100 proteins, 728
scleroderma, 1732 (ab)
Second Update on Psoriatic Disease, S89–57, S89–61, S89–65, S89–106
synovial fluid, S89–61
systemic lupus erythematosus, 504, 728, 1231
treatment outcome, 2276
ultrasonography, S89–61
vascular cell adhesion molecule-1, 1231
ZAP-70 protein-tyrosine kinase, 2276

Biological therapy
abatacept, 1198
amyloidosis, 1348
antimalarials, 1769
Canada, 1875
cardiovascular diseases, 41
disease progression, 2049
Great Britain, 1198
health services accessibility, 1875
juvenile idiopathic arthritis, 1875
methotrexate, 1198
prognosis, 1348
review, 1198
rheumatoid arthritis, 41, 1198, 1348, 2049, 2238
rituximab, 2238
spondylarthritis, 41
systemic lupus erythematosus, 1769
treatment outcome, 2049, 2238
tumor necrosis factor inhibitor, 41

Biomedical research
biological markers, S89–106
diagnosis, S89–106
genetic predisposition to disease, S89–106
psoriatic arthritis, S89–106
Second Update on Psoriatic Disease, S89–106

Biopsy
central nervous system vasculitis, 662
diagnosis, 662, 1413
disease management, 295
gene expression, 1942
giant cell arteritis, 295
glomerulonephritis, 1942
hematuria, 1413
lupus nephritis, 1942
primary angiitis of the central nervous system, 662
remission induction, 1413
systemic lupus erythematosus, 1942
temporal arteries, 295
vasculitis, 1413

Blind loop syndrome
home care services, 1004
intestinal pseudo-obstruction, 1004
parenteral nutrition, 1004
scleroderma, 1004

Blood
juvenile idiopathic arthritis, 2021
protease inhibitors, 2021
regulatory T-lymphocytes, 2021
synovial fluid, 2021
Th17 cells, 2021

Blood pressure
brain, 752
cerebrovascular circulation, 752
magnetic resonance imaging, 752
pathologic processes, 752
systemic lupus erythematosus, 752

Body mass index
ankylosing spondylitis, 2310
disease activity, 1729 (ab)
exercise, 2310
rheumatoid arthritis, 1729 (ab)
signs and symptoms, 2310

Bone
ankylosing spondylitis, 1987
bone density, 1987
photon absorptiometry, 1987
spinal fractures, 1987
spine, 1987

Bone density
ankylosing spondylitis, 1987
bone, 1987
comorbidity, 247
compression fractures, 365
diagnosis, 247
diphosphonates, 1215
femur neck, 1465
glucocorticoids, 1955
juvenile idiopathic arthritis, 365
Mexico, 247
mitochondrial DNA, 1465
organs at risk, 1955
osteoporosis, 247, 1465
photon absorptiometry, 1987
postmenopause, 1215, 1465
prevalence, 365
rheumatoid arthritis, 247, 1215
spinal fractures, 1987
spine, 365, 1987
systemic lupus erythematosus, 1955
tomography, 1215
women's health, 1215, 1465

Bone fractures
ankle, 868
diagnosis, 868, 1717 (ab)
gouty arthritis, 868
osteoporosis, 1717 (ab)
talus, 868

Book reviews
Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia, 454
Pediatric Rheumatology: A Color Handbook, 2231
Rheumatology and the Kidney, 2nd Edition, 2231

Brain
blood pressure, 752
cerebrovascular circulation, 752
magnetic resonance imaging, 752
pathologic processes, 752
systemic lupus erythematosus, 752

Brain diseases
central nervous system lupus vasculitis, 959
diagnosis, 1723 (ab)
pediatrics, 1723 (ab)
systemic lupus erythematosus, 959

Brazil
biological markers, 1948
cause of death, 1971
diagnosis, 1948
disease activity, 1948
disease susceptibility, 6
epidemiology, 141
ethnic groups, 141
genetic polymorphism, 6
immune system, 6
lupus nephritis, 1948
mannose binding lectin, 6
monocyte chemoattractant proteins, 1948
prognosis, 1971
rheumatoid arthritis, 6
spondyloarthritis, 141
survival rate, 1971
systemic sclerosis, 1971

Breast
palpation, 1296
physician's practice patterns, 1296

C

C-reactive protein
adalimumab, 1741 (ab)
bacterial infection, 728, 1518
biological markers, 728, 1518
calcitonin, 728, 1518
disease activity, 1709 (ab)
methotrexate, 1741 (ab)
rheumatoid arthritis, 1518, 1741 (ab)
S100 proteins, 728
scleroderma, 1709 (ab)
systemic lupus erythematosus, 728

Calcinosis
comorbidity, 2043
infection, 2043
knee, 2043
systemic sclerosis, 2043

Calcitonin
bacterial infection, 728, 1518
biological markers, 728, 1518
C-reactive protein, 728, 1518
drug toxicity, 658
mycophenolate mofetil, 658
rheumatoid arthritis, 1518
S100 proteins, 728
systemic inflammatory response syndrome, 658
systemic lupus erythematosus, 728
Calgranulin A
adult-onset Still's disease, 1399
biological markers, 1399
calgranulin B, 1399
disease activity, 1399
follistatin-related proteins, 1399
interleukin-18, 1399
Calgranulin B
adult-onset Still's disease, 1399
biological markers, 1399
calgranulin A, 1399
disease activity, 1399
follistatin-related proteins, 1399
interleukin-18, 1399
Canada
ankylosing spondylitis, 1666, 1725 (ab)
antirheumatic agents, 1497, 1555, 1559, 1583
arthritis, 2071
biological therapy, 1875
classification, 2071
comorbidity, 254
database, 1074
delayed diagnosis, 707
disease activity, 2071
disease management, 524, 1497, 1559, 1583, 1720 (ab), 1747 (ab)
disease-modifying antirheumatic drugs, 707, 1713 (ab), 1730 (ab)
disease severity, 1850
early diagnosis, 2071
education, 1718 (ab)
ethnic groups, 1731 (ab), 1733 (ab), 2253
fibromyalgia, 1720 (ab)
gout, 1747 (ab)
health care quality assurance, 1717 (ab)
health services accessibility, 1705 (ab), 1875
hip fractures, 1378
history of medicine, 1497
hospital outpatient clinics, 1074
hospitalization, 1708 (ab)
infliximab, 1715 (ab), 1725 (ab), 1752 (ab)
juvenile idiopathic arthritis, 1875
liver diseases, 254
magnetic resonance imaging, 1666
medication therapy management, 1752 (ab)
minimally important difference, 1666
myositis, 1733 (ab)
needs assessment, 1555
osteoporosis, 1378
pediatric rheumatic diseases, 1705 (ab), 1731 (ab)
pediatrics, 1718 (ab)
physician's practice patterns, 1555
practice guideline, 1497, 1555, 1559, 1583
pregnancy, 2253
prevalence, 254
psoriatic arthritis, 1850
referral and consultation, 707
rheumatoid arthritis, 707, 1497, 1555, 1559, 1583, 1713 (ab), 1715 (ab), 1717 (ab), 1730 (ab), 1738 (ab), 1752 (ab), 2253
risk factors, 254, 1378, 2253
rural health services, 1724 (ab)
scleroderma, 1724 (ab)
spondylarthritis, 1666
synovitis, 2071
systemic lupus erythematosus, 254, 1074, 1378, 1707 (ab)
systemic sclerosis, 524
treatment, 1850
treatment outcome, 1738 (ab)
Candida
infectious arthritis, 1308
review, 1308
Cannabinoids
drug-seeking behavior, 1720 (ab)
fibromyalgia, 1720 (ab)
Capillary fragility
education, 1113, 1248
microscopic angioscopy, 1113, 1248
scleroderma, 1113, 1248
Capsaicin
knee, 610
osteoarthritis, 610
Cardiac imaging techniques
diagnosis, 448
ischemia, 448
myocarditis, 448
systemic lupus erythematosus, 448
Cardiovascular diseases
ankylosing spondylitis, 1433
arthritis, S90–81
atherosclerosis, 2233, 2261
biological therapy, 41
carotid arteries, 1798, 2233, 2261
carotid artery diseases, 1146
carotid stenosis, 2286
cartilage matrix protein, 1341
cholesterol, 32
comorbidity, 1311, 1722 (ab), 2233, 2261, 2286, S90–81
diagnosis, 1701 (ab)
disease activity, 210
drug therapy, S90–81
ethnic groups, 1798
genetic polymorphism, 939
gout, 1311
growth differentiation factor 15, 939
hydroxymethylglutaryl-CoA reductase inhibitors, 32
hypothyroidism, 954
kidney diseases, S90–81
lipoproteins, 1433
medical records, 1701 (ab)
methotrexate, 1341
mortality, 32, 210
osteoarthritis, 32, 1706 (ab)
outcome assessment, 1146
pegloticase, 1311
platelet activation, 210
psoriatic arthritis, 210, 1433, 1722 (ab)
quality of life, 1311
rheumatic diseases, 1741 (ab)
rheumatoid arthritis, 32, 41, 939, 954, 1146, 1341, 1798, 2233, 2261
risk factors, 954, 1146, 1341, 1433, 1706 (ab), 1798, 2286
spondylarthritis, 41
systemic lupus erythematosus, 2286
3e Initiative 2010, S90–81
tumor necrosis factor inhibitor, 41, 1341
Cardiovascular system
glucocorticoids, 1758
inflammation, 1758
rheumatic diseases, 1758
Carotid arteries
ankylosing spondylitis, 322, 327
aorta, 1291
atherogenic diet, 327
atherosclerosis, 2233, 2261
cardiovascular diseases, 1798, 2233, 2261
color Doppler ultrasonography, 1898
comorbidity, 262, 322, 441, 2233, 2261
depression, 262
diagnosis, 1898
disease activity, 327
epidemiology, 441
ethnic groups, 1798
fatty acids, 327
giant cell arteritis, 1898
GRAPPA 2010, 441
psoriasis, 441
psoriatic arthritis, 441
rheumatoid arthritis, 1798, 2233, 2261
risk factors, 322, 1291, 1798
systemic lupus erythematosus, 262
Takayasu arteritis, 1291
vascular diseases, 262
vasculitis, 1898
Carotid artery diseases
cardiovascular diseases, 1146
outcome assessment, 1146
rheumatoid arthritis, 1146
risk factors, 1146
Carotid stenosis
cardiovascular diseases, 2286
comorbidity, 2286
risk factors, 2286
systemic lupus erythematosus, 2286
Cartilage
hand joints, 161
knee, 161
magnetic resonance imaging, 161
osteoarthritis, 161
osteophyte, 161
Cartilage matrix protein
cardiovascular diseases, 1341
methotrexate, 1341
rheumatoid arthritis, 1341
risk factors, 1341
tumor necrosis factor inhibitor, 1341
Causality
cause of death, 458, 496
death certificates, 458
mortality, 458, 496
systemic lupus erythematosus, 458, 496
vital statistics, 458, 496
Cause of death
Brazil, 1971
causality, 458, 496
death certificates, 458
mortality, 458, 496, S89–32
prognosis, 1971
psoriatic arthritis, S89–32
Second Update on Psoriatic Disease, S89–32
survival rate, 1971
systemic lupus erythematosus, 458, 496
systemic sclerosis, 1971
vital statistics, 458, 496
CE 224,535
drug toxicity, 720
methotrexate, 720
purinergic P2X7, 720
rheumatoid arthritis, 720

Celecoxib
drug toxicity, 1859
gouty arthritis, 1859
treatment outcome, 1859
Celiac disease
risk factors, 1964
systemic lupus erythematosus, 1964
Cell-derived microparticles
ankylosing spondylitis, 594
endothelium, 594
Central muscle relaxants
arthritis, S90–34
drug toxicity, S90–34
pain management, S90–34
review, S90–34
3e Initiative 2010, S90–34
Central nervous system lupus vasculitis
anxiety, 770
biological markers, 504
brain diseases, 959
comorbidity, 770
depression, 770
diagnosis, 2118
interdisciplinary communication, 2118
interferon-alpha, 504
neurologic manifestations, 770, 2118
systemic lupus erythematosus, 504, 770, 959, 1742 (ab), 2118
treatment outcome, 1742 (ab)
Central nervous system vasculitis
biopsy, 662
diagnosis, 662, 1026
differential diagnosis, 1026
image enhancement, 2051
infliximab, 2227
magnetic resonance imaging, 2051
primary angiitis of the central nervous system, 662
signs and symptoms, 1026
treatment outcome, 2227
vasoconstriction, 1026
Cerebrovascular circulation
blood pressure, 752
brain, 752
magnetic resonance imaging, 752
pathologic processes, 752
systemic lupus erythematosus, 752
Certolizumab
golimumab, 712
meta-analysis, 712
rheumatoid arthritis, 712
risk assessment, 712
skin neoplasms, 712
Certolizumab pegol
disease activity, 1707 (ab)
Disease Activity Score-28, 1326
fatigue, 1706 (ab)
joints, 1715 (ab)
methotrexate, 1715 (ab)
rheumatoid arthritis, 1326, 1706 (ab), 1707 (ab), 1715 (ab)
Cervical vertebrae
radiography, 1900
spondylarthritis, 1900
Chemokine CCL2
interferon-gamma, 979
interleukin-6, 979
scleroderma, 979
tumor necrosis factor inhibitor, 979
Child
drug toxicity, 1287
etanercept, 1287
juvenile idiopathic arthritis, 1287
China
human MBD4 protein, 1159
molecular epidemiology, 1159
peptidylarginine deiminase type IV, 1159
rheumatoid arthritis, 1159
Chloroquine
coronary disease, 1099
drug toxicity, 1099
systemic lupus erythematosus, 1099
Cholesterol
cardiovascular diseases, 32
hydroxymethylglutaryl-CoA reductase inhibitors, 32
mortality, 32
osteoarthritis, 32
rheumatoid arthritis, 32
Chondrocalcinosis
diagnosis, 1488
ultrasonography, 1488
Chondrocytes
ankylosing spondylitis, 583
ankylosis, 583
apoptosis, 1473
articular cartilage, 890, 1473
beta catenin, 583
glucosamine, 635
histological techniques, 890
human ADAMTS1 protein, 621
hyaluronic acid, 1473
hypertrophy, 583
MAP kinase 1, 621
matrix metalloproteinases, 621
osteoarthritis, 621, 635
pathologic processes, 621
prostaglandin synthase, 635
synovial fluid, 1473
Chondroitin
drug therapy, 1107
glucosamine, 1107
meta-analysis, 1107
osteoarthritis, 1107
Chronic pain
etiology, 655
whiplash injuries, 655
Classification
arthritis, 2071
back pain, 822
Canada, 2071
diagnosis, 154, 1503
disease activity, 2071
disease management, 2062
early diagnosis, 2071, 2098
epidemiology, 154
Europe, 1687
granulomatosis with polyangiitis (Wegener's), 1687
New Zealand, 2098
psoriatic arthritis, 154
questionnaires, 822
rheumatoid arthritis, 2062, 2098
self-assessment, 822
sensitivity and specificity, 154
synovitis, 2071
treatment outcome, 2062
vasculitis, 1503, 1687
Clinical competence
joints, 1207
palpation, 1207
rheumatoid arthritis, 1207
ultrasound, 1207
Clinical trials
disease activity score, 877
joints, 877
Clinical trials as topic
arthritis, 1733 (ab)
drug therapy, 2066
early diagnosis, 1733 (ab)
rheumatoid arthritis, 2066
Cognitive disorders
diagnosis, 1371
neuropsychological tests, 1371
systemic lupus erythematosus, 1371
Cohort studies
disease-modifying antirheumatic drugs, 2088
physician's practice patterns, 2088
rheumatoid arthritis, 2088
Colchicine
gout, 1458
mortality, 1458
myocardial infarction, 1458
prevalence, 1458
Collagen
localized scleroderma, 660
systemic sclerosis, 660
Color Doppler ultrasonography
arteries, 314
carotid arteries, 1898
diagnosis, 314, 1898
giant cell arteritis, 314, 1898
ischemia, 314
vasculitis, 1898
Combination drug therapy
arthritis, S90–47
drug toxicity, S90–47
methotrexate, 1524
pain management, S90–47
psoriasis, 187
psoriatic arthritis, 187
review, S90–47
rheumatoid arthritis, 1524
3e Initiative 2010, S90–47
treatment outcome, 1524
tumor necrosis factor inhibitor, 1524
Comorbidity
adult-onset Still's disease, 1305
adverse effects, 2359
aged, 665
amyloidosis, 878
ankylosing spondylitis, 322, 2148
anticitrullinated protein antibody, 1493
antineutrophil cytoplasmic antibodies, 2053
antiphospholipid syndrome, 1628
antisynthetase syndrome, 1299
anxiety, 770
arthritis, S90–74, S90–81
atherosclerosis, 2233, 2261
azathioprine, 1104
belimumab, 1632
biological markers, 2193
bone density, 247
calcinosis, 2043
Canada, 254
cardiovascular diseases, 1311, 1722 (ab), 2233, 2261, 2286, S90–81
carotid arteries, 262, 322, 441, 2233, 2261
carotid stenosis, 2286
central nervous system lupus vasculitis, 770
Crohn disease, 2148
decision support techniques, 804
depression, 262, 770, 1722 (ab)
dermatomyositis, 1745 (ab), 2359
diabetes mellitus, 377
diagnosis, 198, 247
disease activity, 86
disease progression, 986
drug therapy, S90–81
drug toxicity, 233, 552, 657, 1104
endothelium, 100
enthesis, 1979
enthesopathy, 359

epidemiology, 441, 2148
esophageal motility disorders, 986
etanercept, 233
etiology, 1095
fingers, 1895
Finland, 377
gangrene, 1895
gastrointestinal tract, 1355, S90–74
genome-wide association study, 2193
giant cell arteritis, 665, 878
glucocorticoids, 552
gout, 1311
granulomatosis with polyangiitis (Wegener's), 2053
GRAPPA 2010, 437, 441
GRAPPA 2011, 2193, 2204
hand, 359
heart diseases, 206, 269
hemophagocytic lymphohistiocytosis, 86, 1745 (ab)
hepatitis B virus, 974
idiopathic pulmonary hypertension, 100
immunosuppression, 1299
incidence, 2148
infection, 1297, 1772, 1814, 2043
infectious arthritis, 157
inflammation, 2359
infliximab, 2267
interleukin-17, 870
interstitial lung diseases, 1104
juvenile idiopathic arthritis, 377
kidney diseases, S90–81
knee, 359, 1979, 2043
Korea, 86
latent tuberculosis, 1297
lichen planus, 1305
liver, S90–74
liver diseases, 254
longitudinal studies, 1829
lower gastrointestinal tract, 1317
lung diseases, 1493, 1628
lupus nephritis, 79, 1766
magnetic resonance imaging, 1979
medical records, 1702 (ab)
meningitis, 2053
metabolic syndrome, 437
methotrexate, 2267
Mexico, 247
microvessels, 100
miliary tuberculosis, 1297
mycophenolate mofetil, 1305
myocarditis, 665
neurologic manifestations, 770
non-Hodgkin lymphoma, 804
nonsteroidal antiinflammatory agents, 1317
osteoarthritis, 359
osteoporosis, 247
pain management, S90–74
paraneoplastic syndromes, 2359
paraproteinemias, 564
pegloticase, 1311
periodontal diseases, 1725 (ab)
polymyalgia rheumatica, 552, 878
polymyositis, 1299
posterior leukoencephalopathy syndrome, 870
predictive factors, 79
prevalence, 254, 564, 974
prognosis, 804
progressive multifocal leukoencephalopathy, 1299
psoriasis, 437, 441, 1303, 1722 (ab), 1979, 2193, 2204
psoriatic arthritis, 437, 441, 564, 1722 (ab), 2193, 2204
pulmonary arterial hypertension, 276
pyoderma gangrenosum, 198
quality of life, 1311
renal insufficiency, 1829, 2053
retinal vasculitis, 1095
review, 1299
rheumatoid arthritis, 233, 247, 1104, 1303, 1317, 1355, 1493, 1705 (ab), 1725 (ab), 2233, 2261, 2267
rheumatoid toxicity, 657
risk factors, 254, 322, 1355, 2286
rituximab, 1303
scleritis, 233
scleroderma, 986
Sjögren's syndrome, 804
spondylarthropathy, 2148
stem cell transplantation, 206, 269
synovial fluid, 157
synovitis, 1979
systemic lupus erythematosus, 79, 86, 254, 262, 770, 870, 974, 1095, 1632, 1766, 1772, 1814, 1895, 2286
systemic sclerosis, 100, 198, 206, 269, 276, 1829, 1895, 2043
3e Initiative 2010, S90–74, S90–81
thrombomodulin, 1766
thrombosis, 1766
tocilizumab, 657
treatment outcome, 206, 269, 276, 2359
tumor necrosis factor inhibitor, 1297, 1705 (ab)
vaccines, 1632
vascular diseases, 262
vascular endothelial growth factors, 870
vascular stiffness, 2267
vasodilation, 100
warfarin, 276

Complementary therapies
pediatric rheumatic diseases, 1750 (ab)
questionnaires, 1750 (ab)

Compression fractures
bone density, 365
juvenile idiopathic arthritis, 365
prevalence, 365
spine, 365

Computer assisted instruction
disease activity, 1710 (ab)
systemic lupus erythematosus, 1710 (ab)

Congenital abnormalities
drug toxicity, 2163
nonsteroidal antiinflammatory agents, 2163
pregnancy, 2163

Connective tissue diseases
diagnosis, 1265
echocardiography, 1265
magnetic resonance imaging, 1265
pulmonary arterial hypertension, 1265
pulmonary fibrosis, 1641
tomography, 1265
ultrasonography, 1641
X-ray computed tomography, 1641

Connective tissue growth factor
fibrosis, 1703 (ab)
scleroderma, 1703 (ab)

Continuing education
arthritis, 1739 (ab)
physician's practice patterns, 1739 (ab)

Coronary artery disease
diagnostic imaging, 1761
positron-emission tomography and computed tomography, 1761
vasculitis, 1761

Coronary disease
chloroquine, 1099
drug toxicity, 1099
longitudinal studies, 968
risk factors, 968
systemic lupus erythematosus, 968, 1099

Corpus callosum
spleen, 1698
systemic lupus erythematosus, 1698

Corrections
Autofeedback from ultrasound images provides rapid improvement in palpation skills for identifying joint swelling in rheumatoid arthritis, 1908
Cardiomyopathy caused by longterm treatment with chloroquine: A rare disease or a rare diagnosis?, 1496
Differences in the incidence of microscopic polyangiitis (Wegener's). Is there a latitudinal gradient?, 202
Digital gangrene in a patient with systemic lupus erythematosus and systemic sclerosis, 2231
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis, 881
Idiopathic orbital inflammation successfully treated using rituximab in a patient with rheumatoid arthritis, 1907
Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study, 2232
Information needs and information-seeking by people with rheumatoid arthritis: a qualitative study, 1106
Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgia, 454
Medication use in systemic lupus erythematosus, 667
Orthopedic surgery among patients with rheumatoid arthritis 1980-2007: A population-based study focused on surgery rates, sex, and mortality, 1496
The problem of rheumatoid arthritis disease activity and remission in clinical practice, 454
Rheumatoid arthritis-associated polymorphisms 6q23 are associated with radiological damage in autoantibody-positive RA, 2057
Scleritis: A paradoxical effect of etanercept? Etanercept - associated inflammatory eye disease, 881

Semiquantified noncalcified coronary plaque in systemic lupus erythematosus, 2366
Ustekinumab for psoriasis and psoriatic arthritis, 1908
Corticosteroids
arthritis, S90–17
cyclophosphamide, 2111
localized scleroderma, 286
lupus nephritis, 2111
methotrexate, 286
pain management, S90–17
remission induction, 1718 (ab)
review, S90–17
systemic lupus erythematosus, 1718 (ab)
3e Initiative 2010, S90–17
treatment outcome, 286, 2111
Cost-benefit analysis
adalimumab, 1712 (ab)
biological agents, 1712 (ab)
drug toxicity, S89–103
juvenile idiopathic arthritis, 1712 (ab)
psoriatic arthritis, S89–103
quality of life, 735
questionnaires, 735
rheumatoid arthritis, 1712 (ab)
Second Update on Psoriatic Disease, S89–103
systemic lupus erythematosus, 735
tumor necrosis factor inhibitor, S89–103
Crohn disease
ankylosing spondylitis, 2148
comorbidity, 2148
epidemiology, 2148
incidence, 2148
spondylarthropathy, 2148
Cross-sectional studies
diagnostic errors, 1445
disease-modifying antirheumatic drugs, 1867
gout, 1445
gouty arthritis, 1445
Internet, 1739 (ab)
juvenile idiopathic arthritis, 1867
Wegener granulomatosis, 1739 (ab)
Cryoglobulinemia
Raynaud disease, 119
vasculitis, 119
Cyclophosphamide
antineutrophil cytoplasmic antibodies, 2012
corticosteroids, 2111
disease severity, 2012
lupus nephritis, 2111
predictive factors, 2012
treatment outcome, 2111
vasculitis, 2012
Cytokines
ankylosing spondylitis, 1918
dendritic cells, 1918
interleukin-6, 1120
rheumatoid arthritis, 18, 1918
scleroderma, 1120
Th17 cells, 18
tumor necrosis factor inhibitor, 18
Cytomegalovirus
disease activity, 1840
granulomatosis with polyangiitis (Wegener's), 1840
T-lymphocytes, 1840

D

Data collection
physician's practice patterns, 949
rheumatoid arthritis, 949
treatment outcome, 949
Database
Canada, 1074
hospital outpatient clinics, 1074
systemic lupus erythematosus, 1074
Databases as topic
rheumatic diseases, 1724 (ab)
Death certificates
causality, 458
cause of death, 458
mortality, 458
systemic lupus erythematosus, 458
vital statistics, 458
Decision making
disease activity, 1
Disease Activity Score-28, 1
fibromyalgia, 1
pathologic processes, 1
rheumatoid arthritis, 1
Decision support techniques
comorbidity, 804
non-Hodgkin lymphoma, 804
prognosis, 804
Sjögren's syndrome, 804
Deglutition disorders
diffuse idiopathic skeletal hyperostosis, 184
hyperostosis, 1482
Delayed diagnosis
ankylosing spondylitis, 1996
Canada, 707
diagnosis, 1996
disease-modifying antirheumatic drugs, 707
intervertebral disc displacement, 1996
low back pain, 1996
lumbar vertebrae, 1996
referral and consultation, 707
rheumatoid arthritis, 707
Delivery of health care
arthritis, 1716 (ab)
education, 1716 (ab)
Demyelinating diseases
osteolysis, 2175
POEMS syndrome, 2175
Dendritic cells
ankylosing spondylitis, 1918
cytokines, 1918
interleukin-6, 1192
monocytes, 1192
rheumatoid arthritis, 1192, 1918
tocilizumab, 1192
Depression
anxiety, 770
carotid arteries, 262
central nervous system lupus vasculitis, 770
comorbidity, 262, 770, 1722 (ab)
neurologic manifestations, 770
psoriasis, 1722 (ab)
systemic lupus erythematosus, 262, 770
vascular diseases, 262
Dermatomyositis
activities of daily living, 2134
adverse effects, 2359
comorbidity, 1745 (ab), 2359
diagnosis, 1744 (ab)
diagnostic imaging, 1659
drug toxicity, 193
etiology, 94
fasciitis, 193
fluorodeoxyglucose F18, 1659
hemophagocytic lymphohistiocytosis, 1745 (ab)
inclusion body myositis, 1744 (ab)
inflammation, 2359
microvessels, 94
myositis, 2134
NADH tetrazolium reductase, 94
paraneoplastic syndromes, 2359
polymyositis, 1659, 2134
positron-emission tomography, 1659
questionnaires, 2134
treatment outcome, 2359
tumor necrosis factor inhibitor, 193
United States, 2134
Diabetes mellitus
acro-osteolysis, 2364
comorbidity, 377
Finland, 377
juvenile idiopathic arthritis, 377
Diagnosis
acute kidney injury, 200
adult-onset Still's disease, 199
ankle, 868
ankle joint, 180
ankylosing spondylitis, 1996
anticitrullinated protein antibody, 1506, 1929
anticitrullinated vimentin antibody, 1506
antineutrophil cytoplasmic antibodies, 1088
arteries, 314
arthritis, 1726 (ab), 1746 (ab)
biological markers, 1407, 1948, S89–65, S89–106
biomedical research, S89–106
biopsy, 662, 1413
bone density, 247
bone fractures, 868, 1717 (ab)
brain diseases, 1723 (ab)
Brazil, 1948
cardiac imaging techniques, 448
cardiovascular diseases, 1701 (ab)
carotid arteries, 1898
central nervous system lupus vasculitis, 2118
central nervous system vasculitis, 662, 1026
chondrocalcinosis, 1488
classification, 154, 1503
cognitive disorders, 1371
color Doppler ultrasonography, 314, 1898
comorbidity, 198, 247
connective tissue diseases, 1265
delayed diagnosis, 1996
dermatomyositis, 1744 (ab)
diagnostic errors, 212, 677, 849
diagnostic imaging, 1678
differential diagnosis, 1026
disease activity, 1948
drug toxicity, 651
echocardiography, 1265
Ehlers-Danlos syndrome, 200
endocarditis, 199
enthesis, 415, 677, 849
epidemiology, 154
exanthema, 195
fever of unknown origin, 199, 875
fibromyalgia, 677, 849, 1294, 1749 (ab), 1750 (ab), 2221
genetic predisposition to disease, S89–106
giant cell arteritis, 314, 1898, 1909
gout, 183, 195, 1314
gouty arthritis, 868, 1314
GRAPPA 2010, 413, 415, 418
hand, 1700
hemarthrosis, 1678
hematuria, 1413

human CC18 protein, 1407
hyperuricemia, 1314
hypothyroidism, 885
immunoassay, 1721 (ab)
inclusion body myositis, 1744 (ab)
inflammation, 183, 415, 418, 1407
interdisciplinary communication, 2118
Internet, 1746 (ab)
intervertebral disc displacement, 1996
ischemia, 314, 448
Japan, 875
juvenile idiopathic arthritis, 645, 1778
low back pain, 1996
lumbar vertebrae, 1996
lupus nephritis, 1721 (ab), 1948
magnetic resonance angiography, 1700
magnetic resonance imaging, 645, 1265, 1844, S89–49
marenostrin, 875
medical records, 1701 (ab)
Mexico, 247
miliary tuberculosis, 651
monocyte chemoattractant proteins, 1948
musculoskeletal diseases, 413
mutation, 875
myocarditis, 448
nail diseases, S89–49
nails, S89–49
neck pain, 1711 (ab)
neurologic manifestations, 2118
neuropsychological tests, 1371
osteoporosis, 247, 1717 (ab)
osteoprotegerin, 1678
pain measurement, 1749 (ab)
pediatrics, 1723 (ab)
positron-emission tomography and computed tomography, 1909
posterior leukoencephalopathy syndrome, 196
primary angiitis of the central nervous system, 662
psoriasis, 413, 415, 418, S89–65
psoriatic arthritis, 154, 413, 415, 418, 677, 849, 1700, 2221, S89–49, S89–65, S89–106
pulmonary arterial hypertension, 1265
pyoderma gangrenosum, 198
radiography, 645
RANK ligand, 1678
registries, 1088
remission induction, 1413
renal artery, 200
retroperitoneal fibrosis, 1407
rheumatic diseases, 1721 (ab)
rheumatoid arthritis, 180, 212, 247, 651, 885, 1506, 1713 (ab), 1912, 1929
risk factors, 885
Second Update on Psoriatic Disease, S89–49, S89–65, S89–106
sensitivity and specificity, 154
signs and symptoms, 1026, 1294, 1750 (ab)
spinal diseases, 418
spondylarthritis, 413, 1844
synovial cysts, 180
synovial fluid, 1726 (ab)
systemic lupus erythematosus, 196, 448, 1371, 2118
systemic sclerosis, 198
talus, 868
temporomandibular joint disorders, 1778
thermography, 183
thoracic wall, 1844
tomography, 1265
tumor necrosis factor inhibitor, 651
ultrasonography, 1488, 1678
uric acid, 195
vasculitis, 1088, 1413, 1503, 1898
vasoconstriction, 1026

Diagnostic errors
cross-sectional studies, 1445
diagnosis, 212, 677, 849
enthesis, 677, 849
fibromyalgia, 677, 849
gout, 1445
gouty arthritis, 1445
pericarditis, 1713 (ab)
psoriatic arthritis, 677, 849
rheumatoid arthritis, 212

Diagnostic imaging
coronary artery disease, 1761
dermatomyositis, 1659
diagnosis, 1678
fluorodeoxyglucose F18, 1659
hemarthrosis, 1678
inflammatory joint disease, 1494
metacarpophalangeal joint, 1494
osteoprotegerin, 1678
polymyositis, 1659
positron-emission tomography, 1659
positron-emission tomography and computed tomography, 1761
RANK ligand, 1678
ultrasonography, 1678
vasculitis, 1761

Differential diagnosis
age of onset, 1008
ankylosing spondylitis, 1008
central nervous system vasculitis, 1026
diagnosis, 1026
signs and symptoms, 1008, 1026
vasoconstriction, 1026

Diffuse idiopathic skeletal hyperostosis
deglutition disorders, 184

Diffuse scleroderma
age of onset, 1241
fibrosis, 1241
mycophenolate mofetil, 1241
scleroderma, 1241
treatment outcome, 1241

Diphosphonates
bone density, 1215
postmenopause, 1215
rheumatoid arthritis, 1215
tomography, 1215
women's health, 1215

Disability
ankylosing spondylitis, 1710 (ab)
Japan, 476
joint diseases, 476
rheumatoid arthritis, 476, 1710 (ab)

Discitis
magnetic resonance imaging, 2332
spinal diseases, 2332
spondylarthritis, 2332

Disease activity
adult-onset Still's disease, 1399
ankylosing spondylitis, 327
anticitrullinated protein antibody, 694
arthritis, 1737 (ab), 2071
atherogenic diet, 327
biological markers, 427, 694, 1399, 1948
body mass index, 1729 (ab)
Brazil, 1948
C-reactive protein, 1709 (ab)
calgranulin A, 1399
calgranulin B, 1399
Canada, 2071
cardiovascular diseases, 210
carotid arteries, 327
certolizumab pegol, 1707 (ab)
classification, 2071
comorbidity, 86
computer assisted instruction, 1710 (ab)
cytomegalovirus, 1840
decision making, 1
diagnosis, 1948
Disease Activity Score-28, 1, 22
disease-modifying antirheumatic drugs, 2081
disease progression, 694
drug toxicity, 1035
early diagnosis, 2071, 2081
fatigue, 1775, 1807
fatty acids, 327
fatty liver, 1035
fibromyalgia, 1, 22
follistatin-related proteins, 1399
granulomatosis with polyangiitis (Wegener's), 1840
GRAPPA 2010, 427
health care costs, 1734 (ab)
hemophagocytic lymphohistiocytosis, 86
human TREM1 protein, 933
interleukin-18, 1399
interleukin-22, 1320
joints, 653
Korea, 86
lupus nephritis, 1948
monocyte chemoattractant proteins, 1948
mortality, 210, 334
nail diseases, 653
outcome assessment, 653, 1729 (ab)
outcome measures, S89–19
pathologic processes, 1, 22
patient global assessment, 2081
platelet activation, 210, 334
predictive factors, 568
prognosis, 694
psoriasis, 427, S89–19
psoriatic arthritis, 210, 334, 427, 568, 653, 1035, S89–19
psychology, 1775, 1807
remission induction, S89–19
rheumatoid arthritis, 1, 22, 694, 904, 933, 1320, 1707 (ab), 1729 (ab), 1734 (ab), 1775, 1807, 2081
rheumatoid factor, 1737 (ab)
scleroderma, 1709 (ab)
seasons, 1391
Second Update on Psoriatic Disease, S89–19
skin diseases, 653
smoking, 904
smoking cessation, 904
synovitis, 2071
systemic lupus erythematosus, 86, 1391, 1710 (ab)
T-lymphocytes, 1840
tumor necrosis factor inhibitor, 334, 568, 1035

Disease Activity Score
clinical trials, 877
drug dosage calculations, 310
drug toxicity, 310
glucocorticoids, 310
joints, 877
patient global assessment, 1155

polymyalgia rheumatica, 310
remission induction, 1155
rheumatoid arthritis, 1155
spontaneous remission, 1155
treatment outcome, 310
Disease Activity Score-28
certolizumab pegol, 1326
decision making, 1
disease activity, 1, 22
fatigue, 28
fibromyalgia, 1, 22
joints, 1334
pain threshold, 28
pathologic processes, 1, 22
rheumatoid arthritis, 1, 22, 28, 1326, 1334
Disease management
antirheumatic agents, 1497, 1559, 1583
biopsy, 295
Canada, 524, 1497, 1559, 1583, 1720 (ab), 1747 (ab)
classification, 2062
early diagnosis, 1751 (ab), 2064
fibromyalgia, 1720 (ab)
giant cell arteritis, 295
gout, 1747 (ab)
history of medicine, 1497
needs assessment, 1720 (ab)
organs at risk, 1732 (ab)
practice guideline, 1497, 1559, 1583
psoriatic arthritis, 1751 (ab)
rheumatoid arthritis, 1497, 1559, 1583, 2062, 2064
scleroderma, 1732 (ab)
systemic sclerosis, 524
temporal arteries, 295
treatment outcome, 2062
Disease-modifying antirheumatic drugs
antibodies, 1835
Canada, 707, 1713 (ab), 1730 (ab)
cohort studies, 2088
cross-sectional studies, 1867
delayed diagnosis, 707
disease activity, 2081
drug therapy, S89–67
drug toxicity, 1729 (ab)
early diagnosis, 2081
gold sodium thiomalate, 716
interstitial lung diseases, 1835
juvenile idiopathic arthritis, 1867
liver diseases, 716
methotrexate, S89–67
myositis, 1835
patient global assessment, 2081
physician's practice patterns, 2088
psoriatic arthritis, S89–67
referral and consultation, 707, 716
rheumatoid arthritis, 707, 716, 1713 (ab), 1729 (ab), 1730 (ab), 2081, 2088
Second Update on Psoriatic Disease, S89–67
Disease progression
ankylosing spondylitis, 2321
anticitrullinated protein antibody, 675, 694, 1078
atlanto-axial joint, 2321
biological markers, 434, 675, 694
biological therapy, 2049
comorbidity, 986
disease activity, 694
esophageal motility disorders, 986
GRAPPA 2010, 434
juvenile idiopathic arthritis, 1078
juvenile rheumatoid arthritis, 1723 (ab)
prevalence, 2321
prognosis, 675, 694
psoriasis, 434
psoriatic arthritis, 434
questionnaires, 434
rheumatoid arthritis, 675, 694, 2049
risk factors, 2321
scleroderma, 986
treatment outcome, 2049
Disease severity
amyloidosis, 2170
antineutrophil cytoplasmic antibodies, 2012
autoantibodies, 2127
Canada, 1850
cyclophosphamide, 2012
familial Mediterranean fever, 2170
genetic predisposition to disease, 2170
GRAPPA 2011, 2198
medical education, 2198
mortality, 2127
predictive factors, 2012
psoriasis, 2198
psoriatic arthritis, 1850, 2198
radiography, 1781
rheumatoid arthritis, 1781
siblings, 2170
single nucleotide polymorphism, 1781
systemic sclerosis, 2127
treatment, 1850
vasculitis, 2012
Disease susceptibility
African Americans, 73
Brazil, 6
genetic polymorphism, 6
human UBE2L3 protein, 73
immune system, 6
interferon-alpha, 73
mannose binding lectin, 6
rheumatoid arthritis, 6
systemic lupus erythematosus, 73
DNA copy number variations
autoimmune diseases, 1703 (ab)
gene dosage, 2142
human FCGR3B protein, 2142
IgG receptors, 2142
risk factors, 2142
Sjögren's syndrome, 2142
Doppler effect
enthesis, S89–24
fibromyalgia, S89–24
psoriatic arthritis, S89–24
Second Update on Psoriatic Disease, S89–24
ultrasonography, S89–24
Doppler ultrasonography
histology, 452
synovial membrane, 452
Drug administration routes
health care costs, 1764
methotrexate, 1764
rheumatoid arthritis, 1764
Drug administration schedule
juvenile idiopathic arthritis, 374
triamcinolone acetonide, 374
triamcinolone hexacetonide, 374
Drug dosage calculations
disease activity score, 310
drug toxicity, 310
glucocorticoids, 310
polymyalgia rheumatica, 310
treatment outcome, 310
Drug hypersensitivity
anaphylaxis, 2225
etanercept, 2225
Drug-seeking behavior
cannabinoids, 1720 (ab)
fibromyalgia, 1720 (ab)
Drug therapy
arthritis, S90–1, S90–81
cardiovascular diseases, S90–81
chondroitin, 1107
clinical trials as topic, 2066
comorbidity, S90–81
disease-modifying antirheumatic drugs, S89–67
glucosamine, 1107
golimumab, 1185, 1740 (ab)
kidney diseases, S90–81
meta-analysis, 1107
methotrexate, 1185, S89–67
osteoarthritis, 1107
pain management, S90–1
psoriatic arthritis, S89–67
review, S90–1
rheumatic diseases, 1740 (ab)
rheumatoid arthritis, 1185, 1733 (ab), 2066
Second Update on Psoriatic Disease, S89–67
3e Initiative 2010, S90–81
tumor necrosis factor inhibitor, 1733 (ab)
Drug toxicity
abatacept, 1546, 1728 (ab), 1903
allopurinol, 659
antidepressive agents, S90–21
antiglomerular basement membrane disease, 1904
antineutrophil cytoplasmic antibody-associated vasculitis, 2153
arthritis, 1735 (ab), S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62
asthma, 1903
azathioprine, 1104
calcitonin, 658
CE 224,535, 720
celecoxib, 1859
central muscle relaxants, S90–34
child, 1287
chloroquine, 1099
combination drug therapy, S90–47
comorbidity, 233, 552, 657, 1104
congenital abnormalities, 2163
coronary disease, 1099
cost-benefit analysis, S89–103
dermatomyositis, 193
diagnosis, 651
disease activity, 1035
disease activity score, 310
disease-modifying antirheumatic drugs, 1729 (ab)
drug dosage calculations, 310
etanercept, 233, 1287
fasciitis, 193
fatty liver, 1035
febuxostat, 659
gastrointestinal tract, 910
Germany, 2153
glucocorticoids, 310, 461, 552, 600, 1758
gouty arthritis, 1859
Great Britain, 1056
hydroxychloroquine, 1735 (ab)
hypersensitivity, 659
infliximab, 1500, 1539, S89–71
interferon-gamma release tests, S89–82
interstitial lung diseases, 1104
intravenous infusions, 1500, 1539
Japan, 486

juvenile idiopathic arthritis, 1287
latent tuberculosis, S89–82
leukoencephalopathies, 1906
lipids, 946
medication adherence, 1500
methotrexate, 486, 720, 1906
miliary tuberculosis, 651
mycophenolate mofetil, 658
neurotransmitter agents, S90–28
nonsteroidal antiinflammatory agents, 2163, S90–56, S90–62
ocrelizumab, 486
opioid analgesics, S90–40
osteoarthritis, 1056
osteoporosis, 461, 600, 1731 (ab)
outcome assessment, 1056
pain management, S90–34, S90–47, S90–59
paracetamol, S90–62
physician's practice patterns, 1056
polymyalgia rheumatica, 310, 552, 1758
postmenopause, 461, 600
pregnancy, 2163, S90–59
psoriasis, S89–71, S89–86
psoriatic arthritis, 1035, S89–71, S89–82, S89–86, S89–103
purinergic P2X7, 720
review, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
rheumatoid arthritis, 233, 486, 651, 720, 910, 946, 1104, 1500, 1539, 1546, 1728 (ab), 1729 (ab), 1903, 1904, 1906
rheumatoid toxicity, 657
risedronate, 1713 (ab)
risk factors, 910, 1056
rituximab, 2153
rofecoxib, 910
scleritis, 233, 1713 (ab)
Second Update on Psoriatic Disease, S89–71, S89–82, S89–86, S89–103
systemic inflammatory response syndrome, 658
systemic lupus erythematosus, 1099
teriparatide, 461, 600
3e Initiative 2010, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62
tocilizumab, 657
treatment outcome, 310, 1859, 2153
tumor necrosis factor inhibitor, 193, 651, 946, 1035, 1546, 1744 (ab), 1904, S89–82, S89–103
urinary bladder neoplasms, 1744 (ab)
ustekinumab, S89–86
zoledronic acid, 1731 (ab)

Drugs
abatacept, 1198, 1546, 1714 (ab), 1728 (ab), 1736 (ab), 1903, S89–100
adalimumab, 63, 1179, 1712 (ab), 1741 (ab), S89–77
allopurinol, 659
anakinra, 2008
antidepressive agents, S90–21
apremilast, 1709 (ab)
azathioprine, 1104
belimumab, 1632
CE 224,535, 720
celecoxib, 1859
certolizumab, 712
certolizumab pegol, 1326, 1706 (ab), 1707 (ab), 1715 (ab)
chloroquine, 1099
chondroitin, 1107
colchicine, 1458
corticosteroids, 286, S90–17
cyclophosphamide, 2012, 2111
duloxetine, 352
etanercept, 185, 233, 836, 1179, 1287, 1533, 2225, S89–74
febuxostat, 659
glucosamine, 1107
golimumab, 712, 1185, 1735 (ab), 1736 (ab), 1740 (ab), S89–90
hydroxychloroquine, 174, 1296, 1735 (ab), 1902
imatinib, 1732 (ab)
infliximab, 664, 701, 864, 1179, 1500, 1539, 1715 (ab), 1719 (ab), 1725 (ab), 1752 (ab), 2227, 2267, S89–71
leflunomide, 1171
methotrexate, 286, 486, 720, 1171, 1179, 1185, 1198, 1341, 1524, 1709 (ab), 1711 (ab), 1714 (ab), 1715 (ab), 1728 (ab), 1741 (ab), 1764, 1906, 2032, 2267, S89–67
mycophenolate mofetil, 658, 1305
neurotransmitter agents, S90–28
ocrelizumab, 486
paracetamol, S90–11, S90–62
pegloticase, 1311, 1450
propylthiouracil, 558
risedronate, 1713 (ab)
rituximab, 125, 893, 1130, 1303, 1483, 1485, 2153, 2235, 2238, 2327
rofecoxib, 910
sulfasalazine, 836
tacrolimus, 1487
teriparatide, 461, 600, 1306
tocilizumab, 60, 657, 916, 1192, 1294, S89–97
triamcinolone acetonide, 374
triamcinolone hexacetonide, 374
ustekinumab, S89–86
warfarin, 276

Duloxetine
knee, 352
osteoarthritis, 352
outcome assessment, 352
pain, 352

Dyslipidemia
apolipoproteins E, 218
genetic polymorphism, 218
inflammation, 218
metabolic syndrome, S89–24
psoriasis, S89–24
psoriatic arthritis, S89–24
rheumatoid arthritis, 218
Second Update on Psoriatic Disease, S89–24
single nucleotide polymorphism, 218
treatment outcome, S89–24

E

Early diagnosis
arthritis, 1733 (ab), 1746 (ab), 2071
Canada, 2071
classification, 2071, 2098
clinical trials as topic, 1733 (ab)
disease activity, 2071, 2081
disease management, 1751 (ab), 2064
disease-modifying antirheumatic drugs, 2081
gait, 1719 (ab)
glucocorticoids, 1732 (ab)
GRAPPA 2011, 2201
health care disparities, 2059
health care quality, access, and evaluation, 2059
Internet, 1746 (ab)
Italy, 2201
methotrexate, 1728 (ab)
New Zealand, 2098
patient global assessment, 2081
psoriasis, 2201
psoriatic arthritis, 1751 (ab), 2201
radiography, 1751 (ab)
rheumatoid arthritis, 1707 (ab), 1719 (ab), 1728 (ab), 1730 (ab), 1732 (ab), 2059, 2064, 2081, 2098
synovitis, 2071
treatment outcome, 1730 (ab)

Echocardiography
connective tissue diseases, 1265
diagnosis, 1265
infliximab, 701
left ventricular dysfunction, 701
magnetic resonance imaging, 1265
pulmonary arterial hypertension, 1265
rheumatoid arthritis, 701
stroke volume, 701
tomography, 1265

Edema
magnetic resonance imaging, 841
nail diseases, 841
onycholysis, 841
polymyalgia rheumatica, 148
psoriatic arthritis, 841
synovitis, 148

Education
arthritis, 1716 (ab)
Canada, 1718 (ab)
capillary fragility, 1113, 1248
delivery of health care, 1716 (ab)
microscopic angioscopy, 1113, 1248
pediatrics, 1718 (ab)
scleroderma, 1113, 1248

Ehlers-Danlos syndrome
acute kidney injury, 200
diagnosis, 200
renal artery, 200

Electronic health records
rheumatoid arthritis, 1721 (ab)
tumor necrosis factor inhibitor, 1721 (ab)

Employment
ethnic groups, 337
knee, 337
osteoarthritis, 337
work disability, 337

Endocarditis
adult-onset Still's disease, 199
diagnosis, 199
fever of unknown origin, 199

Endothelium
ankylosing spondylitis, 594
cell-derived microparticles, 594
comorbidity, 100
idiopathic pulmonary hypertension, 100
microvessels, 100
systemic sclerosis, 100
vasodilation, 100

Enthesis
B-lymphocytes, S89–94
comorbidity, 1979
diagnosis, 415, 677, 849

diagnostic errors, 677, 849
Doppler effect, S89–24
epidemiology, 2341
fibromyalgia, 677, 849, S89–24
GRAPPA 2010, 404, 415
health status, 2341
inflammation, 415
juvenile idiopathic arthritis, 2341
knee, 1979
ligaments, S89–11
magnetic resonance imaging, 1979
pain, 2341
psoriasis, 404, 415, 1703 (ab), 1979
psoriatic arthritis, 404, 415, 677, 849, 1703 (ab), 2045, S89–24
Second Update on Psoriatic Disease, S89–11, S89–24, S89–94
spondylarthritis, S89–11
spondylarthropathy, S89–94
synovial membrane, S89–11
synovitis, 1979
tendons, S89–11
Th17 cells, S89–94
tumor necrosis factor inhibitor, S89–94
ultrasonography, 404, 2045, S89–24
ultrasound, 404
Enthesopathy
comorbidity, 359
etiology, 203
fingers, S89–90
golimumab, S89–90
hand, 203, 359, 1481
inflammation, S89–90
knee, 359, 1481
osteoarthritis, 203, 359, 1481
psoriatic arthritis, S89–90
rheumatic diseases, 203
Second Update on Psoriatic Disease, S89–90
Eosinophilic granuloma
granulomatosis with polyangiitis (Wegener's), 1019
intravenous immunoglobulins, 1019
T-lymphocytes, 1019
treatment outcome, 1019
Epidemiology
alcohol drinking, 1363
ankylosing spondylitis, 2148
Brazil, 141
carotid arteries, 441
classification, 154
comorbidity, 441, 2148
Crohn disease, 2148
diagnosis, 154
enthesis, 2341
ethnic groups, 141
GRAPPA 2010, 441, 445
health status, 2341
incidence, 784, 2148
Japan, 1363
juvenile idiopathic arthritis, 2341
Latin America, 445
managed care programs, 784
nails, 1441
onycholysis, 1441
osteoporosis, S89–36
osteoporotic fractures, S89–36
pain, 2341
prevalence, 784
psoriasis, 441, 445, 1441
psoriatic arthritis, 154, 441, 445, 1441, S89–36
risk factors, 1363
Second Update on Psoriatic Disease, S89–36
sensitivity and specificity, 154
smoking, 1363
spondylarthritis, 445
spondylarthropathy, 2148
spondyloarthritis, 141
systemic lupus erythematosus, 1363
systemic sclerosis, 784
United States, 784
Epithelial cells
apoptosis, 1117, 1256
NF-kappa B, 1256
p38 mitogen-activated protein kinases, 1256
salivary glands, 1117, 1256
Sjögren's syndrome, 1117, 1256
Esophageal motility disorders
comorbidity, 986
disease progression, 986
scleroderma, 986
Etanercept
adalimumab, 1179
anaphylaxis, 2225
ankylosing spondylitis, 836
child, 1287
comorbidity, 233
drug hypersensitivity, 2225
drug toxicity, 233, 1287
infliximab, 1179
Italy, 1179
joints, 185
juvenile idiopathic arthritis, 1287
methotrexate, 1179
patient compliance, 1179
pharmacological biomarkers, 1533
psoriatic arthritis, 185, S89–74
radiography, 185
rheumatoid arthritis, 233, 1179, 1533
scleritis, 233
Second Update on Psoriatic Disease, S89–74
sulfasalazine, 836
treatment outcome, 836
tumor necrosis factor inhibitor, 836
Ethnic groups
ankylosing spondylitis, 1675
Arab world, 1675
arthritis, 1743 (ab)
autoimmune diseases, 1934
Brazil, 141
Canada, 1731 (ab), 1733 (ab), 2253
cardiovascular diseases, 1798
carotid arteries, 1798
employment, 337
epidemiology, 141
GRAPPA 2011, 2216
HLA-B27 antigen, 1675
knee, 337
myositis, 1733 (ab)
North American Indians, 1934
osteoarthritis, 337
pain perception, 1743 (ab)
pediatric rheumatic diseases, 1731 (ab)
Peru, 2216
pregnancy, 2253
prevalence, 1675
psoriasis, 2216
psoriatic arthritis, 2216
rheumatic diseases, 1934
rheumatoid arthritis, 1701 (ab), 1726 (ab), 1792, 1798, 2253
risk factors, 1701 (ab), 1798, 2253
sex, 759
sex characteristics, 759
spondylarthritis, 2216
spondyloarthritis, 141
systemic lupus erythematosus, 759
vitamin D, 1726 (ab), 1792
work disability, 337
Etiology
antineutrophil cytoplasmic antibodies, 4
arthritis, 1706 (ab)
B-cell lymphoma, 4
chronic pain, 655
comorbidity, 1095
dermatomyositis, 94
enthesopathy, 203
fluorescence, 1654
genetic predisposition to disease, S89–7
hand, 203
human T-lymphotropic virus 1, 809
immunologic receptors, 1654
interleukin-17, S89–15
interleukin-23, S89–15
microscopy, 1385
microvessels, 94
NADH tetrazolium reductase, 94
osteoarthritis, 203
oxidative stress, 1654
psoriatic arthritis, S89–7, S89–15
Raynaud disease, 1654
remission, 4
retinal vasculitis, 1095
rheumatic diseases, 203
salivary glands, 809
scleroderma, 1385, 1654
Second Update on Psoriatic Disease, S89–7, S89–15
Sjögren's syndrome, 809
spondylarthritis, S89–15
systemic lupus erythematosus, 1095
T-lymphocytes, S89–7
Th17 cells, S89–15
triage, 1706 (ab)
vascular diseases, 1385
whiplash injuries, 655
EULAR
genetic polymorphism, 1035
human FCGR2A protein, 1035
longitudinal studies, 1035
psoriatic arthritis, 1035
tumor necrosis factor inhibitor, 1035
Europe
ankylosing spondylitis, 2315
classification, 1687
granulomatosis with polyangiitis (Wegener's), 1687
Latin America, 2315
population characteristics, 2315
vasculitis, 1687
Exanthema
diagnosis, 195
gout, 195
uric acid, 195
Exercise
ankylosing spondylitis, 2310
body mass index, 2310
health behaviour, 672
knee, 669
knee replacement arthroplasty, 669
osteoarthritis, 669, 672
risk reduction behavior, 672
signs and symptoms, 2310

F

Facial pain
juvenile idiopathic arthritis, 2352
temporomandibular joint disorders, 2352
Factor VIII
giant cell arteritis, 1705 (ab)

Familial Mediterranean fever
amyloidosis, 2170
disease severity, 2170
genetic predisposition to disease, 2170
siblings, 2170
Fasciitis
dermatomyositis, 193
drug toxicity, 193
tumor necrosis factor inhibitor, 193
Fatigue
certolizumab pegol, 1706 (ab)
disease activity, 1775, 1807
Disease Activity Score-28, 28
pain threshold, 28
psychology, 1775, 1807
rheumatoid arthritis, 28, 1706 (ab), 1775, 1807
Fatty acids
ankylosing spondylitis, 327
atherogenic diet, 327
carotid arteries, 327
disease activity, 327
Fatty liver
disease activity, 1035
drug toxicity, 1035
psoriatic arthritis, 1035
tumor necrosis factor inhibitor, 1035
Febuxostat
allopurinol, 659
drug toxicity, 659
hypersensitivity, 659
Female genitalia
vasculitis, 2229
Femur neck
bone density, 1465
mitochondrial DNA, 1465
osteoporosis, 1465
postmenopause, 1465
women's health, 1465
Fetal development
rheumatoid arthritis, 1718 (ab)
smoking, 1718 (ab)
Fever of unknown origin
adult-onset Still's disease, 199
diagnosis, 199, 875
endocarditis, 199
Japan, 875
marenostrin, 875
mutation, 875
Fibrinogen
rheumatoid arthritis, 1704 (ab)
Fibromyalgia
Canada, 1720 (ab)
cannabinoids, 1720 (ab)
decision making, 1
diagnosis, 677, 849, 1294, 1749 (ab), 1750 (ab), 2221
diagnostic errors, 677, 849
disease activity, 1, 22
Disease Activity Score-28, 1, 22
disease management, 1720 (ab)
Doppler effect, S89–24
drug-seeking behavior, 1720 (ab)
enthesis, 677, 849, S89–24
needs assessment, 1720 (ab)
opioid analgesics, 1749 (ab)
pain measurement, 1749 (ab)
pathologic processes, 1, 22
psoriatic arthritis, 677, 849, 2221, S89–24
rheumatoid arthritis, 1, 22
Second Update on Psoriatic Disease, S89–24
signs and symptoms, 1294, 1750 (ab)
treatment outcome, 1749 (ab)
ultrasonography, S89–24
Fibrosis
age of onset, 1241
connective tissue growth factor, 1703 (ab)
diffuse scleroderma, 1241
galectin 3, 539
genetic predisposition to disease, 2294
immune system, 539
interleukin-6, 2294
mycophenolate mofetil, 1241
pathologic angiogenesis, 539
scleroderma, 1241, 1703 (ab)
systemic sclerosis, 539, 2294
treatment outcome, 1241
Fingers
comorbidity, 1895
enthesopathy, S89–90
gangrene, 1895
golimumab, S89–90
inflammation, S89–90
meta-analysis, 1742 (ab)
psoriatic arthritis, S89–90
scleroderma, 1742 (ab)
Second Update on Psoriatic Disease, S89–90
systemic lupus erythematosus, 1895
systemic sclerosis, 1895
Finland
comorbidity, 377
diabetes mellitus, 377
juvenile idiopathic arthritis, 377
Fluorescence
etiology, 1654
immunologic receptors, 1654
oxidative stress, 1654
Raynaud disease, 1654
scleroderma, 1654
Fluorodeoxyglucose F18
dermatomyositis, 1659
diagnostic imaging, 1659
polymyositis, 1659
positron-emission tomography, 1659
Follistatin-related proteins
adult-onset Still's disease, 1399
biological markers, 1399
calgranulin A, 1399
calgranulin B, 1399
disease activity, 1399
interleukin-18, 1399
France
autoimmune diseases, 532
autoimmunity, 532, 893
genetic predisposition to disease, 532
psoriasis, 893
rheumatoid arthritis, 893
rituximab, 893
systemic sclerosis, 532

G

G-protein-coupled receptors
genetic predisposition to disease, 1166
rheumatoid arthritis, 1166
risk factors, 1166
Gait
early diagnosis, 1719 (ab)
rheumatoid arthritis, 1719 (ab)
Galectin 3
fibrosis, 539
immune system, 539
pathologic angiogenesis, 539
systemic sclerosis, 539
Gangrene
comorbidity, 1895
fingers, 1895
systemic lupus erythematosus, 1895
systemic sclerosis, 1895
Gastroesophageal reflux disease
interstitial lung diseases, 1707 (ab)
scleroderma, 1707 (ab)
Gastrointestinal tract
arthritis, S90–74
comorbidity, 1355, S90–74
drug toxicity, 910
liver, S90–74
pain management, S90–74
quality of life, 992
rheumatoid arthritis, 910, 1355
risk factors, 910, 1355
rofecoxib, 910
scleroderma, 992
3e Initiative 2010, S90–74
Gene dosage
DNA copy number variations, 2142
human FCGR3B protein, 2142
IgG receptors, 2142
risk factors, 2142
Sjögren's syndrome, 2142
Gene expression
biopsy, 1942
glomerulonephritis, 1942
glycosylation, 916
immunoglobulin G, 916
lupus nephritis, 1942
pharmacological biomarkers, 916
rheumatoid arthritis, 916
systemic lupus erythematosus, 1942
tocilizumab, 916
Genetic markers
immunoglobulin G, 2048
risk factors, 2048
Genetic polymorphism
androgen receptors, 10
angiotensin-converting enzyme inhibitors, 686
ankylosing spondylitis, 135
apolipoproteins E, 218
Brazil, 6
cardiovascular diseases, 939
disease susceptibility, 6
dyslipidemia, 218
EULAR, 1035
genetic predisposition to disease, 135, 1603, 1755
growth differentiation factor 15, 939
human FCGR2A protein, 1035
human IL12B protein, 135
immune system, 6
INDEL mutation, 686
inflammation, 218
interleukin-1a, 1755
juvenile idiopathic arthritis, 2032
longitudinal studies, 1035
lupus nephritis, 686
mannose binding lectin, 6
meta-analysis, 686
methotrexate, 2032
psoriatic arthritis, 1035
rheumatoid arthritis, 6, 10, 218, 939
risk factors, 1603
scleroderma, 1755
single nucleotide polymorphism, 218
systemic lupus erythematosus, 686, 1603
thrombosis, 1603
tumor necrosis factor inhibitor, 1035
women's health, 10
Genetic predisposition to disease
amyloidosis, 2170
ankylosing spondylitis, 131, 135, 1756, 1765
anticitrullinated protein antibody, 1490
autoantibodies, 997, 1238
autoimmune diseases, 532
autoimmunity, 532
biological markers, S89–106
biomedical research, S89–106

diagnosis, S89–106
disease severity, 2170
etiology, S89–7
familial Mediterranean fever, 2170
fibrosis, 2294
France, 532
G-protein-coupled receptors, 1166
genetic polymorphism, 135, 1603, 1755
human ANKH protein, 131, 1756
human CCR6 protein, 1765
human IL12B protein, 135
human TNFSF4 protein, 997
interferon-alpha, 1238
interleukin-6, 2294
interleukin-1a, 1755
kidney calculi, 1756
meta-analysis, 997
morbidity, 131
psoriatic arthritis, S89–7, S89–106
rheumatoid arthritis, 1166, 1490, 1765
risk factors, 1166, 1603
scleroderma, 997, 1755
Second Update on Psoriatic Disease, S89–7, S89–106
siblings, 2170
single nucleotide polymorphism, 1765
systemic lupus erythematosus, 1238, 1603
systemic sclerosis, 106, 532, 2294
T-lymphocytes, S89–7
Taiwan, 1765
thrombosis, 1603
Turkey, 106
urotensin II, 106
Genetic variation
gout, 1901
uric acid, 1901
Genome-wide association study
biological markers, 2193
comorbidity, 2193
GRAPPA 2010, 431
GRAPPA 2011, 2193
psoriasis, 431, 2193
psoriatic arthritis, 431, 2193
Germany
antineutrophil cytoplasmic antibody-associated vasculitis, 2153
drug toxicity, 2153
rituximab, 2153
treatment outcome, 2153
Giant cell arteritis
aged, 665
amyloidosis, 878
aortic aneurysm, 2157
aortitis, 2157
arteries, 314
autoimmune diseases, 1275
biopsy, 295
carotid arteries, 1898
color Doppler ultrasonography, 314, 1898
comorbidity, 665, 878
diagnosis, 314, 1898, 1909
disease management, 295
factor VIII, 1705 (ab)
ischemia, 314
myocarditis, 665
physical examination, 303
polymyalgia rheumatica, 878
positron-emission tomography and computed tomography, 1909
prognosis, 2157
risk factors, 1275
scleroderma, 1275
single nucleotide polymorphism, 1275
Takayasu arteritis, 303
temporal arteries, 295
TNF receptor-associated factor 6, 1275
vasculitis, 303, 1898
Glomerulonephritis
biopsy, 1942
gene expression, 1942
lupus nephritis, 1942
systemic lupus erythematosus, 1942
Glucocorticoids
bone density, 1955
cardiovascular system, 1758
comorbidity, 552
disease activity score, 310
drug dosage calculations, 310
drug toxicity, 310, 461, 552, 600, 1758
early diagnosis, 1732 (ab)
H1N1 subtype influenza A virus, 167
inflammation, 1758
influenza vaccines, 167
organs at risk, 1955
osteoporosis, 461, 600
pediatric rheumatic diseases, 167
polymyalgia rheumatica, 310, 552, 1758
postmenopause, 461, 600
rheumatic diseases, 1758
rheumatoid arthritis, 1732 (ab)
systemic lupus erythematosus, 1955
teriparatide, 461, 600
treatment outcome, 310
Glucosamine
chondrocytes, 635
chondroitin, 1107
drug therapy, 1107
meta-analysis, 1107
osteoarthritis, 635, 1107
prostaglandin synthase, 635
Glycosylation
biological markers, 463
gene expression, 916
immunoglobulin G, 463, 916
joints, 463
mannose binding lectin, 463
pharmacological biomarkers, 916
rheumatoid arthritis, 463, 916
tocilizumab, 916
Gold sodium thiomalate
disease-modifying antirheumatic drugs, 716
liver diseases, 716
referral and consultation, 716
rheumatoid arthritis, 716
Golimumab
certolizumab, 712
drug therapy, 1185, 1740 (ab)
enthesopathy, S89–90
fingers, S89–90
inflammation, S89–90
joints, 1736 (ab)
managed care programs, 1740 (ab)
medication adherence, 1740 (ab)
meta-analysis, 712
methotrexate, 1185
psoriatic arthritis, 1735 (ab), 1736 (ab), 1740 (ab), S89–90
remission induction, 1736 (ab)
rheumatic diseases, 1740 (ab)
rheumatoid arthritis, 712, 1185
risk assessment, 712
Second Update on Psoriatic Disease, S89–90
skin neoplasms, 712
treatment outcome, 1735 (ab)
Gout
Canada, 1747 (ab)
cardiovascular diseases, 1311
colchicine, 1458
comorbidity, 1311
cross-sectional studies, 1445
diagnosis, 183, 195, 1314
diagnostic errors, 1445
disease management, 1747 (ab)
exanthema, 195
genetic variation, 1901
gouty arthritis, 1314, 1445
hyperuricemia, 1314
inflammation, 183
mortality, 1458
myocardial infarction, 1458
pegloticase, 1311, 1450
prevalence, 1458
quality of life, 1311, 1450
radiography, 874
thermography, 183
treatment outcome, 1450
ultrasound, 2362
uric acid, 195, 1901, 2362
Gouty arthritis
ankle, 868
bone fractures, 868
celecoxib, 1859
cross-sectional studies, 1445
diagnosis, 868, 1314
diagnostic errors, 1445
drug toxicity, 1859
gout, 1314, 1445
hyperuricemia, 1314
talus, 868
treatment outcome, 1859
Granulomatosis with polyangiitis (Wegener's)
antineutrophil cytoplasmic antibodies, 2053
classification, 1687
comorbidity, 2053
cytomegalovirus, 1840
disease activity, 1840
eosinophilic granuloma, 1019
Europe, 1687
intravenous immunoglobulins, 1019
meningitis, 2053
renal insufficiency, 2053
T-lymphocytes, 1019, 1840
treatment outcome, 1019
vasculitis, 1687
GRAPPA 2010
biological markers, 423, 427, 434
carotid arteries, 441
comorbidity, 437, 441
diagnosis, 413, 415, 418
disease activity, 427
disease progression, 434
enthesis, 404, 415
epidemiology, 441, 445
genome-wide association study, 431
GRAPPA Trainees Symposium, 394
inflammation, 415, 418
Latin America, 445
magnetic resonance imaging, 408
medical education, 394
metabolic syndrome, 437
multimedia, 421
musculoskeletal diseases, 413
outcome measures, 398
physical examination, 421
psoriasis, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445
psoriatic arthritis, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445
questionnaires, 434
spinal diseases, 418
spondylarthritis, 413, 445

ultrasonography, 404
ultrasound, 404
GRAPPA 2011
biological markers, 2181, 2189, 2193
comorbidity, 2193, 2204
disease severity, 2198
early diagnosis, 2201
ethnic groups, 2216
genome-wide association study, 2193
Italy, 2201
medical education, 2184, 2198
musculoskeletal diseases, 2214
outcome measures, 2181, 2196
Peru, 2216
psoriasis, 2181, 2184, 2193, 2196, 2198, 2201, 2204, 2216
psoriatic arthritis, 2181, 2184, 2189, 2193, 2196, 2198, 2201, 2204, 2211, 2216
radiography, 2189
spondylarthritis, 2216
ultrasound, 2211
GRAPPA Trainees Symposium
GRAPPA 2010, 394
medical education, 394
psoriasis, 394
psoriatic arthritis, 394
Great Britain
abatacept, 1198
biological therapy, 1198
drug toxicity, 1056
methotrexate, 1198
osteoarthritis, 1056
outcome assessment, 1056
physician's practice patterns, 1056
review, 1198
rheumatoid arthritis, 1198
risk factors, 1056
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
See GRAPPA
Growth differentiation factor 15
cardiovascular diseases, 939
genetic polymorphism, 939
rheumatoid arthritis, 939

H

Hand
amputation, 1648
arthritis, 1739 (ab)
arthroplasty, 1727 (ab)
comorbidity, 359
diagnosis, 1700
enthesopathy, 203, 359, 1481
etiology, 203
juvenile idiopathic arthritis, 1727 (ab)
knee, 359, 1481
longitudinal studies, 1648
magnetic resonance imaging, 1700, S89–44
osteoarthritis, 203, 359, 1481
psoriatic arthritis, 1700, S89–44
rheumatic diseases, 203
rheumatoid arthritis, S89–44
scleroderma, 1648
Second Update on Psoriatic Disease, S89–44
synovitis, S89–44
thermography, 1739 (ab)
Hand joints
cartilage, 161
knee, 161
magnetic resonance imaging, 161
osteoarthritis, 161
osteophyte, 161
Handheld computers
arthritis, 1751 (ab)
questionnaires, 1751 (ab)
Health Assessment Questionnaire
health status, 54
mortality, 54
quality of life, 54
rheumatoid arthritis, 54
Health behavior
exercise, 672
osteoarthritis, 672
risk reduction behavior, 672
Health care costs
disease activity, 1734 (ab)
drug administration routes, 1764
health resources, 2303
hospitalization, 1611
methotrexate, 1764
rheumatic diseases, 1741 (ab)
rheumatoid arthritis, 1734 (ab), 1764
risk factors, 1611
stroke, 1611
systemic lupus erythematosus, 1611
systemic sclerosis, 2303
Taiwan, 1611
United States, 2303
Health care disparities
early diagnosis, 2059
health care quality, access, and evaluation, 2059
rheumatoid arthritis, 2059
Health care quality, access, and evaluation
early diagnosis, 2059
health care disparities, 2059
rheumatoid arthritis, 2059
Health care quality assurance
Canada, 1717 (ab)
rheumatoid arthritis, 1717 (ab)
Health resources
health care costs, 2303
systemic sclerosis, 2303
United States, 2303
Health services accessibility
arthritis, 1749 (ab)
biological therapy, 1875
Canada, 1705 (ab), 1875
juvenile idiopathic arthritis, 1875
pediatric rheumatic diseases, 1705 (ab)
process assessment "(health care)", 1749 (ab)
socioeconomic factors, 1748 (ab)
specialization, 1748 (ab)
Health status
enthesis, 2341
epidemiology, 2341
Health Assessment Questionnaire, 54
juvenile idiopathic arthritis, 856, 2341
mortality, 54
outcome measures, 856
pain, 2341
quality of life, 54
rheumatoid arthritis, 54
Heart diseases
comorbidity, 206, 269
stem cell transplantation, 206, 269
systemic sclerosis, 206, 269
treatment outcome, 206, 269
Hemarthrosis
diagnosis, 1678
diagnostic imaging, 1678
osteoprotegerin, 1678
RANK ligand, 1678
ultrasonography, 1678
Hematologic neoplasms
Korea, 226
mortality, 226
rheumatoid arthritis, 226
Hematoma
arthritis, 2361
shoulder joint, 2361
Hematuria
biopsy, 1413
diagnosis, 1413
remission induction, 1413
vasculitis, 1413
Hemophagocytic lymphohistiocytosis
comorbidity, 86, 1745 (ab)
dermatomyositis, 1745 (ab)
disease activity, 86
Korea, 86
systemic lupus erythematosus, 86
Hepatitis B antibodies
autoimmune diseases, 1291
immunosuppression, 1291
risk factors, 1291
Hepatitis B virus
comorbidity, 974
prevalence, 974
systemic lupus erythematosus, 974
Hepatitis C
rheumatic diseases, 1726 (ab)
Hip
knee, 1047
knee osteoarthritis, 1064, 1738 (ab)
osteoarthritis, 1047, 1064
patient education, 1047
quality of life, 1047
questionnaires, 1064
reproducibility of results, 1064
self care, 1047, 1738 (ab)
Hip fractures
Canada, 1378
osteoporosis, 1378
risk factors, 1378
systemic lupus erythematosus, 1378
Histological techniques
articular cartilage, 890
chondrocytes, 890
Histology
Doppler ultrasonography, 452
synovial membrane, 452
Histones
neutrophils, 1619
phagocytosis, 1619
systemic lupus erythematosus, 1619
History of medicine
antirheumatic agents, 1497
Canada, 1497
disease management, 1497
practice guideline, 1497
rheumatoid arthritis, 1497
HLA-B27 antigen
ankylosing spondylitis, 1675
ankylosis, 2177
Arab world, 1675
ethnic groups, 1675
interferon-gamma, 574
prevalence, 1675
psoriatic arthritis, 1723 (ab), 2177
spondylarthropathy, 574
unfolded protein response, 574
H1N1 subtype influenza A virus
glucocorticoids, 167
influenza vaccines, 167
pediatric rheumatic diseases, 167
Home care services
blind loop syndrome, 1004
intestinal pseudo-obstruction, 1004
parenteral nutrition, 1004
scleroderma, 1004

Hospital outpatient clinics
Canada, 1074
database, 1074
systemic lupus erythematosus, 1074
Hospitalization
Canada, 1708 (ab)
health care costs, 1611
referral and consultation, 1743 (ab)
rheumatic diseases, 1743 (ab)
risk factors, 1611
stroke, 1611
systemic lupus erythematosus, 1611, 1708 (ab)
Taiwan, 1611
Human ADAMTS1 protein
chondrocytes, 621
MAP kinase 1, 621
matrix metalloproteinases, 621
osteoarthritis, 621
pathologic processes, 621
Human ANKH protein
ankylosing spondylitis, 131, 1756
genetic predisposition to disease, 131, 1756
kidney calculi, 1756
morbidity, 131
Human AQP4 protein
myelitis, 871
rhupus syndrome, 871
Human CC18 protein
biological markers, 1407
diagnosis, 1407
inflammation, 1407
retroperitoneal fibrosis, 1407
Human CCR6 protein
ankylosing spondylitis, 1765
genetic predisposition to disease, 1765
rheumatoid arthritis, 1765
single nucleotide polymorphism, 1765
Taiwan, 1765
Human FCGR2A protein
EULAR, 1035
genetic polymorphism, 1035
longitudinal studies, 1035
psoriatic arthritis, 1035
tumor necrosis factor inhibitor, 1035
Human FCGR3B protein
DNA copy number variations, 2142
gene dosage, 2142
IgG receptors, 2142
risk factors, 2142
Sjögren's syndrome, 2142
Human IL12B protein
ankylosing spondylitis, 135
genetic polymorphism, 135
genetic predisposition to disease, 135
Human IL4R protein
human IL13RA1 protein, 112
single nucleotide polymorphism, 112
systemic sclerosis, 112
Human IL13RA1 protein
human IL4R protein, 112
single nucleotide polymorphism, 112
systemic sclerosis, 112
Human LCN2 protein
biological markers, 1231
lupus nephritis, 1231
systemic lupus erythematosus, 1231
vascular cell adhesion molecule-1, 1231
Human MBD4 protein
China, 1159
molecular epidemiology, 1159
peptidylarginine deiminase type IV, 1159
rheumatoid arthritis, 1159
Human NOD2 protein
synovitis, 1888
Takayasu arteritis, 1888
vasculitis, 1888
Human T-lymphotropic virus 1
etiology, 809
salivary glands, 809
Sjögren's syndrome, 809
Human TNFSF4 protein
autoantibodies, 997
genetic predisposition to disease, 997
meta-analysis, 997
scleroderma, 997
Human TREM1 protein
disease activity, 933
rheumatoid arthritis, 933
Human UBE2L3 protein
African Americans, 73
disease susceptibility, 73
interferon-alpha, 73
systemic lupus erythematosus, 73
Hyaluronic acid
apoptosis, 1473
articular cartilage, 1473
chondrocytes, 1473
synovial fluid, 1473
Hydroxychloroquine
adolescent, 174
arthritis, 1735 (ab)
drug toxicity, 1735 (ab)
Japan, 1296
joint diseases, 1902
nonsteroidal antiinflammatory agents, 1902
patient compliance, 174
rheumatic diseases, 1296
systemic lupus erythematosus, 174
telecommunications, 174
young adult, 174
Hydroxymethylglutaryl-CoA reductase inhibitors
cardiovascular diseases, 32
cholesterol, 32
mortality, 32
osteoarthritis, 32
rheumatoid arthritis, 32
Hyperostosis
deglutition disorders, 1482
Hypersensitivity
allopurinol, 659
drug toxicity, 659
febuxostat, 659
Hypertrophy
ankylosing spondylitis, 583
ankylosis, 583
beta catenin, 583
chondrocytes, 583
Hyperuricemia
diagnosis, 1314
gout, 1314
gouty arthritis, 1314
Hypothyroidism
cardiovascular diseases, 954
diagnosis, 885
rheumatoid arthritis, 885, 954
risk factors, 885, 954

I

Idiopathic pulmonary hypertension
comorbidity, 100
endothelium, 100
microvessels, 100
systemic sclerosis, 100
vasodilation, 100
IgG receptors
DNA copy number variations, 2142
gene dosage, 2142
human FCGR3B protein, 2142
risk factors, 2142
Sjögren's syndrome, 2142
Image enhancement
central nervous system vasculitis, 2051
magnetic resonance imaging, 2051
Imatinib
biological markers, 1732 (ab)
scleroderma, 1732 (ab)
Immune system
Brazil, 6
disease susceptibility, 6
fibrosis, 539
galectin 3, 539
genetic polymorphism, 6
mannose binding lectin, 6
pathologic angiogenesis, 539
rheumatoid arthritis, 6
systemic sclerosis, 539
Immunoassay
diagnosis, 1721 (ab)
rheumatic diseases, 1721 (ab)
Immunoglobulin G
biological markers, 463
gene expression, 916
genetic markers, 2048
glycosylation, 463, 916
joints, 463
mannose binding lectin, 463
pharmacological biomarkers, 916
rheumatoid arthritis, 463, 916
risk factors, 2048
tocilizumab, 916
Immunoglobulin light chains
rheumatoid arthritis, 1130
rituximab, 1130
Immunologic receptors
etiology, 1654
fluorescence, 1654
oxidative stress, 1654
Raynaud disease, 1654
scleroderma, 1654
Immunosuppression
antisynthetase syndrome, 1299
autoimmune diseases, 1291
comorbidity, 1299
hepatitis B antibodies, 1291
polymyositis, 1299
progressive multifocal leukoencephalopathy, 1299
review, 1299
risk factors, 1291
Incidence
ankylosing spondylitis, 2148
comorbidity, 2148
Crohn disease, 2148
epidemiology, 784, 2148
managed care programs, 784
prevalence, 784
spondylarthropathy, 2148
systemic sclerosis, 784
United States, 784
Inclusion body myositis
dermatomyositis, 1744 (ab)
diagnosis, 1744 (ab)
INDEL mutation
angiotensin-converting enzyme inhibitors, 686
genetic polymorphism, 686
lupus nephritis, 686
meta-analysis, 686
systemic lupus erythematosus, 686
Infection
calcinosis, 2043
comorbidity, 1297, 1772, 1814, 2043
inflammatory bowel diseases, 2179
knee, 2043
latent tuberculosis, 1297
longitudinal studies, 1745 (ab), 1746 (ab)
miliary tuberculosis, 1297
periostitis, 2179

psoriatic arthritis, 1745 (ab), 1746 (ab)
systemic lupus erythematosus, 1772, 1814
systemic sclerosis, 2043
tumor necrosis factor inhibitor, 1297
Infectious arthritis
Candida, 1308
comorbidity, 157
review, 1308
synovial fluid, 157
Inflammation
adverse effects, 2359
apolipoproteins E, 218
biological markers, 1407
cardiovascular system, 1758
comorbidity, 2359
dermatomyositis, 2359
diagnosis, 183, 415, 418, 1407
dyslipidemia, 218
enthesis, 415
enthesopathy, S89–90
fingers, S89–90
genetic polymorphism, 218
glucocorticoids, 1758
golimumab, S89–90
gout, 183
GRAPPA 2010, 415, 418
human CC18 protein, 1407
interleukin-6, S89–97
paraneoplastic syndromes, 2359
psoriasis, 415, 418, S89–97
psoriatic arthritis, 415, 418, S89–90, S89–97
retroperitoneal fibrosis, 1407
rheumatic diseases, 1758
rheumatoid arthritis, 218
Second Update on Psoriatic Disease, S89–90, S89–97
single nucleotide polymorphism, 218
socioeconomic factors, 1701 (ab)
spinal diseases, 418
systemic lupus erythematosus, 1701 (ab)
thermography, 183
tocilizumab, S89–97
treatment outcome, 2359
Inflammation mediators
interleukin-6, 1708 (ab)
scleroderma, 1708 (ab)
Inflammatory bowel diseases
infection, 2179
periostitis, 2179
Inflammatory joint disease
diagnostic imaging, 1494
metacarpophalangeal joint, 1494
Infliximab
adalimumab, 1179
ankylosing spondylitis, 1725 (ab)
Canada, 1715 (ab), 1725 (ab), 1752 (ab)
central nervous system vasculitis, 2227
comorbidity, 2267
drug toxicity, 1500, 1539, S89–71
echocardiography, 701
etanercept, 1179
intravenous infusions, 1500, 1539
Italy, 1179
Kawasaki disease, 864
left ventricular dysfunction, 701
medication adherence, 1500
medication therapy management, 1752 (ab)
methotrexate, 1179, 2267
mucocutaneous lymph node syndrome, 864
patient compliance, 1179
plasma exchange, 864
psoriasis, S89–71
psoriatic arthritis, S89–71
radiography, 664
rheumatoid arthritis, 701, 1179, 1500, 1539, 1715 (ab), 1719 (ab), 1752 (ab), 2267
sarcoidosis, 664
Second Update on Psoriatic Disease, S89–71
stroke volume, 701
treatment outcome, 864, 1719 (ab), 2227
vascular stiffness, 2267
Influenza vaccines
glucocorticoids, 167
H1N1 subtype influenza A virus, 167
pediatric rheumatic diseases, 167
Information dissemination
Internet, 883, 899
patient education, 883, 899
rheumatoid arthritis, 899
Intercellular signaling peptides and proteins
antinuclear antibodies, 2104
autoimmune diseases, 2104
rheumatic diseases, 2104
systemic lupus erythematosus, 2104
Interdisciplinary communication
central nervous system lupus vasculitis, 2118
diagnosis, 2118
neurologic manifestations, 2118
systemic lupus erythematosus, 2118
Interferon-alpha
African Americans, 73
autoantibodies, 1238
biological markers, 504
central nervous system lupus vasculitis, 504
disease susceptibility, 73
genetic predisposition to disease, 1238
human UBE2L3 protein, 73
systemic lupus erythematosus, 73, 504, 1238
Interferon-gamma
chemokine CCL2, 979
HLA-B27 antigen, 574
interleukin-6, 979
scleroderma, 979
spondylarthropathy, 574
tumor necrosis factor inhibitor, 979
unfolded protein response, 574
Interferon-gamma release tests
drug toxicity, S89–82
latent tuberculosis, S89–82
psoriatic arthritis, S89–82
Second Update on Psoriatic Disease, S89–82
tumor necrosis factor inhibitor, S89–82
Interleukin-1
adult-onset Still's disease, 2008
anakinra, 2008
Wissler's syndrome, 2008
Interleukin-6
chemokine CCL2, 979
cytokines, 1120
dendritic cells, 1192
fibrosis, 2294
genetic predisposition to disease, 2294
inflammation, S89–97
inflammation mediators, 1708 (ab)
interferon-gamma, 979
monocytes, 1192
psoriasis, 2055, S89–97
psoriatic arthritis, S89–97
rheumatoid arthritis, 60, 1192
scleroderma, 979, 1120, 1708 (ab)
Second Update on Psoriatic Disease, S89–97
sleep disorders, 60
spondylarthritis, 1097
systemic sclerosis, 2294
tocilizumab, 60, 1192, S89–97
tumor necrosis factor inhibitor, 979, 2055
Interleukin-17
comorbidity, 870
etiology, S89–15
interleukin-23, S89–15
posterior leukoencephalopathy syndrome, 870
psoriatic arthritis, S89–15
Second Update on Psoriatic Disease, S89–15
spondylarthritis, S89–15
systemic lupus erythematosus, 870
Th17 cells, S89–15
vascular endothelial growth factors, 870
Interleukin-18
adult-onset Still's disease, 1399, 2000
biological markers, 1399
calgranulin A, 1399
calgranulin B, 1399
disease activity, 1399
follistatin-related proteins, 1399
Korea, 2000
natural killer cells, 2000
Interleukin-21
B-lymphocytes, 1819
systemic lupus erythematosus, 1819
T-lymphocytes, 1819
Interleukin-22
disease activity, 1320
rheumatoid arthritis, 1320, 2220
Interleukin-23
etiology, S89–15
interleukin-17, S89–15
psoriatic arthritis, s89–15
Second Update on Psoriatic Disease, s89–15
spondylarthritis, S89–15
Th17 cells, S89–15
Interleukin-1a
genetic polymorphism, 1755
genetic predisposition to disease, 1755
scleroderma, 1755
Internet
arthritis, 1746 (ab)
cross-sectional studies, 1739 (ab)
diagnosis, 1746 (ab)
early diagnosis, 1746 (ab)
information dissemination, 883, 899
medical education, 1744 (ab)
patient education, 883, 899
rheumatoid arthritis, 899
Wegener granulomatosis, 1739 (ab)
Interstitial lung diseases
antibodies, 1835
azathioprine, 1104
comorbidity, 1104
disease-modifying antirheumatic drugs, 1835
drug toxicity, 1104
gastroesophageal reflux disease, 1707 (ab)
myositis, 1835
rheumatoid arthritis, 1104

scleroderma, 1707 (ab)
Intervertebral disc displacement
ankylosing spondylitis, 1996
delayed diagnosis, 1996
diagnosis, 1996
low back pain, 1996
lumbar vertebrae, 1996
Intestinal pseudo-obstruction
blind loop syndrome, 1004
home care services, 1004
parenteral nutrition, 1004
scleroderma, 1004
Intravenous immunoglobulins
autoimmune diseases, 450
eosinophilic granuloma, 1019
granulomatosis with polyangiitis (Wegener's), 1019
regulatory T-lymphocytes, 450
T-lymphocytes, 1019
treatment outcome, 1019
Intravenous infusions
drug toxicity, 1500, 1539
infliximab, 1500, 1539
medication adherence, 1500
rheumatoid arthritis, 1500, 1539
Ischemia
arteries, 314
cardiac imaging techniques, 448
color Doppler ultrasonography, 314
diagnosis, 314, 448
giant cell arteritis, 314
myocarditis, 448
systemic lupus erythematosus, 448
Italy
adalimumab, 1179
early diagnosis, 2201
etanercept, 1179
GRAPPA 2011, 2201
infliximab, 1179
methotrexate, 1179
patient compliance, 1179
psoriasis, 2201
psoriatic arthritis, 2201
rheumatoid arthritis, 1179

J

Japan
alcohol drinking, 1363
antineutrophil cytoplasmic antibodies, 545
diagnosis, 875
disability, 476
drug toxicity, 486
epidemiology, 1363
fever of unknown origin, 875
hydroxychloroquine, 1296
joint diseases, 476
marenostrin, 875
methotrexate, 486
microscopic polyangiitis, 545
mutation, 875
ocrelizumab, 486
recurrence, 545
rheumatic diseases, 1296
rheumatoid arthritis, 476, 486
risk factors, 545, 1363
smoking, 1363
systemic lupus erythematosus, 1363
Joint diseases
disability, 476
hydroxychloroquine, 1902
Japan, 476
nonsteroidal antiinflammatory agents, 1902
rheumatoid arthritis, 476
Joints
biological markers, 463
certolizumab pegol, 1715 (ab)
clinical competence, 1207
clinical trials, 877
disease activity, 653
disease activity score, 877
Disease Activity Score-28, 1334
etanercept, 185
glycosylation, 463
golimumab, 1736 (ab)
immunoglobulin G, 463
mannose binding lectin, 463
methotrexate, 1715 (ab)
nail diseases, 653
outcome assessment, 653
palpation, 1207
psoriatic arthritis, 185, 653, 1736 (ab)
radiography, 185
rheumatoid arthritis, 463, 1207, 1334, 1715 (ab)
skin diseases, 653
tomography, 1735 (ab)
ultrasound, 1207
Juvenile idiopathic arthritis
See also Juvenile rheumatoid arthritis
adalimumab, 1712 (ab)
anticitrullinated protein antibody, 1078
arthroplasty, 1727 (ab)
biological therapy, 1875
blood, 2021
bone density, 365
Canada, 1875
child, 1287
comorbidity, 377
compression fractures, 365
cost-benefit analysis, 1712 (ab)
cross-sectional studies, 1867
diabetes mellitus, 377
diagnosis, 645, 1778
disease-modifying antirheumatic drugs, 1867
disease progression, 1078
drug administration schedule, 374
drug toxicity, 1287
enthesis, 2341
epidemiology, 2341
etanercept, 1287
facial pain, 2352
Finland, 377
genetic polymorphism, 2032
hand, 1727 (ab)
health services accessibility, 1875
health status, 856, 2341
magnetic resonance imaging, 645
methotrexate, 2032
outcome measures, 856
pain, 2341
prevalence, 365
protease inhibitors, 2021
questionnaires, 1750 (ab)
radiography, 645
regulatory T-lymphocytes, 2021
risk factors, 1880
spine, 365
synovial fluid, 2021
temporomandibular joint disorders, 1778, 1880, 2352
Th17 cells, 2021
tocilizumab, 1294
triamcinolone acetonide, 374
triamcinolone hexacetonide, 374
uveitis, 1294
Juvenile-onset ankylosing spondylitis
age of onset, 887, 1013
ankylosing spondylitis, 887, 1013
signs and symptoms, 1013
treatment outcome, 1013
Juvenile rheumatoid arthritis
See also Juvenile idiopathic arthritis
disease progression, 1723 (ab)

K

Kawasaki disease
infliximab, 864
mucocutaneous lymph node syndrome, 864
plasma exchange, 864
treatment outcome, 864
Kidney calculi
ankylosing spondylitis, 1756
genetic predisposition to disease, 1756
human ANKH protein, 1756
Kidney diseases
arthritis, S90–81
cardiovascular diseases, S90–81
comorbidity, S90–81
drug therapy, S90–81
3e Initiative 2010, S90–81
Knee
calcinosis, 2043
capsaicin, 610
cartilage, 161
comorbidity, 359, 1979, 2043
duloxetine, 352
employment, 337
enthesis, 1979
enthesopathy, 359, 1481
ethnic groups, 337
exercise, 669
hand, 359, 1481
hand joints, 161
hip, 1047
infection, 2043
knee replacement arthroplasty, 669
magnetic resonance imaging, 161, 1979
osteoarthritis, 161, 337, 345, 352, 359, 610, 669, 1047, 1481
osteochondroma, 345
osteophyte, 161
outcome assessment, 352
pain, 352
patient education, 1047
pigmented villonodular synovitis, 345
psoriasis, 1979
quality of life, 1047
recurrence, 345
self care, 1047
synovitis, 1979
systemic sclerosis, 2043
work disability, 337
Knee osteoarthritis
hip, 1064, 1738 (ab)
knee pain, 1716 (ab)
leisure activities, 1745 (ab)
occupational exposure, 1743 (ab)
orthotic devices, 1716 (ab)
osteoarthritis, 1064
pain, 1745 (ab)
questionnaires, 1064
reproducibility of results, 1064
self care, 1738 (ab)
Knee pain
knee osteoarthritis, 1716 (ab)
orthotic devices, 1716 (ab)
Knee replacement arthroplasty
exercise, 669
knee, 669
osteoarthritis, 669
Korea
adult-onset Still's disease, 2000
comorbidity, 86
disease activity, 86
hematologic neoplasms, 226
hemophagocytic lymphohistiocytosis, 86

interleukin-18, 2000
mortality, 226
natural killer cells, 2000
rheumatoid arthritis, 226
systemic lupus erythematosus, 86

L

Latent tuberculosis
comorbidity, 1297
drug toxicity, S89–82
infection, 1297
interferon-gamma release tests, S89–82
miliary tuberculosis, 1297
psoriatic arthritis, S89–82
Second Update on Psoriatic Disease, S89–82
tumor necrosis factor inhibitor, 1297, S89–82
Latin America
ankylosing spondylitis, 2315
epidemiology, 445
Europe, 2315
GRAPPA 2010, 445
population characteristics, 2315
psoriasis, 445
psoriatic arthritis, 445
spondylarthritis, 445
Leadership
medical education, 1737 (ab)
Leflunomide
magnetic resonance imaging, 1171
methotrexate, 1171
plasmapheresis, 1171
rheumatoid arthritis, 1171
treatment outcome, 1171
Left ventricular dysfunction
echocardiography, 701
infliximab, 701
rheumatoid arthritis, 701
stroke volume, 701
Leisure activities
knee osteoarthritis, 1745 (ab)
pain, 1745 (ab)
Leukoencephalopathies
drug toxicity, 1906
methotrexate, 1906
rheumatoid arthritis, 1906
Lichen planus
adult-onset Still's disease, 1305
comorbidity, 1305
mycophenolate mofetil, 1305
Ligaments
enthesis, S89–11
Second Update on Psoriatic Disease, S89–11
spondylarthritis, S89–11
synovial membrane, S89–11
tendons, S89–11
Limited scleroderma
ascites, 1712 (ab)
splenomegaly, 1712 (ab)
Lipids
drug toxicity, 946
rheumatoid arthritis, 946
tumor necrosis factor inhibitor, 946
Lipoproteins
ankylosing spondylitis, 1433
cardiovascular diseases, 1433
psoriatic arthritis, 1433
risk factors, 1433
Liver
arthritis, S90–74
comorbidity, S90–74
gastrointestinal tract, S90–74
pain management, S90–74
3e Initiative 2010, S90–74
Liver diseases
Canada, 254
comorbidity, 254
disease-modifying antirheumatic drugs, 716
gold sodium thiomalate, 716
prevalence, 254
referral and consultation, 716
rheumatoid arthritis, 716
risk factors, 254
systemic lupus erythematosus, 254
Localized scleroderma
collagen, 660
corticosteroids, 286
methotrexate, 286
systemic sclerosis, 660
treatment outcome, 286
Longitudinal studies
amputation, 1648
comorbidity, 1829
coronary disease, 968
EULAR, 1035
genetic polymorphism, 1035
hand, 1648
human FCGR2A protein, 1035
infection, 1745 (ab), 1746 (ab)
psoriatic arthritis, 1035, 1745 (ab), 1746 (ab)
renal insufficiency, 1829
risk factors, 968
scleroderma, 1648
systemic lupus erythematosus, 968
systemic sclerosis, 1829
tumor necrosis factor inhibitor, 1035
Low back pain
ankylosing spondylitis, 1996
delayed diagnosis, 1996
diagnosis, 1996
intervertebral disc displacement, 1996
lumbar vertebrae, 1996
Lower gastrointestinal tract
comorbidity, 1317
nonsteroidal antiinflammatory agents, 1317
rheumatoid arthritis, 1317
Lumbar vertebrae
ankylosing spondylitis, 1996
delayed diagnosis, 1996
diagnosis, 1996
intervertebral disc displacement, 1996
low back pain, 1996
Lung diseases
anticitrullinated protein antibody, 1493
antiphospholipid syndrome, 1628
comorbidity, 1493, 1628
rheumatoid arthritis, 1493
Lupus nephritis
angiotensin-converting enzyme inhibitors, 686
biological markers, 1231, 1948
biopsy, 1942
Brazil, 1948
comorbidity, 79, 1766
corticosteroids, 2111
cyclophosphamide, 2111
diagnosis, 1721 (ab), 1948
disease activity, 1948
gene expression, 1942
genetic polymorphism, 686
glomerulonephritis, 1942
human LCN2 protein, 1231
INDEL mutation, 686
meta-analysis, 686
microvessels, 510
monocyte chemoattractant proteins, 1948
predictive factors, 79
systemic lupus erythematosus, 79, 510, 686, 1231, 1766, 1942
thrombomodulin, 1766
thrombosis, 1766
treatment outcome, 2111
vascular cell adhesion molecule-1, 1231
vasculitis, 510
Lymphocyte depletion
B-lymphocytes, 2276
biological markers, 2276
rheumatoid arthritis, 2276
treatment outcome, 2276
ZAP-70 protein-tyrosine kinase, 2276

M

Magnetic resonance angiography
diagnosis, 1700
hand, 1700
psoriatic arthritis, 1700
Magnetic resonance imaging
ankylosing spondylitis, 1666
arthrography, 1786
biological markers, S89–61
blood pressure, 752
brain, 752
Canada, 1666
cartilage, 161
central nervous system vasculitis, 2051
cerebrovascular circulation, 752
comorbidity, 1979
connective tissue diseases, 1265
diagnosis, 645, 1265, 1844, S89–49
discitis, 2332
echocardiography, 1265
edema, 841
enthesis, 1979
GRAPPA 2010, 408
hand, S89–44
hand joints, 161
image enhancement, 2051
juvenile idiopathic arthritis, 645
knee, 161, 1979
leflunomide, 1171
metatarsophalangeal joint, 1786
methotrexate, 1171
minimally important difference, 1666
nail diseases, 841, S89–49
nails, S89–49
onycholysis, 841
osteoarthritis, 161
osteophyte, 161
pathologic processes, 752
plasmapheresis, 1171
posterior leukoencephalopathy syndrome, 869
psoriasis, 408, 1979
psoriatic arthritis, 408, 841, S89–44, S89–49, S89–61
pulmonary arterial hypertension, 1265
radiography, 645
rheumatoid arthritis, 1171, 1786, S89–44
Second Update on Psoriatic Disease, S89–44, S89–49, S89–61
spinal diseases, 2332
spondylarthritis, 1666, 1844, 2332
synovial fluid, S89–61
synovitis, 1979, S89–44
systemic lupus erythematosus, 752, 869
thoracic wall, 1844
tomography, 1265
treatment outcome, 1171
ultrasonography, S89–61
Managed care programs
epidemiology, 784
golimumab, 1740 (ab)
incidence, 784

prevalence, 784
psoriatic arthritis, 1740 (ab)
systemic sclerosis, 784
United States, 784
Mannose binding lectin
biological markers, 463
Brazil, 6
disease susceptibility, 6
genetic polymorphism, 6
glycosylation, 463
immune system, 6
immunoglobulin G, 463
joints, 463
rheumatoid arthritis, 6, 463
MAP kinase 1
chondrocytes, 621
human ADAMTS1 protein, 621
matrix metalloproteinases, 621
osteoarthritis, 621
pathologic processes, 621
Marenostrin
diagnosis, 875
fever of unknown origin, 875
Japan, 875
mutation, 875
Matrix metalloproteinases
chondrocytes, 621
human ADAMTS1 protein, 621
MAP kinase 1, 621
osteoarthritis, 621
pathologic processes, 621
Medical education
arthritis, 1747 (ab)
disease severity, 2198
GRAPPA 2010, 394
GRAPPA 2011, 2184, 2198
GRAPPA Trainees Symposium, 394
Internet, 1744 (ab)
leadership, 1737 (ab)
patient satisfaction, 1747 (ab)
physician's practice patterns, 2247
psoriasis, 394, 2184, 2198
psoriatic arthritis, 394, 2184, 2198
rheumatoid arthritis, 2247
rheumatology, 880, 1280
teaching, 1280
Medical records
cardiovascular diseases, 1701 (ab)
comorbidity, 1702 (ab)
diagnosis, 1701 (ab)
Medication adherence
drug toxicity, 1500
golimumab, 1740 (ab)
infliximab, 1500
intravenous infusions, 1500
osteoporosis, 1727 (ab)
rheumatic diseases, 1740 (ab)
rheumatoid arthritis, 1500
zoledronic acid, 1727 (ab)
Medication therapy management
Canada, 1752 (ab)
infliximab, 1752 (ab)
rheumatoid arthritis, 1752 (ab)
Meeting reports
Canadian Rheumatology Association Meeting, 1701–1754
Evidence, Expertise, Exchange Initiative 2010 (3e Initiative 2010), S90–1–84
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2010, 391–447
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2011, 2181–2220
Second Update on Psoriatic Disease, S89–1–110
Meningitis
antineutrophil cytoplasmic antibodies, 2053
comorbidity, 2053
granulomatosis with polyangiitis (Wegener's), 2053
renal insufficiency, 2053
Mentors
arthritis, 1717 (ab)
peer group, 1717 (ab)
Meta-analysis
angiotensin-converting enzyme inhibitors, 686
antineutrophil cytoplasmic antibody-associated vasculitis, 1742 (ab)
autoantibodies, 997
certolizumab, 712
chondroitin, 1107
drug therapy, 1107
fingers, 1742 (ab)
genetic polymorphism, 686
genetic predisposition to disease, 997
glucosamine, 1107
golimumab, 712
human TNFSF4 protein, 997
INDEL mutation, 686
lupus nephritis, 686
mortality, 1742 (ab)
osteoarthritis, 1107
pain, 1221
review, 1221
rheumatoid arthritis, 712, 1221
risk assessment, 712
scleroderma, 997, 1742 (ab)
sex characteristics, 1221
skin neoplasms, 712
spondylarthritis, 1221
systemic lupus erythematosus, 686
Metabolic syndrome
comorbidity, 437
dyslipidemia, S89–24
GRAPPA 2010, 437
psoriasis, 437, S89–24
psoriatic arthritis, 437, S89–24
Second Update on Psoriatic Disease, S89–24
treatment outcome, S89–24
Metacarpophalangeal joint
diagnostic imaging, 1494
inflammatory joint disease, 1494
Metatarsophalangeal joint
arthrography, 1786
magnetic resonance imaging, 1786
rheumatoid arthritis, 1786
Methotrexate
abatacept, 1198
adalimumab, 1179, 1741 (ab)
apremilast, 1709 (ab)
biological therapy, 1198
C-reactive protein, 1741 (ab)
cardiovascular diseases, 1341
cartilage matrix protein, 1341
CE 224,535, 720
certolizumab pegol, 1715 (ab)
combination drug therapy, 1524
comorbidity, 2267
corticosteroids, 286
disease-modifying antirheumatic drugs, S89–67
drug administration routes, 1764
drug therapy, 1185, S89–67
drug toxicity, 486, 720, 1906
early diagnosis, 1728 (ab)
etanercept, 1179
genetic polymorphism, 2032
golimumab, 1185
Great Britain, 1198
health care costs, 1764
infliximab, 1179, 2267
Italy, 1179
Japan, 486
joints, 1715 (ab)
juvenile idiopathic arthritis, 2032
leflunomide, 1171
leukoencephalopathies, 1906
localized scleroderma, 286
magnetic resonance imaging, 1171
ocrelizumab, 486
patient compliance, 1179
plasmapheresis, 1171
psoriatic arthritis, 1709 (ab), S89–67
purinergic P2X7, 720
review, 1198
rheumatoid arthritis, 486, 720, 1171, 1179, 1185, 1198, 1341, 1524, 1711 (ab), 1715 (ab), 1728 (ab), 1741 (ab), 1764, 1906, 2267
risk factors, 1341
Second Update on Psoriatic Disease, S89–67
treatment outcome, 286, 1171, 1524
tumor necrosis factor inhibitor, 1341, 1524
vascular stiffness, 2267
Mexico
bone density, 247
comorbidity, 247
diagnosis, 247
osteoporosis, 247
rheumatoid arthritis, 247
Microscopic angioscopy
capillary fragility, 1113, 1248
education, 1113, 1248
scleroderma, 1113, 1248
Microscopic polyangiitis
antineutrophil cytoplasmic antibodies, 455, 545
antineutrophil cytoplasmic antibody-associated vasculitis, 125
Japan, 545
mortality, 455
recurrence, 455, 545
risk factors, 455, 545
rituximab, 125
Wegener granulomatosis, 125
Microscopy
etiology, 1385
scleroderma, 1385
vascular diseases, 1385
Microvessels
comorbidity, 100
dermatomyositis, 94
endothelium, 100
etiology, 94
idiopathic pulmonary hypertension, 100
lupus nephritis, 510
NADH tetrazolium reductase, 94
systemic lupus erythematosus, 510
systemic sclerosis, 100
vasculitis, 510
vasodilation, 100
Miliary tuberculosis
comorbidity, 1297
diagnosis, 651
drug toxicity, 651
infection, 1297
latent tuberculosis, 1297
rheumatoid arthritis, 651
tumor necrosis factor inhibitor, 651, 1297

Minimally important difference
ankylosing spondylitis, 1666
Canada, 1666
magnetic resonance imaging, 1666
spondylarthritis, 1666
Mitochondrial DNA
bone density, 1465
femur neck, 1465
osteoporosis, 1465
postmenopause, 1465
women's health, 1465
Molecular epidemiology
China, 1159
human MBD4 protein, 1159
peptidylarginine deiminase type IV, 1159
rheumatoid arthritis, 1159
Monocyte chemoattractant protein
biological markers, 1948
Brazil, 1948
diagnosis, 1948
disease activity, 1948
lupus nephritis, 1948
Monocytes
dendritic cells, 1192
interleukin-6, 1192
rheumatoid arthritis, 1192
tocilizumab, 1192
Morbidity
ankylosing spondylitis, 131
antiphospholipid syndrome, 516
genetic predisposition to disease, 131
human ANKH protein, 131
mortality, 516
systemic lupus erythematosus, 516
Mortality
antineutrophil cytoplasmic antibodies, 455
antineutrophil cytoplasmic antibody-associated vasculitis, 1742 (ab)
antiphospholipid syndrome, 516
autoantibodies, 2127
cardiovascular diseases, 32, 210
causality, 458, 496
cause of death, 458, 496, S89–32
cholesterol, 32
colchicine, 1458
death certificates, 458
disease activity, 210, 334
disease severity, 2127
gout, 1458
Health Assessment Questionnaire, 54
health status, 54
hematologic neoplasms, 226
hydroxymethylglutaryl-CoA reductase inhibitors, 32
Korea, 226
meta-analysis, 1742 (ab)
microscopic polyangiitis, 455
morbidity, 516
myocardial infarction, 1458
orthopedics, 481
osteoarthritis, 32
platelet activation, 210, 334
prevalence, 1458
psoriatic arthritis, 210, 334, S89–32
quality of life, 54
recurrence, 455
rheumatoid arthritis, 32, 54, 226, 481
risk factors, 455
Second Update on Psoriatic Disease, S89–32
sex, 481
systemic lupus erythematosus, 458, 496, 516
systemic sclerosis, 2127
treatment outcome, 481
tumor necrosis factor inhibitor, 334
vital statistics, 458, 496
Mucocutaneous lymph node syndrome
infliximab, 864
Kawasaki disease, 864
plasma exchange, 864
treatment outcome, 864
Multimedia
GRAPPA 2010, 421
physical examination, 421
psoriasis, 421
psoriatic arthritis, 421
Musculoskeletal diseases
diagnosis, 413
GRAPPA 2010, 413
GRAPPA 2011, 2214
psoriasis, 413
psoriatic arthritis, 413
spondylarthritis, 413
Mutation
diagnosis, 875
fever of unknown origin, 875
Japan, 875
marenostrin, 875
Mycophenolate mofetil
adult-onset Still's disease, 1305
age of onset, 1241
calcitonin, 658
comorbidity, 1305
diffuse scleroderma, 1241
drug toxicity, 658
fibrosis, 1241
lichen planus, 1305
mycophenolic acid, 2223
scleroderma, 1241
systemic inflammatory response syndrome, 658
treatment outcome, 1241
vasculitis, 2223
Mycophenolic acid
mycophenolate mofetil, 2223
vasculitis, 2223
Myelitis
human AQP4 protein, 871
rhupus syndrome, 871
Myocardial infarction
colchicine, 1458
gout, 1458
mortality, 1458
prevalence, 1458
Myocarditis
aged, 665
cardiac imaging techniques, 448
comorbidity, 665
diagnosis, 448
giant cell arteritis, 665
ischemia, 448
systemic lupus erythematosus, 448
Myositis
activities of daily living, 2134
antibodies, 1835
Canada, 1733 (ab)
dermatomyositis, 2134
disease-modifying antirheumatic drugs, 1835
ethnic groups, 1733 (ab)
interstitial lung diseases, 1835
polymyositis, 2134
questionnaires, 2134
United States, 2134

N

NADH tetrazolium reductase
dermatomyositis, 94
etiology, 94
microvessels, 94
Nail diseases
diagnosis, S89–49
disease activity, 653
edema, 841
joints, 653
magnetic resonance imaging, 841, S89–49
nails, S89–49
onycholysis, 841
outcome assessment, 653
psoriatic arthritis, 653, 841, S89–49
Second Update on Psoriatic Disease, S89–49
skin diseases, 653
Nails
diagnosis, S89–49
epidemiology, 1441
magnetic resonance imaging, S89–49
nail diseases, S89–49
onycholysis, 1441
psoriasis, 1441
psoriatic arthritis, 1441, S89–49
Second Update on Psoriatic Disease, S89–49
Natural killer cells
adult-onset Still's disease, 2000
interleukin-18, 2000
Korea, 2000
Neck pain
diagnosis, 1711 (ab)
Needs assessment
antirheumatic agents, 1555
Canada, 1555
disease management, 1720 (ab)
fibromyalgia, 1720 (ab)
physician's practice patterns, 1555
practice guideline, 1555
rheumatoid arthritis, 1555
Neoplasms
prevalence, 1722 (ab)
psoriatic arthritis, 1722 (ab)
Neurologic manifestations
anxiety, 770
central nervous system lupus vasculitis, 770, 2118
comorbidity, 770
depression, 770
diagnosis, 2118
interdisciplinary communication, 2118
systemic lupus erythematosus, 770, 2118
Neuropsychological tests
cognitive disorders, 1371
diagnosis, 1371
systemic lupus erythematosus, 1371
Neurotransmitter agents
arthritis, S90–28
drug toxicity, S90–28
review, S90–28
3e Initiative 2010, S90–28
Neutrophils
histones, 1619
phagocytosis, 1619
systemic lupus erythematosus, 1619
New Zealand
classification, 2098
early diagnosis, 2098
rheumatoid arthritis, 2098
NF-kappa B
apoptosis, 1256
epithelial cells, 1256
p38 mitogen-activated protein kinases, 1256
salivary glands, 1256
Sjögren's syndrome, 1256
Non-Hodgkin lymphoma
comorbidity, 804
decision support techniques, 804
prognosis, 804
Sjögren's syndrome, 804

Nonsteroidal antiinflammatory agents
arthritis, S90–56, S90–62
comorbidity, 1317
congenital abnormalities, 2163
drug toxicity, 2163, S90–56, S90–62
hydroxychloroquine, 1902
joint diseases, 1902
lower gastrointestinal tract, 1317
paracetamol, S90–62
pregnancy, 2163
review, S90–56
rheumatoid arthritis, 1317
3e Initiative 2010, S90–56, S90–62
North American Indians
autoimmune diseases, 1934
ethnic groups, 1934
rheumatic diseases, 1934

O

Obesity
adipokines, 2046
osteoarthritis, 2046
shoulder joint, 2046
Occupational diseases
risk factors, 743
social class, 743
Sweden, 743
systemic lupus erythematosus, 743
United States, 1709 (ab)
Occupational exposure
knee osteoarthritis, 1743 (ab)
Ocrelizumab
drug toxicity, 486
Japan, 486
methotrexate, 486
rheumatoid arthritis, 486
Onycholysis
edema, 841
epidemiology, 1441
magnetic resonance imaging, 841
nail diseases, 841
nails, 1441
psoriasis, 1441
psoriatic arthritis, 841, 1441
Opioid analgesics
arthritis, S90–40
drug toxicity, S90–40
fibromyalgia, 1749 (ab)
review, S90–40
3e Initiative 2010, S90–40
treatment outcome, 1749 (ab)
Organs at risk
bone density, 1955
disease management, 1732 (ab)
glucocorticoids, 1955
scleroderma, 1732 (ab)
systemic lupus erythematosus, 1955
Orthopedics
mortality, 481
rheumatoid arthritis, 481
sex, 481
treatment outcome, 481
Orthotic devices
knee osteoarthritis, 1716 (ab)
knee pain, 1716 (ab)
Osteitis
sternocostoclavicular hyperostosis, 389
Osteoarthritis
adipokines, 2046
capsaicin, 610
cardiovascular diseases, 32, 1706 (ab)
cartilage, 161
cholesterol, 32
chondrocytes, 621, 635
chondroitin, 1107
comorbidity, 359
drug therapy, 1107
drug toxicity, 1056
duloxetine, 352
employment, 337
enthesopathy, 203, 359, 1481
ethnic groups, 337
etiology, 203
exercise, 669, 672
glucosamine, 635, 1107
Great Britain, 1056
hand, 203, 359, 1481
hand joints, 161
health behavior, 672
hip, 1047, 1064
human ADAMTS1 protein, 621
hydroxymethylglutaryl-CoA reductase inhibitors, 32
knee, 161, 337, 345, 352, 359, 610, 669, 1047, 1481
knee osteoarthritis, 1064
knee replacement arthroplasty, 669
magnetic resonance imaging, 161
MAP kinase 1, 621
matrix metalloproteinases, 621
meta-analysis, 1107
mortality, 32
obesity, 2046
osteochondroma, 345
osteophyte, 161
outcome assessment, 352, 1056
pain, 352
pathologic processes, 621
patient education, 1047
physician's practice patterns, 1056
pigmented villonodular synovitis, 345
prostaglandin synthase, 635
quality of life, 1047
questionnaires, 1064
recurrence, 345
reproducibility of results, 1064
rheumatic diseases, 203
rheumatoid arthritis, 32
risk factors, 1056, 1706 (ab)
risk reduction behavior, 672
self care, 1047
shoulder joint, 2046
work disability, 337
Osteochondroma
knee, 345
osteoarthritis, 345
pigmented villonodular synovitis, 345
recurrence, 345
Osteolysis
demyelinating diseases, 2175
POEMS syndrome, 2175
Osteophyte
cartilage, 161
hand joints, 161
knee, 161
magnetic resonance imaging, 161
osteoarthritis, 161
Osteoporosis
bone density, 247, 1465
bone fractures, 1717 (ab)
Canada, 1378
comorbidity, 247
diagnosis, 247, 1717 (ab)
drug toxicity, 461, 600, 1731 (ab)
epidemiology, S89–36
femur neck, 1465
glucocorticoids, 461, 600
hip fractures, 1378
medication adherence, 1727 (ab)
Mexico, 247
mitochondrial DNA, 1465
osteoporotic fractures, S89–36
postmenopause, 461, 600, 1465
psoriatic arthritis, S89–36
rheumatoid arthritis, 247
risk assessment, 1731 (ab)
risk factors, 1378
Second Update on Psoriatic Disease, S89–36
systemic lupus erythematosus, 1378
teriparatide, 461, 600
ultrasonography, 1731 (ab)
women's health, 1465
zoledronic acid, 1727 (ab), 1731 (ab)
Osteoporotic fractures
epidemiology, S89–36
osteoporosis, S89–36
psoriatic arthritis, S89–36
Second Update on Psoriatic Disease, S89–36
Osteoprotegerin
diagnosis, 1678
diagnostic imaging, 1678
hemarthrosis, 1678
RANK ligand, 1678
ultrasonography, 1678
Outcome assessment
adalimumab, 63
biological markers, 795
cardiovascular diseases, 1146
carotid artery diseases, 1146
disease activity, 653, 1729 (ab)
drug toxicity, 1056
duloxetine, 352
Great Britain, 1056
joints, 653
knee, 352
nail diseases, 653
osteoarthritis, 352, 1056
pain, 352
patient global assessment, 1139
physician's practice patterns, 816, 1056, 1139
polymyalgia rheumatica, 795
psoriatic arthritis, 653
quality of life, 63
rheumatoid arthritis, 63, 1139, 1146, 1729 (ab)
risk factors, 1056, 1146
skin diseases, 653
spondylarthritis, 816
spontaneous remission, 1139
Outcome measures
ankylosing spondylitis, 1424
biological markers, 2181
disease activity, S89–19
GRAPPA 2010, 398
GRAPPA 2011, 2181, 2196
health status, 856
juvenile idiopathic arthritis, 856
patient satisfaction, 1424
psoriasis, 398, 2181, 2196, S89–19
psoriatic arthritis, 398, 2181, 2196, S89–19
quality of life, 1424
remission induction, S89–19
Second Update on Psoriatic Disease, S89–19
self-assessment, 1424
Oxidative stress
etiology, 1654
fluorescence, 1654
immunologic receptors, 1654
Raynaud disease, 1654
scleroderma, 1654

P

P38 mitogen-activated protein kinases
apoptosis, 1256
epithelial cells, 1256

NF-kappa B, 1256
salivary glands, 1256
Sjögren's syndrome, 1256
Pain
duloxetine, 352
enthesis, 2341
epidemiology, 2341
health status, 2341
juvenile idiopathic arthritis, 2341
knee, 352
knee osteoarthritis, 1745 (ab)
leisure activities, 1745 (ab)
meta-analysis, 1221
osteoarthritis, 352
outcome assessment, 352
psoriatic arthritis, 844
quality of life, 844
review, 1221
rheumatoid arthritis, 1221
self-assessment, 844
sex characteristics, 1221
spondylarthritis, 1221
Pain management
arthritis, S90–1, S90–11, S90–17, S90–34, S90–47, S90–59, S90–74
central muscle relaxants, S90–34
combination drug therapy, S90–47
comorbidity, S90–74
corticosteroids, S90–17
drug therapy, S90–1
drug toxicity, S90–34, S90–47, S90–59
gastrointestinal tract, S90–74
liver, S90–74
paracetamol, S90–11
pregnancy, S90–59
review, S90–1, S90–11, S90–17, S90–34, S90–47, S90–59
3e Initiative 2010, S90–11, S90–17, S90–34, S90–47, S90–59, S90–74
Pain measurement
arthritis, S90–3
diagnosis, 1749 (ab)
fibromyalgia, 1749 (ab)
review, S90–3
3e Initiative 2010, S90–3
treatment outcome, S90–3
Pain perception
arthritis, 1743 (ab)
ethnic groups, 1743 (ab)
Pain threshold
Disease Activity Score-28, 28
fatigue, 28
rheumatoid arthritis, 28
Painful ophthalmoplegia
rheumatoid arthritis, 1485
rituximab, 1485
treatment outcome, 1485
Palpation
breast, 1296
clinical competence, 1207
joints, 1207
physician's practice patterns, 1296
rheumatoid arthritis, 1207
ultrasound, 1207
Paracetamol
arthritis, S90–11, S90–62
drug toxicity, S90–62
nonsteroidal antiinflammatory agents, S90–62
pain management, S90–11
review, S90–11
3e Initiative 2010, S90–11, S90–62
Paraneoplastic syndromes
adverse effects, 2359
comorbidity, 2359
dermatomyositis, 2359
inflammation, 2359
treatment outcome, 2359
Paraproteinemias
comorbidity, 564
prevalence, 564
psoriatic arthritis, 564
Parenteral nutrition
blind loop syndrome, 1004
home care services, 1004
intestinal pseudo-obstruction, 1004
scleroderma, 1004
Pathologic angiogenesis
fibrosis, 539
galectin 3, 539
immune system, 539
systemic sclerosis, 539
Pathologic processes
blood pressure, 752
brain, 752
cerebrovascular circulation, 752
chondrocytes, 621
decision making, 1
disease activity, 1, 22
Disease Activity Score-28, 1, 22
fibromyalgia, 1, 22
human ADAMTS1 protein, 621
magnetic resonance imaging, 752
MAP kinase 1, 621
matrix metalloproteinases, 621
osteoarthritis, 621
psoriasis, S89–4
psoriatic arthritis, S89–4
rheumatoid arthritis, 1, 22
Second Update on Psoriatic Disease, S89–4
systemic lupus erythematosus, 752
Patient compliance
adalimumab, 1179
adolescent, 174
etanercept, 1179
hydroxychloroquine, 174
infliximab, 1179
Italy, 1179
methotrexate, 1179
rheumatoid arthritis, 1179
systemic lupus erythematosus, 174
telecommunications, 174
young adult, 174
Patient education
hip, 1047
information dissemination, 883, 899
Internet, 883, 899
knee, 1047
osteoarthritis, 1047
quality of life, 1047
rheumatoid arthritis, 899
self care, 1047
Patient global assessment
disease activity, 2081
disease activity score, 1155
disease-modifying antirheumatic drugs, 2081
early diagnosis, 2081
outcome assessment, 1139
physician's practice patterns, 1139
remission induction, 1155
rheumatoid arthritis, 1139, 1155, 2081
spontaneous remission, 1139, 1155
Patient satisfaction
ankylosing spondylitis, 1424
arthritis, 1747 (ab)
medical education, 1747 (ab)
outcome measures, 1424
quality of life, 1424
self-assessment, 1424
Pediatric rheumatic diseases
Canada, 1705 (ab), 1731 (ab)
complementary therapies, 1750 (ab)
ethnic groups, 1731 (ab)
glucocorticoids, 167
granulomatosis with polyangiitis (Wegener's), 1687
health services accessibility, 1705 (ab)
H1N1 subtype influenza A virus, 167
influenza vaccines, 167
juvenile idiopathic arthritis, 365, 374, 645, 856, 1078, 1287, 1294, 1712 (ab), 1727 (ab), 1750 (ab), 1778, 1867, 1875, 1880, 2021, 2032, 2341, 2352
juvenile-onset ankylosing spondylitis, 887, 1013
juvenile rheumatoid arthritis, 1723 (ab)
localized scleroderma, 286
questionnaires, 1750 (ab)
systemic lupus erythematosus, 382, 1698
Pediatrics
brain diseases, 1723 (ab)
Canada, 1718 (ab)
diagnosis, 1723 (ab)
education, 1718 (ab)
Peer group
arthritis, 1717 (ab)
mentors, 1717 (ab)
Pegloticase
cardiovascular diseases, 1311
comorbidity, 1311
gout, 1311, 1450
quality of life, 1311, 1450
treatment outcome, 1450
Peptidylarginine deiminase type IV
China, 1159
human MBD4 protein, 1159
molecular epidemiology, 1159
rheumatoid arthritis, 1159
Pericarditis
diagnostic errors, 1713 (ab)
Periodontal diseases
comorbidity, 1725 (ab)
rheumatoid arthritis, 1725 (ab)
Periostitis
infection, 2179
inflammatory bowel diseases, 2179
Peru
ethnic groups, 2216
GRAPPA 2011, 2216
psoriasis, 2216
psoriatic arthritis, 2216
spondylarthritis, 2216
Phagocytosis
histones, 1619
neutrophils, 1619
systemic lupus erythematosus, 1619
Pharmacological biomarkers
etanercept, 1533
gene expression, 916
glycosylation, 916
immunoglobulin G, 916
rheumatoid arthritis, 916, 1533
tocilizumab, 916
Pharmacology
apoptosis, 679
rheumatoid arthritis, 679
tumor necrosis factor inhibitor, 679
Photon absorptiometry
ankylosing spondylitis, 1987
bone, 1987
bone density, 1987
spinal fractures, 1987
spine, 1987

Physical examination
giant cell arteritis, 303
GRAPPA 2010, 421
multimedia, 421
psoriasis, 421
psoriatic arthritis, 421
Takayasu arteritis, 303
vasculitis, 303
Physical fitness
biological agents, 1725 (ab)
rheumatoid arthritis, 1725 (ab)
Physician's practice patterns
ankylosing spondylitis, 1418
antirheumatic agents, 1555
arthritis, 1739 (ab)
breast, 1296
Canada, 1555
cohort studies, 2088
continuing education, 1739 (ab)
data collection, 949
disease-modifying antirheumatic drugs, 2088
drug toxicity, 1056
Great Britain, 1056
medical education, 2247
needs assessment, 1555
osteoarthritis, 1056
outcome assessment, 816, 1139
palpation, 1296
patient global assessment, 1139
practice guideline, 1555, 1738 (ab)
psoriatic arthritis, S89–39
remission induction, 1418
rheumatoid arthritis, 949, 1139, 1555, 1738 (ab), 2088, 2247
risk factors, 1056
Second Update on Psoriatic Disease, S89–39
spondylarthritis, 816
spontaneous remission, 1139
treatment outcome, 949
tumor necrosis factor inhibitor, 1418
ultrasonography, S89–39
Pigmented villonodular synovitis
knee, 345
osteoarthritis, 345
osteochondroma, 345
recurrence, 345
Plasma exchange
infliximab, 864
Kawasaki disease, 864
mucocutaneous lymph node syndrome, 864
treatment outcome, 864
Plasmapheresis
leflunomide, 1171
magnetic resonance imaging, 1171
methotrexate, 1171
rheumatoid arthritis, 1171
treatment outcome, 1171
Platelet activation
cardiovascular diseases, 210
disease activity, 210, 334
mortality, 210, 334
psoriatic arthritis, 210, 334
tumor necrosis factor inhibitor, 334
POEMS syndrome
demyelinating diseases, 2175
osteolysis, 2175
Polymyalgia rheumatica
amyloidosis, 878
biological markers, 795
comorbidity, 552, 878
disease activity score, 310
drug dosage calculations, 310
drug toxicity, 310, 552, 1758
edema, 148
giant cell arteritis, 878
glucocorticoids, 310, 552, 1758
outcome assessment, 795
synovitis, 148
treatment outcome, 310
Polymyositis
activities of daily living, 2134
antisynthetase syndrome, 1299
comorbidity, 1299
dermatomyositis, 1659, 2134
diagnostic imaging, 1659
fluorodeoxyglucose F18, 1659
immunosuppression, 1299
myositis, 2134
positron-emission tomography, 1659
progressive multifocal leukoencephalopathy, 1299
questionnaires, 2134
review, 1299
rituximab, 1483
signal recognition particle, 1483
treatment outcome, 1483
United States, 2134
Population characteristics
ankylosing spondylitis, 2315
Europe, 2315
Latin America, 2315
Positron-emission tomography
dermatomyositis, 1659
diagnostic imaging, 1659
fluorodeoxyglucose F18, 1659
polymyositis, 1659
Positron-emission tomography and computed tomography
coronary artery disease, 1761
diagnosis, 1909
diagnostic imaging, 1761
giant cell arteritis, 1909
vasculitis, 1761
Posterior leukoencephalopathy syndrome
comorbidity, 870
diagnosis, 196
interleukin-17, 870
magnetic resonance imaging, 869
systemic lupus erythematosus, 196, 869, 870
vascular endothelial growth factors, 870
Postmenopause
bone density, 1215, 1465
diphosphonates, 1215
drug toxicity, 461, 600
femur neck, 1465
glucocorticoids, 461, 600
mitochondrial DNA, 1465
osteoporosis, 461, 600, 1465
rheumatoid arthritis, 1215
teriparatide, 461, 600
tomography, 1215
women's health, 1215, 1465
Practice guideline
antirheumatic agents, 1497, 1555, 1559, 1583
Canada, 1497, 1555, 1559, 1583
disease management, 1497, 1559, 1583
history of medicine, 1497
needs assessment, 1555
physician's practice patterns, 1555, 1738 (ab)
rheumatoid arthritis, 1497, 1555, 1559, 1583, 1738 (ab)
Predictive factors
acute-phase reaction, 1914
antineutrophil cytoplasmic antibodies, 2012
arthralgia, 1914
arthritis, 1914
biological markers, 1914, S89–57
comorbidity, 79
cyclophosphamide, 2012
disease activity, 568
disease severity, 2012
lupus nephritis, 79
psoriatic arthritis, 568, S89–57
remission induction, 470
rheumatoid arthritis, 240, 470
rituximab, 240
Second Update on Psoriatic Disease, S89–57
systemic lupus erythematosus, 79
treatment outcome, 240, 470
tumor necrosis factor inhibitor, 568
vasculitis, 2012
Pregnancy
arthritis, S90–59
Canada, 2253
congenital abnormalities, 2163
drug toxicity, 2163, S90–59
ethnic groups, 2253
nonsteroidal antiinflammatory agents, 2163
pain management, S90–59
review, S90–59
rheumatoid arthritis, 2253
risk factors, 2253
3e Initiative 2010, S90–59
Prevalence
ankylosing spondylitis, 1675, 2321
Arab world, 1675
atlanto-axial joint, 2321
bone density, 365
Canada, 254
colchicine, 1458
comorbidity, 254, 564, 974
compression fractures, 365
disease progression, 2321
epidemiology, 784
ethnic groups, 1675
gout, 1458
hepatitis B virus, 974
HLA-B27 antigen, 1675
incidence, 784
juvenile idiopathic arthritis, 365
liver diseases, 254
managed care programs, 784
mortality, 1458
myocardial infarction, 1458
neoplasms, 1722 (ab)
paraproteinemias, 564
psoriatic arthritis, 564, 1722 (ab)
risk factors, 254, 2321
spine, 365
systemic lupus erythematosus, 254, 974
systemic sclerosis, 784
United States, 784
Primary angiitis of the central nervous system
biopsy, 662
central nervous system vasculitis, 662
diagnosis, 662
Process assessment "(health care)"
arthritis, 1749 (ab)
health services accessibility, 1749 (ab)
Prognosis
amyloidosis, 1348
anticitrullinated protein antibody, 675, 694
aortic aneurysm, 2157
aortitis, 2157
biological markers, 675, 694
biological therapy, 1348
Brazil, 1971

cause of death, 1971
comorbidity, 804
decision support techniques, 804
disease activity, 694
disease progression, 675, 694
giant cell arteritis, 2157
non-Hodgkin lymphoma, 804
remission induction, 1734 (ab)
rheumatoid arthritis, 675, 694, 1348, 1734 (ab)
Sjögren's syndrome, 804
survival rate, 1971
systemic sclerosis, 1971
Progressive multifocal leukoencephalopathy
antisynthetase syndrome, 1299
comorbidity, 1299
immunosuppression, 1299
polymyositis, 1299
review, 1299
Propylthiouracil
antineutrophil cytoplasmic antibodies, 558
renal insufficiency, 558
vasculitis, 558
Prostaglandin synthase
chondrocytes, 635
glucosamine, 635
osteoarthritis, 635
Protease inhibitors
blood, 2021
juvenile idiopathic arthritis, 2021
regulatory T-lymphocytes, 2021
synovial fluid, 2021
Th17 cells, 2021
Psoriasis
abatacept, S89–100
adalimumab, S89–77
autoimmunity, 893
biological markers, 423, 427, 434, 2181, 2193, S89–65
carotid arteries, 441
combination drug therapy, 187
comorbidity, 437, 441, 1303, 1722 (ab), 1979, 2193, 2204
depression, 1722 (ab)
diagnosis, 413, 415, 418, S89–65
disease activity, 427, S89–19
disease progression, 434
disease severity, 2198
drug toxicity, S89–71, S89–86
dyslipidemia, S89–24
early diagnosis, 2201
enthesis, 404, 415, 1703 (ab), 1979
epidemiology, 441, 445, 1441
ethnic groups, 2216
France, 893
genome-wide association study, 431, 2193
GRAPPA 2010, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445
GRAPPA 2011, 2181, 2184, 2193, 2196, 2198, 2201, 2204, 2216
GRAPPA Trainees Symposium, 394
inflammation, 415, 418, S89–97
infliximab, S89–71
interleukin-6, 2055, S89–97
Italy, 2201
knee, 1979
Latin America, 445
magnetic resonance imaging, 408, 1979
medical education, 394, 2184, 2198
metabolic syndrome, 437, S89–24
multimedia, 421
musculoskeletal diseases, 413
nails, 1441
onycholysis, 1441
outcome measures, 398, 2181, 2196, S89–19
pathologic processes, S89–4
Peru, 2216
physical examination, 421
psoriatic arthritis, 187, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445, 1441, 1703 (ab), 2181, 2184, 2193, 2196, 2198, 2201, 2204, 2216, S89–4, S89–19, S89–24, S89–65, S89–71, S89–77, S89–86, S89–97, S89–100
questionnaires, 434
remission induction, S89–19
rheumatoid arthritis, 893, 1303
rituximab, 893, 1303
Second Update on Psoriatic Disease, S89–4, S89–19, S89–24, S89–65, S89–71, S89–77, S89–86, S89–97, S89–100
spinal diseases, 418
spondylarthritis, 413, 445, 2216
synovitis, 1979
T-lymphocytes, S89–100
tocilizumab, S89–97
treatment outcome, S89–24
tumor necrosis factor inhibitor, 2055
ultrasonography, 404
ultrasound, 404
ustekinumab, S89–86
Psoriatic arthritis
abatacept, S89–100
adalimumab, S89–77
ankylosing spondylitis, 1433, 2327, S89–22
ankylosis, 2177
apremilast, 1709 (ab)
asymptomatic diseases, S89–22
biological markers, 423, 427, 434, 2181, 2189, 2193, S89–57, S89–61, S89–65, S89–106
biomedical research, S89–106
Canada, 1850
cardiovascular diseases, 210, 1433, 1722 (ab)
carotid arteries, 441
cause of death, S89–32
classification, 154
combination drug therapy, 187
comorbidity, 437, 441, 564, 1722 (ab), 2193, 2204
cost-benefit analysis, S89–103
diagnosis, 154, 413, 415, 418, 677, 849, 1700, 2221, S89–49, S89–65, S89–106
diagnostic errors, 677, 849
disease activity, 210, 334, 427, 568, 653, 1042, S89–19
disease management, 1751 (ab)
disease-modifying antirheumatic drugs, S89–67
disease progression, 434
disease severity, 1850, 2198
Doppler effect, S89–24
drug therapy, S89–67
drug toxicity, 1035, S89–71, S89–82, S89–86, S89–103
dyslipidemia, S89–24
early diagnosis, 1751 (ab), 2201
edema, 841
enthesis, 404, 415, 677, 849, 1703 (ab), 2045, S89–24
enthesopathy, S89–90
epidemiology, 154, 441, 445, 1441, S89–36
etanercept, 185, S89–74
ethnic groups, 2216
etiology, S89–7, S89–15
EULAR, 1035
fatty liver, 1035
fibromyalgia, 677, 849, 2221, S89–24
fingers, S89–90
genetic polymorphism, 1035
genetic predisposition to disease, S89–7, S89–106
genome-wide association study, 431, 2193
golimumab, 1735 (ab), 1736 (ab), 1740 (ab), S89–90
GRAPPA 2010, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445
GRAPPA 2011, 2181, 2184, 2189, 2193, 2196, 2198, 2201, 2204, 2211, 2216
GRAPPA Trainees Symposium, 394
hand, 1700, S89–44
HLA-B27 antigen, 1723 (ab), 2177
human FCGR2A protein, 1035
infection, 1745 (ab), 1746 (ab)
inflammation, 415, 418, S89–90, S89–97
infliximab, S89–71
interferon-gamma release tests, S89–82
interleukin-6, S89–97
interleukin-17, S89–15
interleukin-23, S89–15
Italy, 2201
joints, 185, 653, 1736 (ab)
latent tuberculosis, S89–82
Latin America, 445
lipoproteins, 1433
longitudinal studies, 1035, 1745 (ab), 1746 (ab)
magnetic resonance imaging, 408, 841, 1700, S89–44, S89–49, S89–61
managed care programs, 1740 (ab)
medical education, 394, 2184, 2198
metabolic syndrome, 437, S89–24
methotrexate, 1709 (ab), S89–67
mortality, 210, 334, S89–32
multimedia, 421
musculoskeletal diseases, 413
nail diseases, 653, 841, S89–49
nails, 1441, S89–49
neoplasms, 1722 (ab)
onycholysis, 841, 1441
osteoporosis, S89–36
osteoporotic fractures, S89–36
outcome assessment, 653
outcome measures, 398, 2181, 2196, S89–19
pain, 844
paraproteinemias, 564
pathologic processes, S89–4
Peru, 2216
physical examination, 421
physician's practice patterns, S89–39
platelet activation, 210, 334
predictive factors, 568, S89–57

prevalence, 564, 1722 (ab)
psoriasis, 187, 394, 398, 404, 408, 413, 415, 418, 421, 423, 427, 431, 434, 437, 441, 445, 1441, 1703 (ab), 2181, 2184, 2193, 2196, 2198, 2201, 2204, 2216, S89–4, S89–19, S89–24, S89–65, S89–71, S89–77, S89–86, S89–97, S89–100
quality of life, 844
questionnaires, 434
radiography, 185, 1751 (ab), 2189, S89–54
remission induction, 1736 (ab), S89–19
rheumatoid arthritis, S89–44
risk factors, 1433
rituximab, 2235, 2327
Second Update on Psoriatic Disease, S89–4, S89–7, S89–15, S89–19, S89–22, S89–24, S89–32, S89–36, S89–39, S89–44, S89–49, S89–54, S89–57, S89–61, S89–65, S89–67, S89–71, S89–74, S89–77, S89–82, S89–86, S89–90, S89–97, S89–100, S89–103, S89–106
self-assessment, 844
sensitivity and specificity, 154
skin diseases, 653
spinal diseases, 418
spondylarthritis, 413, 445, 2216, 2235, 2327, S89–15
spondylarthropathy, S89–22
synovial fluid, S89–61
synovitis, S89–44
T-lymphocytes, S89–7, S89–100
Th17 cells, S89–15
tocilizumab, S89–97
treatment, 1850
treatment outcome, 1735 (ab), 2327, S89–24
tumor necrosis factor inhibitor, 334, 568, 1035, S89–82, S89–103
ultrasonography, 404, 2045, S89–24, S89–39, S89–61
ultrasound, 404, 2211
ustekinumab, S89–86

Psychology
disease activity, 1775, 1807
fatigue, 1775, 1807
rheumatoid arthritis, 1775, 1807

Pubic bone
sacrococcygeal region, 1306
stress fractures, 1306
teriparatide, 1306

Pulmonary arterial hypertension
comorbidity, 276
connective tissue diseases, 1265
diagnosis, 1265
echocardiography, 1265
magnetic resonance imaging, 1265
systemic sclerosis, 276
tomography, 1265
treatment outcome, 276
warfarin, 276

Pulmonary fibrosis
connective tissue diseases, 1641
ultrasonography, 1641
X-ray computed tomography, 1641

Purinergic P2X7
CE 224,535, 720
drug toxicity, 720
methotrexate, 720
rheumatoid arthritis, 720

Pyoderma gangrenosum
comorbidity, 198
diagnosis, 198
systemic sclerosis, 198

Q

Quality of life
adalimumab, 63
ankylosing spondylitis, 1424
arthritis, 1727 (ab)
cardiovascular diseases, 1311
comorbidity, 1311
cost-benefit analysis, 735
gastrointestinal tract, 992
gout, 1311, 1450
Health Assessment Questionnaire, 54
health status, 54
hip, 1047
knee, 1047
mortality, 54
osteoarthritis, 1047
outcome assessment, 63
outcome measures, 1424
pain, 844
patient education, 1047
patient satisfaction, 1424
pegloticase, 1311, 1450
psoriatic arthritis, 844
questionnaires, 735
rheumatoid arthritis, 54, 63
scleroderma, 992
self-assessment, 844, 1424
self care, 1047
social work, 1727 (ab)
systemic lupus erythematosus, 735
treatment outcome, 1450

Questionnaires
abatacept, 1736 (ab)
activities of daily living, 2134
arthritis, 1751 (ab)
back pain, 822
biological markers, 434
classification, 822
complementary therapies, 1750 (ab)
cost-benefit analysis, 735
dermatomyositis, 2134
disease progression, 434
GRAPPA 2010, 434
handheld computers, 1751 (ab)
hip, 1064
juvenile idiopathic arthritis, 1750 (ab)
knee osteoarthritis, 1064
myositis, 2134
osteoarthritis, 1064
pediatric rheumatic diseases, 1750 (ab)
polymyositis, 2134
psoriasis, 434
psoriatic arthritis, 434
quality of life, 735
reproducibility of results, 1064
rheumatoid arthritis, 1736 (ab)
self-assessment, 822
systemic lupus erythematosus, 735
United States, 2134

R

Radiography
biological markers, 2189
cervical vertebrae, 1900
diagnosis, 645
disease severity, 1781
early diagnosis, 1751 (ab)
etanercept, 185
gout, 874
GRAPPA 2011, 2189
infliximab, 664
joints, 185
juvenile idiopathic arthritis, 645
magnetic resonance imaging, 645
psoriatic arthritis, 185, 1751 (ab), 2189, S89–54
rheumatoid arthritis, 1781
sarcoidosis, 664
Second Update on Psoriatic Disease, S89–54
single nucleotide polymorphism, 1781
spondylarthritis, 1900

RANK ligand
diagnosis, 1678
diagnostic imaging, 1678
hemarthrosis, 1678
osteoprotegerin, 1678
ultrasonography, 1678

Raynaud disease
cryoglobulinemia, 119
etiology, 1654
fluorescence, 1654
immunologic receptors, 1654
oxidative stress, 1654
scleroderma, 1654
vasculitis, 119

Recurrence
antineutrophil cytoplasmic antibodies, 455, 545
Japan, 545
knee, 345
microscopic polyangiitis, 455, 545
mortality, 455
osteoarthritis, 345
osteochondroma, 345
pigmented villonodular synovitis, 345
risk factors, 455, 545

Referral and consultation
Canada, 707
delayed diagnosis, 707
disease-modifying antirheumatic drugs, 707, 716
gold sodium thiomalate, 716
hospitalization, 1743 (ab)
liver diseases, 716
rheumatic diseases, 1743 (ab)
rheumatoid arthritis, 707, 716

Registries
antineutrophil cytoplasmic antibodies, 1088
diagnosis, 1088
vasculitis, 1088

Regulatory T-lymphocytes
autoimmune diseases, 450
blood, 2021
intravenous immunoglobulins, 450
juvenile idiopathic arthritis, 2021
protease inhibitors, 2021
synovial fluid, 2021
Th17 cells, 2021

Remission
antineutrophil cytoplasmic antibodies, 4
B-cell lymphoma, 4
etiology, 4

Remission induction
activities of daily living, 1704 (ab)
ankylosing spondylitis, 1418
biopsy, 1413
corticosteroids, 1718 (ab)
diagnosis, 1413
disease activity, S89–19
disease activity score, 1155
golimumab, 1736 (ab)
hematuria, 1413
outcome measures, S89–19
patient global assessment, 1155
physician's practice patterns, 1418
predictive factors, 470
prognosis, 1734 (ab)

psoriasis, S89–19
psoriatic arthritis, 1736 (ab), S89–19
rheumatoid arthritis, 470, 1155, 1704 (ab), 1734 (ab)
Second Update on Psoriatic Disease, S89–19
spontaneous remission, 1155
systemic lupus erythematosus, 1718 (ab)
treatment outcome, 470
tumor necrosis factor inhibitor, 1418
vasculitis, 1413
Renal artery
acute kidney injury, 200
diagnosis, 200
Ehlers-Danlos syndrome, 200
Renal insufficiency
antineutrophil cytoplasmic antibodies, 558, 2053
comorbidity, 1829, 2053
granulomatosis with polyangiitis (Wegener's), 2053
longitudinal studies, 1829
meningitis, 2053
propylthiouracil, 558
systemic sclerosis, 1829
vasculitis, 558
Reproducibility of results
hip, 1064
knee osteoarthritis, 1064
osteoarthritis, 1064
questionnaires, 1064
Respiratory function tests
ankylosing spondylitis, 1854
tumor necrosis factor inhibitor, 1854
Retinal vasculitis
comorbidity, 1095
etiology, 1095
systemic lupus erythematosus, 1095
Retroperitoneal fibrosis
biological markers, 1407
diagnosis, 1407
human CC18 protein, 1407
inflammation, 1407
Review
abatacept, 1198
antidepressive agents, S90–21
antisynthetase syndrome, 1299
arthritis, S90–1, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
biological therapy, 1198
Candida, 1308
central muscle relaxants, S90–34
combination drug therapy, S90–47
comorbidity, 1299
corticosteroids, S90–17
drug therapy, S90–1
drug toxicity, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
Great Britain, 1198
immunosuppression, 1299
infectious arthritis, 1308
meta-analysis, 1221
methotrexate, 1198
neurotransmitter agents, S90–28
nonsteroidal antiinflammatory agents, S90–56
opioid analgesics, S90–40
pain, 1221
pain management, S90–1, S90–11, S90–17, S90–34, S90–47, S90–59
pain measurement, S90–3
paracetamol, S90–11
polymyositis, 1299
pregnancy, S90–59
progressive multifocal leukoencephalopathy, 1299
rheumatoid arthritis, 1198, 1221
sex characteristics, 1221
spondylarthritis, 1221
3e Initiative 2010, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
treatment outcome, S90–3
Rheumatic diseases
antibodies, 1716 (ab)
antinuclear antibodies, 2104
autoimmune diseases, 1934, 2104
cardiovascular diseases, 1741 (ab)
cardiovascular system, 1758
databases as topic, 1724 (ab)
diagnosis, 1721 (ab)
drug therapy, 1740 (ab)
enthesopathy, 203
ethnic groups, 1934
etiology, 203
glucocorticoids, 1758
golimumab, 1740 (ab)
hand, 203
health care costs, 1741 (ab)
hepatitis C, 1726 (ab)
hospitalization, 1743 (ab)
hydroxychloroquine, 1296
immunoassay, 1721 (ab)
inflammation, 1758
intercellular signaling peptides and proteins, 2104
Japan, 1296
medication adherence, 1740 (ab)
North American Indians, 1934
osteoarthritis, 203
referral and consultation, 1743 (ab)
systemic lupus erythematosus, 2104
triage, 1716 (ab)
Rheumatoid arthritis
abatacept, 1198, 1546, 1714 (ab), 1728 (ab), 1736 (ab), 1903
activities of daily living, 1704 (ab)
adalimumab, 63, 1179, 1741 (ab)
amyloidosis, 1348
androgen receptors, 10
ankle joint, 180
ankylosing spondylitis, 1710 (ab), 1765, 1918
anticitrullinated protein antibody, 675, 694, 929, 1490, 1493, 1506, 1509, 1929
anticitrullinated vimentin antibody, 1506
antiglomerular basement membrane disease, 1904
antirheumatic agents, 1497, 1555, 1559, 1583
apolipoproteins E, 218
apoptosis, 679
arthrography, 1786
asthma, 1903
atherosclerosis, 2233, 2261
autoimmunity, 893
azathioprine, 1104
B-lymphocytes, 2276
bacterial infection, 1518
biological agents, 1712 (ab), 1725 (ab)
biological markers, 463, 675, 694, 1518, 2276
biological therapy, 41, 1198, 1348, 2049, 2238
body mass index, 1729 (ab)
bone density, 247, 1215
Brazil, 6
C-reactive protein, 1518, 1741 (ab)
calcitonin, 1518
Canada, 707, 1497, 1555, 1559, 1583, 1713 (ab), 1715 (ab), 1717 (ab), 1730 (ab), 1738 (ab), 1752 (ab), 2253
cardiovascular diseases, 32, 41, 939, 954, 1146, 1341, 1798, 2233, 2261
carotid arteries, 1798, 2233, 2261
carotid artery diseases, 1146
cartilage matrix protein, 1341
CE 224,535, 720
certolizumab, 712
certolizumab pegol, 1326, 1706 (ab), 1707 (ab), 1715 (ab)
China, 1159
cholesterol, 32
classification, 2062, 2098
clinical competence, 1207
clinical trials as topic, 2066
cohort studies, 2088
combination drug therapy, 1524
comorbidity, 233, 247, 1104, 1303, 1317, 1355, 1493, 1705 (ab), 1725 (ab), 2233, 2261, 2267
cost-benefit analysis, 1712 (ab)
cytokines, 18, 1918
data collection, 949
decision making, 1
delayed diagnosis, 707
dendritic cells, 1192, 1918
diagnosis, 180, 212, 247, 651, 885, 1506, 1713 (ab), 1912, 1929
diagnostic errors, 212
diphosphonates, 1215
disability, 476, 1710 (ab)
disease activity, 1, 22, 694, 904, 933, 1320, 1707 (ab), 1729 (ab), 1734 (ab), 1775, 1807, 2081
disease activity score, 1155
Disease Activity Score-28, 1, 22, 28, 1326, 1334
disease management, 1497, 1559, 1583, 2062, 2064
disease-modifying antirheumatic drugs, 707, 716, 1713 (ab), 1729 (ab), 1730 (ab), 2081, 2088
disease progression, 675, 694, 2049
disease severity, 1781
disease susceptibility, 6
drug administration routes, 1764
drug therapy, 1185, 1733 (ab), 2066
drug toxicity, 233, 486, 651, 720, 910, 946, 1104, 1500, 1539, 1546, 1728 (ab), 1729 (ab), 1903, 1904, 1906
dyslipidemia, 218
early diagnosis, 1707 (ab), 1719 (ab), 1728 (ab), 1730 (ab), 1732 (ab), 2059, 2064, 2081, 2098
echocardiography, 701
electronic health records, 1721 (ab)
etanercept, 233, 1179, 1533
ethnic groups, 1701 (ab), 1726 (ab), 1792, 1798, 2253
fatigue, 28, 1706 (ab), 1775, 1807
fetal development, 1718 (ab)

fibrinogen, 1704 (ab)
fibromyalgia, 1, 22
France, 893
G-protein-coupled receptors, 1166
gait, 1719 (ab)
gastrointestinal tract, 910, 1355
gene expression, 916
genetic polymorphism, 6, 10, 218, 939
genetic predisposition to disease, 1166, 1490, 1765
glucocorticoids, 1732 (ab)
glycosylation, 463, 916
gold sodium thiomalate, 716
golimumab, 712, 1185
Great Britain, 1198
growth differentiation factor 15, 939
hand, S89–44
Health Assessment Questionnaire, 54
health care costs, 1734 (ab), 1764
health care disparities, 2059
health care quality, access, and evaluation, 2059
health care quality assurance, 1717 (ab)
health status, 54
hematologic neoplasms, 226
history of medicine, 1497
human CCR6 protein, 1765
human MBD4 protein, 1159
human TREM1 protein, 933
hydroxymethylglutaryl-CoA reductase inhibitors, 32
hypothyroidism, 885, 954
immune system, 6
immunoglobulin G, 463, 916
immunoglobulin light chains, 1130
inflammation, 218
infliximab, 701, 1179, 1500, 1539, 1715 (ab), 1719 (ab), 1752 (ab), 2267
information dissemination, 899
interleukin-6, 60, 1192
interleukin-22, 1320, 2220
Internet, 899
interstitial lung diseases, 1104
intravenous infusions, 1500, 1539
Italy, 1179
Japan, 476, 486
joint diseases, 476
joints, 463, 1207, 1334, 1715 (ab)
Korea, 226
leflunomide, 1171
left ventricular dysfunction, 701
leukoencephalopathies, 1906
lipids, 946
liver diseases, 716
lower gastrointestinal tract, 1317
lung diseases, 1493
lymphocyte depletion, 2276
magnetic resonance imaging, 1171, 1786, S89–44
mannose binding lectin, 6, 463
medical education, 2247
medication adherence, 1500
medication therapy management, 1752 (ab)
meta-analysis, 712, 1221
metatarsophalangeal joint, 1786
methotrexate, 486, 720, 1171, 1179, 1185, 1198, 1341, 1524, 1711 (ab), 1715 (ab), 1728 (ab), 1741 (ab), 1764, 1906, 2267
Mexico, 247
miliary tuberculosis, 651
molecular epidemiology, 1159
monocytes, 1192
mortality, 32, 54, 226, 481
needs assessment, 1555
New Zealand, 2098
nonsteroidal antiinflammatory agents, 1317
ocrelizumab, 486
orthopedics, 481
osteoarthritis, 32
osteoporosis, 247
outcome assessment, 63, 1139, 1146, 1729 (ab)
pain, 1221
pain threshold, 28
painful ophthalmoplegia, 1485
palpation, 1207
pathologic processes, 1, 22
patient compliance, 1179
patient education, 899
patient global assessment, 1139, 1155, 2081
peptidylarginine deiminase type IV, 1159
periodontal diseases, 1725 (ab)
pharmacological biomarkers, 916, 1533
pharmacology, 679
physical fitness, 1725 (ab)
physician's practice patterns, 949, 1139, 1555, 1738 (ab), 2088, 2247
plasmapheresis, 1171
postmenopause, 1215
practice guideline, 1497, 1555, 1559, 1583, 1738 (ab)
predictive factors, 240, 470
pregnancy, 2253
prognosis, 675, 694, 1348, 1734 (ab)
psoriasis, 893, 1303
psoriatic arthritis, S89–44
psychology, 1775, 1807
purinergic P2X7, 720
quality of life, 54, 63
questionnaires, 1736 (ab)
radiography, 1781
referral and consultation, 707, 716
remission induction, 470, 1155, 1704 (ab), 1734 (ab)
review, 1198, 1221
risk assessment, 712
risk factors, 885, 910, 954, 1146, 1166, 1341, 1355, 1701 (ab), 1798, 2253
rituximab, 240, 893, 1130, 1303, 1485, 2238
rofecoxib, 910
scleritis, 233
Second Update on Psoriatic Disease, S89–44
sex, 46, 481
sex characteristics, 1221
signs and symptoms, 1893
single nucleotide polymorphism, 218, 1765, 1781
skin neoplasms, 712
sleep disorders, 60, 1709 (ab)
smoking, 904, 1718 (ab)
smoking cessation, 904
Spain, 1509
spondylarthritis, 41, 1221
spontaneous remission, 1139, 1155
STAT3 transcription factor, 1509
STAT4 transcription factor, 1509
stroke volume, 701
Sweden, 1509
synovial cysts, 180
synovitis, S89–44
Taiwan, 1765
Th17 cells, 18
tibial fractures, 1893
tocilizumab, 60, 916, 1192
tomography, 1215
treatment outcome, 46, 240, 470, 481, 949, 1171, 1485, 1524, 1719 (ab), 1730 (ab), 1738 (ab), 2049, 2062, 2238, 2276
tuberculosis, 1730 (ab)
tumor necrosis factor inhibitor, 18, 41, 46, 651, 679, 929, 946, 1341, 1524, 1546, 1705 (ab), 1721 (ab), 1730 (ab), 1733 (ab), 1904
ultrasound, 1207
vascular stiffness, 2267
vitamin D, 1726 (ab), 1792
women's health, 10, 1215
ZAP-70 protein-tyrosine kinase, 2276

Rheumatoid factor
arthritis, 1737 (ab)
disease activity, 1737 (ab)

Rheumatoid toxicity
comorbidity, 657
drug toxicity, 657
tocilizumab, 657

Rheumatology
medical education, 880, 1280
teaching, 1280

Rhupus syndrome
human AQP4 protein a, 871
myelitis, 871

Risedronate
drug toxicity, 1713 (ab)
scleritis, 1713 (ab)

Risk assessment
certolizumab, 712
golimumab, 712
meta-analysis, 712
osteoporosis, 1731 (ab)
rheumatoid arthritis, 712
skin neoplasms, 712
ultrasonography, 1731 (ab)

Risk factors
alcohol drinking, 1363
ankylosing spondylitis, 322, 1433, 2321
antineutrophil cytoplasmic antibodies, 455, 545
aorta, 1291
atlanto-axial joint, 2321
autoimmune diseases, 1275, 1291
Canada, 254, 1378, 2253
cardiovascular diseases, 954, 1146, 1341, 1433, 1706 (ab), 1798, 2286
carotid arteries, 322, 1291, 1798
carotid artery diseases, 1146
carotid stenosis, 2286
cartilage matrix protein, 1341
celiac disease, 1964
comorbidity, 254, 322, 1355, 2286
coronary disease, 968
diagnosis, 885
disease progression, 2321
DNA copy number variations, 2142
drug toxicity, 910, 1056
epidemiology, 1363
ethnic groups, 1701 (ab), 1798, 2253
G-protein-coupled receptors, 1166
gastrointestinal tract, 910, 1355
gene dosage, 2142
genetic markers, 2048
genetic polymorphism, 1603
genetic predisposition to disease, 1166, 1603

giant cell arteritis, 1275
Great Britain, 1056
health care costs, 1611
hepatitis B antibodies, 1291
hip fractures, 1378
hospitalization, 1611
human FCGR3B protein, 2142
hypothyroidism, 885, 954
IgG receptors, 2142
immunoglobulin G, 2048
immunosuppression, 1291
Japan, 545, 1363
juvenile idiopathic arthritis, 1880
lipoproteins, 1433
liver diseases, 254
longitudinal studies, 968
methotrexate, 1341
microscopic polyangiitis, 455, 545
mortality, 455
occupational diseases, 743
osteoarthritis, 1056, 1706 (ab)
osteoporosis, 1378
outcome assessment, 1056, 1146
physician's practice patterns, 1056
pregnancy, 2253
prevalence, 254, 2321
psoriatic arthritis, 1433
recurrence, 455, 545
rheumatoid arthritis, 885, 910, 954, 1146, 1166, 1341, 1355, 1701 (ab), 1798, 2253
rofecoxib, 910
scleroderma, 1275
single nucleotide polymorphism, 1275
Sjögren's syndrome, 2142
smoking, 1363
social class, 743, 777
stroke, 1611
Sweden, 743
systemic lupus erythematosus, 254, 743, 777, 968, 1363, 1378, 1603, 1611, 1964, 2286
Taiwan, 1611
Takayasu arteritis, 1291
temporomandibular joint disorders, 1880
thrombosis, 1603
TNF receptor-associated factor 6, 1275
treatment outcome, 777
tumor necrosis factor inhibitor, 1341

Risk reduction behavior
exercise, 672
health behavior, 672
osteoarthritis, 672

Rituximab
ankylosing spondylitis, 2327
antineutrophil cytoplasmic antibody-associated vasculitis, 125, 2153
autoimmunity, 893
biological therapy, 2238
comorbidity, 1303
drug toxicity, 2153
France, 893
Germany, 2153
immunoglobulin light chains, 1130
microscopic polyangiitis, 125
painful ophthalmoplegia, 1485
polymyositis, 1483
predictive factors, 240
psoriasis, 893, 1303
psoriatic arthritis, 2235, 2327
rheumatoid arthritis, 240, 893, 1130, 1303, 1485, 2238
signal recognition particle, 1483
spondylarthritis, 2235, 2327
treatment outcome, 240, 1483, 1485, 2153, 2238, 2327
Wegener granulomatosis, 125

Rofecoxib
drug toxicity, 910
gastrointestinal tract, 910
rheumatoid arthritis, 910
risk factors, 910

Rural health services
Canada, 1724 (ab)

S

S100 proteins
bacterial infection, 728
biological markers, 728
C-reactive protein, 728
calcitonin, 728
systemic lupus erythematosus, 728

Sacrococcygeal region
pubic bone, 1306
stress fractures, 1306
teriparatide, 1306

Salivary glands
apoptosis, 1117, 1256
epithelial cells, 1117, 1256
etiology, 809
human T-lymphotropic virus 1, 809
NF-kappa B, 1256
p38 mitogen-activated protein kinases, 1256
Sjögren's syndrome, 809, 1117, 1256

Sarcoidosis
infliximab, 664
radiography, 664

Schoenlein-Henoch purpura
spermatic cord, 2041

Scleritis
comorbidity, 233
drug toxicity, 233, 1713 (ab)
etanercept, 233
rheumatoid arthritis, 233
risedronate, 1713 (ab)

Scleroderma
age of onset, 1241
amputation, 1648
autoantibodies, 997
autoimmune diseases, 1275
biological markers, 1732 (ab)
blind loop syndrome, 1004
C-reactive protein, 1709 (ab)
Canada, 1724 (ab)
capillary fragility, 1113, 1248
chemokine CCL2, 979
comorbidity, 986
connective tissue growth factor, 1703 (ab)
cytokines, 1120
diffuse scleroderma, 1241
disease activity, 1709 (ab)
disease management, 1732 (ab)
disease progression, 986
education, 1113, 1248
esophageal motility disorders, 986
etiology, 1385, 1654
fibrosis, 1241, 1703 (ab)
fingers, 1742 (ab)
fluorescence, 1654
gastroesophageal reflux disease, 1707 (ab)
gastrointestinal tract, 992
genetic polymorphism, 1755
genetic predisposition to disease, 997, 1755
giant cell arteritis, 1275
hand, 1648
home care services, 1004
human TNFSF4 protein, 997
imatinib, 1732 (ab)
immunologic receptors, 1654
inflammation mediators, 1708 (ab)
interferon-gamma, 979
interleukin-6, 979, 1120, 1708 (ab)
interleukin-1a, 1755
interstitial lung diseases, 1707 (ab)
intestinal pseudo-obstruction, 1004
longitudinal studies, 1648
meta-analysis, 997, 1742 (ab)
microscopic angioscopy, 1113, 1248
microscopy, 1385
mycophenolate mofetil, 1241
organs at risk, 1732 (ab)
oxidative stress, 1654
parenteral nutrition, 1004
quality of life, 992
Raynaud disease, 1654
risk factors, 1275
single nucleotide polymorphism, 1275
TNF receptor-associated factor 6, 1275
treatment outcome, 1241
tumor necrosis factor inhibitor, 979
vascular diseases, 1385

Seasons
disease activity, 1391
systemic lupus erythematosus, 1391

Second Update on Psoriatic Disease
abatacept, S89–100
adalimumab, S89–77
ankylosing spondylitis, S89–22
asymptomatic diseases, S89–22
B-lymphocytes, S89–94
biological markers, S89–57, S89–61, S89–65, S89–106
biomedical research, S89–106
cause of death, S89–32
cost-benefit analysis, S89–103
diagnosis, S89–49, S89–65, S89–106
disease activity, S89–19
disease-modifying antirheumatic drugs, S89–67
Doppler effect, S89–24
drug therapy, S89–67
drug toxicity, S89–71, S89–82, S89–86, S89–103
dyslipidemia, S89–24
enthesis, S89–11, S89–24, S89–94
enthesopathy, S89–90
epidemiology, S89–36
etanercept, S89–74
etiology, S89–7, S89–15
fibromyalgia, S89–24
fingers, S89–90
genetic predisposition to disease, S89–7, S89–106
golimumab, S89–90
hand, S89–44
inflammation, S89–90, S89–97
infliximab, S89–71
interferon-gamma release tests, S89–82
interleukin-6, S89–97
interleukin-17, S89–15
interleukin-23, S89–15
latent tuberculosis, S89–82
ligaments, S89–11
magnetic resonance imaging, S89–44, S89–49, S89–61
metabolic syndrome, S89–24
methotrexate, S89–67
mortality, S89–32
nail diseases, S89–49

nails, S89–49
osteoporosis, S89–36
osteoporotic fractures, S89–36
outcome measures, S89–19
pathologic processes, S89–4
physician's practice patterns, S89–39
predictive factors, S89–57
psoriasis, S89–4, S89–19, S89–24, S89–65, S89–71, S89–77, S89–86, S89–97, S89–100
psoriatic arthritis, S89–4, S89–7, S89–15, S89–19, S89–22, S89–24, S89–32, S89–36, S89–39, S89–44, S89–49, S89–54, S89–57, S89–61, S89–65, S89–67, S89–71, S89–74, S89–77, S89–82, S89–86, S89–90, S89–97, S89–100, S89–103, S89–106
radiography, S89–54
remission induction, S89–19
rheumatoid arthritis, S89–44
spondylarthritis, S89–11, S89–15
spondylarthropathy, S89–22, S89–94
synovial fluid, S89–61
synovial membrane, S89–11
synovitis, S89–44
T-lymphocytes, S89–7, S89–100
tendons, S89–11
Th17 cells, S89–15, S89–94
tocilizumab, S89–97
treatment outcome, S89–24
tumor necrosis factor inhibitor, S89–82, S89–94, S89–103
ultrasonography, S89–24, S89–39, S89–61
ustekinumab, S89–86

Self-assessment
ankylosing spondylitis, 1424
back pain, 822
classification, 822
outcome measures, 1424
pain, 844
patient satisfaction, 1424
psoriatic arthritis, 844
quality of life, 844, 1424
questionnaires, 822

Self care
hip, 1047, 1738 (ab)
knee, 1047
knee osteoarthritis, 1738 (ab)
osteoarthritis, 1047
patient education, 1047
quality of life, 1047

Sensitivity and specificity
classification, 154
diagnosis, 154
epidemiology, 154
psoriatic arthritis, 154

Sex
ethnic groups, 759
mortality, 481
orthopedics, 481
rheumatoid arthritis, 46, 481
sex characteristics, 759
systemic lupus erythematosus, 759
treatment outcome, 46, 481
tumor necrosis factor inhibitor, 46

Sex characteristics
ethnic groups, 759
meta-analysis, 1221
pain, 1221
review, 1221
rheumatoid arthritis, 1221
sex, 759
spondylarthritis, 1221
systemic lupus erythematosus, 759

Shoulder joint
adipokines, 2046
arthritis, 2361
hematoma, 2361
obesity, 2046
osteoarthritis, 2046

Siblings
amyloidosis, 2170
disease severity, 2170
familial Mediterranean fever, 2170
genetic predisposition to disease, 2170

Signal recognition particle
polymyositis, 1483
rituximab, 1483
treatment outcome, 1483

Signs and symptoms
age of onset, 1008, 1013, 1110
ankylosing spondylitis, 1008, 1013, 2310
body mass index, 2310
central nervous system vasculitis, 1026
diagnosis, 1026, 1294, 1750 (ab)
differential diagnosis, 1008, 1026
exercise, 2310
fibromyalgia, 1294, 1750 (ab)
juvenile-onset ankylosing spondylitis, 1013
rheumatoid arthritis, 1893
spondylarthritis, 1110
tibial fractures, 1893
treatment outcome, 1013
vasoconstriction, 1026

Single nucleotide polymorphism
ankylosing spondylitis, 1765
apolipoproteins E, 218
autoimmune diseases, 1275
disease severity, 1781
dyslipidemia, 218
genetic polymorphism, 218
genetic predisposition to disease, 1765
giant cell arteritis, 1275
human CCR6 protein, 1765
human IL4R protein, 112
human IL13RA1 protein, 112
inflammation, 218
radiography, 1781
rheumatoid arthritis, 218, 1765, 1781
risk factors, 1275
scleroderma, 1275
systemic sclerosis, 112
Taiwan, 1765
TNF receptor-associated factor 6, 1275

Sjögren's syndrome
apoptosis, 1117, 1256
comorbidity, 804
decision support techniques, 804
DNA copy number variations, 2142
epithelial cells, 1117, 1256
etiology, 809
gene dosage, 2142
human FCGR3B protein, 2142
human T-lymphotropic virus 1, 809
IgG receptors, 2142
NF-kappa B, 1256
non-Hodgkin lymphoma, 804
p38 mitogen-activated protein kinases, 1256
prognosis, 804
risk factors, 2142
salivary glands, 809, 1117, 1256

Skin diseases
disease activity, 653
joints, 653
nail diseases, 653
outcome assessment, 653
psoriatic arthritis, 653

Skin neoplasms
certolizumab, 712
golimumab, 712
meta-analysis, 712
rheumatoid arthritis, 712
risk assessment, 712

Sleep disorders
interleukin-6, 60
rheumatoid arthritis, 60, 1709 (ab)
tocilizumab, 60

Smoking
alcohol drinking, 1363
ankylosing spondylitis, 1710 (ab)
disease activity, 904
epidemiology, 1363
fetal development, 1718 (ab)
Japan, 1363
rheumatoid arthritis, 904, 1718 (ab)
risk factors, 1363
smoking cessation, 904
systemic lupus erythematosus, 1363

Smoking cessation
disease activity, 904
rheumatoid arthritis, 904
smoking, 904

Social class
occupational diseases, 743
risk factors, 743, 777
Sweden, 743
systemic lupus erythematosus, 743, 777
treatment outcome, 777

Social work
arthritis, 1727 (ab)
quality of life, 1727 (ab)

Socioeconomic factors
health services accessibility, 1748 (ab)
inflammation, 1701 (ab)
specialization, 1748 (ab)
systemic lupus erythematosus, 1701 (ab)

Spain
anticitrullinated protein antibody, 1509
rheumatoid arthritis, 1509
STAT3 transcription factor, 1509
STAT4 transcription factor, 1509
Sweden, 1509

Specialization
health services accessibility, 1748 (ab)
socioeconomic factors, 1748 (ab)

Spermatic cord
Schoenlein-Henoch purpura, 2041

Spinal diseases
diagnosis, 418
discitis, 2332
GRAPPA 2010, 418
inflammation, 418
magnetic resonance imaging, 2332
psoriasis, 418
psoriatic arthritis, 418
spondylarthritis, 2332

Spinal fractures
ankylosing spondylitis, 1987
bone, 1987
bone density, 1987
photon absorptiometry, 1987
spine, 1987

Spine
ankylosing spondylitis, 1987
bone, 1987

bone density, 365, 1987
compression fractures, 365
juvenile idiopathic arthritis, 365
photon absorptiometry, 1987
prevalence, 365
spinal fractures, 1987
Spleen
corpus callosum, 1698
systemic lupus erythematosus, 1698
Splenomegaly
ascites, 1712 (ab)
limited scleroderma, 1712 (ab)
Spondylarthritis
age of onset, 1110
ankylosing spondylitis, 1666, 2327
biological therapy, 41
Brazil, 141
Canada, 1666
cardiovascular diseases, 41
cervical vertebrae, 1900
diagnosis, 413, 1844
discitis, 2332
enthesis, S89–11
epidemiology, 141, 445
ethnic groups, 141, 2216
etiology, S89–15
GRAPPA 2010, 413, 445
GRAPPA 2011, 2216
interleukin-6, 1097
interleukin-17, S89–15
interleukin-23, S89–15
Latin America, 445
ligaments, S89–11
magnetic resonance imaging, 1666, 1844, 2332
meta-analysis, 1221
minimally important difference, 1666
musculoskeletal diseases, 413
outcome assessment, 816
pain, 1221
Peru, 2216
physician's practice patterns, 816
psoriasis, 413, 445, 2216
psoriatic arthritis, 413, 445, 2216, 2235, 2327, S89–15
radiography, 1900
review, 1221
rheumatoid arthritis, 41, 1221
rituximab, 2235, 2327
Second Update on Psoriatic Disease, S89–11, S89–15
sex characteristics, 1221
signs and symptoms, 1110
spinal diseases, 2332
synovial membrane, S89–11
tendons, S89–11
Th17 cells, S89–15
thoracic wall, 1844
treatment outcome, 2327
tumor necrosis factor inhibitor, 41
Spondylarthropathy
ankylosing spondylitis, 2148, S89–22
asymptomatic diseases, S89–22
B-lymphocytes, S89–94
comorbidity, 2148
Crohn disease, 2148
enthesis, S89–94
epidemiology, 2148
HLA-B27 antigen, 574
incidence, 2148
interferon-gamma, 574
psoriatic arthritis, S89–22
Second Update on Psoriatic Disease, S89–22, S89–94
Th17 cells, S89–94
tumor necrosis factor inhibitor, S89–94
unfolded protein response, 574
Spontaneous remission
disease activity score, 1155
outcome assessment, 1139
patient global assessment, 1139, 1155
physician's practice patterns, 1139
remission induction, 1155
rheumatoid arthritis, 1139, 1155
systemic lupus erythematosus, 1702 (ab)
STAT3 transcription factor
anticitrullinated protein antibody, 1509
rheumatoid arthritis, 1509
Spain, 1509
STAT4 transcription factor, 1509
Sweden, 1509
STAT4 transcription factor
anticitrullinated protein antibody, 1509
rheumatoid arthritis, 1509
Spain, 1509
STAT3 transcription factor, 1509
Sweden, 1509
Stem cell transplantation
comorbidity, 206, 269
heart diseases, 206, 269
systemic sclerosis, 206, 269
treatment outcome, 206, 269
Sternocostoclavicular hyperostosis
osteitis, 389
Stress fractures
pubic bone, 1306
sacrococcygeal region, 1306
teriparatide, 1306
Stroke
health care costs, 1611
hospitalization, 1611
risk factors, 1611
systemic lupus erythematosus, 1611
Taiwan, 1611
Stroke volume
echocardiography, 701
infliximab, 701
left ventricular dysfunction, 701
rheumatoid arthritis, 701
Sulfasalazine
ankylosing spondylitis, 836
etanercept, 836
treatment outcome, 836
tumor necrosis factor inhibitor, 836
Survival rate
Brazil, 1971
cause of death, 1971
prognosis, 1971
systemic sclerosis, 1971
Sweden
anticitrullinated protein antibody, 1509
occupational diseases, 743
rheumatoid arthritis, 1509
risk factors, 743
social class, 743
Spain, 1509
STAT3 transcription factor, 1509
STAT4 transcription factor, 1509
systemic lupus erythematosus, 743
Synovial cysts
ankle joint, 180
diagnosis, 180
rheumatoid arthritis, 180
Synovial fluid
apoptosis, 1473
arthritis, 1726 (ab)
articular cartilage, 1473
biological markers, S89–61
blood, 2021
chondrocytes, 1473
comorbidity, 157
diagnosis, 1726 (ab)
hyaluronic acid, 1473
infectious arthritis, 157
juvenile idiopathic arthritis, 2021
magnetic resonance imaging, S89–61
protease inhibitors, 2021
psoriatic arthritis, S89–61
regulatory T-lymphocytes, 2021
Second Update on Psoriatic Disease, S89–61
Th17 cells, 2021
ultrasonography, S89–61
Synovial membrane
Doppler ultrasonography, 452
enthesis, S89–11
histology, 452
ligaments, S89–11
Second Update on Psoriatic Disease, S89–11
spondylarthritis, S89–11
tendons, S89–11
Synovitis
arthritis, 2071
Canada, 2071
classification, 2071
comorbidity, 1979
disease activity, 2071
early diagnosis, 2071
edema, 148
enthesis, 1979
hand, S89–44
human NOD2 protein, 1888
knee, 1979
magnetic resonance imaging, 1979, S89–44
polymyalgia rheumatica, 148
psoriasis, 1979
psoriatic arthritis, S89–44
rheumatoid arthritis, S89–44
Second Update on Psoriatic Disease, S89–44
Takayasu arteritis, 1888
vasculitis, 1888
Systemic inflammatory response syndrome
calcitonin, 658
drug toxicity, 658
mycophenolate mofetil, 658
Systemic lupus erythematosus
adolescent, 174
African Americans, 73
alcohol drinking, 1363
angiotensin-converting enzyme inhibitors, 686
annexin A5, 382
antimalarials, 1769
antinuclear antibodies, 2104
antiphospholipid antibodies, 382
antiphospholipid syndrome, 516
anxiety, 770
autoantibodies, 1238, 1708 (ab)
autoimmune diseases, 2104
B-lymphocytes, 1819
bacterial infection, 728
belimumab, 1632
biological markers, 504, 728, 1231
biological therapy, 1769
biopsy, 1942
blood pressure, 752
bone density, 1955
brain, 752
brain diseases, 959
C-reactive protein, 728
calcitonin, 728
Canada, 254, 1074, 1378, 1708 (ab)

cardiac imaging techniques, 448
cardiovascular diseases, 2286
carotid arteries, 262
carotid stenosis, 2286
causality, 458, 496
cause of death, 458, 496
celiac disease, 1964
central nervous system lupus vasculitis, 504, 770, 959, 1742 (ab), 2118
cerebrovascular circulation, 752
chloroquine, 1099
cognitive disorders, 1371
comorbidity, 79, 86, 254, 262, 770, 870, 974, 1095, 1632, 1766, 1772, 1814, 1895, 2286
computer assisted instruction, 1710 (ab)
coronary disease, 968, 1099
corpus callosum, 1698
corticosteroids, 1718 (ab)
cost-benefit analysis, 735
database, 1074
death certificates, 458
depression, 262, 770
diagnosis, 196, 448, 1371, 2118
disease activity, 86, 1391, 1710 (ab)
disease susceptibility, 73
drug toxicity, 1099
epidemiology, 1363
ethnic groups, 759
etiology, 1095
fingers, 1895
gangrene, 1895
gene expression, 1942
genetic polymorphism, 686, 1603
genetic predisposition to disease, 1238, 1603
glomerulonephritis, 1942
glucocorticoids, 1955
health care costs, 1611
hemophagocytic lymphohistiocytosis, 86
hepatitis B virus, 974
hip fractures, 1378
histones, 1619
hospital outpatient clinics, 1074
hospitalization, 1611, 1708 (ab)
human LCN2 protein, 1231
human UBE2L3 protein, 73
hydroxychloroquine, 174
INDEL mutation, 686
infection, 1772, 1814
inflammation, 1701 (ab)
intercellular signaling peptides and proteins, 2104
interdisciplinary communication, 2118
interferon-alpha, 73, 504, 1238
interleukin-17, 870
interleukin-21, 1819
ischemia, 448
Japan, 1363
Korea, 86
liver diseases, 254
longitudinal studies, 968
lupus nephritis, 79, 510, 686, 1231, 1766, 1942
magnetic resonance imaging, 752, 869
meta-analysis, 686
microvessels, 510
morbidity, 516
mortality, 458, 496, 516
myocarditis, 448
neurologic manifestations, 770, 2118
neuropsychological tests, 1371
neutrophils, 1619
occupational diseases, 743
organs at risk, 1955
osteoporosis, 1378
pathologic processes, 752
patient compliance, 174
phagocytosis, 1619
posterior leukoencephalopathy syndrome, 196, 869, 870
predictive factors, 79
prevalence, 254, 974
quality of life, 735
questionnaires, 735
remission induction, 1718 (ab)
retinal vasculitis, 1095
rheumatic diseases, 2104
risk factors, 254, 743, 777, 968, 1363, 1378, 1603, 1611, 1964, 2286
S100 proteins, 728
seasons, 1391
sex, 759
sex characteristics, 759
smoking, 1363
social class, 743, 777
socioeconomic factors, 1701 (ab)
spleen, 1698
spontaneous remission, 1702 (ab)
stroke, 1611
Sweden, 743
systemic sclerosis, 1895
T-lymphocytes, 1819
Taiwan, 1611
telecommunications, 174
thrombomodulin, 1766
thrombosis, 1603, 1766
treatment outcome, 777, 1742 (ab)
vaccines, 1632
vascular cell adhesion molecule-1, 1231
vascular diseases, 262
vascular endothelial growth factors, 870
vasculitis, 510
vital statistics, 458, 496
young adult, 174

Systemic sclerosis
antinuclear antibodies, 787
autoantibodies, 787, 2127
autoimmune diseases, 532
autoimmunity, 532
Brazil, 1971
calcinosis, 2043
Canada, 524
cause of death, 1971
collagen, 660
comorbidity, 100, 198, 206, 269, 276, 1829, 1895, 2043
diagnosis, 198
disease management, 524
disease severity, 2127
endothelium, 100
epidemiology, 784
fibrosis, 539, 2294
fingers, 1895
France, 532
galectin 3, 539
gangrene, 1895
genetic predisposition to disease, 106, 532, 2294
health care costs, 2303
health resources, 2303
heart diseases, 206, 269
human IL4R protein, 112
human IL13RA1 protein, 112
idiopathic pulmonary hypertension, 100
immune system, 539
incidence, 784
infection, 2043
interleukin-6, 2294
knee, 2043
localized scleroderma, 660
longitudinal studies, 1829
managed care programs, 784
microvessels, 100
mortality, 2127
pathologic angiogenesis, 539
prevalence, 784
prognosis, 1971
pulmonary arterial hypertension, 276
pyoderma gangrenosum, 198
renal insufficiency, 1829
single nucleotide polymorphism, 112
stem cell transplantation, 206, 269
survival rate, 1971
systemic lupus erythematosus, 1895
treatment outcome, 206, 269, 276
Turkey, 106
United States, 784, 2303
urotensin II, 106
vasodilation, 100
warfarin, 276

T

T-lymphocytes
abatacept, S89–100
B-lymphocytes, 1819
cytomegalovirus, 1840
disease activity, 1840
eosinophilic granuloma, 1019
etiology, S89–7
genetic predisposition to disease, S89–7
granulomatosis with polyangiitis (Wegener's), 1019, 1840
interleukin-21, 1819
intravenous immunoglobulins, 1019
psoriasis, S89–100
psoriatic arthritis, S89–7, S89–100
Second Update on Psoriatic Disease, S89–7, S89–100
systemic lupus erythematosus, 1819
treatment outcome, 1019

Tacrolimus
Takayasu arteritis, 1487
treatment outcome, 1487

Taiwan
ankylosing spondylitis, 1765
genetic predisposition to disease, 1765
health care costs, 1611
hospitalization, 1611
human CCR6 protein, 1765
rheumatoid arthritis, 1765
risk factors, 1611
single nucleotide polymorphism, 1765
stroke, 1611
systemic lupus erythematosus, 1611

Takayasu arteritis
aorta, 1291
carotid arteries, 1291
giant cell arteritis, 303
human NOD2 protein, 1888
physical examination, 303
risk factors, 1291
synovitis, 1888
tacrolimus, 1487
treatment outcome, 1487
vasculitis, 303, 1888

Talus
ankle, 868
bone fractures, 868
diagnosis, 868
gouty arthritis, 868

Teaching
medical education, 1280

rheumatology, 1280
Telecommunications
adolescent, 174
hydroxychloroquine, 174
patient compliance, 174
systemic lupus erythematosus, 174
young adult, 174
Temporal arteries
biopsy, 295
disease management, 295
giant cell arteritis, 295
Temporomandibular joint disorders
diagnosis, 1778
facial pain, 2352
juvenile idiopathic arthritis, 1778, 1880, 2352
risk factors, 1880
Tendons
enthesis, S89–11
ligaments, S89–11
Second Update on Psoriatic Disease, S89–11
spondylarthritis, S89–11
synovial membrane, S89–11
Teriparatide
drug toxicity, 461, 600
glucocorticoids, 461, 600
osteoporosis, 461, 600
postmenopause, 461, 600
pubic bone, 1306
sacrococcygeal region, 1306
stress fractures, 1306
Th1 cells
ankylosing spondylitis, 830
Th17 cells, 830
tumor necrosis factor inhibitor, 830
Th17 cells
ankylosing spondylitis, 830
B-lymphocytes, S89–94
blood, 2021
cytokines, 18
enthesis, S89–94
etiology, S89–15
interleukin-17, S89–15
interleukin-23, S89–15
juvenile idiopathic arthritis, 2021
protease inhibitors, 2021
psoriatic arthritis, S89–15
regulatory T-lymphocytes, 2021
rheumatoid arthritis, 18
Second Update on Psoriatic Disease, S89–15, S89–94
spondylarthritis, S89–15
spondylarthropathy, S89–94
synovial fluid, 2021
Th1 cells, 830
tumor necrosis factor inhibitor, 18, 830, S89–94
Thermography
arthritis, 1739 (ab)
diagnosis, 183
gout, 183
hand, 1739 (ab)
inflammation, 183
Thoracic wall
diagnosis, 1844
magnetic resonance imaging, 1844
spondylarthritis, 1844
3e Initiative 2010
antidepressive agents, S90–21
arthritis, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62, S90–74, S90–81
cardiovascular diseases, S90–81
central muscle relaxants, S90–34
combination drug therapy, S90–47
comorbidity, S90–74, S90–81
corticosteroids, S90–17
drug therapy, S90–81
drug toxicity, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59, S90–62
gastrointestinal tract, S90–74
kidney diseases, S90–81
liver, S90–74
neurotransmitter agents, S90–28
nonsteroidal antiinflammatory agents, S90–56, S90–62
opioid analgesics, S90–40
pain management, S90–11, S90–17, S90–34, S90–47, S90–59, S90–74
pain measurement, S90–3
paracetamol, S90–11, S90–62
pregnancy, S90–59
review, S90–3, S90–11, S90–17, S90–21, S90–28, S90–34, S90–40, S90–47, S90–56, S90–59
treatment outcome, S90–3
Thrombomodulin
comorbidity, 1766
lupus nephritis, 1766
systemic lupus erythematosus, 1766
thrombosis, 1766
Thrombosis
comorbidity, 1766
genetic polymorphism, 1603
genetic predisposition to disease, 1603
lupus nephritis, 1766
risk factors, 1603
systemic lupus erythematosus, 1603, 1766
thrombomodulin, 1766
Tibial fractures
rheumatoid arthritis, 1893
signs and symptoms, 1893
TNF receptor-associated factor 6
autoimmune diseases, 1275
giant cell arteritis, 1275
risk factors, 1275
scleroderma, 1275
single nucleotide polymorphism, 1275
Tocilizumab
comorbidity, 657
dendritic cells, 1192
drug toxicity, 657
gene expression, 916
glycosylation, 916
immunoglobulin G, 916
inflammation, S89–97
interleukin-6, 60, 1192, S89–97
juvenile idiopathic arthritis, 1294
monocytes, 1192
pharmacological biomarkers, 916
psoriasis, S89–97
psoriatic arthritis, S89–97
rheumatoid arthritis, 60, 916, 1192
rheumatoid toxicity, 657
Second Update on Psoriatic Disease, S89–97
sleep disorders, 60
uveitis, 1294
Tomography
bone density, 1215
connective tissue diseases, 1265
diagnosis, 1265
diphosphonates, 1215
echocardiography, 1265
joints, 1735 (ab)
magnetic resonance imaging, 1265
postmenopause, 1215
pulmonary arterial hypertension, 1265
rheumatoid arthritis, 1215
women's health, 1215
Treatment
Canada, 1850
disease severity, 1850
psoriatic arthritis, 1850
Treatment outcome
adverse effects, 2359
age of onset, 1013, 1241
ankylosing spondylitis, 836, 1013, 2327
antineutrophil cytoplasmic antibody-associated vasculitis, 2153
arthritis, S90–3
B-lymphocytes, 2276
biological markers, 2276
biological therapy, 2049, 2238
Canada, 1738 (ab)
celecoxib, 1859
central nervous system lupus vasculitis, 1742 (ab)
central nervous system vasculitis, 2227
classification, 2062
combination drug therapy, 1524
comorbidity, 206, 269, 276, 2359
corticosteroids, 286, 2111
cyclophosphamide, 2111
data collection, 949
dermatomyositis, 2359
diffuse scleroderma, 1241
disease activity score, 310
disease management, 2062
disease progression, 2049
drug dosage calculations, 310
drug toxicity, 310, 1859, 2153
dyslipidemia, S89–24
early diagnosis, 1730 (ab)
eosinophilic granuloma, 1019
etanercept, 836
fibromyalgia, 1749 (ab)
fibrosis, 1241
Germany, 2153
glucocorticoids, 310
golimumab, 1735 (ab)
gout, 1450
gouty arthritis, 1859
granulomatosis with polyangiitis (Wegener's), 1019
heart diseases, 206, 269
inflammation, 2359
infliximab, 864, 1719 (ab), 2227
intravenous immunoglobulins, 1019
juvenile-onset ankylosing spondylitis, 1013
Kawasaki disease, 864
leflunomide, 1171
localized scleroderma, 286
lupus nephritis, 2111
lymphocyte depletion, 2276
magnetic resonance imaging, 1171
metabolic syndrome, S89–24
methotrexate, 286, 1171, 1524
mortality, 481
mucocutaneous lymph node syndrome, 864
mycophenolate mofetil, 1241
opioid analgesics, 1749 (ab)
orthopedics, 481
pain measurement, S90–3
painful ophthalmoplegia, 1485
paraneoplastic syndromes, 2359
pegloticase, 1450
physician's practice patterns, 949

plasma exchange, 864
plasmapheresis, 1171
polymyalgia rheumatica, 310
polymyositis, 1483
predictive factors, 240, 470
psoriasis, S89–24
psoriatic arthritis, 1735 (ab), 2327, S89–24
pulmonary arterial hypertension, 276
quality of life, 1450
remission induction, 470
review, S90–3
rheumatoid arthritis, 46, 240, 470, 481, 949, 1171, 1485, 1524, 1719 (ab), 1730 (ab), 1738 (ab), 2049, 2062, 2238, 2276
risk factors, 777
rituximab, 240, 1483, 1485, 2153, 2238, 2327
scleroderma, 1241
Second Update on Psoriatic Disease, S89–24
sex, 46, 481
signal recognition particle, 1483
signs and symptoms, 1013
social class, 777
spondylarthritis, 2327
stem cell transplantation, 206, 269
sulfasalazine, 836
systemic lupus erythematosus, 777, 1742 (ab)
systemic sclerosis, 206, 269, 276
T-lymphocytes, 1019
tacrolimus, 1487
Takayasu arteritis, 1487
3e Initiative 2010, S90–3
tumor necrosis factor inhibitor, 46, 836, 1524
warfarin, 276
ZAP-70 protein-tyrosine kinase, 2276

Triage
antibodies, 1716 (ab)
arthritis, 1706 (ab), 1748 (ab)
etiology, 1706 (ab)
rheumatic diseases, 1716 (ab)

Triamcinolone acetonide
drug administration schedule, 374
juvenile idiopathic arthritis, 374
triamcinolone hexacetonide, 374

Triamcinolone hexacetonide
drug administration schedule, 374
juvenile idiopathic arthritis, 374
triamcinolone acetonide, 374

Tuberculosis
rheumatoid arthritis, 1730 (ab)
tumor necrosis factor inhibitor, 1730 (ab)

Tumor necrosis factor inhibitor
abatacept, 1546
ankylosing spondylitis, 830, 836, 1418, 1854
anticitrullinated protein antibody, 929
antiglomerular basement membrane disease, 1904
apoptosis, 679
B-lymphocytes, S89–94
biological therapy, 41
cardiovascular diseases, 41, 1341
cartilage matrix protein, 1341
chemokine CCL2, 979
combination drug therapy, 1524
comorbidity, 1297, 1705 (ab)
cost-benefit analysis, S89–103
cytokines, 18
dermatomyositis, 193
diagnosis, 651
disease activity, 334, 568, 1035
drug therapy, 1733 (ab)
drug toxicity, 193, 651, 946, 1035, 1546, 1744 (ab), 1904, S89–82, S89–103
electronic health records, 1721 (ab)
enthesis, S89–94
etanercept, 836
EULAR, 1035
fasciitis, 193
fatty liver, 1035
genetic polymorphism, 1035
human FCGR2A protein, 1035
infection, 1297
interferon-gamma, 979
interferon-gamma release tests, S89–82
interleukin-6, 979, 2055
latent tuberculosis, 1297, S89–82
lipids, 946
longitudinal studies, 1035
methotrexate, 1341, 1524
miliary tuberculosis, 651, 1297
mortality, 334
pharmacology, 679
physician's practice patterns, 1418
platelet activation, 334
predictive factors, 568
psoriasis, 2055
psoriatic arthritis, 334, 568, 1035, S89–82, S89–103
remission induction, 1418
respiratory function tests, 1854
rheumatoid arthritis, 18, 41, 46, 651, 679, 929, 946, 1341, 1524, 1546, 1705 (ab), 1721 (ab), 1730 (ab), 1733 (ab), 1904
risk factors, 1341
scleroderma, 979
Second Update on Psoriatic Disease, S89–82, S89–94, S89–103
sex, 46
spondylarthritis, 41
spondylarthropathy, S89–94
sulfasalazine, 836
Th1 cells, 830
Th17 cells, 18, 830, S89–94
treatment outcome, 46, 836, 1524
tuberculosis, 1730 (ab)
urinary bladder neoplasms, 1744 (ab)

Turkey
genetic predisposition to disease, 106
systemic sclerosis, 106
urotensin II, 106

U

Ultrasonography
biological markers, S89–61
chondrocalcinosis, 1488
connective tissue diseases, 1641
diagnosis, 1488, 1678
diagnostic imaging, 1678
Doppler effect, S89–24
enthesis, 404, 2045, S89–24
fibromyalgia, S89–24
GRAPPA 2010, 404
hemarthrosis, 1678
magnetic resonance imaging, S89–61
osteoporosis, 1731 (ab)
osteoprotegerin, 1678
physician's practice patterns, S89–39
psoriasis, 404
psoriatic arthritis, 404, 2045, S89–24, S89–39, S89–61
pulmonary fibrosis, 1641
RANK ligand, 1678
risk assessment, 1731 (ab)
Second Update on Psoriatic Disease, S89–24, S89–39, S89–61
synovial fluid, S89–61
ultrasound, 404
X-ray computed tomography, 1641

Ultrasound
clinical competence, 1207
enthesis, 404
gout, 2362
GRAPPA 2010, 404
GRAPPA 2011, 2211
joints, 1207
palpation, 1207
psoriasis, 408
psoriatic arthritis, 404, 2211
rheumatoid arthritis, 1207
ultrasonography, 404
uric acid, 2362

Unfolded protein response
HLA-B27 antigen, 574
interferon-gamma, 574
spondylarthropathy, 574

United States
activities of daily living, 2134
dermatomyositis, 2134
epidemiology, 784
health care costs, 2303
health resources, 2303
incidence, 784
managed care programs, 784
myositis, 2134
occupational diseases, 1709 (ab)
polymyositis, 2134
prevalence, 784
questionnaires, 2134
systemic sclerosis, 784, 2303

Uric acid
diagnosis, 195
exanthema, 195
genetic variation, 1901
gout, 195, 1901, 2362
ultrasound, 2362

Urinary bladder neoplasms
drug toxicity, 1744 (ab)
tumor necrosis factor inhibitor, 1744 (ab)

Urotensin II
genetic predisposition to disease, 106
systemic sclerosis, 106
Turkey, 106

Ustekinumab
drug toxicity, S89–86
psoriasis, S89–86
psoriatic arthritis, S89–86
Second Update on Psoriatic Disease, S89–86

Uveitis
juvenile idiopathic arthritis, 1294
tocilizumab, 1294

V

Vaccines
belimumab, 1632
comorbidity, 1632
systemic lupus erythematosus, 1632

Vascular cell adhesion molecule-1
biological markers, 1231
human LCN2 protein, 1231
lupus nephritis, 1231
systemic lupus erythematosus, 1231

Vascular diseases
carotid arteries, 262

comorbidity, 262
depression, 262
etiology, 1385
microscopy, 1385
scleroderma, 1385
systemic lupus erythematosus, 262
Vascular endothelial growth factors
comorbidity, 870
interleukin-17, 870
posterior leukoencephalopathy syndrome, 870
systemic lupus erythematosus, 870
Vascular stiffness
comorbidity, 2267
infliximab, 2267
methotrexate, 2267
rheumatoid arthritis, 2267
Vasculitis
antineutrophil cytoplasmic antibodies, 558, 1088, 2012
biopsy, 1413
carotid arteries, 1898
classification, 1503, 1687
color Doppler ultrasonography, 1898
coronary artery disease, 1761
cryoglobulinemia, 119
cyclophosphamide, 2012
diagnosis, 1088, 1413, 1503, 1898
diagnostic imaging, 1761
disease severity, 2012
Europe, 1687
female genitalia, 2229
giant cell arteritis, 303, 1898
granulomatosis with polyangiitis (Wegener's), 1687
hematuria, 1413
human NOD2 protein, 1888
lupus nephritis, 510
microvessels, 510
mycophenolate mofetil, 2223
mycophenolic acid, 2223
physical examination, 303
positron-emission tomography and computed tomography, 1761
predictive factors, 2012
propylthiouracil, 558
Raynaud disease, 119
registries, 1088
remission induction, 1413
renal insufficiency, 558
synovitis, 1888
systemic lupus erythematosus, 510
Takayasu arteritis, 303, 1888
Vasoconstriction
central nervous system vasculitis, 1026
diagnosis, 1026
differential diagnosis, 1026
signs and symptoms, 1026
Vasodilation
comorbidity, 100
endothelium, 100
idiopathic pulmonary hypertension, 100
microvessels, 100
systemic sclerosis, 100
Vital statistics
causality, 458, 496
cause of death, 458, 496
death certificates, 458
mortality, 458, 496
systemic lupus erythematosus, 458, 496
Vitamin D
arthritis, 1703 (ab)
ethnic groups, 1726 (ab), 1792
rheumatoid arthritis, 1726 (ab), 1792
vitamin D deficiency, 1703 (ab)
Vitamin D deficiency
arthritis, 1703 (ab)
vitamin D, 1703 (ab)

W

Warfarin
comorbidity, 276
pulmonary arterial hypertension, 276
systemic sclerosis, 276
treatment outcome, 276
Wegener granulomatosis
See also Granulomatosis with polyangiitis (Wegener's)
antineutrophil cytoplasmic antibody-associated vasculitis, 125
cross-sectional studies, 1739 (ab)
Internet, 1739 (ab)
microscopic polyangiitis, 125
rituximab, 125
Whiplash injuries
chronic pain, 655
etiology, 655
Wissler's syndrome
adult-onset Still's disease, 2008
anakinra, 2008
interleukin-1, 2008
Women's health
androgen receptors, 10
bone density, 1215, 1465
diphosphonates, 1215
femur neck, 1465
genetic polymorphism, 10
mitochondrial DNA, 1465
osteoporosis, 1465
postmenopause, 1215, 1465
rheumatoid arthritis, 10, 1215
tomography, 1215
Work disability
employment, 337
ethnic groups, 337
knee, 337
osteoarthritis, 337

X

X-ray computed tomography
connective tissue diseases, 1641
pulmonary fibrosis, 1641
ultrasonography, 1641

Y

Young adult
adolescent, 174
hydroxychloroquine, 174
patient compliance, 174
systemic lupus erythematosus, 174
telecommunications, 174

Z

ZAP-70 protein-tyrosine kinase
B-lymphocytes, 2276
biological markers, 2276
lymphocyte depletion, 2276
rheumatoid arthritis, 2276
treatment outcome, 2276
Zoledronic acid
drug toxicity, 1731 (ab)
medication adherence, 1727 (ab)
osteoporosis, 1727 (ab), 1731 (ab)

Journal of Rheumatology, Volume 39, 2012

CONTENT INDEX

Pages 1–2424 and Supplement 89-90

VOLUME 39: NO. 1 JANUARY 2012

Editorials

Tender Points in Rheumatoid Arthritis — How Do They Help Us? *T. Starz* 1

B Cell Strategy to Maintain Remission in ANCA-associated Vasculitides? *S. Adler, P.M. Villiger* 4

Articles

Mannose-binding Lectin Gene Polymorphisms in Brazilian Patients with RA *F.L. Martiny,T.D. Veit, C.V. Brenol, et al* 6

CAG Repeat Polymorphism in the Androgen Receptor Gene in Women with RA *V. Dziedziejko, M. Kurzawski, K. Safranow, et al* . . 10

TNF Blockade Differentially Affects Innate Inflammatory and Th17 Cytokines in RA *S.M. Zivojinovic, N.N. Pejnovic, M.N. Sefik-Bukilica, L.V. Kovacevic, I.I. Soldatovic, N.S. Damjanov* 18

Look Beyond the Disease Activity Score of 28 Joints (DAS28): Tender Points Influence the DAS28 in Patients with RA *E. Ton, M.F. Bakker, S.M.M. Verstappen, et al, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group* 22

Pain Thresholds in RA: The Effect of Tender Point Counts and Disease Duration *L.C. Pollard, F. Ibrahim, E.H. Choy, D.L. Scott* 28

Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in OA and RA *X. Sheng, M.J. Murphy, T.M. MacDonald, L. Wei* 32

Biological Drug Treatment of RA and SpA: Effects on QT Interval and QT Dispersion *M. Di Franco, M. Paradiso, F. Ceccarelli, et al* 41

Sex Differences in Response to Anti-TNF Therapy in Early and Established RA — Results from the DANBIO Registry *D. Jawaheer, J. Olsen, M.L. Hetland* 46

Mortality Risk by Functional Status and Health-related Quality of Life in Patients with RA *K. Michaud, M. Vera-Llonch, G. Oster* 54

Sleep Disturbances and IL-6 Receptor Inhibition in RA *K. Fragiadaki, M.G. Tektonidou, M. Konsta, G.P. Chrousos, P.P. Sfikakis* 60

Health-related Quality of Life Outcomes of Adalimumab for Patients with Early RA: Results from a Randomized Multicenter Study *V. Strand, A.M. Rentz, M.A. Cifaldi, N. Chen, S. Roy, D. Revicki* 63

The Autoimmune Disease Risk Allele of UBE2L3 in African American Patients with SLE: A Recessive Effect Upon Subphenotypes *S. Agik, B.S. Franek, A.A. Kumar, et al* 73

Frequency of Class III and IV Nephritis in SLE Without Clinical Renal Involvement: An Analysis of Predictive Measures *D. Wakasugi, T. Gono, Y. Kawaguchi, et al* 79

Reactive Hemophagocytic Syndrome in Adult Korean Patients with SLE: A Case-Control Study and Literature Review *J-M. Kim, S-K. Kwok, J.H. Ju, H-Y. Kim, S-H. Park* 86

NADH-TR Identifies Microvasculature Activation in Muscle from Adult Patients with Dermatomyositis *C. Charles-Schoeman, M.A. Verity* 94

PAH in SSc Is Associated with Profound Impairment of Microvascular Endothelium-dependent Vasodilatation *H.M.A. Hofstee, A.E. Voskuyl, A. Vonk Noordegraal, Y.M. Smulders, P.E. Postmus, B.A.C. Dijkmans, E.H. Serné* 100

Association Between Thr21Met and Ser89Asn Polymorphisms of the Urotensin II Gene and SSc *Y. Pehlivan, B. Gogebakan, S. Oztuzcu, et al* 106

Polymorphisms in the IL-4, IL-13, and Corresponding Receptor Genes Are Not Associated with SSc and Do Not Influence Gene Expression *J.C.A. Broen, P. Dieude, M.C. Vonk, et al* 112

Clinical Significance of Cryofibrinogenemia: Possible Pathophysiological Link with Raynaud's Phenomenon *M.S. Soyfoo, A. Goubella, E. Cogan, J-C. Wautrecht, A. Ocmant, P. Stordeur* 119

Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis *C. Roubaud-Baudron, C. Pagnoux, N. Méaux-Ruault, et al, for the French Vasculitis Study Group* 125

***ANKH* and Susceptibility to and Severity of Ankylosing Spondylitis** *F.M. Pimentel-Santos, D. Ligeiro, M. Matos, et al, and the CORPOREA Study Group* 131

Association of *IL-12B* Genetic Polymorphism with the Susceptibility and Disease Severity of Ankylosing Spondylitis *R-H. Wong, J.C-C. Wei, C-H. Huang, et al* 135

Ethnic Influence in Clinical and Functional Measures of Brazilian Patients with Spondyloarthritis *T.L. Skare, A.B. Bortoluzzo, C.R. Gonçalves, et al* 141

Clinical Characteristics of Patients with RS3PE Compared to Patients with Pure Polymyalgia Rheumatica *M. Kimura, Y. Tokuda, H. Oshiawa, et al* 148

The CIASsification for Psoriatic ARthritis (CASPAR) Criteria — A Retrospective Feasibility, Sensitivity, and Specificity Study *W. Tillett, L. Costa, D. Jadon, et al* 154

Concomitant Septic Arthritis in Crystal Monoarthritis *L.E. Papanicolas, P. Hakendorf, D.L. Gordon* 157

Hand Joint Space Narrowing and Osteophytes Are Associated with MRI-defined Knee Cartilage Thickness and Radiographic Knee OA: Data from the Osteoarthritis Initiative *I.K. Haugen, S. Cotofana, M. Englund, et al, for the Osteoarthritis Initiative Investigators* 161

Pediatric Rheumatology

Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease *N.E. Aikawa, L.M.A. Campos, C.A. Silva, et al* . . . 167

Usefulness of Cellular Text Messaging for Improving Adherence Among Adolescents and Young Adults with SLE *T.V. Ting, D. Kudalkar, S. Nelson, et al* 174

Images in Rheumatology

Giant Intraosseous Synovial Cyst with Intraarticular Communication with the Ankle Joint in Longstanding RA *Y.E. Amin, Y. Ragab, N. El-Shaarawy, A. Kamal* . . 180

Thermography Detects Subclinical Inflammation in Chronic Tophaceous Gout *M. Schiavenato, R.G. Thiele* 182

An Unusual Cause of Dysphagia *C. Palazzi, S. D'Angelo, I. Olivieri* 184

Correspondence

Psoriatic Arthritis: Radiographic Joint Repair Following Etanercept Therapy *I. Garcia-Valladares, R. Cuchacovich, L.R. Espinoza* 185

Reply *L. Eder, V. Chandran, D.D. Gladman* 185

Beneficial Effect of N-acetylcysteine on ANCA-associated Vasculitis *S.J. Park, K.S. Pai, J.H. Kim, J.I. Shin* 186

Reply *F.J. Fernández-Fernández, P. Sesma* 186

Letters

Combination Biologic Treatment of Refractory Psoriasis and Psoriatic Arthritis *R. Cuchacovich, I. Garcia-Valladares, L.R. Espinoza* 187

Anti-TNF Inhibitor Therapy-induced Dermatomyositis and Fasciitis *G. Riolo, T.E. Towheed* 193

Tophaceous Pustule-like Rash in a Patient with Gout *M.R. Chehab, J. Goyal, N. Schlesinger* 195

Atypical Posterior Reversible Encephalopathy Syndrome: A Flare of SLE *C. Monteiro, I. Almeida, D. Dias, E. Santos* 197

Pyoderma Gangrenosum in a Patient with SSc *J. Feld, R. Bergman, S. Weltfriend, D. Zisman* . . . 198

A Rare Presentation of Endocarditis in AOSD in Diagnosis of Fever of Unknown Origin *B.M. Ertugrul, G. Uyar, B. Ozturk, S. Sakarya* . . . 199

Renal Infarction Due to Spontaneous Renal Artery Dissection in Ehlers-Danlos Syndrome Type IV *R. Conway, D. Bergin, R.J. Coughlan, J.J. Carey* 200

Correction

Differences in the Incidence of Microscopic Polyangiitis and Granulomatosis with Polyangiitis (Wegener's). Is There a Latitudinal Gradient? *L. Corral-Gudino, M. Borao-Cengotita-Bengoa, J.L. Lerma-Marquez, J. del Pino-Montes* 202

Meetings in Rheumatology xii

Editorials

The Puzzle of Generalized Osteoarthritis (OA) — Is OA a Systemic Enthesopathy?
I.K. Haugen 203

Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: If You Are Confused, Remember: "It Is a Matter of the Heart"
R.K. Burt, S.J. Shah, M. Gheorghiade, E. Ruderman, J. Schroeder 206

Guilty by Association: Platelet Reactivity and Inflammation in Psoriatic Arthritis
P. MacMullan 210

Review

The Need to Better Classify and Diagnose Early and Very Early RA *H. Zeidler* 212

Articles

ApoE Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in RA
T.E. Toms, J.P. Smith, V.F. Panoulas, H. Blackmore, K.M.J. Douglas, G.D. Kitas 218

Mortality and Incidence of Malignancy in Korean Patients with RA
Y.J. Kim, J-S. Shim, C-B. Choi, S-C. Bae 226

Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
C. Gaujoux-Viala, C. Giampietro, T. Gaujoux, et al 233

Effectiveness of Rituximab in Patients with RA: Observational Study from the British Society for Rheumatology Biologics Register *M.M. Soliman, K.L. Hyrich, M. Lunt, K.D. Watson, D.P.M. Symmons, D.M. Ashcroft, and the British Society for Rheumatology Biologics Register* 240

Performance of Risk Indices for Identifying Low BMD and Osteoporosis in Mexican Mestizo Women with RA *L. Gonzalez-Lopez, J.I. Gamez-Nava, A. Vega-Lopez, et al* 247

Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with SLE
D. Huang, E. Aghdassi, J. Su, et al 254

Association Between Depression and Vascular Disease in SLE *C.M. Greco, T. Li, A. Sattar, et al* 262

Optimization of Autologous Stem Cell Transplantation for SSc — A Single-center Longterm Experience in 26 Patients with Severe Organ Manifestations
J.C. Henes, M. Schmalzing, W. Vogel, et al 269

Warfarin in SSc-associated and Idiopathic PAH. A Bayesian Approach to Evaluating Treatment for Uncommon Disease *S.R. Johnson, J.T. Granton, G.A. Tomlinson, et al* 276

MTX and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study
K.S. Torok, T. Arkachaisri 286

Clinical Course and Management of a Consecutive Series of Patients with "Healed Temporal Arteritis"
Y.C. Lee, R.F. Padera, E.H. Noss, et al 295

Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis
P.C. Grayson, G. Tomasson, D. Cuthbertson, et al, and the Vasculitis Clinical Research Consortium 303

Contribution of the PMR Activity Score to Glucocorticoid Dosage Adjustment in Everyday Practice *C. Cleuziou, A. Binard, M. De Bandt, J-M. Berthelot, A. Saraux* 310

Involvement of the Femoropopliteal Arteries in GCA: Clinical and Color Duplex Sonography
M. Czihal, F. Tató, A. Rademacher, P. Kuhlencordt, H. Schulze-Koops, U. Hoffmann 314

Assessment of Preclinical Atherosclerosis in Patients with AS
W. Hamdi, M.C. Bouaziz, I. Zouch, et al 322

Plasma Phospholipid Fatty Acid Content Is Related to Disease Activity in AS
B. Sundström, G. Johansson, H. Kokkonen, T. Cederholm, S. Wållberg-Jonsson 327

Platelet Reactivity and Disease Activity in Subjects with PsA *M.N.D. Di Minno, S. Iervolino, R. Peluso, R. Scarpa, G. Di Minno* 334

Racial Differences in Knee OA Pain: Potential Contribution of Occupational and Household Tasks
K.D. Allen, J-C. Chen, L.F. Callahan, et al 337

Osteochondral Destruction in Pigmented Villonodular Synovitis During the Clinical Course
Y. Nishida, S. Tsukushi, H. Nakashima, et al 345

Clinically Relevant Outcomes Based on Analysis of Pooled Data from 2 Trials of Duloxetine in Patients with Knee OA
M.C. Hochberg, M. Wohlreich, P. Gaynor, S. Hanna, R. Risser 352

Relation of Hand Enthesophytes with Knee Enthesopathy: Is OA Related to a Systemic Enthesopathy?
N. Gibson, A. Guermazi, M. Clancy, et al 359

Pediatric Rheumatology

Prevalence of Vertebral Compression Fractures and Associated Factors in Children and Adolescents with Severe JIA
K.P. Markula-Patjas, H.L. Valta, L.I. Kerttula, et al 365

A Dose Schedule for Intraarticular Steroids in Juvenile Arthritis
B.A. Eberhard, N.T. Ilowite, C. Sison 374

Simultaneous JIA and Diabetes Mellitus Type 1 — A Finnish Nationwide Study
H. Pohjankoski, H. Kautiainen, M. Korppi, A. Savolainen 377

Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases
D.M. Wahezi, N.T. Ilowite, S. Rajpathak, J.H. Rand 382

Images in Rheumatology

Osteitis Condensans of the Sternal Manubrium and Ossification of the Costoclavicular Ligaments
F. Paparo, M. Parodi, M. Revelli, G. Ferrero, G. Garlaschi, M.A. Cimmino 389

Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Miami, Florida, USA, December 9-11, 2010

Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
P.J. Mease, D.D. Gladman 391

GRAPPA Trainees Symposium 2010
C.T. Ritchlin 394

Development of Composite Measures for PsA
P.S. Helliwell, O. FitzGerald, P.J. Mease 398

The Ultrasound Imaging Module
G.S. Kaeley, C.J. Bakewell 404

MRI in PsA — Update on Current Status and Future Perspectives
M. Østergaard, R.P. Poggenborg 408

The Need to Define Musculoskeletal Inflammation
A. Garg, D.D. Gladman, P.J. Mease 413

Distinguishing Inflammatory from Noninflammatory Arthritis, Enthesitis, and Dactylitis in PsA
P.J. Mease 415

Inflammatory Spinal Disease in PsA
D.D. Gladman 418

Psoriasis and PsA Video Project
J.L. Woodcock, P.J. Mease, K. Callis Duffin 421

Strategies for Biomarker Development in Psoriatic Disease
C.T. Ritchlin 423

Update on Biomarkers in PsA
O. FitzGerald, V. Chandran 427

Genetics of Psoriasis and PsA
P. Rahman, J.T. Elder 431

The Path Forward to Biomarker Discovery in Psoriatic Disease
D.D. Gladman, C.T. Ritchlin, O. FitzGerald 434

Comorbidities of PsA — Metabolic Syndrome and Prevention
S.P. Raychaudhuri 437

Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis
W-H. Boehncke 441

Global Partnering Opportunities and Challenges of Psoriasis and PsA in Latin America
L.R. Espinoza, S.M.A. Toloza, R. Valle-Onate, P.J. Mease 445

Letters

Subendocardial Ischemia and Myocarditis in SLE Detected by Cardiac MRI
P. Goykhman, P.K. Mehta, M. Minissian, et al 448

IVIG Expands Regulatory T Cells in Autoimmune Rheumatic Disease
J. Bayry, L. Mouthon, S.V. Kaveri 450

Doppler Imaging and Histology of the Synovium
J.M. Koski 452

Book Review

Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia 454

Corrections

The Problem of RA Disease Activity and Remission in Clinical Practice
T.S. Shaver, J.D. Anderson, D.N. Weidensaul, et al 454

Is Fatigue an Inflammatory Variable in RA? Analyses of Fatigue in RA, OA, and FM
M.J. Bergman, S.S. Shahouri, T.S. Shaver, et al 454

Meetings in Rheumatology x

VOLUME 39: NO. 3 — MARCH 2012

Editorials

Can We Identify Patients with Microscopic Polyangiitis Who Are at Risk of Relapse?
R.A. Luqmani 455

Mortality and Multiple Causes of Death in Systemic Lupus Erythematosus — Role of the Death Certificate
M. Abu-Shakra, V. Novack 458

Teriparatide for Glucocorticoid-induced Osteoporosis
A. Diez-Perez, E. Sole 461

Articles

IgG Glycosylation Changes and *MBL2* Polymorphisms: Associations with Markers of Systemic Inflammation and Joint Destruction in RA
L.N. Troelsen, S. Jacobsen, J.L. Abrahams, et al . 463

Remission in Early RA: Predicting Treatment Response
M.H.Y. Ma, F. Ibrahim, D. Walker, et al 470

The Influence of Individual Joint Impairment on Functional Disability in RA Using a Large Observational Database of Japanese Patients
K. Shidara, E. Inoue, D. Hoshi, et al 476

Orthopedic Surgery Among Patients with RA 1980-2007: A Population-based Study Focused on Surgery Rates, Sex, and Mortality
C.A. Shourt, C.S. Crowson, S.E. Gabriel, E.L. Matteson 481

Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with RA with an Inadequate Response to MTX Therapy: A Placebo-controlled Double-blind Parallel-group Study
M. Harigai, Y. Tanaka, Shingo Maisawa, and the JA21963 Study Group 486

Mortality Profile Related to SLE: A Multiple Cause-of-death Analysis
D.C.C. Souza, A.H. Santo, E.I. Sato 496

Utility of IFN-α as a Biomarker in Central Neuropsychiatric Involvement in SLE
H. Fragoso-Loyo, Y. Atisha-Fregoso, C.A. Núñez-Álvarez, L. Llorente, J. Sánchez-Guerrero 504

Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis
P.M. Izmirly, M. Shvartsbeyn, S. Meehan, et al . . . 510

Morbidity, Mortality, and Organ Damage in Patients with APS *E.P. Grika, P.D. Ziakas, E. Zintzaras, H.M. Moutsopoulos, P.G. Vlachoyiannopoulos* . . . 516

Agreement with Guidelines from a Large Database for Management of SSc: Results from the Canadian Scleroderma Research Group
J. Pope, S. Harding, S. Khimdas, A. Bonner, the Canadian Scleroderma Research Group, M. Baron 524

Familial Autoimmunity in SSc. Results of a French-based Case-Control Family Study
E. Koumakis, P. Dieudé, J. Avouac, A. Kahan, Y. Allanore, and Association des Sclérodermiques de France 532

Serum Levels of Galectin-3: Possible Association with Fibrosis, Aberrant Angiogenesis, and Immune Activation in Patients with SSc
T. Taniguchi, Y. Asano, K. Akamata, et al 539

Risk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis
T. Wada, A. Hara, Y. Arimura, K-E. Sada, H. Makino, and the Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan . . 545

Adverse Events During Longterm Low-dose Glucocorticoid Treatment of PMR: A Retrospective Study
M. Mazzantini, C. Torre, M. Miccoli, et al 552

Propylthiouracil-induced Antineutrophil Cytoplasmic Antibody (ANCA)-associated Renal Vasculitis Versus Primary ANCA-associated Renal Vasculitis: A Comparative Study
Y-X. Chen, W. Zhang, X-N. Chen, et al 558

Prevalence of Monoclonal Gammopathy Among Patients with PsA
L. Eder, A. Thavaneswaran, D. Pereira, G. Sussman, D.D. Gladman 564

Predictors of Early Minimal Disease Activity in Patients with PsA Treated with TNF-α Blockers
S. Iervolino, M.N.D. Di Minno, R. Peluso, et al . . . 568

IFN-γ Contributes to HLA-B27-associated Unfolded Protein Response in Spondyloarthropathies
Y. Feng, J. Ding, C.M. Fan, P. Zhu 574

Aberrant Chondrocyte Hypertrophy and Activation of β-Catenin Signaling Precede Joint Ankylosis in *ank/ank* Mice
F. Las Heras, K.P.H. Pritzker, A. So, et al 583

Evaluation of Circulating Endothelial and Platelet Microparticles in Men with AS
I. Sari, G. Bozkaya, H. Kirbiyik, et al 594

Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study
D. Karras, I. Stoykov, W.F. Lems, et al 600

Civamide Cream 0.075% in Patients with OA of the Knee: A 12-Week Randomized Controlled Clinical Trial with a Longterm Extension
T.J. Schnitzer, J-P. Pelletier, D.M. Haselwood, et al 610

Aggravation of ADAMTS and MMP Production and Role of ERK1/2 Pathway in the Interaction of Osteoarthritic Subchondral Bone Osteoblasts and Articular Cartilage Chondrocytes — Possible Pathogenic Role in OA
I. Prasadam, R. Crawford, Y. Xiao 621

Glucosamine Sulfate Reduces PGE$_2$ Production in Osteoarthritic Chondrocytes Through Inhibition of Microsomal PGE Synthase-1 *M. Kapoor, F. Mineau, H. Fahmi, J-P. Pelletier, J. Martel-Pelletier* 635

Pediatric Rheumatology

MRI and Radiographic Assessment of Carpal Depressions in Children with JIA: Normal Variants or Erosions? *P. Boavida, R. Hargunani, C.M. Owens, K. Rosendahl* 645

Images in Rheumatology

Miliary Nodularity in a Patient Receiving TNF Inhibitors Is Not Always Miliary TB
M. Haroon, B. Cushen, D. Veale 651

Correspondence

Patient Assessments of Skin, Joint, and Nail Disease Activity in PsA
A. Kavanaugh, T. Catalan, S. Cassell 653

Reply
A. Cauli, D.D. Gladman, A. Mathieu, G. Porru, A. Vacca, P.J. Mease, and the GRAPPA 3PPsA Study Group 654

Whiplash: Nothing to Lose Sleep Over
R. Ferrari, A.S. Russell 655

Reply *B.P. Radanov, A.F. Mannion, P. Ballinari* 656

Letters

Psoriasis Onset with TCZ Treatment for RA
D. Wendling, H. Letho-Gyselinck, X. Guillot, C. Prati 657

Acute Inflammatory Syndrome with Elevated Procalcitonin Induced by MPS
J. Loock, P. Lamprecht, W.L. Gross 658

Febuxostat Hypersensitivity *A.M. Abeles* 659

Nodular/Keloidal Scleroderma: Acquired Collagenous Nodules in SSc
E.N. Le, J.M. Junkins-Hopkins, N.S. Sherber, F.M. Wigley 660

CNS Vasculitis: All That Glitters Is Not Gold
M. Haroon, E. Molloy, M. Farrell, S. Alraqi 662

Radiographic Improvement in Sarcoid Arthropathy after Infliximab Treatment
B. Mehta, P. Efthimiou 664

Myopericarditis Revealing GCA in the Elderly
A. Daumas, P. Rossi, A. Jacquier, B. Granel 665

Correction

Medication Use in Systemic Lupus Erythematosus
S. Bernatsky, C. Peschken, PR Fortin, et al 667

Meetings in Rheumatology x

VOLUME 39: NO. 4 — APRIL 2012

Editorials

Osteoarthritis, Exercise, and Knee Replacement
J.F. Fries, B. Bruce, S. Shoor 669

Exercise and Osteoarthritis: Not Necessarily an All-or-Nothing Proposition! *A.C. Gelber* 672

Anti-Citrullinated Peptide/Protein Antibodies and Structural Prognosis of Rheumatoid Arthritis: Quantity Versus Quality *O. Meyer* 675

Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to "Characterize" and "Refine" Clinical Definitions
J.L. Fernández-Sueiro 677

Reviews

Apoptosis as a Mechanism of Action of TNF Antagonists in Rheumatoid Arthritis
D. Makrygiannakis, A.I. Catrina 679

Relationship Between ACE Insertion/Deletion Gene Polymorphism and SLE/Lupus Nephritis: A Systematic Review and Metaanalysis
T-B. Zhou, Y-G. Liu, N. Lin, Y-H. Qin, K. Huang, M-B. Shao, D-D. Peng 686

Articles

ACPA, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in RA *K. Shiozawa, Y. Kawasaki, T. Yamane, R. Yoshihara, Y. Tanaka, K. Uto, S. Shiozawa* . . . 694

Infliximab Treatment Increases LVEF in Patients with RA: Assessment of Heart Function by Echocardiography, ET-1, IL-6, and NT-pro Brain Natriuretic Peptide *P.J. Kotyla, A. Owczarek, J. Rakoczy, M. Lewicki, E.J. Kucharz, P. Emery* . . 701

Time to Consultation and DMARD Treatment of Patients with RA — Northern Alberta Perspective
J.A. Nanji, M. Choi, R. Ferrari, C. Lyddell, A.S. Russell 707

Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with RA: Metaanalysis of Randomized Controlled Trials *P. Le Blay, G. Mouterde, T. Barnetche, J. Morel, B. Combe* . . 712

Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics
J.M. Cheung, D. Scarsbrook, A.V. Klinkhoff 716

Efficacy and Safety of CE-224,535, an Antagonist of P2X$_7$ Receptor, in Treatment of Patients with RA Inadequately Controlled by MTX *T.C. Stock, B.J. Bloom, N. Wei, S. Ishaq, W. Park, X. Wang, et al* 720

CRP Is a More Sensitive and Specific Marker for Diagnosing Bacterial Infections in SLE Compared to S100A8/A9 and Procalcitonin *H-A. Kim, J-Y. Jeon, J-M. An, B-R. Koh, C-H. Suh* 728

Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with SLE
M.J. Harrison, Y. Ahmad, S. Haque, N. Dale, L-S. Teh, N. Snowden, et al 735

Occupational Risk Factors for SLE: a Nationwide Study Based on Hospitalizations in Sweden
X. Li, J. Sundquist, K. Sundquist, B. Zöller 743

Blood Pressure and Vascular Dysfunction Underlie Elevated Cerebral Blood Flow in SLE *C. Gasparovic, C. Qualls, E.R. Greene, W.L. Sibbitt Jr, C.A. Roldan* 752

Differences between Male and Female SLE in a Multiethnic Population
T.C. Tan, H. Fang, L.S. Magder, M.A. Petri 759

Are Cognitive and Olfactory Dysfunctions in NPSLE Dependent on Anxiety or Depression?
S. Cavaco, A. Martins da Silva, E. Santos, E. Coutinho, A. Marinho, I. Moreira, et al 770

Low Socioeconomic Status Is Associated with Cardiovascular Risk Factors and Outcomes in SLE
J.W. Maynard, H. Fang, M.A. Petri 777

Epidemiology of SSc in a Large US Managed Care Population *D.E. Furst, A.W. Fernandes, Ş.R. Iorga, W. Greth, T. Bancroft* 784

Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with SSc *M. Hudson, M. Mahler, J. Pope, D. You, S. Tatibouet, R. Steele, et al, Canadian Scleroderma Research Group* . . . 787

Patient-reported Outcomes in Polymyalgia Rheumatica
E.L. Matteson, H. Maradit-Kremers, M.A. Cimmino, W.A. Schmidt, M. Schirmer, C. Salvarani, et al . . . 795

A Clinical Prediction Rule for Lymphoma Development in Primary Sjögren's Syndrome
C. Baldini, P. Pepe, N. Luciano, F. Ferro, R. Talarico, S. Grossi, et al 804

Detection of HTLV-1 in the Labial Salivary Glands of Patients with Sjögren's Syndrome: A Distinct Clinical Subgroup? *S-J. Lee, J.S. Lee, M-G. Shin, Y. Tanaka, D-J. Park, T-J. Kim, et al* 809

Performance of the ASAS Classification for Axial and Peripheral Spondyloarthritis in an Established Clinical Cohort: Comparison with Criteria Sets of Amor and the ESSG *P.P. Cheung, S. Paternotte, V. Burki, A. Durnez, M. Elhai, I. Fabreguet, et al* . 816

Preliminary Validation of a Self-reported Screening Questionnaire for Inflammatory Back Pain
S.O. Keeling, S.R. Majumdar, B. Conner-Spady, M.C. Battié, L.J. Carroll, W.P. Maksymowych 822

***In Vivo* Peripheral Blood Proinflammatory T Cells in Patients with AS** *L. Limón-Camacho, M.I. Vargas-Rojas, J. Vázquez-Mellado, J. Casasola-Vargas, J.F. Moctezuma, R. Burgos-Vargas, L. Llorente* . . 830

Clinical Efficacy of Etanercept Versus Sulfasalazine in AS Subjects with Peripheral Joint Involvement
J. Braun, K. Pavelka, C. Ramos-Remus, A. Dimic, B. Vlahos, B. Freundlich, A.S. Koenig 836

Nail Disease in PsA: Distal Phalangeal Bone Edema Detected by MRI Predicts Development of Onycholysis and Hyperkeratosis *N. Dalbeth, K. Pui, M. Lobo, A. Doyle, P.B. Jones, W.J. Taylor, F.M. McQueen* 841

Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in PsA
Y-Y. Leung, K-W. Ho, T-Y. Zhu, L-S. Tam, E.W. Kun, E.K-M. Li 844

Identification of the Clinical Features Distinguishing PsA and Fibromyalgia
A. Marchesoni, F. Atzeni, A. Spadaro, E. Lubrano, G. Provenzano, A. Cauli, et al 849

Pediatric Rheumatology

Parent and Child Acceptable Symptom State in JIA
G. Filocamo, A. Consolaro, B. Schiappapietra, N. Ruperto, A. Pistorio, N. Solari, et al 856

Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to IVIG Therapy: Report of an Open-label Case Series
M. Mori, T. Imagawa, R. Hara, M. Kikuchi, T. Hara, T. Nozawa, et al 864

Images in Rheumatology

Gouty Arthritis of the Ankle Masquerading as a Talus Fracture *M. Yang, B. Guo, D. Liang, D. Shi, L. Yang, J. Cao* 868

Correspondence

Posterior Reversible Encephalopathy Syndrome
A. Ortiz, S. Roverano, S. Paira 869

Could Increased VEGF Induced by IL-17 Be the Cause of Posterior Reversible Encephalopathy Syndrome in SLE?
S.J. Park, K.S. Pai, J.H. Kim, J.I. Shin 870

Reply *I.R. Varaprasad, S. Agrawal* 871

High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rhupus Syndrome
S. Sciascia, D. Roccatello, D. Rossi, A. Russo, M.O. Mereuta, R. Cavallo 871

Reply *A.R. Chogle* 873

Clarification of the Modified Radiographic Damage Scoring Method for Gout
N. Dalbeth, F.M. McQueen 874

Reply *J-Y. Choe, S-K. Kim* 874

Letters

Clinical Relevance of *MEFV* Gene Mutations in Japanese Patients with Unexplained Fever
K. Migita, H. Ida, H. Moriuchi, K. Agematsu 875

Does a Joint Count Calibration Exercise Make a Difference? Implications for Clinical Trials and Training *L.K. Stamp, A. Harrison, C. Frampton, M.M. Corkill* 877

Amyloidosis and Giant Cell Arteritis/Polymyalgia Rheumatica
K. Legault, A. Shroff, M. Crowther, N. Khalidi 878

Teaching Basic Rheumatology *I. Kushner* 880

Corrections

Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
C. Gaujoux-Viala, C. Giampietro, T. Gaujoux, H-K. Ea, C. Prati, P. Orcel, D. Wendling, F. Lioté 881

Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis
P.M. Izmirly, M. Shvartsbeyn, S. Meehan, A. Franks, A. Braun, E. Ginzler, S.X. Xu, H. Yee, T. Rivera, C. Esmon, L. Barisoni, J.T. Merrill, J.P. Buyon, R. Clancy 881

Meetings in Rheumatology xii

VOLUME 39: NO. 5 **MAY 2012**

Editorials

Health Information on the Internet
N. Alcorn, R. Madhok 883

Hypothyroidism in Rheumatoid Arthritis — To Screen or Not to Screen?
H.G. Raterman, M.T. Nurmohamed 885

Juvenile Versus Adult-Onset Ankylosing Spondylitis: Are We Comparing Apples and Oranges?
R. Conway, F.D. O'Shea 887

Consider the Tidemark *P.A. Simkin* 890

Review

Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for RA: Data from the French AIR Registry
L. Thomas, F. Canoui-Poitrine, J-E. Gottenberg, A. Economu-Dubosc, F. Medkour, X. Chevalier, et al 893

Articles

YouTube for Information on RA — A Wakeup Call?
A.G. Singh, S. Singh, P.P. Singh 899

Smoking, Smoking Cessation, and Disease Activity in a Large Cohort of Patients with RA
M.C. Fisher, M.C. Hochberg, M. El-Taha, J.M. Kremer, C. Peng, J.D. Greenberg, CORRONA Investigators 904

Risk of GI Events in Patients with RA After Withdrawal of Rofecoxib
C.A. Marra, L.D. Lynd, L. Colley, S.S. Harvard, D. Lacaille, E. Schwenger, et al 910

Peripheral Blood Gene Expression and IgG Glycosylation Profiles as Markers of Tocilizumab Treatment in RA *B. Mesko, S. Poliska, S. Szamosi, Z. Szekanecz, J. Podani, C. Varadi, et al* 916

Heterogeneity of ACPA and Response to Anti-TNF Agents in RA *B.A. Fisher, D. Plant, K. Lundberg, P. Charles, A. Barton, P.J. Venables, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate* 929

Levels of Plasma-soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Are Correlated with Disease Activity in RA
S.T. Choi, E-J. Kang, Y.J. Ha, J-S. Song 933

Polymorphisms of the Genes Encoding *CD40* and Growth Differentiation Factor 15 and in the 9p21.3 Region in Patients with RA and CVD
L. Ärlestig, S. Rantapää-Dahlqvist 939

TNF-α Inhibitor Use Is Not Associated with Lipid Changes in RA
A. Bili, S.J. Morris, J.A. Sartorius, H.L. Kirchner, J.L. Antohe, S. Dancea, M.C. Wasko 946

Treating RA to Target: A Canadian Physician Survey
B. Haraoui, W. Bensen, L. Bessette, S. Le Clercq, C. Thorne, J. Wade 949

Hypothyroidism as a Risk Factor for Development of Cardiovascular Disease in Patients with RA
S.S. McCoy, C.S. Crowson, S.E. Gabriel, E.L. Matteson 954

Changes in Regional Brain Morphology in Neuropsychiatric SLE *P.C. Cagnoli, P.C. Sundgren, A. Kairys, C.C. Graft, D.J. Clauw, S. Gebarski, et al* 959

Longitudinal Evolution of Risk of Coronary Heart Disease in SLE *I. Karp, M. Abrahamowicz, P.R. Fortin, L. Pilote, C. Neville, C.A. Pineau, J.M. Esdaile* . . . 968

HBV-associated Antigen Deposition in Renal Tissue from Patients with SLE
Z. Wang, M. Li, X. Zeng, X. Liu 974

Systemic Sclerosis Fibroblasts Show Specific Alterations of IFN-γ and TNF-α-induced Modulation of IL-6 and CCL2
A. Antonelli, P. Fallahi, S.M. Ferrari, D. Giuggioli, M. Colaci, A. Di Domenicantonio, C. Ferri 979

Progression of Esophageal Dysmotility in Systemic Sclerosis
J. Vischio, F. Saeed, M. Karimeddini, A. Mubashir, R. Feinn, G. Caldito, et al 986

Effect of GI Manifestations on Quality of Life in 87 Consecutive Patients with Systemic Sclerosis
M.A. Omair, P. Lee 992

Independent Replication and Metaanalysis of Association Studies Establish *TNFSF4* as a Susceptibility Gene Preferentially Associated with the Subset of ACA-positive Patients with Systemic Sclerosis
B. Coustet, M. Bouaziz, P. Dieudé, M. Guedj, L. Bossini-Castillo, S. Agarwal, et al 997

Home Parenteral Nutrition in Patients with Systemic Sclerosis: A Retrospective Review of 12 Cases
H. Jawa, G. Fernandes, O. Saqui, J.P. Allard . . . 1004

Clinical Features of Late-onset Ankylosing Spondylitis: Comparison with Early-onset Disease
C. Montilla, J. Del Pino-Montes, E. Collantes-Estevez, P. Font, P. Zarco, J. Mulero, et al and the REGISPONSER Study Group 1008

Clinical, Functional, and Radiographic Differences Among Juvenile-onset, Adult-onset, and Late-onset Ankylosing Spondylitis
H-A. Chen, C-H. Chen, H-T. Liao, Y-J. Lin, P-C. Chen, W-S. Chen, et al 1013

High-dose IVIG Treatment Increases Regulatory T Cells in Patients with Eosinophilic Granulomatosis with Polyangiitis
N. Tsurikisawa, H. Saito, C. Oshikata, T. Tsuburai, K. Akiyama 1019

Challenging the Diagnosis of Primary Angiitis of the CNS: A Single-center Retrospective Study
A. Néel, E. Auffray-Calvier, B. Guillon, A-M. Fontenoy, D. Loussouarn, C. Pagnoux, M.A. Hamidou 1026

***FCGR2A/CD32A* and *FCGR3A/CD16A* Variants and EULAR Response to TNF-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup**
J. Ramírez, J.L. Fernández-Sueiro, R. López-Mejías, C. Montilla, M. Arias, C. Moll, et al 1035

Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving TNF-α Blockers
M.N.D. Di Minno, S. Iervolino, R. Peluso, A. Russolillo, R. Lupoli, R. Scarpa, et al, and the CaRRDS Study Group 1042

Challenges in Evaluating an Arthritis Self-management Program for People with Hip and Knee OA in Real-world Clinical Settings
I.N. Ackerman, R. Buchbinder, R.H. Osborne . . . 1047

How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with OA in the UK?
N.K. Arden, A.B. Hauber, A.F. Mohamed, F.R. Johnson, P.M. Peloso, D.J. Watson, et al. . . 1056

Validity and Responsiveness of the Dutch McMaster Toronto Arthritis Patient Preference Questionnaire (MACTAR) in Patients with OA of the Hip or Knee
D-J.J.A. Barten, M.F. Pisters, T. Takken, C. Veenhof 1064

***Meeting Report* University of Toronto Lupus Clinic Turns 40**
D.D. Gladman, M.B. Urowitz 1074

Pediatric Rheumatology

ACPA and Radiological Progression in Juvenile Idiopathic Arthritis *J. Lipińska, H. Brózik, J. Stańczyk, E. Smolewska* 1078

Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with ANCA-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe)
K. Morishita, S.C. Li, E. Muscal, S. Spalding, J. Guzman, A. Uribe, et al, for the ARChiVe Investigators Network 1088

Images in Rheumatology

SLE-associated Retinal Vasculitis
R.R. Butendieck, K. Parikh, M. Stewart, C. Davidge-Pitts, A. Abril 1095

Correspondence

Interleukin 6 Blockade in Spondyloarthritis
E. Koumakis, A. Feydy, A. Kahan, Y. Allanore . . . 1097

Reply *J-D. Cohen* 1098

Letters

Cardiomyopathy Caused by Longterm Treatment with Chloroquine: A Rare Disease, or a Rare Diagnosis? *E. Tönnesmann, I. Stroehmann, R. Kandolf, et al* 1099

Pulmonary Toxicity After Initiation of Azathioprine for Treatment of Interstitial Pneumonia in a Patient with RA
T. Ishida, T. Kotani, T. Takeuchi, S. Makino 1104

Correction

Information Needs and Information-seeking by People with Rheumatoid Arthritis: A Qualitative Study
M. Gornitsky, L. Wang, R. Roots, P. Rogers, D. Lacaille 1106

Meetings in Rheumatology x

VOLUME 39: NO. 6 **JUNE 2012**

Editorials

Interpretation of Metaanalyses: Pitfalls Should Be More Widely Recognized *Y.E. Henrotin* 1107

Late-Onset Spondyloarthritis: Subset That Should Not Be Forgotten
I. Olivieri, S. D'Angelo, C. Palazzi, P. Leccese, A. Padula 1110

Training in Capillaroscopy: A Growing Interest
M. Cutolo, V. Smith, A. Sulli 1113

The Salivary Gland Epithelial Cell in Sjögren's Syndrome: What Are the Steps Involved in Wounding or Killing Their Secretory Function?
R.I. Fox 1117

Reviews

IL-6 in Systemic Sclerosis and Potential Implications for Targeted Therapy
C. Muangchan, J.E. Pope 1120

Rheumatic Manifestations of Autoimmune Thyroid Disease: The Other Autoimmune Disease
C.E. Tagoe, A. Zezon, S. Khattri 1125

Articles

Rituximab Therapy Leads to Reduced Imprints of Receptor Revision in Immunoglobulin κ and λ Light Chains
A. Palanichamy, K. Muhammad, P. Roll, S. Kleinert, T. Dörner, H-P. Tony 1130

Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice
K.R. Masri, T.S. Shaver, S.H. Shahouri, et al . . . 1139

Carotid Atherosclerosis, Disease Measures, Oxidized LDL, and Atheroprotective Natural Antibodies for CVD in Early RA — An Inception Cohort Study
S. Ajeganova, U. de Faire, T. Jogestrand, J. Frostegård, I. Hafström 1146

Remission in Early RA — A Comparison of New ACR/EULAR Remission Criteria to Established Criteria
B. Kuriya, Y. Sun, G. Boire, et al, for the Canadian Early Arthritis Cohort Study 1155

PADI4 and MBD4 Polymorphisms in Chinese Patients with RA
J. Cheng, H. Zhang, C. Zhuang, R. Liu 1159

***NPSR1* Gene Is Associated with Reduced Risk of RA**
G. Robledo, M.A. González-Gay, B. Fernández-Gutiérrez, et al 1166

Effects of Double Filtration Plasmapheresis, Leflunomide, and MTX on Inflammatory Changes Found Through MRI in Early RA
X. Yu, L. Wang, P. Xu, et al 1171

Longterm Retention of TNF-α Inhibitor Therapy in a Large Italian Cohort of Patients with RA from the GISEA Registry: An Appraisal of Predictors
F. Iannone, E. Gremese, F. Atzeni, et al, and the Gruppo Italiano di Studio sulle Early Arthritides (GISEA) 1179

Effect of Golimumab on Patient-reported Outcomes in RA: Results from the GO-FORWARD Study
M.C. Genovese, C. Han, E.C. Keystone, et al . . . 1185

Tocilizumab Treatment Decreases Circulating Myeloid Dendritic Cells and Monocytes, 2 Components of the Myeloid Lineage
C. Richez, T. Barnetche, L. Khoryati, et al 1192

Indirect Treatment Comparison of Abatacept with MTX Versus Other Biologic Agents for Active RA Despite MTX Therapy in the UK
P. Guyot, P.C. Taylor, R. Christensen, et al 1198

Autofeedback from Ultrasound Images Provides Rapid Improvement in Palpation Skills for Identifying Joint Swelling in RA
M. Ogasawara, G. Murayama, Y. Yamada, et al . . 1207

Effect of RA on Volumetric BMD and Bone Geometry, Assessed by Peripheral Quantitative Computed Tomography in Postmenopausal Women Treated with Bisphosphonates
S. Tournis, V. Samdanis, S. Psarelis, et al 1215

Sex Differences in Pain Scores and Localization in Inflammatory Arthritis: A Systematic Review and Metaanalysis
C. Barnabe, L. Bessette, C. Flanagan, et al 1221

Urinary VCAM, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus Nephritis
A.N. Kiani, T. Wu, H. Fang, et al 1231

Genetic Ancestry, Serum IFN-α Activity, and Autoantibodies in SLE
K. Ko, B.S. Franek, M. Marion, et al 1238

A Prospective Observational Study of MMF Treatment in Progressive Diffuse Cutaneous SSc of Recent Onset
F.A. Mendoza, S.J. Nagle, J.B. Lee, S.A. Jimenez 1241

Interreader Reliability in Assessment of Nailfold Capillary Abnormalities by Beginners: Pilot Study of an Intensive Videocapillaroscopy Training Program
M. Gutierrez, C. Bertolazzi, M. Tardella, et al . . . 1248

p38MAPK and NF-κB Facilitate CD40-mediated Salivary Epithelial Cell Death
L. Ping, N. Ogawa, Y. Zhang, S. Sugai, Y. Masaki, X. Weiguo 1256

Comparison of the Diagnostic Utility of Cardiac MRI, Computed Tomography, and Echocardiography in Assessment of Suspected PAH in Patients with CTD
S. Rajaram, A.J. Swift, D. Capener, et al 1265

Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in SSc and GCA
F.D. Carmona, A. Serrano, L. Rodriguez-Rodriguez, et al, the Spanish Scleroderma Group, the Spanish Giant Cell Arteritis Group, M.A. González-Gay, J Martín 1275

Building a Rheumatology Education Academy: Insights from Assessment of Needs During a Rheumatology Division Retreat
J.R. Berman, J. Aizer, A.R. Bass, et al 1280

Pediatric Rheumatology

Safety and Efficacy of Etanercept in a Cohort of Patients with JIA Under 4 Years of Age
C. Bracaglia, P.S. Buonuomo, A.E. Tozzi, et al . . 1287

Images in Rheumatology

Arteriosclerosis of Whole Aorta in Takayasu Arteritis
K. Umekita, Y. Hashiba, Y. Kariya-Kaneko, M. Matsuda, A. Okayama 1291

Correspondence

Do Low Titers of Antibody Against HBsAg Carry a Risk of Viral Reactivation During Immunosuppressive Therapy for Rheumatic Diseases?
S. Mori 1292

Reply *M. Kato, T. Atsumi* 1293

Purpose and Significance of the 2010 Criteria and Modification of the 2010 Criteria for Fibromyalgia
K. Toda 1294

Letters

Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with JIA?
C. Tappeiner, C. Heinz, G. Ganser, A. Heiligenhaus 1294

Should Rheumatologists Palpate the Breast?
J.J. Canoso 1296

Use of Hydroxychloroquine in Japan
M. Kishimoto, G.A. Deshpande, N. Yokogawa, J.P. Buyon, M. Okada 1296

Miliary TB Following Negative LTBI Screening Prior to TNF-α Antagonists: Implications for Management?
B.W. Teh, A.C. Street, E.S. McBryde, J.T. Denholm 1297

PML in a Patient with Polymyositis: Case Report and Literature Review
M. Dastmalchi, J. Laki, I.E. Lundberg, E. Iacobaeus 1299

Atypical Psoriasis Following Rituximab for RA
S.A. Hardcastle, S. Gibbs, L. Williamson 1303

Lichen Planus in Association with AOSD Successfully Treated with MMF
Y. Emad, Y. Ragab, N. El-Shaarawy 1305

Enhanced Healing of Sacral and Pubic Insufficiency Fractures by Teriparatide
C-C. Wu, J.C-C. Wei, C-P. Hsieh, C-T. Yu 1306

Rare Case of Septic Arthritis Caused by *Candida krusei*: Case Report and Literature Review *H. Lu, M.F. Marengo, C.N. Mihu, G. Garcia-Manero, M.E. Suarez-Almazor* 1308

Meetings in Rheumatology x

VOLUME 39: NO. 7 **JULY 2012**

Editorials

Debulking the Urate Load to Feel Better
P. Richette 1311

Axial Gout: Cinderella of Gouty Arthropathy
L.A. Saketkoo, I. Garcia-Valladares, L.R. Espinoza 1314

Gastrointestinal Events in Rheumatoid Arthritis: Time for the Lower Gastrointestinal Tract
M.T. Nurmohamed 1317

Articles

Increased Serum IL-22 in Patients with RA and Correlation with Disease Activity
L.F. da Rocha Jr, A.L.B.P. Duarte, A.T. Dantas, et al 1320

Timing and Magnitude of Initial Change in DAS28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in RA Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial *D.M. van der Heijde, E.C. Keystone, J.R. Curtis, et al* 1326

Use of the 28-Joint Count Yields Significantly Higher Concordance Between Different Examiners Than the 66/68-Joint Count
M. Grunke, M.N. Witt, M. Ronneberger, et al . . . 1334

Relations of Serum COMP to Cardiovascular Risk Factors and Endothelial Function in Patients with RA Treated with MTX and TNF-α Inhibitors
G. Hjeltnes, I. Hollan, Ø. Førre, A. Wiik, T. Lyberg, K. Mikkelsen, S. Agewall 1341

Treatment with Biologic Agents Improves the Prognosis of Patients with RA and Amyloidosis
T. Kuroda, N. Tanabe, D. Kobayashi, et al 1348

Increased Incidence and Impact of Upper and Lower GI Events in Patients with RA in Olmsted County, Minnesota: A Longitudinal Population-based Study *E. Myasoedova, E.L. Matteson, N.J. Talley, C.S. Crowson* 1355

Cigarette Smoking, Alcohol Consumption, and Risk of SLE: A Case-control Study in a Japanese Population
C. Kiyohara, M. Washio, T. Horiuchi, et al, and the Kyushu Sapporo SLE Study Group 1363

Screening for Cognitive Impairment in SLE
J.G. Hanly, L. Su, A. Omisade, V.T. Farewell, J.D. Fisk 1371

Ten-year Absolute Fracture Risk and Hip Bone Strength in Canadian Women with SLE
J.J.Y. Lee, E. Aghdassi, A.M. Cheung, et al 1378

Vascular Leak Is a Central Feature in the Pathogenesis of SSc *T.M. Frech, M.P. Revelo, S.G. Drakos, M.A. Murtaugh, B.A. Markewitz, A.D. Sawitzke, D.Y. Li* 1385

Seasonal Variation in the Activity of SLE
A. Duarte-Garcia, H. Fang, C.H. To, L.S. Magder, M. Petri 1392

Serum S100A8/A9, But Not Follistatin-like Protein 1 and IL-18, May Be a Useful Biomarker of Disease Activity in Adult-onset Still's Disease
H-A. Kim, J-M. An, J-Y. Nam, J-Y. Jeon, C-H. Suh 1399

CCL18 — Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis
F. Kollert, M. Binder, C. Probst, et al 1407

Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy
D. Geetha, P. Seo, C. Ellis, M. Kuperman, S.M. Levine 1413

Dosage Adjustment of Anti-TNF-α Inhibitor in AS Is Effective in Maintaining Remission in Clinical Practice
J. Paccou, M-A. Baclé-Boutry, E. Solau-Gervais, P. Bele-Philippe, R-M. Flipo 1418

Patient-acceptable Symptom State as an Outcome Measure in the Daily Care of Patients with AS
C. Rodríguez-Lozano, M-Á. Gantes, B. González, et al 1424

Prediction of Cardiovascular Events in Patients with AS and PsA: Role of Lipoproteins in a High-risk Population
A.G. Semb, T.K. Kvien, D. DeMicco, et al 1433

PsA and Onycholysis — Results from the Cross-sectional Reykjavik Psoriatic Arthritis Study
T.J. Love, J.E. Gudjor sson, H. Valdimarsson, B. Gudbjornsson 1441

Correlates of Axial Gout: A Cross-sectional Study
R.M. Konatalapalli, E. Lumezanu, J.S. Jelinek, M.D. Murphey, H. Wang, A. Weinstein 1445

Improved HRQOL and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials
V. Strand, D. Khanna, J.A. Singh, A. Forsythe, N.L. Edwards 1450

Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout
D.B. Crittenden, R.A. Lehmann, L. Schneck, et al 1458

Mitochondrial DNA Copy Number in Peripheral Blood Is Associated with Femoral Neck BMD in Postmenopausal Women
J-H. Kim, D-C. Lee 1465

Preventing Friction-induced Chondrocyte Apoptosis: Comparison of Human Synovial Fluid and Hylan G-F 20
K.A. Waller, L.X. Zhang, B.C. Fleming, G.D. Jay 1473

Correspondence

Hand Enthesophytes and Knee Enthesopathy: Is OA Related to a Systemic Enthesopathy?
A.L. Tan, D. McGonagle 1481

Reply *N. Gibson, D.T. Felson* 1481

Hyperostosis-related Dysphagia
D.Wendling, C. Prati, X. Guillot 1482

Reply *C. Palazzi, S. D'Angelo, I. Olivieri* 1483

Letters

Anti-signal Recognition Particle-positive Juvenile Polymyositis Successfully Treated with Rituximab
N.J.C. Luca, A. Atkinson, C. Hawkins, B.M. Feldman 1483

Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with RA
I. Ibrahim, A. Barton, A. Ibrahim, P. Ho 1485

Successful Treatment of Refractory Takayasu Arteritis with Tacrolimus
H. Yamazaki, T. Nanki, M. Harigai, N. Miyasaka 1487

Calcium Pyrophosphate Deposition: Sonographic Features in a Familial Case
L. Di Geso, E. Filippucci, M. Gutierrez, W. Grassi 1488

Effect of RA Susceptibility Genes on the Immune Response to Viral Citrullinated Peptides in RA
F. Pratesi, E. Petit-Teixeira, J. Sidney, et al 1490

Level of Anticitrullinated Peptide/Protein Antibody Is Not Associated with Lung Diseases in RA
L-H. Jearn, T-Y. Kim 1493

High-resolution Peripheral Quantitative CT Imaging Protocol for MCP Joints in Inflammatory Arthritis: The SPECTRA Collaboration
C. Barnabe, L. Feehan 1494

Corrections

Cardiomyopathy Caused by Longterm Treatment with Chloroquine: A Rare Disease, or a Rare Diagnosis?
E. Tönnesmann, I. Stroehmann, R. Kandolf, H. Wolburg, K. Strach, F. Musshoff, K. Tiemann, T. Lewalter 1496

Orthopedic Surgery Among Patients with Rheumatoid Arthritis 1980-2007: A Population-based Study Focused on Surgery Rates, Sex, and Mortality
C.A. Shourt, C.S. Crowson, S.E. Gabriel, E.L. Matteson 1496

Meetings in Rheumatology x

VOLUME 39: SUPPLEMENT 89 **JULY 2012**

Proceedings of the Second Update on Psoriatic Disease
University Federico II Congress Center
Naples, Italy
July 6–7, 2011

Foreword: **Second Update on Psoriatic Disease** *J.M.H. Moll* 1

New Insights into the Concept of Psoriatic Disease *R. Scarpa* 4

Pathogenetic Overview of Psoriatic Disease *M. Haroon, O. FitzGerald* 7

The Synovio-entheseal Complex and Its Role in Tendon and Capsular Associated Inflammation *D. McGonagle, S.Z. Aydin, A.L. Tan* 11

Th17 and IL-23 in the Pathogenesis of PsA and SpA *A. Cauli, A. Mathieu* 15

Remission in PsA *A. Caperon, P.S. Helliwell* 19

New Insights in Occult PsA *C. Palazzi, S. D'Angelo, E. Lubrano, I. Olivieri* 22

Metabolic Syndrome in Patients with Psoriatic Disease *J.M. Gelfand, H. Yeung* . . 24

Entheseal Power Doppler Ultrasonography: A Comparison of PsA and Fibromyalgia *A. Marchesoni, O. De Lucia, L. Rotunno, G. De Marco, M. Manara* 29

Mortality and Causes of Death in PsA *R. Arumugam, N.J. McHugh* 32

Osteoporosis and PsA *A. Del Puente, A. Esposito, A. Parisi, et al.* 36

PsA: Need for Ultrasound in Everyday Clinical Practice *W. Grassi, M. Gutierrez* . 39

Dynamic Contrast-enhanced MRI of Articular and Extraarticular Synovial Structures of the Hands in Patients with PsA *M.A. Cimmino, F. Barbieri, M. Boesen, et al* 44

New Developments in MRI of the Nail Unit *E. Soscia, C. Sirignano, O. Catalano, et al* 49

The Radiological Assessment of Axial Involvement in PsA *E. Lubrano, A. Marchesoni, I. Olivieri, et al.* 54

Biomarker Development in PsA *C. Ritchlin* 57

Synovial Biomarkers in PsA *U. Fiocco, F. Oliviero, P. Sfriso, et al* 61

Soluble Biomarkers May Differentiate Psoriasis from PsA *V. Chandran* 65

The Actual Role of Therapy with Traditional DMARD in PsA *E.R. Soriano* 67

Infliximab in PsA *F. Cantini, L. Niccoli, C. Nannini, O. Kaloudi, E. Cassara* 71

Etanercept in PsA *A. Spadaro, E. Lubrano, N. Ferrara, R. Scarpa* 74

Adalimumab in PsA *C. Salvarani, N. Pipitone, M. Catanoso, et al.* 77

Screening and Monitoring of Latent Tubercular Infection in Patients Taking TNF-α Blockers for PsA *A. Sanduzzi, M. Bocchino, M. Atteno, et al* 82

Ustekinumab for Psoriasis and PsA *A.B. Gottlieb, A.M. Goldminz* 86

Treatment of PsA with TNF Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL) *A. Kavanaugh, P. Mease* 90

Should We Consider TNF as the Only Target in Spondyloarthritides? *G. Ferraccioli, E. Gremese* 94

IL-6 Blockade: Tocilizumab in PsA *F. Atzeni, D. Ventura, A. Batticciotto, L. Boccassini, P. Sarzi-Puttini* 97

The Inhibitor of Costimulation of T Cells: Abatacept *F. Iannone, G. Lapadula* . . . 100

Pharmacoeconomic Issues in PsA *I. Olivieri, S. D'Angelo, C. Palazzi, A. Padula, E. Lubrano, L.G. Mantovani* 103

Future Trends in Research in PsA *D.D. Gladman* 106

VOLUME 39: NO. 8 **AUGUST 2012**

Editorials

Management of Rheumatoid Arthritis 2012: A Canadian State of the Art *J. Karsh* 1497

Infusion Reactions Related to Infliximab Therapy Are Not Usually Associated with Drug Discontinuation *G. Cullen, A.S. Cheifetz* 1500

Classification Criteria and Diagnostic Tests for Vasculitides *N. Ruperto* 1503

Articles

Diagnostic Value of Anti-Sa and Anticitrullinated Protein Antibodies in RA *Y-F. Hou, G-Z. Sun, H-S. Sun, W-P. Pan, W-B. Liu, C-Q. Zhang* 1506

Variants within STAT Genes Reveal Association with ACPA-negative RA in 2 European Populations *M. Seddighzadeh, A. Gonzalez, B. Ding, et al, and the Rheumatoid Arthritis Network and Coordinated Project* 1509

Procalcitonin Is a Specific Marker for Detecting Bacterial Infection in Patients with RA *H. Sato, N. Tanabe, A. Murasawa, et al* 1517

Differential Gene Expression Profiles May Differentiate Responder and Nonresponder Patients with RA for MTX Monotherapy and MTX plus TNF Inhibitor Combined Therapy *R.D.R. Oliveira, V. Fontana, C.M. Junta, et al* . . . 1524

Etanercept Concentration in Patients with RA and Its Potential Influence on Treatment Decisions: A Pilot Study *C.I. Daïen, V. Daïen, E. Parussini, A-M. Dupuy, B. Combe, J. Morel* 1533

Safety of Infliximab Treatment in Patients with RA in a Real-world Clinical Setting: Description and Evaluation of Infusion Reactions *J. Kelsall, P. Rogers, G. Galindo, M.A. De Vera* . 1539

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with RA and an Inadequate Response to TNF Inhibitor Therapy *M.C. Genovese, M. Schiff, M. Luggen, M. Le Bars, R. Aranda, A. Elegbe, M. Dougados* 1546

Emerging Issues in Pharmacological Management of RA: Results of a National Needs Assessment Survey Identifying Practice Variations for the Development of Canadian Rheumatology Association Clinical Practice Recommendations *V.P. Bykerk, O. Schieir, P. Akhavan, G.S. Hazlewood, C.K. Cheng, C. Bombardier* . . . 1555

Canadian Rheumatology Associatio Recommendations for Pharmacological Management of RA with Traditional and Biologic DMARD *V.P. Bykerk, P. Akhavan, G.S. Hazlewood, et al* 1559

Canadian Rheumatology Association Recommendations for the Pharmacological Management of RA with Traditional and Biologic DMARD: Part II Safety *C. Bombardier, G.S. Hazlewood, P. Akhavan, et al* 1583

Genetic Risk Factors for Thrombosis in SLE *R. Kaiser, Y. Li, M. Chang, et al* 1603

Risks, Subtypes, and Hospitalization Costs of Stroke Among Patients with SLE: A Retrospective Cohort Study in Taiwan *I-K. Wang, C-H. Muo, Y-C. Chang, et al* 1611

Combination of Autoantibodies Against Different Histone Proteins Influences Complement-dependent Phagocytosis of Necrotic Cell Material by Polymorphonuclear Leukocytes in SLE *B. Gullstrand, M.H. Lefort, H. Tydén, et al* 1619

Pulmonary Hemorrhage in Antiphospholipid Antibody Syndrome *A. Scheiman Elazary, M.J. Cohen, S. Aamar, et al* 1628

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with SLE in the BLISS-76 Trial *W.W. Chatham, D.J. Wallace, W. Stohl, et al, on behalf of the BLISS-76 Study Group* 1632

Ultrasound in the Assessment of Pulmonary Fibrosis in Connective Tissue Disorders: Correlation with HRCT *M. Tardella, M. Gutierrez, F. Salaffi, et al* 1641

Digital Amputation in SSc: Prevalence and Clinical Associations. A Retrospective Longitudinal Study *P. Caramaschi, D. Biasi, C. Caimmi, et al* 1648

Noninvasive Measurement of Skin Autofluorescence Is Increased in Patients with SSc: An Indicator of Increased Advanced Glycation Endproducts? *A.K. Murray, T.L. Moore, J.B. Manning, C.E.M. Griffiths, A.L. Herrick* 1654

Detection of Inflammatory Lesions by FDG-PET in Patients with Polymyositis and Dermatomyositis *T. Owada, R. Maezawa, K. Kurasawa, H. Okada, S. Arai, T. Fukuda* 1659

Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint MRI Indices for AS *W.P. Maksymowych, R.G. Lambert, L.S. Brown, A.L. Pangan* 1666

HLA-B27 Prevalence in Arab Populations and Among Patients with AS *K.N. Mustafa, M. Hammoudeh, M.A. Khan* 1675

RANK-RANKL-OPG in Hemophilic Arthropathy: From Clinical and Imaging Diagnosis to Histopathology *D. Melchiorre, A.F. Milia, S. Linari, et al* 1678

Pediatric Rheumatology

Increased Sensitivity of the EMA Algorithm for Classification of Childhood Granulomatosis with Polyangiitis *A.G. Uribe, A.M. Huber, S. Kim, et al, for the ARChiVe Investigators Network* 1687

Images in Rheumatology

Reversible Splenial Lesion Syndrome in Pediatric SLE *G.S. Soon, L.H. Rodan, S. Laughlin, R.M. Laxer, S. Benseler, E.D. Silverman* 1698

MR Angiography in Psoriatic Arthritis of the Hand *R. Rokutanda, M. Kishimoto, M. Okada* 1700

Canadian Rheumatology Association Meeting Victoria, British Columbia, Canada March 28–31, 2012

Abstracts 1701

Correspondence

Association of IL-1α Promoter Polymorphism (–889C/T) with Susceptibility to Systemic Sclerosis *W-J. Peng, B-X. Wang, H-F. Pan, J. Wang* 1755

Reply *M. Petrek* 1755

***ANKH* and Renal Stone Formation in Ankylosing Spondylitis** *C. Korkmaz, J.A. Sayer* 1756

Reply *F.M. Pimentel-Santos, J.C. Branco* 1757

A Difficult Case of Polymyalgia Rheumatica *O.Z. Karaahmet, A. Bal, E. Unlu, A. Cakci* 1758

Beneficial Cardiovascular Effects of Low-dose Glucocorticoid Therapy in Inflammatory Rheumatic Diseases *E. Bartoloni, A. Alunno, G. Santoboni, R. Gerli* . . 1758

Reply *M. Mazzantini* 1761

Letters

Myocardial PET/CT Scan Revealing Right Coronary Artery Involvement in Large Vessel Vasculitis *M. Piga, L. Ruffini, C. Salvarani, A. Mathieu* 1761

Subcutaneous Methotrexate to Cut Costs? *R. Hassanzadeh, C. Mangan, J. France, S. Bawa* . . 1764

A SNP of CCR6 (rs3093024) Is Associated with Susceptibility to RA But Not AS, in a Taiwanese Population *W-C. Chang, P-Y. Woon, J.C-C. Wei, et al* 1765 . . . . . .

Recombinant Human Soluble Thrombomodulin for Treatment of Thrombotic Microangiopathy Associated with Lupus Nephritis *K. Tonooka, H. Ito, T. Shibata, S. Ozaki* 1766

Meetings in Rheumatology x

VOLUME 39: NO. 9 **SEPTEMBER 2012**

Editorials

Reconsidering Antimalarials in Systemic Lupus Erythematosus: Developments of Translational Clinical Interest *S. Venuturupalli, V. Gudsoorkar, D. Wallace* 1769

Another Consequence of Severe Lupus: Invasive Fungal Disease *C.E. Barber, C. Barnabe* 1772

Furthering Our Understanding of Fatigue in Rheumatoid Arthritis *S. Hewlett, E. Choy, J. Kirwan* 1775

The Difficult Diagnosis of Temporomandibular Joint Arthritis *R. Saurenmann* 1778

Articles

RA-associated Polymorphisms at 6q23 Are Associated with Radiological Damage in Autoantibody-positive RA *J. Maxwell, I. Marinou, K-P. Kuet, et al* 1781

Magnetic Resonance Arthrography of Lesser MTP Joints in Patients with RA: Relationship to Clinical, Biomechanical, and Radiographic Variables *H.J. Siddle, R.J. Hodgson, P. O'Connor, et al* 1786

Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with RA in North American Natives *C.A. Hitchon, Y. Sun, D.B. Robinson, C.A. Peschken, C.N. Bernstein, K.A. Siminovitch, H.S. El-Gabalawy* 1792

The Carotid Artery Atherosclerosis Burden and Its Relation to Cardiovascular Risk Factors in Black and White Africans with Established RA: A Cross-sectional Study *A. Solomon, A.J. Woodiwiss, A.T. Abdool-Carrim, B.A. Stevens, G.R. Norton, P.H. Dessein* 1798

A Multidimensional Model of Fatigue in Patients with RA *P.M. Nicassio, S.R. Ormseth, M.K. Custodio, M.R. Irwin, R. Olmstead, M.H. Weisman* 1807

Invasive Fungal Infections in Patients with SLE *M.U. Martínez-Martínez, D. Herrera-van Oostdam, S. Román-Acosta, M. Magaña-Aquino, L. Baranda-Cándido, C. Abud-Mendoza* 1814

IL-21 Correlates with T Cell and B Cell Subset Alterations in SLE *B. Terrier, N. Costedoat-Chalumeau, M. Garrido, et al* 1819

Longitudinal Study of Renal Function in SSc *M. Caron, M. Hudson, M. Baron, S. Nessim, Canadian Scleroderma Research Group, R. Steele* 1829

Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts DMARD Use *R. Stanciu, M. Guiguet, L. Musset, et al* 1835

Expansions of CD4+CD28– and CD8+CD28– T Cells in Granulomatosis with Polyangiitis and Microscopic Polyangiitis Are Associated with CMV Infection But Not with Disease Activity *P. Eriksson, C. Sandell, K. Backteman, J. Ernerudh* 1840

Anterior Chest Wall Involvement in Early Stages of Spondyloarthritis: Advanced Diagnostic Tools *R. Ramonda, M. Lorenzin, A. Lo Nigro, et al* . . . 1844

Psoriatic Arthritis in Canadian Clinical Practice: The PsA Assessment in Rheumatology *D.D. Gladman, V. Chandran, A. Thavaneswaran, M. Zummer* 1850

Efficacy of Incentive Spirometer Exercise on Pulmonary Functions of Patients with Ankylosing Spondylitis Stabilized by TNF Inhibitor Therapy *M.W. So, H.M. Heo, B.S. Koo, Y-G. Kim, C-K. Lee, B. Yoo* 1854

Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial *H.R. Schumacher, M.F. Berger, J. Li-Yu, F. Perez-Ruiz, R. Burgos-Vargas, C. Li* . . . 1859

Pediatric Rheumatology

DMARD Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry *T. Beukelman, S. Ringold, T.E. Davis, E. Morgan DeWitt, C.F. Pelajo, P.F. Weiss, Y. Kimura, for the CARRA Registry Investigators* 1867

Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis *C.M.A. Leblanc, B. Lang, A. Bencivenga, et al* . . 1875

Risk Factors for TMJ Arthritis in Children with Juvenile Idiopathic Arthritis *M.L. Stoll, T. Sharpe, T. Beukelman, J. Good, D. Young, R.Q. Cron* . . . 1880

Blau Arteritis Resembling Takayasu Disease with a Novel NOD2 Mutation *R.P. Khubchandani, R. Hasija, I. Touitou, C. Khemani, C.H. Wouters, C.D. Rose* . . . 1888

Images in Rheumatology

Tibial Insufficiency Fractures in RA: A New Clinical Sign *R. Conway, D. Bergin, J.J. Carey, R.J. Coughlan* 1893

Digital Gangrene in a Patient with SLE and SSc *M.A. Omair, A. Bookman, S. Mittoo* 1895

Correspondence

Arteriosclerosis or Vasculitis? Color Duplex Sonography in Giant Cell Arteritis *M. Milchert, K. Fischer, J. Flicinski, H. Przepiera-Bedzak, M. Brzosko* 1898

Reply *M. Czihal* 1899

Letters

Cervical Vertebral Squaring in Patients without Spondyloarthritis *M.M. Ward, T.J. Learch, M.H. Weisman* 1900

Absence of *SLC22A12/URAT1* Gene Mutations in Patients with Primary Gout *R.J. Torres, E. De Miguel, R. Bailen, J.G. Puig* . 1901

NSAID Versus NSAID with HCQ in Treatment of Chemotherapy-related Arthropathy: Open-label Multicenter Pilot Study *H-A. Kim, H-J. Choi, H-J. Baek, et al* 1902

CTLA4 Ig-induced Asthma in the Treatment of RA *J. Bao, T. Li, J. Zhao, C-Y. Zhang* 1903

TNF-α Inhibitor-induced Antiglomerular Basement Membrane Antibody Disease in a Patient with RA *K. Nishimura, J. Saegusa, S. Kawano, A. Morinobu* . . . 1904

Reversible Leukoencephalopathy After Oral MTX *H. Koppen, J.A. Wessels, J.A.P.M. Ewals, F.F.E. Treurniet* 1906

Corrections

Idiopathic Orbital Inflammation Successfully Treated Using Rituximab in a Patient with Rheumatoid Arthritis *I. Ibrahim, A. Barton, A. Ibrahim, P. Ho* 1907

Autofeedback from Ultrasound Images Provides Rapid Improvement in Palpation Skills for Identifying Joint Swelling in Rheumatoid Arthritis *M. Ogasawara, G. Murayama, Y. Yamada, T. Nemoto, M. Kageyama, S. Toyama, et al.* 1908

Ustekinumab for Psoriasis and Psoriatic Arthritis *A.B. Gottlieb, A.M. Goldminz* 1908

Meetings in Rheumatology x

VOLUME 39: SUPPLEMENT 90 **SEPTEMBER 2012**

Pain Management by Pharmacotherapy in Inflammatory Arthritis. Systematic Literature Reviews of the 3e Initiative 2010

Introduction **Pain Management by Pharmacotherapy in Inflammatory Arthritis. Systematic Literature Reviews of the 3e Initiative 2010** *D.M. van der Heijde* 1

Measuring Pain and Efficacy of Pain Treatment in Inflammatory Arthritis: A Systematic Literature Review *M. Englbrecht, I.H. Tarner, D.M. van der Heijde, B. Manger, C. Bombardier, U. Müller-Ladner* 3

Paracetamol for the Management of Pain in Inflammatory Arthritis: A Systematic Literature Review *G. Hazlewood, D.M. van der Heijde, C. Bombardier* 11

The Role of Corticosteroids for Pain Relief in Persistent Pain of Inflammatory Arthritis: A Systematic Literature Review *I.H. Tarner, M. Englbrecht, M. Schneider, D.M. van der Heijde, U. Müller-Ladner* . . . 17

The Efficacy and Safety of Antidepressants in Inflammatory Arthritis: A Cochrane Systematic Review *B.L. Richards, S.L. Whittle, D.M. van der Heijde, R. Buchbinder* 21

Efficacy and Safety of Neuromodulators in Inflammatory Arthritis: A Cochrane Systematic Review *B.L. Richards, S.L. Whittle, D.M. van der Heijde, R. Buchbinder* 28

The Efficacy and Safety of Muscle Relaxants in Inflammatory Arthritis: A Cochrane Systematic Review *B.L. Richards, S.L. Whittle, D.M. van der Heijde, R. Buchbinder* 34

The Efficacy and Safety of Opioids in Inflammatory Arthritis: A Cochrane Systematic Review *S.L. Whittle, B.L. Richards, D.M. van der Heijde, R. Buchbinder* 40

Combination Therapy for Pain Management in Inflammatory Arthritis: A Cochrane Systematic Review *S. Ramiro, H. Radner, D.M. van der Heijde, R. Buchbinder, D. Aletaha, R.B. Landewé* 47

Safety and Efficacy of On-demand Versus Continuous Use of Nonsteroidal Antiinflammatory Drugs in Patients with Inflammatory Arthritis: A Systematic Literature Review *K. Adams, C. Bombardier, D.M. van der Heijde* . . 56

Safety of Pain Therapy During Pregnancy and Lactation in Patients with Inflammatory Arthritis: A Systematic Literature Review *K. Adams, C. Bombardier, D.M. van der Heijde* 59

Safety of Nonsteroidal Antiinflammatory Drugs and/or Paracetamol in People Receiving Methotrexate for Inflammatory Arthritis: A Cochrane Systematic Review *A.N. Colebatch, J.L. Marks, D.M. van der Heijde, C.J. Edwards* 62

How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review *H. Radner, S. Ramiro, D.M. van der Heijde, R. Landewé, R. Buchbinder, D. Aletaha* 74

Pain Pharmacotherapy in Patients with Inflammatory Arthritis and Concurrent Cardiovascular or Renal Disease: A Cochrane Systematic Review *J.L. Marks, D.M. van der Heijde, A.N. Colebatch, R. Buchbinder, C.J. Edwards* 81

VOLUME 39: NO. 10 — OCTOBER 2012

Editorials

Positron Emission Tomography/Computed Tomography for the Diagnosis and Assessment of Giant Cell Arteritis: When to Consider It and Why *A. Clifford, S. Burrell, J.G. Hanly* 1909

Palindromic Rheumatism: A Pre-Rheumatoid Arthritis State? *S.J. Katz, A.S. Russell* 1912

Articles

The Acute-phase Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia — A Prospective Cohort Study *M. Limper, L. van de Stadt, W. Bos, et al* 1914

Cytokine Secretion by Pathogen Recognition Receptor-stimulated Dendritic Cells in RA and AS *C. Prevosto, J.C. Goodall, J.S. Hill Gaston* 1918

Palindromic Rheumatism with Positive ACPA Is Not Synonymous with RA. A Longterm Followup Study *R. Sanmartí, S. Cabrera-Villalba, J.A. Gómez-Puerta, et al* 1929

Rheumatic Disease Among Oklahoma Tribal Populations: A Cross-sectional Study *J.R. Gaddy, E.S. Vista, J.M. Robertson, et al* . . . 1934

Relationship of Intrarenal Gene Expression and the Histological Class of Lupus Nephritis — A Study on Repeat Renal Biopsy *J. Lu, C-C. Szeto, L-S. Tam, et al* 1942

Monocyte Chemoattractant-1 as a Urinary Biomarker for the Diagnosis of Activity of Lupus Nephritis in Brazilian Patients *R.F. Rosa, K. Takei, N.C. Araújo, S.M.A. Loduca, J.C.M. Szajubok, W.H. Chahade* 1948

Increased Organ Damage Associated with Deterioration in Volumetric Bone Density and Bone Microarchitecture in Patients with SLE on Longterm Glucocorticoid Therapy *X.L. Tang, T.Y. Zhu, V.W. Hung, et al* 1955

Increased Risk of SLE in 29,000 Patients with Biopsy-verified Celiac Disease *J.F. Ludvigsson, A. Rubio-Tapia, V. Chowdhary, J.A. Murray, J.F. Simard* 1964

Survival, Causes of Death, and Prognostic Factors in SSc: Analysis of 947 Brazilian Patients *P.D. Sampaio-Barros, A.B. Bortoluzzo, R.G. Marangoni, et al* 1971

Knee Enthesitis and Synovitis on MRI in Patients with Psoriasis without Arthritic Symptoms *Y. Emad, Y. Ragab, T. Gheita, et al; Knee Enthesitis Working Group* 1979

Vertebral Fractures in AS Are Associated with Lower BMD in Both Central and Peripheral Skeleton *E. Klingberg, M. Geijer, J. Göthlin, et al* 1987

Initial Diagnosis of Lumbar Disc Herniation Is Associated with a Delay in Diagnosis of AS *V. Gerdan, S. Akar, D. Solmaz, et al* 1996

Natural Killer Cell Cytolytic Function in Korean Patients with AOSD *J.H. Park, H-S. Kim, J.S. Lee, J.J. Kim, K-H. Jung, Y-W. Park, D-H. Yoo* 2000

Beneficial Effect of IL-1 Inhibition with Anakinra in AOSD. An Open, Randomized, Multicenter Study *D. Nordström, A. Knight, R. Luukkainen, et al* . . 2008

Pediatric Rheumatology

Do Adult Disease Severity Subclassifications Predict Use of Cyclophosphamide in Children with ANCA-associated Vasculitis? An Analysis of ARChiVe Study Treatment Decisions *K. Morishita, J. Guzman, P. Chira, et al, for the ARChiVe Investigators Network* 2012

Comparison of Blood and Synovial Fluid Th17 and Novel Peptidase Inhibitor 16 Treg Cell Subsets in JIA *R.H. Grose, D.J. Millard, C. Mavrangelos, et al* 2021

***ABCB1* and *ABCC3* Gene Polymorphisms Are Associated with First-year Response to MTX in JIA** *M.C.F.J. De Rotte, M. Bulatovic, M.W. Heijstek, et al* 2032

Images in Rheumatology

Spermatic Pedicle Inflammation as the Initial Sign of Henoch-Schönlein Purpura *C. Bachmeyer, Z. Bourgou, M. Benjoar, B. Langman, A. Hanouna, L. Guillevin* 2041

Infected Calcinosis of the Knee in Limited Cutaneous SSc *M. Hughes, T.J. Freemont, J. Denton, A.L. Herrick* 2043

Correspondence

Psoriatic Arthritis and Sonographic Entheseal Index *F. Ozkan, M. Inci, K. Ozyurt, B. Bakan* 2045

Reply *A. Marchesoni, O. de Lucia* 2045

Letters

Obesity-related Adipokines and Shoulder OA *R. Gandhi, M. Takahashi, R. Rizek, O. Dessouki, N.N. Mahomed* 2046

Genetic Markers of IgG as Potential Risk Factors for IgG4-related Disease *J.P. Pandey* 2048

Failure to Control Progression of RA After a Decade of Biologic Therapy *M. Scheinberg, R.Z. Filippi, R. Hands, C. Pitzalis* 2049

A Remarkable Pattern of Subcortical Vessel Wall Enhancement in Granulomatous Angiitis of the CNS *N. Schoenmaker, M.R. Germans, D. Troost, E. Richard* 2051

Renal Involvement in MPO-ANCA-positive Granulomatosis with Polyangiitis with Chronic Hypertrophic Pachymeningitis *H. Hasegawa, H. Kohsaka, K. Takada, N. Miyasaka* 2053

TNF-associated Palmoplantar Pustular Psoriasis Treated with IL-6 Blocker *S. Younis, D. Rimar, G. Slobodin, I. Rosner* 2055

Correction

Rheumatoid Arthritis-associated Polymorphisms at 6q23 Are Associated with Radiological Damage in Autoantibody-positive RA *J. Maxwell, I. Marinou, K-P. Kuet, G. Orozco, D. Moore, A. Barton, J. Worthington, G. Wilson* 2057

Meetings in Rheumatology x

VOLUME 39: NO. 11 — NOVEMBER 2012

Editorials

Reflecting on Early Arthritis *D. Kovacs, K.D. Torralba, D.A. Fox, D.H. Solomon, R.S. Panush* . . 2059

Rheumatoid Arthritis Classification Criteria: Moving with the Times *M.A. Quinn* 2062

A Rheumatologist Managing Patients with Rheumatoid Arthritis: An Artisan But Also An Artist! *M. Dougados* 2064

Review

Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe RA *K.S. Jayasundara, E.C. Keystone, J.L. Parker* . . 2066

Articles

The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity *V.P. Bykerk, S. Jamal, G. Boire, et al* 2071

Increasing Treatment in Early RA Is Not Determined by the DAS But by Physician Global Assessment: Results from the CATCH Study *L. Pyne, V.P. Bykerk, G. Boire, et al for the CATCH Investigators* 2081

Time to DMARD Treatment in RA and Its Predictors: A National, Multicenter, Retrospective Cohort *R. Tavares, J.E. Pope, J-L. Tremblay, et al* 2088

Comparison of the 2010 ACR/EULAR and the 1987 ARA Classification Criteria for RA in an Early Arthritis Cohort in New Zealand *R. Raja, P.T. Chapman, J.L. O'Donnell, J. Ipenburg, C. Frampton, M. Hurst, L.K. Stamp* 2098

Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases *M. Mahler, T. Parker, C.L. Peebles, et al* 2104

Renal Outcome in Patients with Lupus Nephritis Using a Steroid-free Regimen of Monthly IV Cyclophosphamide: A Prospective Observational Study *R. Fischer-Betz, G. Chehab, O. Sander, S. Vordenbäumen, A. Voiculescu, R. Brinks, M. Schneider* 2111

Prospective Study of Clinical Phenotypes in Neuropsychiatric SLE; Multidisciplinary Approach to Diagnosis and Therapy *E.J.M. Zirkzee, G.M. Steup-Beekman, R.C. van der Mast, et al* . . . 2118

The Belgian Systemic Sclerosis Cohort: Correlations Between Disease Severity Scores, Cutaneous Subsets, and Autoantibody Profile *M. Vanthuyne, V. Smith, E. De Langhe, et al* . . . 2127

The Myositis Activities Profile — Initial Validation for Assessment of Polymyositis/Dermatomyositis in the USA *H. Alexanderson, A.M. Reed, S.R. Ytterberg* 2134

Low Copy Number of the Fc-γ Receptor 3B Gene *FCGR3B* Is a Risk Factor for Primary Sjögren's Syndrome *J.C. Nossent, M. Rischmueller, S. Lester* . . . 2142

Incidence of Spondyloarthropathy in Patients with Crohn's Disease: A Population-based Study *R. Shivashankar, E.V. Loftus Jr, W.J. Tremaine, T. Bongartz, W.S. Harmsen, A.R. Zinsmeister, E.L. Matteson* 2148

Efficacy and Safety of Rituximab Treatment in Patients with ANCA-associated Vasculitides: Results from a German Registry (GRAID) *P. Roll, E. Ostermeier, M. Haubitz, et al* 2153

Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup *O. Espitia, A. Néel, C. Leux, et al* 2157

Pediatric Rheumatology

Major Malformations Following Exposure to NSAID During the First Trimester of Pregnancy *S. Daniel, I. Matok, R. Gorodischer, G. Koren, E. Uziel, A. Wiznitzer, A. Levy* 2163

Familial Mediterranean Fever in Siblings *Z.B. Özçakar, B.D. Erdogan, A.H. Elhan, F. Yalçinkaya* 2170

Images in Rheumatology

Osteolytic Lesion with Thick Sclerotic Walls and Demyelinating Polyneuropathy *A. Forestier, G. Lefebvre, X. Leroy, et al* 2175

Complete Ankylosis in Longterm HLA-B27-negative Psoriatic Arthritis *M. Frerix, U. Müller-Ladner, U. Lange* 2177

Periostitis in a Patient with Inflammatory Bowel Disease *F. Bailly, D. Petrover, M. Allez, P. Richette* . . . 2179

Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Naples, Italy, July 7-9, 2011

***Prologue* 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)** *P.J. Mease, D.D. Gladman* 2181

GRAPPA Trainees Symposium 2011: A Report from the GRAPPA 2011 Annual Meeting *Z. Ash, C.T. Ritchlin* 2184

Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting *O. Fitzgerald, C.T. Ritchlin, P.J. Mease* 2189

Biomarkers for Comorbidities in Psoriasis: A Report from the GRAPPA 2011 Annual Meeting *D.D. Gladman* 2193

GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting *P.S. Helliwell, O. Fitzgerald, P.J. Mease, D.D. Gladman* 2196

Psoriasis and Psoriatic Arthritis Video Project: An Update from the GRAPPA 2011 Annual Meeting *K. Callis Duffin, A.W. Armstrong, P.J. Mease* . . . 2198

Psoriatic Arthritis and Psoriasis Projects in Italy: A Report from the GRAPPA 2011 Annual Meeting *A. Cauli, E. Lubrano, R. Scarpa, I. Olivieri* 2201

Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists' Perspective: A Report from the GRAPPA 2011 Annual Meeting *A.W. Armstrong, K. Callis Duffin, A. Garg, et al* 2204

GRAPPA 2011: Proceedings from the Ultrasound Imaging Module *G.S. Kaeley, M.A. D'Agostino, W. Grassi, M. Østergaard, I. Olivieri* 2211

On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting *A. Garg, D.D. Gladman, P.J. Mease* 2214

Psoriasis and Psoriatic Arthritis in Peruvian Aborigines: A Report from the GRAPPA 2011 Annual Meeting *S.M.A. Toloza, O. Vega-Hinojosa, V. Chandran, R. Valle-Onate, L.R. Espinoza* 2216

Correspondence

Interleukin 22, a Potential Therapeutic Target for RA *Q. Xie, S-C. Wang, J. Li* 2220

Reply *L.F. da Rocha Jr, A.L. Duarte, A.T. Dantas, H.A. Maniz, I.R. Pitta, S.L. Galdino, M.G.R. Pitta* 2221

Differentiation of the Clinical Features of Psoriatic Arthritis and Fibromyalgia *T. Konno* 2221

Reply *A. Marchesoni, F. Atzeni* 2222

Letters

Lower 12-hour Trough Concentrations of Mycophenolic Acid in Patients with Active Systemic Vasculitides Taking Mycophenolate Mofetil *S. Djabarouti, D. Breilh, E. Lazaro, J-L. Pellegrin, J-F. Viallard* 2223

Etanercept Allergy and Anaphylaxis *A. Quismorio, B. Brahmbhatt, M. Houng, R.S. Panush* 2225

Refractory Primary CNS Vasculitis of Childhood: Successful Treatment with Infliximab *M. Batthish, B. Banwell, S. Laughlin, W. Halliday, C. Peschken, E. Paras, S. Benseler.* 2227

Vasculitis of the Female Genital Tract: Not Always a Localized Condition *S.C. West, L.J. Zwi, D. Spriggs, F.M. McQueen* 2229

Book Reviews

Pediatric Rheumatology: A Color Handbook . . 2231

Rheumatology and the Kidney, 2nd Edition . . . 2231

Corrections

Incidence of Spondyloarthropathy in Patients with Crohn's Disease: A Population-based Study *R. Shivashankar, E.V. Loftus Jr, W.J. Tremaine, T. Bongartz, W.S. Harmsen, A.R. Zinsmeister, E.L. Matteson* 2231

Digital Gangrene in a Patient with Systemic Lupus Erythematosus and Systemic Sclerosis *M.A. Omair, A. Bookman, S. Mittoo* 2232

Meetings in Rheumatology x

VOLUME 39: NO. 12 **DECEMBER 2012**

Editorials

Atherosclerosis and Cardiovascular Disease in Rheumatoid Arthritis *J. Frostegård* 2233

Is There a Role for Rituximab in the Treatment of Spondyloarthritis and Psoriatic Arthritis? *P.J. Mease* 2235

Articles

Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with RA and an Inadequate Response to 1 or More TNF Inhibitors: 5-Year Data from the REFLEX Study *E.C. Keystone, S.B. Cohen, P. Emery, et al.* 2238

Effect of Rheumatologist Education on Systematic Measurements and Treatment Decisions in RA: The Metrix Study *J. Pope, C. Thorne, A. Cividino, K. Lucas* 2247

Pregnancy and the Risk of RA in a Highly Predisposed North American Native Population *C.A. Peschken, D.B. Robinson, C.A. Hitchon, I. Smolik, D. Hart, C.N. Bernstein, H.S. El-Gabalawy* 2253

Different Type of Carotid Arterial Wall Remodeling in RA Compared with Healthy Subjects: A Case-Control Study *A.M. van Sijl, K. van den Hurk, M.J. Peters, et al* 2261

Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early RA — A Randomized Trial *L-S. Tam, Q. Shang, E.K. Li, et al* 2267

ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in RA *E. Gremese, B. Tolusso, A.L. Fedele, S. Canestri, S. Alivernini, G. Ferraccioli* 2276

Semiquantified Noncalcified Coronary Plaque in SLE *A.N. Kiani, J. Vogel-Claussen, A. Zadeh, L.S. Magder, J. Lima, M. Petri* 2286

Influence of the *IL6* Gene in Susceptibility to Systemic Sclerosis *M.C. Cénit, C.P. Simeón, M.C. Vonk, et al.* 2294

Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population *D.E. Furst, A.W. Fernandes, S.R. Iorga, W. Greth, T. Bancroft* 2303

Increased BMI in AS Is Associated with Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise *L. Durcan, F. Wilson, R. Conway, G. Cunnane, F.D. O'Shea* 2310

Comparison of the Clinical Expression of Patients with AS from Europe and Latin America *M. Benegas, E. Muñoz-Gomariz, P. Font, et al* . 2315

Prevalence and Risk Factors of Anterior Atlantoaxial Subluxation in AS *J-S. Lee, S. Lee, S-Y. Bang, et al* 2321

Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology *D. Wendling, M. Dougados, F. Berenbaum, et al, on behalf of the French Society of Rheumatology and the Club Rhumatismes et Inflammation* . . . 2327

Discovertebral Erosions in Patients with Enteropathic Spondyloarthritis *R. Peluso, M.N. Di Minno, V. Bruner, et al* 2332

Pediatric Rheumatology

ERA Is Associated with Higher Pain Intensity and Poorer Health Status in Comparison with Other Categories of JIA: The Childhood Arthritis and Rheumatology Research Alliance Registry *P.F. Weiss, T. Beukelman, L.E. Schanberg, Y. Kimura, R.A. Colbert, for the CARRA Registry Investigators.* 2341

Orofacial Symptoms Related to TMJ Arthritis in JIA: Smallest Detectable Difference in Self-reported Pain Intensity *P. Stoustrup, K.D. Kristensen, C. Verna, A. Küseler, T. Herlin, T.K. Pedersen* . . 2352

Images in Rheumatology

Resolution of Muscle Inflammation After Tumor Removal in a Woman with Paraneoplastic Dermatomyositis *G. Primiano, D. Plantone, D. Sauchelli, C. Cuccagna, R. Renna, R. Iorio, S. Servidei.* 2359

The Dancing Hare (Milwaukee Hematoma) *A.P. Rozin, K. Toledano, A. Balbir-Gurman* 2361

Sonographic Appearance of Synovial Crystal Deposits in 2 Patients with Gout *A. Checa* . . . 2362

Letter

Acroosteolysis in Diabetes Mellitus *A.N. Baer, Z. Abou Zahr, S. Khan, M. Polydefkis* . . . 2364

Correction

Semiquantified Noncalcified Coronary Plaque in Systemic Lupus Erythematosus *A.N. Kiani, J. Vogel-Claussen, A. Zadeh, L.S. Magder, J. Lima, M. Petri* 2366

Reviewer Index 2367

Author Index 2368

Subject Index 2380

Content Index 2415

Meetings in Rheumatology x